<!DOCTYPE html>
<html lang="en-US" data-bt-theme="Industrial 1.3.1">
<head>

<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no">
<meta name="mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="robots" content="index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1">
<script type="06cd7e663a0e46d4271fe72d-text/javascript">if(navigator.userAgent.match(/MSIE|Internet Explorer/i)||navigator.userAgent.match(/Trident\/7\..*?rv:11/i)){var href=document.location.href;if(!href.match(/[?&]nowprocket/)){if(href.indexOf("?")==-1){if(href.indexOf("#")==-1){document.location.href=href+"?nowprocket=1"}else{document.location.href=href.replace("#","?nowprocket=1#")}}else{if(href.indexOf("#")==-1){document.location.href=href+"&nowprocket=1"}else{document.location.href=href.replace("#","&nowprocket=1#")}}}}</script><script type="06cd7e663a0e46d4271fe72d-text/javascript">class RocketLazyLoadScripts{constructor(e){this.triggerEvents=e,this.eventOptions={passive:!0},this.userEventListener=this.triggerListener.bind(this),this.delayedScripts={normal:[],async:[],defer:[]},this.allJQueries=[]}_addUserInteractionListener(e){this.triggerEvents.forEach((t=>window.addEventListener(t,e.userEventListener,e.eventOptions)))}_removeUserInteractionListener(e){this.triggerEvents.forEach((t=>window.removeEventListener(t,e.userEventListener,e.eventOptions)))}triggerListener(){this._removeUserInteractionListener(this),"loading"===document.readyState?document.addEventListener("DOMContentLoaded",this._loadEverythingNow.bind(this)):this._loadEverythingNow()}async _loadEverythingNow(){this._delayEventListeners(),this._delayJQueryReady(this),this._handleDocumentWrite(),this._registerAllDelayedScripts(),this._preloadAllScripts(),await this._loadScriptsFromList(this.delayedScripts.normal),await this._loadScriptsFromList(this.delayedScripts.defer),await this._loadScriptsFromList(this.delayedScripts.async),await this._triggerDOMContentLoaded(),await this._triggerWindowLoad(),window.dispatchEvent(new Event("rocket-allScriptsLoaded"))}_registerAllDelayedScripts(){document.querySelectorAll("script[type=rocketlazyloadscript]").forEach((e=>{e.hasAttribute("src")?e.hasAttribute("async")&&!1!==e.async?this.delayedScripts.async.push(e):e.hasAttribute("defer")&&!1!==e.defer||"module"===e.getAttribute("data-rocket-type")?this.delayedScripts.defer.push(e):this.delayedScripts.normal.push(e):this.delayedScripts.normal.push(e)}))}async _transformScript(e){return await this._requestAnimFrame(),new Promise((t=>{const n=document.createElement("script");let i;[...e.attributes].forEach((e=>{let t=e.nodeName;"type"!==t&&("data-rocket-type"===t&&(t="type",i=e.nodeValue),n.setAttribute(t,e.nodeValue))})),e.hasAttribute("src")&&this._isValidScriptType(i)?(n.addEventListener("load",t),n.addEventListener("error",t)):(n.text=e.text,t()),e.parentNode.replaceChild(n,e)}))}_isValidScriptType(e){return!e||""===e||"string"==typeof e&&["text/javascript","text/x-javascript","text/ecmascript","text/jscript","application/javascript","application/x-javascript","application/ecmascript","application/jscript","module"].includes(e.toLowerCase())}async _loadScriptsFromList(e){const t=e.shift();return t?(await this._transformScript(t),this._loadScriptsFromList(e)):Promise.resolve()}_preloadAllScripts(){var e=document.createDocumentFragment();[...this.delayedScripts.normal,...this.delayedScripts.defer,...this.delayedScripts.async].forEach((t=>{const n=t.getAttribute("src");if(n){const t=document.createElement("link");t.href=n,t.rel="preload",t.as="script",e.appendChild(t)}})),document.head.appendChild(e)}_delayEventListeners(){let e={};function t(t,n){!function(t){function n(n){return e[t].eventsToRewrite.indexOf(n)>=0?"rocket-"+n:n}e[t]||(e[t]={originalFunctions:{add:t.addEventListener,remove:t.removeEventListener},eventsToRewrite:[]},t.addEventListener=function(){arguments[0]=n(arguments[0]),e[t].originalFunctions.add.apply(t,arguments)},t.removeEventListener=function(){arguments[0]=n(arguments[0]),e[t].originalFunctions.remove.apply(t,arguments)})}(t),e[t].eventsToRewrite.push(n)}function n(e,t){let n=e[t];Object.defineProperty(e,t,{get:()=>n||function(){},set(i){e["rocket"+t]=n=i}})}t(document,"DOMContentLoaded"),t(window,"DOMContentLoaded"),t(window,"load"),t(window,"pageshow"),t(document,"readystatechange"),n(document,"onreadystatechange"),n(window,"onload"),n(window,"onpageshow")}_delayJQueryReady(e){let t=window.jQuery;Object.defineProperty(window,"jQuery",{get:()=>t,set(n){if(n&&n.fn&&!e.allJQueries.includes(n)){n.fn.ready=n.fn.init.prototype.ready=function(t){e.domReadyFired?t.bind(document)(n):document.addEventListener("rocket-DOMContentLoaded",(()=>t.bind(document)(n)))};const t=n.fn.on;n.fn.on=n.fn.init.prototype.on=function(){if(this[0]===window){function e(e){return e.split(" ").map((e=>"load"===e||0===e.indexOf("load.")?"rocket-jquery-load":e)).join(" ")}"string"==typeof arguments[0]||arguments[0]instanceof String?arguments[0]=e(arguments[0]):"object"==typeof arguments[0]&&Object.keys(arguments[0]).forEach((t=>{delete Object.assign(arguments[0],{[e(t)]:arguments[0][t]})[t]}))}return t.apply(this,arguments),this},e.allJQueries.push(n)}t=n}})}async _triggerDOMContentLoaded(){this.domReadyFired=!0,await this._requestAnimFrame(),document.dispatchEvent(new Event("rocket-DOMContentLoaded")),await this._requestAnimFrame(),window.dispatchEvent(new Event("rocket-DOMContentLoaded")),await this._requestAnimFrame(),document.dispatchEvent(new Event("rocket-readystatechange")),await this._requestAnimFrame(),document.rocketonreadystatechange&&document.rocketonreadystatechange()}async _triggerWindowLoad(){await this._requestAnimFrame(),window.dispatchEvent(new Event("rocket-load")),await this._requestAnimFrame(),window.rocketonload&&window.rocketonload(),await this._requestAnimFrame(),this.allJQueries.forEach((e=>e(window).trigger("rocket-jquery-load"))),window.dispatchEvent(new Event("rocket-pageshow")),await this._requestAnimFrame(),window.rocketonpageshow&&window.rocketonpageshow()}_handleDocumentWrite(){const e=new Map;document.write=document.writeln=function(t){const n=document.currentScript;n||console.error("WPRocket unable to document.write this: "+t);const i=document.createRange(),r=n.parentElement;let a=e.get(n);void 0===a&&(a=n.nextSibling,e.set(n,a));const o=document.createDocumentFragment();i.setStart(o,0),o.appendChild(i.createContextualFragment(t)),r.insertBefore(o,a)}}async _requestAnimFrame(){return new Promise((e=>requestAnimationFrame(e)))}static run(){const e=new RocketLazyLoadScripts(["keydown","mousemove","touchmove","touchstart","touchend","wheel"]);e._addUserInteractionListener(e)}}RocketLazyLoadScripts.run();
</script>
<title>Active pharmaceutical ingredients - Ikigai&reg; Corporation</title>
<link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto%3A100%2C200%2C300%2C400%2C500%2C600%2C700%2C800%2C900%2C100italic%2C200italic%2C300italic%2C400italic%2C500italic%2C600italic%2C700italic%2C800italic%2C900italic%7CMontserrat%3A100%2C200%2C300%2C400%2C500%2C600%2C700%2C800%2C900%2C100italic%2C200italic%2C300italic%2C400italic%2C500italic%2C600italic%2C700italic%2C800italic%2C900italic%7CMontserrat%3A100%2C200%2C300%2C400%2C500%2C600%2C700%2C800%2C900%2C100italic%2C200italic%2C300italic%2C400italic%2C500italic%2C600italic%2C700italic%2C800italic%2C900italic%7CRoboto%3A100%2C200%2C300%2C400%2C500%2C600%2C700%2C800%2C900%2C100italic%2C200italic%2C300italic%2C400italic%2C500italic%2C600italic%2C700italic%2C800italic%2C900italic%7CMontserrat%3A100%2C200%2C300%2C400%2C500%2C600%2C700%2C800%2C900%2C100italic%2C200italic%2C300italic%2C400italic%2C500italic%2C600italic%2C700italic%2C800italic%2C900italic%7CRoboto%3A100%2C100italic%2C200%2C200italic%2C300%2C300italic%2C400%2C400italic%2C500%2C500italic%2C600%2C600italic%2C700%2C700italic%2C800%2C800italic%2C900%2C900italic%7CRoboto%20Slab%3A100%2C100italic%2C200%2C200italic%2C300%2C300italic%2C400%2C400italic%2C500%2C500italic%2C600%2C600italic%2C700%2C700italic%2C800%2C800italic%2C900%2C900italic&#038;subset=latin%2Clatin-ext&#038;display=swap">
<link rel="stylesheet" href="./../../../../wp-content/cache/min/1/94ef57cb2a7e04898d8df31f764bfef2.css" media="all" data-minify="1">
<meta name="description" content="API (Active Pharmaceutical Ingredient) determines the active component which is included in the medicine. CATEGORY :ALLAPI. ANTIBIOTICSAPI. BOLDENONE SERIESAPI. CANRENONE DERIVATIVESAPI. CORTICAL STEROIDAPI. DHEA &amp; DERIVATIVESAPI. ESTROGENAPI. NANDROLONE SERIESAPI. OTHERSAPI. PROGESTERONE &amp; INTERMEDIATEAPI. STARTING MATERIALAPI. TESTOSTERONE SERIES">
<link rel="canonical" href="./index.html">
<meta property="og:locale" content="en_US">
<meta property="og:type" content="article">
<meta property="og:title" content="Active pharmaceutical ingredients - Ikigai&reg; Corporation">
<meta property="og:description" content="API (Active Pharmaceutical Ingredient) determines the active component which is included in the medicine. CATEGORY :ALLAPI. ANTIBIOTICSAPI. BOLDENONE SERIESAPI. CANRENONE DERIVATIVESAPI. CORTICAL STEROIDAPI. DHEA &amp; DERIVATIVESAPI. ESTROGENAPI. NANDROLONE SERIESAPI. OTHERSAPI. PROGESTERONE &amp; INTERMEDIATEAPI. STARTING MATERIALAPI. TESTOSTERONE SERIES">
<meta property="og:url" content="./active-pharmaceutical-ingredients/">
<meta property="og:site_name" content="Ikigai&reg; Corporation">
<meta property="article:modified_time" content="2021-01-28T12:32:49+00:00">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:label1" content="Est. reading time">
<meta name="twitter:data1" content="1 minute">
<script type="application/ld+json" class="yoast-schema-graph">{"@context":"https://schema.org","@graph":[{"@type":"WebSite","@id":"./#website","url":"./","name":"Ikigai&reg; Corporation","description":"Leading suppliers of API (active pharmaceutical ingredients)","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"./?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"WebPage","@id":"./active-pharmaceutical-ingredients/#webpage","url":"./active-pharmaceutical-ingredients/","name":"Active pharmaceutical ingredients - Ikigai&reg; Corporation","isPartOf":{"@id":"./#website"},"datePublished":"2020-01-30T19:55:43+00:00","dateModified":"2021-01-28T12:32:49+00:00","description":"API (Active Pharmaceutical Ingredient) determines the active component which is included in the medicine. CATEGORY :ALLAPI. ANTIBIOTICSAPI. BOLDENONE SERIESAPI. CANRENONE DERIVATIVESAPI. CORTICAL STEROIDAPI. DHEA & DERIVATIVESAPI. ESTROGENAPI. NANDROLONE SERIESAPI. OTHERSAPI. PROGESTERONE & INTERMEDIATEAPI. STARTING MATERIALAPI. TESTOSTERONE SERIES","breadcrumb":{"@id":"./active-pharmaceutical-ingredients/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["./active-pharmaceutical-ingredients/"]}]},{"@type":"BreadcrumbList","@id":"./active-pharmaceutical-ingredients/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"./"},{"@type":"ListItem","position":2,"name":"Active pharmaceutical ingredients"}]}]}</script>

<link rel="dns-prefetch" href="https://use.fontawesome.com">
<link rel="dns-prefetch" href="https://fonts.googleapis.com">
<link href="https://fonts.gstatic.com" crossorigin rel="preconnect">
<style type="text/css">img.wp-smiley,
img.emoji {
	display: inline !important;
	border: none !important;
	box-shadow: none !important;
	height: 1em !important;
	width: 1em !important;
	margin: 0 .07em !important;
	vertical-align: -0.1em !important;
	background: none !important;
	padding: 0 !important;
}</style>

<style id="industrial-style-inline-css" type="text/css">select, input{font-family: Roboto;} input:not([type='checkbox']):not([type='radio']), textarea, select{ font-family: "Montserrat";} input:not([type='checkbox']):not([type='radio']):not([type='submit']):focus, textarea:focus{-webkit-box-shadow: 0 0 4px 0 #58a0d3; box-shadow: 0 0 4px 0 #58a0d3;} html a:hover, .btLightSkin a:hover, .btDarkSkin .btLightSkin a:hover, .btLightSkin .btDarkSkin .btLightSkin a:hover, .btDarkSkin a:hover, .btLightSkin .btDarkSkin a:hover, .btDarkSkin.btLightSkin .btDarkSkin a:hover{ color: #58a0d3;} .btLightSkin .btText a, .btDarkSkin .btLightSkin .btText a, .btLightSkin .btDarkSkin .btLightSkin .btText a, .btDarkSkin .btText a, .btLightSkin .btDarkSkin .btText a, .btDarkSkin.btLightSkin .btDarkSkin .btText a{color: #58a0d3;} body{font-family: "Roboto",Arial,sans-serif;} .btContentHolder cite{ font-family: Montserrat;} h1, h2, h3, h4, h5, h6{font-family: "Montserrat";} .btContentHolder table thead th{ background-color: #58a0d3; font-family: Montserrat;} .btAccentColorBackground{background-color: #58a0d3 !important;} .btAccentColorBackground .headline b.animate.animated{color: #1a86d3;} .btAccentColorBackground .btDash.bottomDash .dash:after{border-color: #1a86d3;} .btAccentDarkColorBackground{background-color: #2e7ab0 !important;} .btAccentDarkColorBackground .headline b.animate.animated{color: #1a86d3;} .btAccentVeryDarkColorBackground{background-color: #19425f !important;} .btAccentLightColorBackground{background-color: rgba(88,160,211,0.7) !important;} .btAlternateColorBackground{background-color: #1a86d3 !important;} .btAlternateDarkColorBackground{background-color: #125b8f !important;} .btAlternateVeryDarkColorBackground{background-color: #0c3e61 !important;} .btAlternateLightColorBackground{background-color: rgba(26,134,211,0.6) !important;} .btAccentDarkHeader .btPreloader .animation > div:first-child, .btLightAccentHeader .btPreloader .animation > div:first-child{ background-color: #2e7ab0;} .btPreloader .animation .preloaderLogo{height: 100px;} .mainHeader{ font-family: "Montserrat";} .btMenuVertical.btAccentDarkHeader .mainHeader, .btMenuVertical.btLightAccentHeader .mainHeader{background-color: #58a0d3;} .btMenuVertical.btLightAlternateHeader .mainHeader{background-color: #1a86d3;} .menuPort{font-family: "Montserrat";} .menuPort nav ul li a:hover{color: #58a0d3 !important;} .menuPort nav > ul > li > a{line-height: 100px;} .btTextLogo{ line-height: 100px;} .btLogoArea .logo img{height: 100px;} .btHorizontalMenuTrigger{ line-height: 100px;} .btMenuHorizontal .menuPort nav > ul > li.current-menu-ancestor > a:after, .btMenuHorizontal .menuPort nav > ul > li.current-menu-item > a:after{ background-color: #58a0d3;} .btAccentDarkHeader.btMenuHorizontal .menuPort nav > ul > li.current-menu-ancestor > a:after, .btAccentDarkHeader.btMenuHorizontal .menuPort nav > ul > li.current-menu-item > a:after, .btAccentLightHeader.btMenuHorizontal .menuPort nav > ul > li.current-menu-ancestor > a:after, .btAccentLightHeader.btMenuHorizontal .menuPort nav > ul > li.current-menu-item > a:after{background-color: #1a86d3;} .btMenuHorizontal .menuPort nav > ul > li > ul li.current-menu-ancestor > a, .btMenuHorizontal .menuPort nav > ul > li > ul li.current-menu-item > a{color: #58a0d3 !important;} body.btMenuHorizontal .subToggler{ line-height: 100px;} .btMenuHorizontal .topBarInMenu{ height: 100px;} .btLightSkin.btAccentLightHeader.btMenuHorizontal .btBelowLogoArea .menuPort > nav > ul > li > a:hover, .btDarkSkin.btAccentLightHeader.btMenuHorizontal .btBelowLogoArea .menuPort > nav > ul > li > a:hover, .btLightSkin.btAccentLightHeader.btMenuHorizontal .topBar .menuPort > nav > ul > li > a:hover, .btDarkSkin.btAccentLightHeader.btMenuHorizontal .topBar .menuPort > nav > ul > li > a:hover{color: #1a86d3 !important;} .btAccentLightHeader.btMenuHorizontal:not(.btBelowMenu) .btBelowLogoArea, .btAccentLightHeader.btMenuHorizontal:not(.btBelowMenu) .topBar, .btAccentLightHeader.btMenuHorizontal.btStickyHeaderActive .btBelowLogoArea, .btAccentLightHeader.btMenuHorizontal.btStickyHeaderActive .topBar{background-color: #58a0d3;} .btAccentLightHeader.btMenuHorizontal:not(.btBelowMenu) .btBelowLogoArea:before, .btAccentLightHeader.btMenuHorizontal:not(.btBelowMenu) .topBar:before, .btAccentLightHeader.btMenuHorizontal.btStickyHeaderActive .btBelowLogoArea:before, .btAccentLightHeader.btMenuHorizontal.btStickyHeaderActive .topBar:before{ background-color: #58a0d3;} .btAccentLightHeader.btMenuHorizontal.btBelowMenu:not(.btStickyHeaderActive) .mainHeader .btBelowLogoArea, .btAccentLightHeader.btMenuHorizontal.btBelowMenu:not(.btStickyHeaderActive) .mainHeader .topBar{background-color: #58a0d3;} .btLightSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .menuPort > nav > ul > li > a:hover, .btDarkSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .menuPort > nav > ul > li > a:hover, .btLightSkin.btLightHeader.btMenuHorizontal .topBar .menuPort > nav > ul > li > a:hover, .btDarkSkin.btLightHeader.btMenuHorizontal .topBar .menuPort > nav > ul > li > a:hover{color: #1a86d3 !important;} .btLightSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .menuPort > nav > ul > li > a:hover, .btDarkSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .menuPort > nav > ul > li > a:hover{color: #1a86d3 !important;} .btAccentDarkHeader.btMenuHorizontal:not(.btBelowMenu) .mainHeader, .btAccentDarkHeader.btMenuHorizontal.btStickyHeaderActive .mainHeader{background-color: #58a0d3;} .btAccentDarkHeader.btMenuHorizontal.btBelowMenu:not(.btStickyHeaderActive) .mainHeader .port .btLogoArea{background-color: #58a0d3;} .btLightSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .menuPort > nav > ul > li > a:hover, .btDarkSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .menuPort > nav > ul > li > a:hover{color: #1a86d3 !important;} .btLightAccentHeader.btMenuHorizontal:not(.btBelowMenu) .mainHeader, .btLightAccentHeader.btMenuHorizontal.btStickyHeaderActive .mainHeader{background-color: #58a0d3;} .btLightAccentHeader.btMenuHorizontal.btBelowMenu:not(.btStickyHeaderActive) .mainHeader .port .btLogoArea{background-color: #58a0d3;} .btLightSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .menuPort > nav > ul > li > a:hover, .btDarkSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .menuPort > nav > ul > li > a:hover{color: #58a0d3 !important;} .btLightAlternateHeader.btMenuHorizontal:not(.btBelowMenu) .mainHeader, .btLightAlternateHeader.btMenuHorizontal.btStickyHeaderActive .mainHeader{background-color: #1a86d3;} .btLightAlternateHeader.btMenuHorizontal.btBelowMenu:not(.btStickyHeaderActive) .mainHeader .port .btLogoArea{background-color: #1a86d3;} .btAccentDarkHeader.btMenuVertical > .menuPort .logo, .btLightAccentHeader.btMenuVertical > .menuPort .logo{background-color: #58a0d3;} .btLightAlternateHeader.btMenuVertical > .menuPort .logo{background-color: #1a86d3;} .btMenuVertical > .menuPort .btCloseVertical:before:hover{color: #58a0d3;} @media (min-width: 1200px){.btMenuVerticalOn .btVerticalMenuTrigger .btIco a:before{color: #58a0d3 !important;} }.btMenuHorizontal .topBarInLogoArea{ height: 100px;} .btMenuHorizontal .topBarInLogoArea .topBarInLogoAreaCell{border: 0 solid #58a0d3;} .btSearchInner.btFromTopBox{ background: #58a0d3;} .btSearchInner.btFromTopBox form button:hover:before{color: #58a0d3;} .btDarkSkin .btSiteFooter .port:before, .btLightSkin .btDarkSkin .btSiteFooter .port:before, .btDarkSkin.btLightSkin .btDarkSkin .btSiteFooter .port:before{background-color: #58a0d3;} .btMediaBox.btQuote, .btMediaBox.btLink{ background-color: #58a0d3;} .btArticleListItem .headline a:hover{color: #58a0d3;} .btCommentsBox .vcard .posted{ font-family: "Montserrat";} .btCommentsBox .commentTxt p.edit-link, .btCommentsBox .commentTxt p.reply{ font-family: "Montserrat";} .comment-respond .btnOutline button[type="submit"]{font-family: "Montserrat";} a#cancel-comment-reply-link:hover{color: #58a0d3;} .post-password-form input[type="submit"]{ background: #58a0d3; font-family: "Montserrat";} .btPagination{font-family: "Montserrat";} .btPagination .paging a:hover:after{border-color: #58a0d3;} span.btHighlight{ background-color: #58a0d3;} .btArticleCategories a:not(:first-child):before{ background-color: #58a0d3;} .btArticleMeta{font-family: "Montserrat";} body:not(.btNoDashInSidebar) .btBox > h4:after, body:not(.btNoDashInSidebar) .btCustomMenu > h4:after, body:not(.btNoDashInSidebar) .btTopBox > h4:after{ border-bottom: 3px solid #58a0d3;} .btBox ul li.current-menu-item > a, .btCustomMenu ul li.current-menu-item > a, .btTopBox ul li.current-menu-item > a{color: #58a0d3;} .btBox .ppTxt .header .headline a a:hover, .btCustomMenu .ppTxt .header .headline a a:hover, .btTopBox .ppTxt .header .headline a a:hover{color: #58a0d3;} .btBox p.posted, .btBox .quantity, .btCustomMenu p.posted, .btCustomMenu .quantity, .btTopBox p.posted, .btTopBox .quantity{ font-family: Montserrat;} .widget_calendar table caption{background: #58a0d3; font-family: "Montserrat";} .widget_rss li a.rsswidget{font-family: "Montserrat";} .fancy-select .trigger.open{color: #58a0d3;} .fancy-select ul.options li:hover{color: #58a0d3;} .widget_shopping_cart .total{ font-family: Montserrat;} .widget_shopping_cart .widget_shopping_cart_content .mini_cart_item .ppRemove a.remove{ background-color: #58a0d3;} .widget_shopping_cart .widget_shopping_cart_content .mini_cart_item .ppRemove a.remove:hover{background-color: #1a86d3;} .menuPort .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetIcon span.cart-contents, .topTools .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetIcon span.cart-contents, .topBarInLogoArea .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetIcon span.cart-contents{ background-color: #1a86d3; font: normal 10px/1 Montserrat;} .btMenuVertical .menuPort .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetInnerContent .verticalMenuCartToggler, .btMenuVertical .topTools .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetInnerContent .verticalMenuCartToggler, .btMenuVertical .topBarInLogoArea .widget_shopping_cart .widget_shopping_cart_content .btCartWidgetInnerContent .verticalMenuCartToggler{ background-color: #58a0d3;} .widget_recent_reviews{font-family: Montserrat;} .widget_price_filter .price_slider_wrapper .ui-slider .ui-slider-handle{ background-color: #58a0d3;} .btBox .tagcloud a, .btTags ul a{ background: #58a0d3; font-family: "Montserrat";} .btSidebar .btIconWidget:hover .btIconWidgetText, footer .btIconWidget:hover .btIconWidgetText{color: #58a0d3;} .btTopBox.widget_bt_text_image .widget_sp_image-description{ font-family: 'Roboto',arial,sans-serif;} .btMenuHorizontal .topTools .btIconWidget:hover, .btMenuHorizontal .topBarInMenu .btIconWidget:hover{color: #58a0d3;} .btMenuHorizontal .topTools .btAccentIconWidget, .btMenuHorizontal .topBarInMenu .btAccentIconWidget{background-color: #58a0d3;} .btTopToolsInMenuArea.btMenuHorizontal .topTools .btAccentIconWidget, .btTopToolsInMenuArea.btMenuHorizontal .topBarInMenu .btAccentIconWidget{background-color: #1a86d3;} .btTopToolsInMenuArea.btMenuHorizontal .topTools .btAccentIconWidget:hover, .btTopToolsInMenuArea.btMenuHorizontal .topBarInMenu .btAccentIconWidget:hover{color: #58a0d3;} .btAccentLightHeader.btMenuHorizontal .topTools .btAccentIconWidget, .btLightAccentHeader.btMenuHorizontal .topTools .btAccentIconWidget, .btAccentLightHeader.btMenuHorizontal .topBarInMenu .btAccentIconWidget, .btLightAccentHeader.btMenuHorizontal .topBarInMenu .btAccentIconWidget{background-color: #1a86d3;} .btMenuHorizontal .topTools .btAccentIconWidget:hover, .btMenuHorizontal .topBarInMenu .btAccentIconWidget:hover{color: #1a86d3;} .btTopToolsInMenuArea.btLightAccentHeader.btMenuHorizontal .topTools .btAccentIconWidget:hover, .btTopToolsInMenuArea.btLightAccentHeader.btMenuHorizontal .topBarInMenu .btAccentIconWidget:hover{background-color: #58a0d3;} .btLightSkin.btAccentLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btDarkSkin.btAccentLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btLightSkin.btAccentLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btDarkSkin.btAccentLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before{color: #1a86d3;} .btLightSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:hover:before, .btDarkSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:hover:before, .btLightSkin.btLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:hover:before, .btDarkSkin.btLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:hover:before{color: #1a86d3;} .btLightSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btDarkSkin.btLightHeader.btMenuHorizontal .btBelowLogoArea .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btLightSkin.btLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before, .btDarkSkin.btLightHeader.btMenuHorizontal .topBar .btIco.btIcoDefaultType.btIcoDefaultColor .btIcoHolder:hover:before{color: #1a86d3;} .btLightSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before{color: #1a86d3;} .btLightSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .btIco.btIcoDefaultType .btIcoHolder:hover:before, .btDarkSkin.btAccentDarkHeader.btMenuHorizontal .mainHeader .btIco.btIcoDefaultType .btIcoHolder:hover:before{color: #1a86d3;} .btLightSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before{color: #1a86d3;} .btLightSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType .btIcoHolder:hover:before, .btDarkSkin.btLightAccentHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType .btIcoHolder:hover:before{color: #1a86d3;} .btLightSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before{color: #58a0d3;} .btLightSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType .btIcoHolder:hover:before, .btDarkSkin.btLightAlternateHeader.btMenuHorizontal .mainHeader .btLogoArea .btIco.btIcoDefaultType .btIcoHolder:hover:before{color: #58a0d3;} .btSpecialHeaderIcon .btIco .btIcoHolder:before, .btSpecialHeaderIcon .btIconWidgetTitle, .btSpecialHeaderIcon .btIconWidgetText{color: #58a0d3 !important;} .btLightSkin .btBox .btSearch button:hover, .btDarkSkin .btLightSkin .btBox .btSearch button:hover, .btLightSkin .btDarkSkin .btLightSkin .btBox .btSearch button:hover, .btDarkSkin .btBox .btSearch button:hover, .btLightSkin .btDarkSkin .btBox .btSearch button:hover, .btDarkSkin.btLightSkin .btDarkSkin .btBox .btSearch button:hover, .btLightSkin form.woocommerce-product-search button:hover, .btDarkSkin .btLightSkin form.woocommerce-product-search button:hover, .btLightSkin .btDarkSkin .btLightSkin form.woocommerce-product-search button:hover, .btDarkSkin form.woocommerce-product-search button:hover, .btLightSkin .btDarkSkin form.woocommerce-product-search button:hover, .btDarkSkin.btLightSkin .btDarkSkin form.woocommerce-product-search button:hover{background: #58a0d3 !important; border-color: #58a0d3 !important;} .topTools .widget_search button, .topBarInMenu .widget_search button{ background: #58a0d3;} .topTools .widget_search button:before, .topBarInMenu .widget_search button:before{ color: #58a0d3;} .topTools .widget_search button:hover, .topBarInMenu .widget_search button:hover{background: #2e7ab0;} .btIcoFilledType.btIcoAccentColor.btIconHexagonShape.btIco .btIcoHolder .hex{fill: #58a0d3;} .btIcoFilledType.btIcoAlternateColor.btIconHexagonShape.btIco .btIcoHolder .hex{fill: #1a86d3;} .btIcoOutlineType.btIcoAccentColor.btIconHexagonShape.btIco .btIcoHolder .hex{ stroke: #58a0d3;} .btIcoOutlineType.btIcoAlternateColor.btIconHexagonShape.btIco .btIcoHolder .hex{ stroke: #1a86d3;} .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin.btLightSkin .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAccentColor.btIco:hover .btIcoHolder .hex{fill: #58a0d3; stroke: #58a0d3;} .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin.btLightSkin .btDarkSkin .btIconHexagonShape.btIcoOutlineType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex{fill: #1a86d3; stroke: #1a86d3;} .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex, .btDarkSkin.btLightSkin .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAlternateColor.btIco:hover .btIcoHolder .hex{ stroke: #1a86d3;} .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btLightSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btLightSkin .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex, .btDarkSkin.btLightSkin .btDarkSkin .btIconHexagonShape.btIcoFilledType.btIcoAccentColor.btIco:hover .btIcoHolder .hex{ stroke: #58a0d3;} .btIconHexagonShape .btIco.btIcoFilledType .btIcoHolder svg .hex{ fill: #58a0d3;} .btIconHexagonShape .btIco.btIcoFilledType:hover .btIcoHolder svg .hex{stroke: #58a0d3;} .btIconHexagonShape .btIco.btIcoOutlineType .btIcoHolder svg .hex{stroke: #58a0d3;} .btIconHexagonShape .btIco.btIcoOutlineType:hover .btIcoHolder svg .hex{stroke: #58a0d3; fill: #58a0d3;} .btIco.btIcoFilledType.btIcoAccentColor .btIcoHolder:before, .btIco.btIcoOutlineType.btIcoAccentColor:hover .btIcoHolder:before{-webkit-box-shadow: 0 0 0 1em #58a0d3 inset; box-shadow: 0 0 0 1em #58a0d3 inset;} .btIco.btIcoFilledType.btIcoAccentColor:hover .btIcoHolder:before, .btIco.btIcoOutlineType.btIcoAccentColor .btIcoHolder:before{-webkit-box-shadow: 0 0 0 1px #58a0d3 inset; box-shadow: 0 0 0 1px #58a0d3 inset; color: #58a0d3;} .btIco.btIcoFilledType.btIcoAlternateColor .btIcoHolder:before, .btIco.btIcoOutlineType.btIcoAlternateColor:hover .btIcoHolder:before{-webkit-box-shadow: 0 0 0 1em #1a86d3 inset; box-shadow: 0 0 0 1em #1a86d3 inset;} .btIco.btIcoFilledType.btIcoAlternateColor:hover .btIcoHolder:before, .btIco.btIcoOutlineType.btIcoAlternateColor .btIcoHolder:before{-webkit-box-shadow: 0 0 0 1px #1a86d3 inset; box-shadow: 0 0 0 1px #1a86d3 inset; color: #1a86d3;} .btLightSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btLightSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before, .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before, .btLightSkin .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btLightSkin .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before, .btDarkSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before, .btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before, .btDarkSkin.btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoAccentColor .btIcoHolder:before, .btDarkSkin.btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoDefaultColor:hover .btIcoHolder:before{color: #58a0d3;} .btLightSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before, .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before, .btLightSkin .btDarkSkin .btLightSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before, .btDarkSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before, .btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before, .btDarkSkin.btLightSkin .btDarkSkin .btIco.btIcoDefaultType.btIcoAlternateColor .btIcoHolder:before{color: #1a86d3;} .btIcoAccentColor span{color: #58a0d3;} .btIcoAlternateColor span{color: #1a86d3;} .btIcoDefaultColor:hover span{color: #58a0d3;} .btBtn{ font-family: "Montserrat";} .btnFilledStyle.btnAccentColor, .btnOutlineStyle.btnAccentColor:hover{background-color: #58a0d3; border: 2px solid #58a0d3;} .btnOutlineStyle.btnAccentColor, .btnFilledStyle.btnAccentColor:hover{ border: 2px solid #58a0d3; color: #58a0d3;} .btnOutlineStyle.btnAccentColor span, .btnFilledStyle.btnAccentColor:hover span, .btnOutlineStyle.btnAccentColor span:before, .btnFilledStyle.btnAccentColor:hover span:before, .btnOutlineStyle.btnAccentColor a, .btnFilledStyle.btnAccentColor:hover a, .btnOutlineStyle.btnAccentColor .btIco a:before, .btnFilledStyle.btnAccentColor:hover .btIco a:before, .btnOutlineStyle.btnAccentColor button, .btnFilledStyle.btnAccentColor:hover button{color: #58a0d3 !important;} .btnBorderlessStyle.btnAccentColor span, .btnBorderlessStyle.btnNormalColor:hover span, .btnBorderlessStyle.btnAccentColor span:before, .btnBorderlessStyle.btnNormalColor:hover span:before, .btnBorderlessStyle.btnAccentColor a, .btnBorderlessStyle.btnNormalColor:hover a, .btnBorderlessStyle.btnAccentColor .btIco a:before, .btnBorderlessStyle.btnNormalColor:hover .btIco a:before, .btnBorderlessStyle.btnAccentColor button, .btnBorderlessStyle.btnNormalColor:hover button{color: #58a0d3;} .btnFilledStyle.btnAlternateColor, .btnOutlineStyle.btnAlternateColor:hover{background-color: #1a86d3; border: 2px solid #1a86d3;} .btnOutlineStyle.btnAlternateColor, .btnFilledStyle.btnAlternateColor:hover{ border: 2px solid #1a86d3; color: #1a86d3;} .btnOutlineStyle.btnAlternateColor span, .btnFilledStyle.btnAlternateColor:hover span, .btnOutlineStyle.btnAlternateColor span:before, .btnFilledStyle.btnAlternateColor:hover span:before, .btnOutlineStyle.btnAlternateColor a, .btnFilledStyle.btnAlternateColor:hover a, .btnOutlineStyle.btnAlternateColor .btIco a:before, .btnFilledStyle.btnAlternateColor:hover .btIco a:before, .btnOutlineStyle.btnAlternateColor button, .btnFilledStyle.btnAlternateColor:hover button{color: #1a86d3 !important;} .btnBorderlessStyle.btnAlternateColor span, .btnBorderlessStyle.btnAlternateColor span:before, .btnBorderlessStyle.btnAlternateColor a, .btnBorderlessStyle.btnAlternateColor .btIco a:before, .btnBorderlessStyle.btnAlternateColor button{color: #1a86d3;} .btCounterHolder{font-family: "Montserrat";} .btCounterHolder .btCountdownHolder .days_text, .btCounterHolder .btCountdownHolder .hours_text, .btCounterHolder .btCountdownHolder .minutes_text, .btCounterHolder .btCountdownHolder .seconds_text{ font-family: Montserrat; color: #58a0d3;} .btProgressContent{font-family: "Montserrat";} .btProgressContent .btProgressAnim{ background-color: #58a0d3;} .btShowTitle{ border-left: 4px solid #58a0d3;} .btAccentColorBackground .btShowTitle{border-left: 4px solid #1a86d3;} .btPriceTable .btPriceTableHeader{background: #58a0d3;} .btPriceTableSticker{ font-family: "Montserrat";} .header .btSuperTitle{font-family: "Montserrat";} .header .btSubTitle{font-family: "Roboto";} .btDash.bottomDash .dash:after{ border-bottom: 4px solid #58a0d3;} .btDash.topDash .btSuperTitle:after, .btDash.topDash .btSuperTitle:before{ border-top: 1px solid #58a0d3;} .btNoMore{ font-family: Montserrat;} .btGridContent .header .btSuperTitle a:hover{color: #58a0d3;} .btCatFilter{ font-family: Montserrat;} .btCatFilter .btCatFilterItem:hover{color: #58a0d3;} .btCatFilter .btCatFilterItem.active{color: #58a0d3;} .nbs a .nbsItem .nbsDir{ font-family: "Montserrat";} .btLightSkin .btSimpleArrows .nbs a:hover:before, .btDarkSkin .btLightSkin .btSimpleArrows .nbs a:hover:before, .btLightSkin .btDarkSkin .btLightSkin .btSimpleArrows .nbs a:hover:before, .btDarkSkin .btSimpleArrows .nbs a:hover:before, .btLightSkin .btDarkSkin .btSimpleArrows .nbs a:hover:before, .btDarkSkin.btLightSkin .btDarkSkin .btSimpleArrows .nbs a:hover:before{color: #58a0d3 !important;} .neighboringArticles .nbs a .nbsItem .nbsDir{ font-family: 'Roboto',arial,sans-serif;} .neighboringArticles .nbs a:hover .nbsDir{color: #58a0d3;} .recentTweets small:before{ color: #58a0d3;} .btInfoBar .btInfoBarMeta p strong{color: #58a0d3;} .tabsHeader li{ font-family: "Montserrat";} .tabsVertical .tabAccordionTitle{ font-family: "Montserrat";} .btVisualizer{font-family: Montserrat;} form.wpcf7-form .wpcf7-submit{ background-color: #58a0d3;} .btAnimNav li.btAnimNavDot{ font-family: Montserrat;} .btAnimNav li.btAnimNavNext:hover, .btAnimNav li.btAnimNavPrev:hover{border-color: #58a0d3; color: #58a0d3;} .headline b.animate.animated{ color: #58a0d3;} .headline em.animate{ font-family: Roboto;} p.demo_store{ background-color: #58a0d3;} .woocommerce .woocommerce-info a: not(.button), .woocommerce .woocommerce-message a: not(.button), .woocommerce-page .woocommerce-info a: not(.button), .woocommerce-page .woocommerce-message a: not(.button){color: #58a0d3;} .woocommerce .woocommerce-message:before, .woocommerce .woocommerce-info:before, .woocommerce-page .woocommerce-message:before, .woocommerce-page .woocommerce-info:before{ color: #58a0d3;} .woocommerce a.button, .woocommerce input[type="submit"], .woocommerce button[type="submit"], .woocommerce input.button, .woocommerce input.alt:hover, .woocommerce a.button.alt:hover, .woocommerce .button.alt:hover, .woocommerce button.alt:hover, .woocommerce-page a.button, .woocommerce-page input[type="submit"], .woocommerce-page button[type="submit"], .woocommerce-page input.button, .woocommerce-page input.alt:hover, .woocommerce-page a.button.alt:hover, .woocommerce-page .button.alt:hover, .woocommerce-page button.alt:hover{ font-family: Montserrat;} .woocommerce a.button:hover, .woocommerce input[type="submit"]:hover, .woocommerce .button:hover, .woocommerce button:hover, .woocommerce input.alt, .woocommerce a.button.alt, .woocommerce .button.alt, .woocommerce button.alt, .woocommerce-page a.button:hover, .woocommerce-page input[type="submit"]:hover, .woocommerce-page .button:hover, .woocommerce-page button:hover, .woocommerce-page input.alt, .woocommerce-page a.button.alt, .woocommerce-page .button.alt, .woocommerce-page button.alt{ font-family: "Montserrat";} .woocommerce p.lost_password:before, .woocommerce-page p.lost_password:before{ color: #58a0d3;} .woocommerce form.login p.lost_password a:hover, .woocommerce-page form.login p.lost_password a:hover{color: #58a0d3;} .woocommerce .added:after, .woocommerce .loading:after, .woocommerce-page .added:after, .woocommerce-page .loading:after{ background-color: #58a0d3;} .woocommerce form .form-row .select2-container, .woocommerce-page form .form-row .select2-container{ font-family: "Montserrat";} .woocommerce div.product p.price, .woocommerce div.product span.price, .woocommerce-page div.product p.price, .woocommerce-page div.product span.price{ font-family: "Montserrat"; color: #58a0d3;} .woocommerce div.product .stock, .woocommerce-page div.product .stock{color: #58a0d3;} .woocommerce div.product a.reset_variations:hover, .woocommerce-page div.product a.reset_variations:hover{color: #58a0d3;} .woocommerce .added_to_cart, .woocommerce-page .added_to_cart{ font-family: Montserrat;} .woocommerce .products ul li.product .btPriceTableSticker, .woocommerce ul.products li.product .btPriceTableSticker, .woocommerce-page .products ul li.product .btPriceTableSticker, .woocommerce-page ul.products li.product .btPriceTableSticker{ background: #1a86d3;} .woocommerce .products ul li.product .price, .woocommerce ul.products li.product .price, .woocommerce-page .products ul li.product .price, .woocommerce-page ul.products li.product .price{ font-family: "Montserrat";} .woocommerce nav.woocommerce-pagination, .woocommerce-page nav.woocommerce-pagination{ font-family: "Montserrat";} .woocommerce nav.woocommerce-pagination ul li a:focus, .woocommerce nav.woocommerce-pagination ul li a:hover, .woocommerce nav.woocommerce-pagination ul li a.next, .woocommerce nav.woocommerce-pagination ul li a.prev, .woocommerce nav.woocommerce-pagination ul li span.current, .woocommerce-page nav.woocommerce-pagination ul li a:focus, .woocommerce-page nav.woocommerce-pagination ul li a:hover, .woocommerce-page nav.woocommerce-pagination ul li a.next, .woocommerce-page nav.woocommerce-pagination ul li a.prev, .woocommerce-page nav.woocommerce-pagination ul li span.current{background: #58a0d3;} .woocommerce .star-rating span:before, .woocommerce-page .star-rating span:before{ color: #58a0d3;} .woocommerce p.stars a[class^="star-"].active:after, .woocommerce p.stars a[class^="star-"]:hover:after, .woocommerce-page p.stars a[class^="star-"].active:after, .woocommerce-page p.stars a[class^="star-"]:hover:after{color: #58a0d3;} .woocommerce-cart table.cart td.product-remove a.remove{ color: #58a0d3; border: 1px solid #58a0d3;} .woocommerce-cart table.cart td.product-remove a.remove:hover{background-color: #58a0d3;} .woocommerce-cart .cart_totals .discount td{color: #58a0d3;} .woocommerce-account header.title .edit{ color: #58a0d3;} .woocommerce-account header.title .edit:before{ color: #58a0d3;} .btLightSkin.woocommerce-page .product .headline a:hover, .btDarkSkin .btLightSkin.woocommerce-page .product .headline a:hover, .btLightSkin .btDarkSkin .btLightSkin.woocommerce-page .product .headline a:hover, .btDarkSkin.woocommerce-page .product .headline a:hover, .btLightSkin .btDarkSkin.woocommerce-page .product .headline a:hover, .btDarkSkin.btLightSkin .btDarkSkin.woocommerce-page .product .headline a:hover{color: #58a0d3;} .btQuoteBooking .btTotalNextWrapper{ font-family: "Montserrat";} .btQuoteBooking .btContactNext{ border: #58a0d3 2px solid; color: #58a0d3;} .btQuoteBooking .btContactNext:hover, .btQuoteBooking .btContactNext:active{background-color: #58a0d3 !important;} .btQuoteBooking .btQuoteSwitch:hover{-webkit-box-shadow: 0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} .btQuoteBooking .btQuoteSwitch.on .btQuoteSwitchInner{ background: #58a0d3;} .btQuoteBooking .dd.ddcommon.borderRadiusTp .ddTitleText, .btQuoteBooking .dd.ddcommon.borderRadiusBtm .ddTitleText{ -webkit-box-shadow: 5px 0 0 #58a0d3 inset,0 2px 10px rgba(0,0,0,.2); box-shadow: 5px 0 0 #58a0d3 inset,0 2px 10px rgba(0,0,0,.2);} .btQuoteBooking .ui-slider .ui-slider-handle{ background: #58a0d3;} .btQuoteBooking .btQuoteBookingForm .btQuoteTotal{ background: #58a0d3;} .btQuoteBooking .btContactFieldMandatory.btContactFieldError input, .btQuoteBooking .btContactFieldMandatory.btContactFieldError textarea{border: 1px solid #58a0d3; -webkit-box-shadow: 0 0 0 1px #58a0d3 inset; box-shadow: 0 0 0 1px #58a0d3 inset;} .btQuoteBooking .btContactFieldMandatory.btContactFieldError .dd.ddcommon.borderRadius .ddTitleText{border: 1px solid #58a0d3; -webkit-box-shadow: 0 0 0 1px #58a0d3 inset; box-shadow: 0 0 0 1px #58a0d3 inset;} .btQuoteBooking .btContactFieldMandatory.btContactFieldError input:hover, .btQuoteBooking .btContactFieldMandatory.btContactFieldError textarea:hover{-webkit-box-shadow: 0 0 0 1px #58a0d3 inset,0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 1px #58a0d3 inset,0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} .btQuoteBooking .btContactFieldMandatory.btContactFieldError .dd.ddcommon.borderRadius:hover .ddTitleText{-webkit-box-shadow: 0 0 0 1px #58a0d3 inset,0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 1px #58a0d3 inset,0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} .btQuoteBooking .btContactFieldMandatory.btContactFieldError input:focus, .btQuoteBooking .btContactFieldMandatory.btContactFieldError textarea:focus{-webkit-box-shadow: 0 0 0 1px #58a0d3 inset,5px 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 1px #58a0d3 inset,5px 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} .btQuoteBooking .btContactFieldMandatory.btContactFieldError .dd.ddcommon.borderRadiusTp .ddTitleText{-webkit-box-shadow: 0 0 0 1px #58a0d3 inset,5px 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 1px #58a0d3 inset,5px 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} .btQuoteBooking .btSubmitMessage{color: #58a0d3;} .btDatePicker .ui-datepicker-header{ background-color: #58a0d3;} .btQuoteBooking .btContactSubmit{font-family: "Montserrat"; background-color: #58a0d3; border: 1px solid #58a0d3;} .btQuoteBooking .btContactSubmit:hover{ color: #58a0d3;} .btPayPalButton:hover{-webkit-box-shadow: 0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2); box-shadow: 0 0 0 #58a0d3 inset,0 1px 5px rgba(0,0,0,.2);} #btSettingsPanel #btSettingsPanelToggler:before{ color: #58a0d3;} #btSettingsPanel h4{ background-color: #58a0d3;} #btSettingsPanel .btSettingsPanelRow.btAccentColorRow .trigger, #btSettingsPanel .btSettingsPanelRow.btAccentColorRow select{border-color: #58a0d3;} #btSettingsPanel .btSettingsPanelRow.btAlternateColorRow .trigger, #btSettingsPanel .btSettingsPanelRow.btAlternateColorRow select{border-color: #1a86d3;} .wp-block-button__link:hover{color: #58a0d3 !important;}
.tagcloud a { color: #ffffff; } .btTopToolsInMenuArea.btMenuHorizontal .topTools .btAccentIconWidget, .btTopToolsInMenuArea.btMenuHorizontal .topBarInMenu .btAccentIconWidget { background-color: #02b3f9; }</style>
<link rel="stylesheet" id="industrial-print-css" href="./../../../../wp-content/themes/industrial/print.css?ver=5.8" type="text/css" media="print">
<style id="elementor-frontend-inline-css" type="text/css">@font-face{font-family:eicons;src:url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.eot?5.10.0);src:url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.eot?5.10.0#iefix) format("embedded-opentype"),url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.woff2?5.10.0) format("woff2"),url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.woff?5.10.0) format("woff"),url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.ttf?5.10.0) format("truetype"),url(./../wp-content/plugins/elementor/assets/lib/eicons/fonts/eicons.svg?5.10.0#eicon) format("svg");font-weight:400;font-style:normal}</style>
<style id="font-awesome-official-v4shim-inline-css" type="text/css">@font-face {
font-family: "FontAwesome";
font-display: block;
src: url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.eot"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.eot?#iefix") format("embedded-opentype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.woff2") format("woff2"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.woff") format("woff"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.ttf") format("truetype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-brands-400.svg#fontawesome") format("svg");
}

@font-face {
font-family: "FontAwesome";
font-display: block;
src: url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.eot"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.eot?#iefix") format("embedded-opentype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.woff2") format("woff2"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.woff") format("woff"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.ttf") format("truetype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-solid-900.svg#fontawesome") format("svg");
}

@font-face {
font-family: "FontAwesome";
font-display: block;
src: url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.eot"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.eot?#iefix") format("embedded-opentype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.woff2") format("woff2"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.woff") format("woff"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.ttf") format("truetype"),
		url("https://use.fontawesome.com/releases/v5.13.0/webfonts/fa-regular-400.svg#fontawesome") format("svg");
unicode-range: U+F004-F005,U+F007,U+F017,U+F022,U+F024,U+F02E,U+F03E,U+F044,U+F057-F059,U+F06E,U+F070,U+F075,U+F07B-F07C,U+F080,U+F086,U+F089,U+F094,U+F09D,U+F0A0,U+F0A4-F0A7,U+F0C5,U+F0C7-F0C8,U+F0E0,U+F0EB,U+F0F3,U+F0F8,U+F0FE,U+F111,U+F118-F11A,U+F11C,U+F133,U+F144,U+F146,U+F14A,U+F14D-F14E,U+F150-F152,U+F15B-F15C,U+F164-F165,U+F185-F186,U+F191-F192,U+F1AD,U+F1C1-F1C9,U+F1CD,U+F1D8,U+F1E3,U+F1EA,U+F1F6,U+F1F9,U+F20A,U+F247-F249,U+F24D,U+F254-F25B,U+F25D,U+F267,U+F271-F274,U+F279,U+F28B,U+F28D,U+F2B5-F2B6,U+F2B9,U+F2BB,U+F2BD,U+F2C1-F2C2,U+F2D0,U+F2D2,U+F2DC,U+F2ED,U+F328,U+F358-F35B,U+F3A5,U+F3D1,U+F410,U+F4AD;
}</style>
<script  data-rocket-type="text/javascript" src="./../../../../wp-includes/js/jquery/jquery.min.js?ver=3.6.0" id="jquery-core-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-includes/js/jquery/jquery-migrate.min.js?ver=3.3.2" id="jquery-migrate-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/bold-page-builder/script_fe.js?ver=1620657753" id="bt_bb_fe-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/industrial/bt_elements.js?ver=1620657753" id="bt_plugin_enqueue-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/modal-for-elementor/js/jquery.cookie.js?ver=1620657753" id="jquery-cookie-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/themes/industrial/framework/js/html5shiv.min.js?ver=1" id="html5shiv-min-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/themes/industrial/framework/js/respond.min.js?ver=1" id="respond-min-js" defer></script>
<script  data-rocket-type="text/javascript" id="industrial-header-misc-js-before">
window.BoldThemesURI = "./wp-content/themes/industrial"; window.BoldThemesAJAXURL = "./wp-admin/admin-ajax.php";window.boldthemes_text = [];window.boldthemes_text.previous = 'previous';window.boldthemes_text.next = 'next';
</script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/header.misc.js?ver=1620657753" id="industrial-header-misc-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/sticky-header-effects-for-elementor/assets/js/she-header.js?ver=1620657753" id="she-header-js" defer></script>
<link rel="https://api.w.org/" href="./../../../../wp-json/index.html">
<link rel="alternate" type="application/json" href="./../../../../wp-json/wp/v2/pages/3408/index.html">
<meta name="generator" content="WordPress 5.8">
<link rel="shortlink" href="./../../../../index.html?p=3408">
<link rel="alternate" type="application/json+oembed" href="./../../../../wp-json/oembed/1.0/embed/index.html?url=https%3A%2F%2F%2Factive-pharmaceutical-ingredients%2F">
<link rel="alternate" type="text/xml+oembed" href="./../../../../wp-json/oembed/1.0/embed/index.html?url=https%3A%2F%2F%2Factive-pharmaceutical-ingredients%2F&#038;format=xml">
<script  data-rocket-type="text/javascript">
            ( function () {
                window.lae_fs = { can_use_premium_code: false};
            } )();
        </script>
<link rel="preload" as="font" href="./../../../../wp-content/themes/industrial/fonts/Productivity.woff?uo8kwk" crossorigin>
<link rel="preload" as="font" href="./../../../../wp-content/themes/industrial/fonts/Development.ttf?uo8kwk" crossorigin>
<link rel="preload" as="font" href="./../../../../wp-content/themes/industrial/fonts/Construction.ttf?uo8kwk" crossorigin>
<link rel="preload" as="font" href="./../../../../wp-content/themes/industrial/fonts/CraftEssential.ttf?uo8kwk" crossorigin>
<link rel="preload" as="font" href="./../../../../wp-content/themes/industrial/fonts/Pe-icon-7-stroke.woff?d7yf1v" crossorigin>
<link rel="icon" href="./../../../../wp-content/uploads/2018/10/cropped-cropped-imgonline-com-ua-Compressed-09lij2UbRT-com-1-32x32.jpg" sizes="32x32">
<link rel="icon" href="./../../../../wp-content/uploads/2018/10/cropped-cropped-imgonline-com-ua-Compressed-09lij2UbRT-com-1-192x192.jpg" sizes="192x192">
<link rel="apple-touch-icon" href="./../../../../wp-content/uploads/2018/10/cropped-cropped-imgonline-com-ua-Compressed-09lij2UbRT-com-1-180x180.jpg">
<meta name="msapplication-TileImage" content="./../../../../wp-content/uploads/2018/10/cropped-cropped-imgonline-com-ua-Compressed-09lij2UbRT-com-1-270x270.jpg">
<noscript><style id="rocket-lazyload-nojs-css">.rll-youtube-player, [data-lazy-src]{display:none !important;}</style></noscript>

<script  async src="https://www.googletagmanager.com/gtag/js?id=UA-124610061-1"></script>
<script >
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());

  gtag('config', 'UA-124610061-1');
	
</script>

<script  async src="https://www.googletagmanager.com/gtag/js?id=AW-634803173"></script>
<script >
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());

  gtag('config', 'AW-634803173');
</script>

<script >
  gtag('event', 'conversion', {'send_to': 'AW-634803173/aDeACK-KstABEOWn2a4C'});
</script>

<script >(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-KJ8SPBQ');</script>

<script async src="./../../../../cdn-cgi/bm/cv/669835187/api.js"></script>
</head>
<body class="page-template-default page page-id-3408 bt_bb_plugin_active bt_bb_fe_preview_toggle has-navmenu has-megamenu bodyPreloader btMenuLeftEnabled btMenuBelowLogo btStickyEnabled btHideHeadline btLightSkin btTopToolsInMenuArea btRemovePreloader btSoftRoundedButtons btLightAlternateHeader btNoSidebar cookies-not-set elementor-default elementor-kit-3445 elementor-page elementor-page-3408" data-autoplay="0">

<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-KJ8SPBQ" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>

<div class="btPageWrap" id="top">
<header class="mainHeader btClear gutter ">
<div class="port">
<div class="btLogoArea menuHolder btClear">
<span class="btVerticalMenuTrigger">&nbsp;<span class="btIco btIcoDefaultType"><a href="#" target="_self" data-ico-fa="&#xf0c9;" class="btIcoHolder"></a></span></span>
<span class="btHorizontalMenuTrigger">&nbsp;<span class="btIco btIcoDefaultType"><a href="#" target="_self" data-ico-fa="&#xf0c9;" class="btIcoHolder"></a></span></span>
<div class="logo">
<span>
<a href="./../../../../index.html"><img class="btMainLogo" data-hw="1" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Ikigai&reg; Corporation" data-lazy-src="./../../../../wp-content/uploads/2020/05/logo-2.png"><noscript><img class="btMainLogo" data-hw="1" src="./../../../../wp-content/uploads/2020/05/logo-2.png" alt="Ikigai&reg; Corporation"></noscript>
<img class="btAltLogo" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Ikigai&reg; Corporation" data-lazy-src="./../../../../wp-content/uploads/2018/10/cropped-imgonline-com-ua-Compressed-09lij2UbRT-com.jpg"><noscript><img class="btAltLogo" src="./../../../../wp-content/uploads/2018/10/cropped-imgonline-com-ua-Compressed-09lij2UbRT-com.jpg" alt="Ikigai&reg; Corporation"></noscript></a> </span>
</div>
<div class="topBarInLogoArea">
<div class="topBarInLogoAreaCell">
<span class="btIconWidget btAccentIconWidget btWidgetWithText"><span class="btIconWidgetIcon"><span class="btIco btIcoDefaultType btIcoDefaultColor"><span data-ico-pr="&#xf10f;" class="btIcoHolder"></span></span></span><span class="btIconWidgetContent"><span class="btIconWidgetTitle">Working hours:</span><span class="btIconWidgetText">Mon - Fri 9.00 - 18.00</span></span></span> </div>
</div>
</div>
<div class="btBelowLogoArea btClear"> <div class="menuPort">
<div class="topBarInMenu">
<div class="topBarInMenuCell">
<span id="time610e3a31c10e7" class="btIconWidget"><span class="btIconWidgetIcon"><span class="btIco btIcoDefaultType btIcoDefaultColor"><span data-ico-fa="&#xf017;" class="btIcoHolder"></span></span></span><span class="btIconWidgetContent"><span class="btIconWidgetTitle">Hong Kong time</span><span class="btIconWidgetText"></span></span></span><div class="btTopBox widget_search">
<h2 class="widgettitle">Search</h2>
<div class="btSearch">
<span class="btIco btIcoDefaultType btIcoDefaultColor"><a href="#" target="_self" data-ico-fa="&#xf002;" class="btIcoHolder" style="color:#fff"></a></span>
<div class="btSearchInner gutter" role="search">
<div class="btSearchInnerContent port">
 <form action="./index.html" method="get">
<div class="col-lg-12 form-control-group"><input type="text" id="elastic"placeholder="Looking for..."></div>
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/azithromycin/"style="
    color: #fff;
"><li class="hide">Azithromycin</li></a>
	<a href="./../../../../portfolio/doxycycline/"style="
    color: #fff;
"><li class="hide">Doxycycline</li></a>
	<a href="./../../../../portfolio/levofloxacin/"style="
    color: #fff;
"><li class="hide">Levofloxacin</li></a>
	<a href="./../../../../portfolio/metronidazole/"style="
    color: #fff;
"><li class="hide">Metronidazole</li></a>
	<a href="./../../../../portfolio/trimethoprim/"style="
    color: #fff;
"><li class="hide">Trimethoprim</li></a>
	<a href="./../../../../portfolio/sulfamethoxazole/"style="
    color: #fff;
"><li class="hide">Sulfamethoxazole</li></a>
	<a href="./../../../../portfolio/ciprofloxacin/"style="
    color: #fff;
"><li class="hide">Ciprofloxacin</li></a>
	<a href="./../../../../portfolio/cephalexin/"style="
    color: #fff;
"><li class="hide">Cephalexin</li></a>
	<a href="./../../../../portfolio/clindamycin/"style="
    color: #fff;
"><li class="hide">Clindamycin</li></a>
	<a href="./../../../../portfolio/clavulanic-acid/"style="
    color: #fff;
"><li class="hide">Clavulanic acid</li></a>



</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/amoxicillin/"style="
    color: #fff;
"><li class="hide">Amoxicillin</li></a>
	<a href="./../../../../portfolio/boldenone-cypionate/"style="
    color: #fff;
"><li class="hide">Boldenone cypionate</li></a>
	<a href="./../../../../portfolio/boldenone-propionate/"style="
    color: #fff;
"><li class="hide">Boldenone propionate</li></a>
	<a href="./../../../../portfolio/boldenone-acetate/"style="
    color: #fff;
"><li class="hide">Boldenone acetate</li></a>
	<a href="./../../../../portfolio/boldenone-undecylenate/"style="
    color: #fff;
"><li class="hide">Boldenone undecylenate</li></a>
	<a href="./../../../../portfolio/boldenone/"style="
    color: #fff;
"><li class="hide">Boldenone</li></a>
	<a href="./../../../../portfolio/spironolactone/"style="
    color: #fff;
"><li class="hide">Spironolactone</li></a>
	<a href="./../../../../portfolio/11a-hydroxy-canrenone/"style="
    color: #fff;
"><li class="hide">11a Hydroxy Canrenone</li></a>
	<a href="./../../../../portfolio/canrenone/"style="
    color: #fff;
"><li class="hide">Canrenone</li></a>
	<a href="./../../../../portfolio/prednisolone-acetate/"style="
    color: #fff;
"><li class="hide">Prednisolone acetate</li></a>



</ul></div> <div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/prednisolone/"style="
    color: #fff;
"><li class="hide">Prednisolone</li></a>
	<a href="./../../../../portfolio/anecortave-acetate/"style="
    color: #fff;
"><li class="hide">Anecortave acetate</li></a>
	<a href="./../../../../portfolio/prednisone-acetate/"style="
    color: #fff;
"><li class="hide">Prednisone acetate</li></a>
	<a href="./../../../../portfolio/prednisone/"style="
    color: #fff;
"><li class="hide">Prednisone</li></a>
	<a href="./../../../../portfolio/hydrocortisone-acetate/"style="
    color: #fff;
"><li class="hide">Hydrocortisone Acetate</li></a>
	<a href="./../../../../portfolio/hydrocortisone/"style="
    color: #fff;
"><li class="hide">Hydrocortisone</li></a>
	<a href="./../../../../portfolio/cortisone-acetate/"style="
    color: #fff;
"><li class="hide">Cortisone Acetate</li></a>
	<a href="./../../../../portfolio/cortisone/"style="
    color: #fff;
"><li class="hide">Cortisone</li></a>
	<a href="./../../../../portfolio/7-keto-dhea/"style="
    color: #fff;
"><li class="hide">7-Keto DHEA</li></a>
	<a href="./../../../../portfolio/androstanolone/"style="
    color: #fff;
"><li class="hide">Androstanolone</li></a>
	


</ul></div> <div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/mestanolone/"style="
    color: #fff;
"><li class="hide">Mestanolone</li></a>
	<a href="./../../../../portfolio/epiandrosterone/"style="
    color: #fff;
"><li class="hide">Epiandrosterone</li></a>
	<a href="./../../../../portfolio/estradiol-valerate/"style="
    color: #fff;
"><li class="hide">Estradiol Valerate</li></a>
	<a href="./../../../../portfolio/estradiol-cypionate/"style="
    color: #fff;
"><li class="hide">Estradiol Cypionate</li></a>
	<a href="./../../../../portfolio/estradiol-enanthate/"style="
    color: #fff;
"><li class="hide">Estradiol Enanthate</li></a>
<a href="./../../../../portfolio/estradiol-benzoate/"style="
    color: #fff;
"><li class="hide">Estradiol Benzoate</li></a>
	<a href="./../../../../portfolio/estriol/"style="
    color: #fff;
"><li class="hide">Estriol</li></a>
	<a href="./../../../../portfolio/estradiol/"style="
    color: #fff;
"><li class="hide">Estradiol</li></a>
	<a href="./../../../../portfolio/estrone/"style="
    color: #fff;
"><li class="hide">Estrone</li></a>
	<a href="./../../../../portfolio/dehydronandrolone-acetate/"style="
    color: #fff;
"><li class="hide">Dehydronandrolone Acetate</li></a>
	


</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/nandrolone-undecanoate/"style="
    color: #fff;
"><li class="hide">Nandrolone Undecanoate</li></a>
	<a href="./../../../../portfolio/nandrolone-cypionate/"style="
    color: #fff;
"><li class="hide">Nandrolone Cypionate</li></a>
	<a href="./../../../../portfolio/nandrolone-propionate/"style="
    color: #fff;
"><li class="hide">Pandrolone Propionate</li></a>
	<a href="./../../../../portfolio/nandrolone-phenylpropionate/"style="
    color: #fff;
"><li class="hide">Nandrolone Phenylpropionate</li></a>
	<a href="./../../../../portfolio/nandrolone-decanoate/"style="
    color: #fff;
"><li class="hide">Nandrolone Decanoate</li></a>
<a href="./../../../../portfolio/nandrolone-base-（19-nor-testosterone）/"style="
    color: #fff;
"><li class="hide">Nandrolone</li></a>
	<a href="./../../../../portfolio/drostanolone-enanthate/"style="
    color: #fff;
"><li class="hide">Drostanolone Enanthate</li></a>
	<a href="./../../../../portfolio/drostanolone-propionate/"style="
    color: #fff;
"><li class="hide">Drostanolone Propionate</li></a>
	<a href="./../../../../portfolio/metenolone-acetate/"style="
    color: #fff;
"><li class="hide">Metenolone Acetate</li></a>
	<a href="./../../../../portfolio/trenbolone-enanthate/"style="
    color: #fff;
"><li class="hide">Trenbolone Enanthate</li></a>
	


</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/trenbolone-acetate/"style="
    color: #fff;
"><li class="hide">Trenbolone Acetate</li></a>
	<a href="./../../../../portfolio/fluoxymesterone/"style="
    color: #fff;
"><li class="hide">Fluoxymesterone</li></a>
	<a href="./../../../../portfolio/mesterolone/"style="
    color: #fff;
"><li class="hide">Mesterolone</li></a>
<a href="./../../../../portfolio/altrenogest//"style="
    color: #fff;
"><li class="hide">Altrenogest</li></a>
	<a href="./../../../../portfolio/exemestane/"style="
    color: #fff;
"><li class="hide">Exemestane</li></a>
	<a href="./../../../../portfolio/oxandrolone/"style="
    color: #fff;
"><li class="hide">Oxandrolone</li></a>
	<a href="./../../../../portfolio/methandienone/"style="
    color: #fff;
"><li class="hide">Methandienone</li></a>
	<a href="./../../../../portfolio/oxymetholone/"style="
    color: #fff;
"><li class="hide">Oxymetholone</li></a>
	<a href="./../../../../portfolio/stanozolol/"style="
    color: #fff;
"><li class="hide">Stanozolol</li></a>
	<a href="./../../../../portfolio/methenolone-enanthate/"style="
    color: #fff;
"><li class="hide">Methenolone Enanthate</li></a>
	


</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/progesterone/"style="
    color: #fff;
"><li class="hide">Progesterone</li></a>
	<a href="./../../../../portfolio/20-formylpregn-4-en-3-one/"style="
    color: #fff;
"><li class="hide">20-Formylpregn-4-en-3-one</li></a>
	<a href="./../../../../portfolio/14-androstadienedioneadd/"style="
    color: #fff;
"><li class="hide">1,4-Androstadienedione(add)</li></a>
	<a href="./../../../../portfolio/4-androstenedione4-ad/"style="
    color: #fff;
"><li class="hide">4-Androstenedione (4-AD)</li></a>
	<a href="./../../../../portfolio/1-testosterone/"style="
    color: #fff;
"><li class="hide">1-Testosterone</li></a>
	<a href="./../../../../portfolio/methyl-1-testosterone/"style="
    color: #fff;
"><li class="hide">Methyl-1-Testosterone</li></a>
	<a href="./../../../../portfolio/testosterone-undecanoate/"style="
    color: #fff;
"><li class="hide">Testosterone Undecanoate</li></a>
	<a href="./../../../../portfolio/testosterone-isocaproate/"style="
    color: #fff;
"><li class="hide">Testosterone Isocaproate</li></a>
	<a href="./../../../../portfolio/testosterone-propionate/"style="
    color: #fff;
"><li class="hide">Testosterone Propionate</li></a>
	<a href="./../../../../portfolio/testosterone-phenylpropionate/"style="
    color: #fff;
"><li class="hide">Testosterone Phenylpropionate</li></a>



</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/sitolactone/"style="
    color: #fff;
"><li class="hide">Sitolactone</li></a>
	<a href="./../../../../portfolio/testosterone-enanthate/"style="
    color: #fff;
"><li class="hide">Testosterone Enanthate</li></a>
	<a href="./../../../../portfolio/testosterone-decanoate/"style="
    color: #fff;
"><li class="hide">Testosterone Decanoate</li></a>
	<a href="./../../../../portfolio/testosterone-cypionate/"style="
    color: #fff;
"><li class="hide">Testosterone Cypionate</li></a>
	<a href="./../../../../portfolio/testosterone-acetate/"style="
    color: #fff;
"><li class="hide">Testosterone Acetate</li></a>
	<a href="./../../../../portfolio/methyltestosterone/"style="
    color: #fff;
"><li class="hide">Methyltestosterone</li></a>
	<a href="./../../../../portfolio/testosterone/"style="
    color: #fff;
"><li class="hide">Testosterone</li></a>
	<a href="./../../../../portfolio/magnesium-stearate/"style="
    color: #fff;
"><li class="hide">Magnesium Stearate</li></a>
	<a href="./../../../../portfolio/bis4-nitrophenylsulfane/"style="
    color: #fff;
"><li class="hide">Bis(4-nitrophenylsulfane)</li></a>
	<a href="./../../../../portfolio/n-benzhydrylpiperazine/"style="
    color: #fff;
"><li class="hide">N-Benzhydrylpiperazine</li></a>

	



</ul></div> <div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	
<a href="./../../../../portfolio/zinc-stearate/"style="
    color: #fff;
"><li class="hide">Zinc stearate</li></a>
	<a href="./../../../../portfolio/sodium-starch-glycolate/"style="
    color: #fff;
"><li class="hide">Sodium starch glycolate</li></a>
	<a href="./../../../../portfolio/microcrystalline-cellulose/"style="
    color: #fff;
"><li class="hide">microcrystalline Cellulose</li></a>
	<a href="./../../../../portfolio/croscarmellose-sodium/"style="
    color: #fff;
"><li class="hide">CROSCARMELLOSE SODIUM</li></a>
	<a href="./../../../../portfolio/calcium-stearate/"style="
    color: #fff;
"><li class="hide">Calcium stearate</li></a>
	<a href="./../../../../portfolio/calcium-lactate/"style="
    color: #fff;
"><li class="hide">Calcium lactate</li></a>
	<a href="./../../../../portfolio/calcium-acetate/"style="
    color: #fff;
"><li class="hide">Calcium acetate</li></a>
	<a href="./../../../../portfolio/1-aminoindan/"style="
    color: #fff;
"><li class="hide">1-Aminoindan</li></a>
	<a href="./../../../../portfolio/44-sulfonylbisnitrobenzene/"style="
    color: #fff;
"><li class="hide">4,4′-sulfonylbis(nitrobenzene)</li></a>
	<a href="./../../../../portfolio/dehydroepiandrosterone-enanthate/"style="
    color: #fff;
"><li class="hide">Dehydroepiandrosterone Enanthate</li></a>




</ul></div> <div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/11a17a-dihydroxyprogesterone/"style="
    color: #fff;
"><li class="hide">11a,17a-Dihydroxyprogesterone</li></a>
	<a href="./../../../../portfolio/17a-hydroxyprogesterone-hpg/"style="
    color: #fff;
"><li class="hide">17a-Hydroxyprogesterone (HPG)</li></a>
    <a href="./../../../../portfolio/dehydroepiandrosterone-acetate-prasterone-acetate/"style="
    color: #fff;
"><li class="hide">Dehydroepiandrosterone Acetate Prasterone Acetate</li></a>
	<a href="./../../../../portfolio/dehydroepiandrosterone-dheaprasterone/"style="
    color: #fff;
"><li class="hide">Dehydroepiandrosterone DHEA, Prasterone</li></a>
	<a href="./../../../../portfolio/trenbolone-cyclohexylmethylcarbonate/"style="
    color: #fff;
"><li class="hide">Trenbolone Cyclohexylmethylcarbonate</li></a>
	<a href="./../../../../portfolio/4-chlorodehydromethyltestosterone/"style="
    color: #fff;
"><li class="hide">4-Chlorodehydromethyltestosterone</li></a>
	<a href="./../../../../portfolio/21-hydroxy-20-methylpregn-4-en-3-one/"style="
    color: #fff;
"><li class="hide">21-Hydroxy-20-methylpregn-4-en-3-one</li></a>
	<a href="./../../../../portfolio/9a-hydroxy-4-androstenedione-（9a-ohad）/"style="
    color: #fff;
"><li class="hide">9a-Hydroxy-4-androstenedione（9a-OHAD)</li></a>
	<a href="./../../../../portfolio/44-difluorobenzhydrylpiperazine/"style="
    color: #fff;
"><li class="hide">4,4′-Difluorobenzhydrylpiperazine</li></a>
	<a href="./../../../../portfolio/ethyl-6-4-iodophenyl-1/"style="
    color: #fff;
"><li class="hide">Ethyl 6-(4-iodophenyl)-1-(4-methoxy phenyl)-7- oxo-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4- c]pyridine-3-carboxylate</li></a>
	



</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
		<a href="./../../../../portfolio/ethyl-1-4-methoxyphenyl-7/"style="
    color: #fff;
"><li class="hide">Ethyl 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro1H-pyrazolo[3,4-c]pyridine-3-carboxylate</li></a>
		<a href="./../../../../portfolio/5-bromo-2-chloro4ethoxydiphenylmethane/"style="
    color: #fff;
"><li class="hide">5-Bromo-2-chloro4’ethoxydiphenylmethane</li></a>
	<a href="./../../../../portfolio/15-anhydro-1-c-4-chloro-3/"style="
    color: #fff;
"><li class="hide">1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-,2,3,4,6-tetraacetate, (1S)- D-Glucitol</li></a>
	<a href="./../../../../portfolio/2346-tetra-o-trimethylsilyl-s-d-glucolactone/"style="
    color: #fff;
"><li class="hide">2,3,4,6-tetra-O-trimethylsilyl-ß-D-glucolactone</li></a>
	<a href="./../../../../portfolio/carbamic-acid-n-1s2r/"style="
    color: #fff;
"><li class="hide">Carbamic acid, N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)[(4-nitrophenyl)sulfonyl]amino]-1- (phenylmethyl)propyl]-,1,1-dimethylethylester</li></a>
	<a href="./../../../../portfolio/10s-1011-dihydro-10-hydroxy/"style="
    color: #fff;
"><li class="hide">(10S)-10,11-Dihydro-10-hydroxy-5Hdibenz[b,f]azepine-5-carboxamide</li></a>
	<a href="./../../../../portfolio/1011-dihydro-10-hydroxy-5h/"style="
    color: #fff;
"><li class="hide">10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide</li></a>
	<a href="./../../../../portfolio/3-3-dichloro-1-4-iodophenyl-piperidin-2-one/"style="
    color: #fff;
"><li class="hide">3, 3-dichloro-1-(4-iodophenyl) piperidin-2-one</li></a>
	<a href="./../../../../portfolio/1-23-dichlorophenyl-piperazine/"style="
    color: #fff;
"><li class="hide">1-(2,3-Dichlorophenyl) Piperazine HCl</li></a>
	<a href="./../../../../portfolio/1e-n-hydroxy-5-methoxy-1/"style="
    color: #fff;
"><li class="hide">(1E)-N-Hydroxy-5-Methoxy-1-(4-Trifluoromethylphenyl)Pentan-1-Imine</li></a>
	


</ul></div> 
<div class="col-6" style="
    max-width: 50%;
    float: left;
"><ul class="elastic">
	<a href="./../../../../portfolio/2-bromo-4-benzyloxy-3-nitroacetophenone/"style="
    color: #fff;
"><li class="hide">2-Bromo-4′-benzyloxy-3′-nitroacetophenone</li></a>
	<a href="./../../../../portfolio/24-dihydro-4-4-4-4-methoxyphenyl-1/"style="
    color: #fff;
"><li class="hide">2,4-Dihydro-4-[4-[4-(4-methoxyphenyl)-1- piperazinyl]phenyl]-2-(1-methyl propyl)-3H-1,2,4-triazol-3-one</li></a>
	<a href="./../../../../portfolio/1-acetyl-4-4-hydroxyphenyl-piperazine/"style="
    color: #fff;
"><li class="hide">1-Acetyl-4-(4-hydroxyphenyl) piperazine</li></a>
	<a href="./../../../../portfolio/1r-2-2-4-nitrophenylethylamino-1/"style="
    color: #fff;
"><li class="hide">(1R)-2-{[2-(4-nitrophenyl)ethyl]amino}-1-phenylethanol</li></a>
	<a href="./../../../../portfolio/5-methylpyridin-21h-one-2-hydroxy-5/"style="
    color: #fff;
"><li class="hide">5-methylpyridin-2(1H)-one/2-Hydroxy-5- methylpyridine</li></a>
	<a href="./../../../../portfolio/dibenzo-b-f-1-4-thiazepin-1110h-one/"style="
    color: #fff;
"><li class="hide">Dibenzo [b, f] [1, 4] thiazepin- 11(10H)-one</li></a>
	<a href="./../../../../portfolio/4-4-5s-5-aminomethyl-2-oxo-13/"style="
    color: #fff;
"><li class="hide">4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one hydrochloride</li></a>
<a href="./../../../../portfolio/2-5s-2-oxo-3-4-3-oxomorpholin-4-yl/"style="
    color: #fff;
"><li class="hide">2-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl) phenyl]-1,3-oxazolidin-5-yl}methyl)-1H-isoindole-1,3(2H)-dione</li></a>
	<a href="./../../../../portfolio/2-3ar4s6r6as-6/"style="
    color: #fff;
"><li class="hide">2-(((3aR,4S,6R,6aS)-6-((5-amino-6-chlo ro-2-(propylthio)pyrimidin-4-yl)amino) -2,2-dimethyltetrahydro-3aH-cyclo penta[d][1,3]dioxol-4-yl)oxy)ethanol</li></a>
	<a href="./../../../../portfolio/1-acetamido-35-dimethyl-adamantane/"style="
    color: #fff;
"><li class="hide">1-Acetamido 3,5-dimethyl Adamantane*</li></a>
	



</ul></div> 

</form>
<div class="btSearchInnerClose"><span class="btIco "><a href="#" target="_self" data-ico-fa="&#xf00d;" class="btIcoHolder" style="color:#fff"></a></span></div>
</div>
</div>
</div>
</div> </div>
</div>
<nav>
<ul id="menu-primary-menu" class="menu">
<li id="menu-item-3253" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-home menu-item-3253"><a title="						" href="./../../../../index.html">Home</a></li>
<li id="menu-item-3403" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3403">
<a href="./../../../../about-us/index.html">About us</a><ul class="sub-menu">
<li id="menu-item-3399" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3399"><a href="./../../../../about-us/index.html#company_profile">Company Profile/ Who we are?</a></li>
<li id="menu-item-3400" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3400"><a href="./../../../../about-us/index.html#vision&#038;values">Vision &#038; Values</a></li>
<li id="menu-item-3401" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3401"><a href="./../../../../about-us/index.html#business_segment">Business Segments</a></li>
<li id="menu-item-3402" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-3402"><a href="./../../../../about-us/index.html#geographic_spread">Geographic spread</a></li>
</ul>
</li>
<li id="menu-item-3459" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3459"><a href="./../../../../our-technology/index.html">Our Technology</a></li>
<li id="menu-item-3256" class="menu-item menu-item-type-post_type menu-item-object-page current-menu-ancestor current-menu-parent current_page_parent current_page_ancestor menu-item-has-children menu-item-3256">
<a title="						" href="./../../../../services/index.html">Product Portfolio</a><ul class="sub-menu">
<li id="menu-item-3415" class="menu-item menu-item-type-post_type menu-item-object-page current-menu-item page_item page-item-3408 current_page_item menu-item-3415"><a href="./../../../../active-pharmaceutical-ingredients/index.html" aria-current="page">Active pharmaceutical ingredients</a></li>
<li id="menu-item-3868" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3868"><a href="./../../../../pharmaceutical_intermediates/index.html">Pharmaceutical intermediates</a></li>
<li id="menu-item-3414" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3414"><a href="./../../../../pharmaceutical_excipients/index.html">Pharmaceutical excipients</a></li>
</ul>
</li>
<li id="menu-item-3872" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3872">
<a href="./../../../../policies/index.html">Policies</a><ul class="sub-menu">
<li id="menu-item-3497" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-privacy-policy menu-item-3497"><a href="./../../../../services/privacy-policy/index.html">Privacy Statement</a></li>
<li id="menu-item-3739" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3739"><a href="./../../../../services/ordering-details-terms-and-conditions/index.html">Ordering Details, Terms, and Conditions</a></li>
<li id="menu-item-3738" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3738"><a href="./../../../../services/browser-recommendation/index.html">Browser Recommendation</a></li>
<li id="menu-item-3737" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3737"><a href="./../../../../services/new-product-suggestion/index.html">New Product Suggestion</a></li>
</ul>
</li>
<li id="menu-item-3594" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3594"><a href="./../../../../services/partner_with_us/index.html">Partner with us</a></li>
<li id="menu-item-3494" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3494"><a href="./../../../../careers/index.html">Careers</a></li>
<li id="menu-item-4734" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4734"><a href="./../../../../library/index.html">Library</a></li>
<li id="menu-item-3438" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3438"><a href="./../../../../contact/index.html">Contact</a></li>
</ul> </nav>
</div>
</div>
</div>
</header>


<!--page-content-here-->
<div class="btContentWrap btClear" bis_skin_checked="1" style="padding-top: 121.484px;">
<section class="boldSection bottomSemiSpaced btPageHeadline gutter  topSemiSpaced btTextLeft " data-parallax="0.8" data-parallax-offset="0"><div class="port" bis_skin_checked="1"><header class="header btClear large"><div class="btSuperTitle" bis_skin_checked="1"><span><div class="btBreadCrumbs" bis_skin_checked="1"><nav><ul><li><a href="/../../../../">Home</a></li><li>Category</li></ul></nav></div></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline">Articles Archives - Page 2 of 4 - Ikigai® Corporation</span></h2></div></header></div></section> <div class="btContentHolder" bis_skin_checked="1">
<div class="btContent" bis_skin_checked="1">
<article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5218 post type-post status-publish format-standard hentry category-articles animated"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g" class="avatar avatar-144 photo lazyloaded" height="144" width="144" srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" data-ll-status="loaded"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>14.06.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/06/14/long-term-prospective-study-of-the-influence-of-estrone-levels-on-events-in-postmenopausal-women-with-or-at-high-risk-for-coronary-artery-disease/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/06/14/long-term-prospective-study-of-the-influence-of-estrone-levels-on-events-in-postmenopausal-women-with-or-at-high-risk-for-coronary-artery-disease/">Long-Term Prospective Study of the Influence of Estrone Levels on Events in Postmenopausal Women with or at High Risk for Coronary Artery Disease</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><p><span class=""><b>Antonio de Padua Mansur</b>,<sup>1</sup>&nbsp;</span><span class="">Tereza Cristina B. F. Silva,<sup>1</sup>&nbsp;</span><span class="">Julio Yoshio Takada,<sup>1</sup>&nbsp;</span><span class="">Solange Desirée Avakian,<sup>1</sup>&nbsp;</span><span class="">Célia Maria C. Strunz,<sup>1</sup>&nbsp;</span><span class="">Luiz Antonio Machado César,<sup>1</sup>&nbsp;</span><span class="">José Mendes Aldrighi,<sup>2</sup>&nbsp;and&nbsp;</span><span class="">José Antonio F. Ramires<sup>1</sup></span></p>
<h4 id="abstract" class="header">Abstract</h4>
<hr>
<p>&nbsp;</p>
<p><i>Background</i>. The link between endogenous estrogen, coronary artery disease (CAD), and death in postmenopausal women is uncertain. We analyzed the association between death and blood levels of estrone in postmenopausal women with known coronary artery disease (CAD) or with a high-risk factor score for CAD.&nbsp;<i>Methods</i>. 251 postmenopausal women age 50–90 years not on estrogen therapy. Fasting blood for estrone and heart disease risk factors were collected at baseline. Women were grouped according to their estrone levels (&lt;15 and ≥15 pg/mL). Fatal events were recorded after 5.8+-1.4 years of followup. <i>Results</i>. The Kaplan-Meier survival curve showed a significant trend (P=0.039) of greater all-cause mortality in women with low estrone levels (&lt;15 pg/mL). Cox multivariate regression analysis model adjusted for body mass index, diabetes, dyslipidemia, family history, and estrone showed estrone (OR=0.45; P=0.038) as the only independent variable for all-cause mortality. Multivariate regression model adjusted for age, body mass index, hypertension, diabetes, dyslipidemia, family history, and estrone showed that only age (OR=1.06; P=0,017) was an independent predictor of all-cause mortality. <i>Conclusions</i>. Postmenopausal women with known CAD or with a high-risk factor score for CAD and low estrone levels (&lt;15 pg/mL) had increased all-cause mortality.</p>
<p>&nbsp;</p>
<h4 id="background">1. Background</h4>
<hr>
<p>&nbsp;</p>
<p>Endogenous estrogens are associated with greater vascular protection in premenopausal women [<a class="refAnchor">1</a>]. Estradiol is the main and most active representative of endogenous estrogens in premenopausal women. This protection occurs through genomic and nongenomic actions [<a class="refAnchor">2</a>]. The antiatherogenic and antithrombogenic effects of estradiol slow the process of atherosclerosis, and therefore cardiovascular events occur later in women compared to men [<a class="refAnchor">3</a>]. In postmenopausal women, a significant reduction in estradiol production occurs due to ovarian failure. The natural protection ceases to exist, and at this stage, a gradual and progressive increase begins in cardiovascular events in women. However, hormone replacement therapy with estrogen and progesterone was not effective in primary or secondary prevention of cardiovascular events in postmenopausal women [<a class="refAnchor">4</a>,&nbsp;<a class="refAnchor">5</a>]. Several hypotheses have been considered to justify these results, among them, the characteristics of exogenous estrogens, the high dose used, the association of progestins, and time since menopause [<a class="refAnchor">6</a>]. It is known, however, that in postmenopausal women production of endogenous estrogen is very low. In this period, estrone is the main representative of the endogenous estrogens and is produced by several tissues, especially adipose tissue. Estrone is the result of the process of aromatization of androstenedione that occurs in fat cells [<a class="refAnchor">7</a>]. Obese women have higher plasma concentrations of estrone [<a class="refAnchor">8</a>]. However, the influence of estrone on cardiovascular protection in postmenopausal women is unknown. A previous study showed higher plasma levels of estrone in obese patients with coronary artery disease (CAD) or at high risk for coronary heart disease [<a class="refAnchor">9</a>]. The same study also showed that increased plasma levels of estrone were associated with a nonsignificant trend toward a lower incidence of cardiovascular events. However, the follow-up period was only 2 years. The current study analyzed, in the same population, the effects of serum estrone in death from all causes in a long-term followup.</p>
<p>&nbsp;</p>
<h4 id="methods">2. Methods</h4>
<hr>
<p>&nbsp;</p>
<h5 id="sec2.1">2.1. Study Populations</h5>
<p>Participants were 251 postmenopausal women aged 50 to 90 years who had known CAD or were at high risk for CAD based on a risk factor score of 4 or more points, using the score developed for use in raloxifene trials [<a class="refAnchor">10</a>]. Patients using postmenopausal hormone therapy and with advanced stage or clinically limiting disease were not included in the study. Women were patients in the ambulatory care clinic of a tertiary cardiology hospital, who were followed from March 2004 to December 2010. Primary end-point was death of any cause. Follow-up data were obtained through telephone calls and validated if given by a family member. Five patients were missed.</p>
<h5 id="sec2.2">2.2. Clinical Characteristics</h5>
<p>Baseline clinical characteristics included body mass index (BMI), blood pressure, medication use, and history of cardiac procedures and cardiac events. Laboratory tests for biologic CAD risk factors included fasting venous blood glucose, triglycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol, C-reactive protein, and estrone. Risk factors for CAD were diabetes mellitus (fasting blood glucose ≥126 mg/dL [<a class="refAnchor">11</a>]); hypertension (diastolic blood pressure ≥90 mm Hg [<a class="refAnchor">12</a>]); dyslipidemia (triglycerides ≥200 mg/dL and/or LDL cholesterol ≥130 mg/dL [<a class="refAnchor">13</a>]); family history (CAD occurring in parents before age 55 for men, 65 for women and siblings); at least 6 months of daily smoking of any kind or quantity of tobacco [<a class="refAnchor">14</a>]; obesity status based on BMI (kg/m<sup>2</sup>) defined by the National Institutes of Health and the World Health Organization as normal (≥18.5 to &lt;25), overweight (≥25 to &lt;30), and obese (≥30) [<a class="refAnchor">15</a>].</p>
<h5 id="sec2.3">2.3. Laboratory Measurements</h5>
<p>Morning blood was collected after a requested 12-hour fast. Estrone samples were measured on frozen plasma by a manual processing radioimmunoassay method using DSL 8700 (Diagnostic Systems Laboratories, Inc., Webster, TX, USA) with reference values 14.1–102.6 pg/mL for postmenopausal women. Based on the lower limit of the reference value in this laboratory, low estrone levels were defined as &lt;15 pg/mL (43 patients) versus ≥15 pg/mL (208 patients). High sensitivity C-reactive protein was measured using an immunoturbidimetric ultrasensitive detection method, (Roche Diagnostics GmbH, D-68298 Mannheim, Germany), with a normal reference value &lt;0.5 mg/dL.</p>
<p>The ethics committee of the Heart Institute (InCor) approved the study design, and all participants provided written informed consent.</p>
<h5 id="sec2.4">2.4. Statistical Analysis</h5>
<p>A sample size of at least 200 patients, with 100 subjects per treatment group, was determined to give 80% power to detect a 20% difference in the incidence of cardiovascular events with a 5% significance level.</p>
<p>The chi-square test was used for analysis of categorical variables, and Student’s&nbsp;&nbsp;test or 2-way ANOVA analysis was used for continuous variables. Mortality analyses used Kaplan-Meier estimation curves stratified by low or normal estrone levels (&lt;15 and ≥15 pg/mL, resp.). Three models of Cox multivariate regression analysis were done. Model 1 was adjusted for age, hypertension, body mass index, diabetes, dyslipidemia, and estrone; model 2 was adjusted for hypertension, body mass index, diabetes, dyslipidemia, and estrone; model 3 was adjusted for body mass index, diabetes, dyslipidemia, and estrone. The statistical software used was SAS 9.2 (SAS Institute Inc, Cary, NC, USA).</p>
<p>&nbsp;</p>
<h4 id="results">3. Results</h4>
<hr>
<p>&nbsp;</p>
<p>Baseline clinical and laboratory characteristics of the patients and group comparisons of estrone levels of &lt;15 and ≥15 pg/mL are shown in Table&nbsp;<a href="https://www.hindawi.com/journals/tswj/2012/363595/tab1/" target="_blank" rel="noopener">1</a>. Estrone histogram is shown in Figure&nbsp;<a href="https://www.hindawi.com/journals/tswj/2012/363595/fig1/" target="_blank" rel="noopener">1</a>. Mean estrone levels were, respectively, 10.8+-2.1 and 27.6+-12.9 pg/mL (P&lt;0.001). Women with a low estrone level were older (72+-7,5 versus 69.2+-6.7 years; ), thinner ( 27.9+-4.6 versus 30+-5.4  kg/m<sup>2</sup>; P=0.020), and had less hypertension (95% versus 88%; P=0.036), diabetes (37% versus 62%; P=0.003), and lower triglyceride (148.9+-63.1 versus 178.5+-123.8 mg/dL; P=0.023), glucose ( 107.5+-32.8 versus 137.3+-59.5 mg/dL; P=0.002), and C-reactive protein levels ( 0.45+- 0.55 versus 0.70+-0.31 mg/dL; P=0.045). Women with BMI ≥30 kg/m<sup>2</sup> were younger ( 70.5+-7.4 versus 68.7+-6.3 ; P=0.046) and had more hypertension (92% versus 99%; P=0.009), less diabetes (52% versus 31%; P=0.001), and lower HDL ( 54.3+-13.2 versus 50.9+-11.3 mg/dL; P=0.033) and LDL ( 117+-35.8 versus 107+-35.6 mg/dL; P=0.029). Estrone was greater in patients with BMI ≥30 kg/m<sup>2</sup> (22,4+-9.9 versus 28.2+-16.4 ; P=0.001) (Table <a href="https://www.hindawi.com/journals/tswj/2012/363595/tab2/" target="_blank" rel="noopener">2</a>). Death was associated with higher age ( 69.2+-6.9 versus 72.6+-7.2 years; P=0.010) and almost significant higher prevalence of hypertension (96% versus 88%; P=0.051) and LDL plasma levels ( 111.2+-37.1 versus 121.3+-25.2 mg/dL; P=0.054) (Table <a href="https://www.hindawi.com/journals/tswj/2012/363595/tab3/" target="_blank" rel="noopener">3</a>). There were 32 deaths, 27 (84%) attributed to cardiovascular disease (23 to CAD and 4 to stroke), 3 to pneumonia, and 2 to cancer (1 lung and 1 bone). The Kaplan-Meier survival curve showed a significant trend (P=0.039) of greater all-cause mortality in women with low estrone levels (&lt;15 pg/mL) (Figure <a href="https://www.hindawi.com/journals/tswj/2012/363595/fig2/" target="_blank" rel="noopener">2</a>). Three models of Cox regression analysis were done: model 1 was adjusted for age, body mass index, hypertension, diabetes, dyslipidemia, family history, and estrone; model 2 was adjusted for body mass index, hypertension, diabetes, dyslipidemia, family history, and estrone; model 3 was adjusted for body mass index, diabetes, dyslipidemia, family history, and estrone. In model 1, age (OR = 1.05 [95%CI: 1.00–1.11]; P=0.016) was the only independent predictor of all-cause mortality; in model 2, hypertension (OR = 2.44 [95%CI: 0.83–7.20]; P=0.030); in model 3, estrone (OR = 0.45 [95%CI: 0.21–0.95]; P=0.038) (Table <a href="https://www.hindawi.com/journals/tswj/2012/363595/tab4/" target="_blank" rel="noopener">4</a>).</p>
<h2>Table 1</h2>
<div class="floats-full-page-caption" bis_skin_checked="1">Baseline clinical characteristics and comparison of estrone &lt;15 pg/mL and estrone ≥15 pg/mL in 251 patients.</div>
<div class="floats-full-page-content" bis_skin_checked="1">
<table id="tab1" class="table-group">
<tbody>
<tr>
<td>
<table class="table">
<tbody>
<tr>
<td class="thead-hr" colspan="5">
<hr>
</td>
</tr>
<tr class="thead">
<td align="left"></td>
<td align="center">Baseline&nbsp;𝑁&nbsp;=&nbsp;2&nbsp;5&nbsp;1</td>
<td align="center">Estrone &lt;15 pg/mL,&nbsp;𝑁&nbsp;=&nbsp;4&nbsp;3&nbsp;(17%)</td>
<td align="center">Estrone ≥15 pg/mL,&nbsp;𝑁&nbsp;=&nbsp;2&nbsp;0&nbsp;8&nbsp;(83%)</td>
<td align="center">𝑃</td>
</tr>
<tr>
<td class="thead-hr" colspan="5">
<hr>
</td>
</tr>
<tr>
<td align="left">Age (years)</td>
<td align="center">6&nbsp;9&nbsp;.&nbsp;7&nbsp;±&nbsp;7&nbsp;.&nbsp;0</td>
<td align="center">7&nbsp;2&nbsp;±&nbsp;7&nbsp;.&nbsp;5</td>
<td align="center">6&nbsp;9&nbsp;.&nbsp;2&nbsp;±&nbsp;6&nbsp;.&nbsp;7</td>
<td align="center">0.016</td>
</tr>
<tr>
<td align="left">Body mass index (kg/m<sup>2</sup>)</td>
<td align="center">2&nbsp;9&nbsp;.&nbsp;7&nbsp;±&nbsp;5&nbsp;.&nbsp;3</td>
<td align="center">2&nbsp;7&nbsp;.&nbsp;9&nbsp;±&nbsp;4&nbsp;.&nbsp;6</td>
<td align="center">3&nbsp;0&nbsp;±&nbsp;5&nbsp;.&nbsp;4</td>
<td align="center">0.020</td>
</tr>
<tr>
<td align="left">Hypertension</td>
<td align="center">238 (95)</td>
<td align="center">38 (88)</td>
<td align="center">200 (96)</td>
<td align="center">0.036</td>
</tr>
<tr>
<td align="left">Diabetes</td>
<td align="center">144 (57)</td>
<td align="center">16 (37)</td>
<td align="center">128 (62)</td>
<td align="center">0.003</td>
</tr>
<tr>
<td align="left">Dyslipidemia</td>
<td align="center">233 (93)</td>
<td align="center">40 (93)</td>
<td align="center">193 (93)</td>
<td align="center">0.956</td>
</tr>
<tr>
<td align="left">Family history</td>
<td align="center">170 (68)</td>
<td align="center">31 (72)</td>
<td align="center">139 (67)</td>
<td align="center">0.641</td>
</tr>
<tr>
<td align="left">Coronary artery disease</td>
<td align="center">189 (75)</td>
<td align="center">35 (81)</td>
<td align="center">154 (74)</td>
<td align="center">0.308</td>
</tr>
<tr>
<td align="left">Smoking</td>
<td align="center">25 (10)</td>
<td align="center">4 (10)</td>
<td align="center">21 (10)</td>
<td align="center">0.837</td>
</tr>
<tr>
<td align="left">SBP (mm Hg)</td>
<td align="center">1&nbsp;4&nbsp;1&nbsp;.&nbsp;8&nbsp;±&nbsp;1&nbsp;8&nbsp;.&nbsp;4</td>
<td align="center">1&nbsp;3&nbsp;7&nbsp;.&nbsp;7&nbsp;±&nbsp;2&nbsp;1&nbsp;.&nbsp;2</td>
<td align="center">1&nbsp;4&nbsp;2&nbsp;.&nbsp;6&nbsp;±&nbsp;1&nbsp;7&nbsp;.&nbsp;7</td>
<td align="center">0.110</td>
</tr>
<tr>
<td align="left">DBP (mm Hg)</td>
<td align="center">8&nbsp;3&nbsp;±&nbsp;9&nbsp;.&nbsp;9</td>
<td align="center">8&nbsp;0&nbsp;.&nbsp;7&nbsp;±&nbsp;1&nbsp;0&nbsp;.&nbsp;8</td>
<td align="center">8&nbsp;3&nbsp;.&nbsp;5&nbsp;±&nbsp;9&nbsp;.&nbsp;6</td>
<td align="center">0.092</td>
</tr>
<tr>
<td align="left">Triglycerides (mg/dL)</td>
<td align="center">1&nbsp;7&nbsp;3&nbsp;.&nbsp;4&nbsp;±&nbsp;1&nbsp;1&nbsp;6&nbsp;.&nbsp;1</td>
<td align="center">1&nbsp;4&nbsp;8&nbsp;.&nbsp;9&nbsp;±&nbsp;6&nbsp;3&nbsp;.&nbsp;1</td>
<td align="center">1&nbsp;7&nbsp;8&nbsp;.&nbsp;5&nbsp;±&nbsp;1&nbsp;2&nbsp;3&nbsp;.&nbsp;8</td>
<td align="center">0.023</td>
</tr>
<tr>
<td align="left">Total cholesterol (mg/dL)</td>
<td align="center">1&nbsp;9&nbsp;9&nbsp;.&nbsp;3&nbsp;±&nbsp;4&nbsp;1&nbsp;.&nbsp;1</td>
<td align="center">2&nbsp;0&nbsp;0&nbsp;.&nbsp;7&nbsp;±&nbsp;4&nbsp;0&nbsp;.&nbsp;7</td>
<td align="center">1&nbsp;9&nbsp;9&nbsp;±&nbsp;4&nbsp;1&nbsp;.&nbsp;2</td>
<td align="center">0.808</td>
</tr>
<tr>
<td align="left">HDL cholesterol (mg/dL)</td>
<td align="center">5&nbsp;2&nbsp;.&nbsp;8&nbsp;±&nbsp;1&nbsp;2&nbsp;.&nbsp;5</td>
<td align="center">5&nbsp;4&nbsp;.&nbsp;8&nbsp;±&nbsp;1&nbsp;3&nbsp;.&nbsp;1</td>
<td align="center">5&nbsp;2&nbsp;.&nbsp;4&nbsp;±&nbsp;1&nbsp;2&nbsp;.&nbsp;3</td>
<td align="center">0.247</td>
</tr>
<tr>
<td align="left">LDL cholesterol (mg/dL)</td>
<td align="center">1&nbsp;1&nbsp;2&nbsp;.&nbsp;7&nbsp;±&nbsp;3&nbsp;6</td>
<td align="center">1&nbsp;1&nbsp;6&nbsp;.&nbsp;1&nbsp;±&nbsp;3&nbsp;7&nbsp;.&nbsp;8</td>
<td align="center">1&nbsp;1&nbsp;2&nbsp;±&nbsp;3&nbsp;5&nbsp;.&nbsp;7</td>
<td align="center">0.496</td>
</tr>
<tr>
<td align="left">Glucose (mg/dL)</td>
<td align="center">1&nbsp;3&nbsp;2&nbsp;.&nbsp;2&nbsp;±&nbsp;5&nbsp;6&nbsp;.&nbsp;9</td>
<td align="center">1&nbsp;0&nbsp;7&nbsp;.&nbsp;5&nbsp;±&nbsp;3&nbsp;2&nbsp;.&nbsp;8</td>
<td align="center">1&nbsp;3&nbsp;7&nbsp;.&nbsp;3&nbsp;±&nbsp;5&nbsp;9&nbsp;.&nbsp;5</td>
<td align="center">0.002</td>
</tr>
<tr>
<td align="left">C reactive protein (mg/dL)</td>
<td align="center">0&nbsp;.&nbsp;6&nbsp;5&nbsp;±&nbsp;1&nbsp;.&nbsp;2&nbsp;2</td>
<td align="center">0&nbsp;.&nbsp;4&nbsp;5&nbsp;±&nbsp;0&nbsp;.&nbsp;5&nbsp;5</td>
<td align="center">0&nbsp;.&nbsp;7&nbsp;0&nbsp;±&nbsp;1&nbsp;.&nbsp;3&nbsp;1</td>
<td align="center">0.045</td>
</tr>
<tr>
<td align="left"><i>Estrone (pg/mL)</i></td>
<td align="center">2&nbsp;4&nbsp;.&nbsp;9&nbsp;±&nbsp;1&nbsp;3&nbsp;.&nbsp;4</td>
<td align="center">1&nbsp;0&nbsp;.&nbsp;8&nbsp;±&nbsp;2&nbsp;.&nbsp;1</td>
<td align="center">2&nbsp;7&nbsp;.&nbsp;6&nbsp;±&nbsp;1&nbsp;2&nbsp;.&nbsp;9</td>
<td align="center">&lt;0.001</td>
</tr>
<tr class="table-tr">
<td colspan="5">
<hr class="tbody-hr">
</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr class="table-fn">
<td>SBP: systolic blood pressure; DBP: diastolic blood pressure.<p></p>
<p>&nbsp;</p></td>
</tr>
</tbody>
</table>
</div>
<p>&nbsp;</p>
<h2>Table 2</h2>
<div class="floats-full-page-caption" bis_skin_checked="1">Baseline clinical characteristics and comparison of body mass index (BMI) &lt;30 kg/m<sup>2</sup>&nbsp;and ≥30 kg/m<sup>2</sup>&nbsp;in 246 patients.</div>
<div class="floats-full-page-content" bis_skin_checked="1">
<table id="tab2" class="table-group">
<tbody>
<tr>
<td>
<table class="table">
<tbody>
<tr>
<td class="thead-hr" colspan="4">
<hr>
</td>
</tr>
<tr class="thead">
<td align="left"></td>
<td align="center">I&nbsp;M&nbsp;C&nbsp;&lt;30 kg/m<sup>2</sup>  (&nbsp;𝑁&nbsp;=&nbsp;1&nbsp;4&nbsp;1&nbsp;)</td>
<td align="center">I&nbsp;M&nbsp;C&nbsp;≥30 kg/m<sup>2</sup>  (&nbsp;𝑁&nbsp;=&nbsp;1&nbsp;0&nbsp;5&nbsp;)</td>
<td align="center"><i>P</i></td>
</tr>
<tr>
<td class="thead-hr" colspan="4">
<hr>
</td>
</tr>
<tr>
<td align="left">Age (years)</td>
<td align="center">7&nbsp;0&nbsp;.&nbsp;5&nbsp;±&nbsp;7&nbsp;.&nbsp;4</td>
<td align="center">6&nbsp;8&nbsp;.&nbsp;7&nbsp;±&nbsp;6&nbsp;.&nbsp;3</td>
<td align="center">0.046</td>
</tr>
<tr>
<td align="left">Hypertension</td>
<td align="center">129 (92)</td>
<td align="center">104 (99)</td>
<td align="center">0.009</td>
</tr>
<tr>
<td align="left">Diabetes</td>
<td align="center">73 (52)</td>
<td align="center">33 (31)</td>
<td align="center">0.001</td>
</tr>
<tr>
<td align="left">Dyslipidemia</td>
<td align="center">131 (93)</td>
<td align="center">97 (92)</td>
<td align="center">0.667</td>
</tr>
<tr>
<td align="left">Family history</td>
<td align="center">94 (67)</td>
<td align="center">76 (72)</td>
<td align="center">0.337</td>
</tr>
<tr>
<td align="left">Coronary artery disease</td>
<td align="center">36 (26)</td>
<td align="center">24 (23)</td>
<td align="center">0.629</td>
</tr>
<tr>
<td align="left">Smoking</td>
<td align="center">14 (10)</td>
<td align="center">11 (10)</td>
<td align="center">0.888</td>
</tr>
<tr>
<td align="left">SBP (mm Hg)</td>
<td align="center">1&nbsp;3&nbsp;9&nbsp;.&nbsp;6&nbsp;±&nbsp;1&nbsp;9&nbsp;.&nbsp;8</td>
<td align="center">1&nbsp;4&nbsp;4&nbsp;.&nbsp;6&nbsp;±&nbsp;1&nbsp;5&nbsp;.&nbsp;9</td>
<td align="center">0.026</td>
</tr>
<tr>
<td align="left">DBP (mm Hg)</td>
<td align="center">8&nbsp;1&nbsp;.&nbsp;8&nbsp;±&nbsp;1&nbsp;0&nbsp;.&nbsp;4</td>
<td align="center">8&nbsp;4&nbsp;.&nbsp;6&nbsp;7&nbsp;±&nbsp;8&nbsp;.&nbsp;9</td>
<td align="center">0.020</td>
</tr>
<tr>
<td align="left">Triglycerides (mg/dL)</td>
<td align="center">1&nbsp;6&nbsp;0&nbsp;.&nbsp;2&nbsp;±&nbsp;8&nbsp;1&nbsp;.&nbsp;0</td>
<td align="center">1&nbsp;9&nbsp;0&nbsp;.&nbsp;9&nbsp;±&nbsp;1&nbsp;4&nbsp;9&nbsp;.&nbsp;3</td>
<td align="center">0.055</td>
</tr>
<tr>
<td align="left">Total cholesterol (mg/dL)</td>
<td align="center">2&nbsp;0&nbsp;2&nbsp;.&nbsp;9&nbsp;±&nbsp;4&nbsp;1&nbsp;.&nbsp;7</td>
<td align="center">1&nbsp;9&nbsp;4&nbsp;.&nbsp;7&nbsp;±&nbsp;3&nbsp;9&nbsp;.&nbsp;9</td>
<td align="center">0.116</td>
</tr>
<tr>
<td align="left">HDL cholesterol (mg/dL)</td>
<td align="center">5&nbsp;4&nbsp;.&nbsp;3&nbsp;±&nbsp;1&nbsp;3&nbsp;.&nbsp;2</td>
<td align="center">5&nbsp;0&nbsp;.&nbsp;9&nbsp;±&nbsp;1&nbsp;1&nbsp;.&nbsp;3</td>
<td align="center">0.033</td>
</tr>
<tr>
<td align="left">LDL cholesterol (mg/dL)</td>
<td align="center">1&nbsp;1&nbsp;7&nbsp;.&nbsp;0&nbsp;±&nbsp;3&nbsp;5&nbsp;.&nbsp;8</td>
<td align="center">1&nbsp;0&nbsp;7&nbsp;.&nbsp;0&nbsp;±&nbsp;3&nbsp;5&nbsp;.&nbsp;6</td>
<td align="center">0.029</td>
</tr>
<tr>
<td align="left">Glucose (mg/dL)</td>
<td align="center">1&nbsp;2&nbsp;8&nbsp;.&nbsp;6&nbsp;±&nbsp;5&nbsp;7&nbsp;.&nbsp;2</td>
<td align="center">1&nbsp;3&nbsp;6&nbsp;.&nbsp;9&nbsp;±&nbsp;5&nbsp;6&nbsp;.&nbsp;3</td>
<td align="center">0.249</td>
</tr>
<tr>
<td align="left">C reactive protein (mg/dL)</td>
<td align="center">0&nbsp;.&nbsp;2&nbsp;5&nbsp;±&nbsp;0&nbsp;.&nbsp;1&nbsp;3</td>
<td align="center">0&nbsp;.&nbsp;6&nbsp;3&nbsp;±&nbsp;0&nbsp;.&nbsp;5&nbsp;7</td>
<td align="center">0.779</td>
</tr>
<tr>
<td align="left"><i>Estrone (pg/mL)</i></td>
<td align="center">2&nbsp;2&nbsp;.&nbsp;4&nbsp;±&nbsp;9&nbsp;.&nbsp;9</td>
<td align="center">2&nbsp;8&nbsp;.&nbsp;2&nbsp;±&nbsp;1&nbsp;6&nbsp;.&nbsp;4</td>
<td align="center">0.001</td>
</tr>
<tr class="table-tr">
<td colspan="4">
<hr class="tbody-hr">
</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr class="table-fn">
<td>SBP: systolic blood pressure; DBP: diastolic blood pressure.<p></p>
<p>&nbsp;</p></td>
</tr>
</tbody>
</table>
</div>
<h2>Table 3</h2>
<div class="floats-full-page-caption" bis_skin_checked="1">Baseline clinical characteristics and comparison of 246 patients by survival status (32 deaths).</div>
<div class="floats-full-page-content" bis_skin_checked="1">
<table id="tab3" class="table-group">
<tbody>
<tr>
<td>
<table class="table">
<tbody>
<tr>
<td class="thead-hr" colspan="4">
<hr>
</td>
</tr>
<tr class="thead">
<td align="left"></td>
<td align="center">Alive&nbsp;(&nbsp;𝑁&nbsp;=&nbsp;2&nbsp;1&nbsp;4&nbsp;)</td>
<td align="center">Death&nbsp;(&nbsp;𝑁&nbsp;=&nbsp;3&nbsp;2&nbsp;)</td>
<td align="center">𝑃</td>
</tr>
<tr>
<td class="thead-hr" colspan="4">
<hr>
</td>
</tr>
<tr>
<td align="left">Age (years)</td>
<td align="center">6&nbsp;9&nbsp;.&nbsp;2&nbsp;±&nbsp;6&nbsp;.&nbsp;9</td>
<td align="center">7&nbsp;2&nbsp;.&nbsp;6&nbsp;±&nbsp;7&nbsp;.&nbsp;2</td>
<td align="center">0.010</td>
</tr>
<tr>
<td align="left">Body mass index</td>
<td align="center">2&nbsp;9&nbsp;.&nbsp;7&nbsp;±&nbsp;5&nbsp;.&nbsp;2</td>
<td align="center">2&nbsp;8&nbsp;.&nbsp;3&nbsp;±&nbsp;5&nbsp;.&nbsp;7</td>
<td align="center">0.157</td>
</tr>
<tr>
<td align="left">Hypertension</td>
<td align="center">205 (96)</td>
<td align="center">28 (88)</td>
<td align="center">0.051</td>
</tr>
<tr>
<td align="left">Diabetes</td>
<td align="center">93 (43)</td>
<td align="center">13 (41)</td>
<td align="center">0.763</td>
</tr>
<tr>
<td align="left">Dyslipidemia</td>
<td align="center">200 (93)</td>
<td align="center">28 (88)</td>
<td align="center">0.227</td>
</tr>
<tr>
<td align="left">Coronary artery disease</td>
<td align="center">54 (25)</td>
<td align="center">6 (19)</td>
<td align="center">0.426</td>
</tr>
<tr>
<td align="left">Family history</td>
<td align="center">151 (71)</td>
<td align="center">19 (59)</td>
<td align="center">0.202</td>
</tr>
<tr>
<td align="left">Smoking</td>
<td align="center">23 (11)</td>
<td align="center">2 (6)</td>
<td align="center">0.432</td>
</tr>
<tr>
<td align="left">SBP (mm Hg)</td>
<td align="center">1&nbsp;4&nbsp;1&nbsp;.&nbsp;4&nbsp;±&nbsp;1&nbsp;8&nbsp;.&nbsp;2</td>
<td align="center">1&nbsp;4&nbsp;3&nbsp;.&nbsp;1&nbsp;±&nbsp;1&nbsp;9&nbsp;.&nbsp;7</td>
<td align="center">0.612</td>
</tr>
<tr>
<td align="left">DBP (mm Hg)</td>
<td align="center">8&nbsp;2&nbsp;.&nbsp;9&nbsp;±&nbsp;9&nbsp;.&nbsp;8</td>
<td align="center">8&nbsp;2&nbsp;.&nbsp;8&nbsp;±&nbsp;1&nbsp;0&nbsp;.&nbsp;2</td>
<td align="center">0.938</td>
</tr>
<tr>
<td align="left">Triglycerides (mg/dL)</td>
<td align="center">1&nbsp;7&nbsp;2&nbsp;.&nbsp;2&nbsp;±&nbsp;1&nbsp;1&nbsp;9</td>
<td align="center">1&nbsp;7&nbsp;0&nbsp;.&nbsp;6&nbsp;±&nbsp;1&nbsp;0&nbsp;1</td>
<td align="center">0.908</td>
</tr>
<tr>
<td align="left">Total cholesterol (mg/dL)</td>
<td align="center">1&nbsp;9&nbsp;8&nbsp;.&nbsp;4&nbsp;±&nbsp;4&nbsp;1&nbsp;.&nbsp;9</td>
<td align="center">2&nbsp;0&nbsp;4&nbsp;±&nbsp;3&nbsp;3&nbsp;.&nbsp;9</td>
<td align="center">0.468</td>
</tr>
<tr>
<td align="left">HDL cholesterol (mg/dL)</td>
<td align="center">5&nbsp;3&nbsp;.&nbsp;3&nbsp;±&nbsp;1&nbsp;2&nbsp;.&nbsp;8</td>
<td align="center">5&nbsp;0&nbsp;.&nbsp;6&nbsp;±&nbsp;1&nbsp;0&nbsp;.&nbsp;7</td>
<td align="center">0.251</td>
</tr>
<tr>
<td align="left">LDL cholesterol (mg/dL)</td>
<td align="center">1&nbsp;1&nbsp;1&nbsp;.&nbsp;2&nbsp;±&nbsp;3&nbsp;7&nbsp;.&nbsp;1</td>
<td align="center">1&nbsp;2&nbsp;1&nbsp;.&nbsp;3&nbsp;±&nbsp;2&nbsp;5&nbsp;.&nbsp;2</td>
<td align="center">0.054</td>
</tr>
<tr>
<td align="left">Glucose (mg/dL)</td>
<td align="center">1&nbsp;3&nbsp;2&nbsp;.&nbsp;6&nbsp;±&nbsp;5&nbsp;6&nbsp;.&nbsp;4</td>
<td align="center">1&nbsp;3&nbsp;1&nbsp;.&nbsp;3&nbsp;±&nbsp;6&nbsp;4&nbsp;.&nbsp;5</td>
<td align="center">0.904</td>
</tr>
<tr>
<td align="left">C reactive protein (mg/dL)</td>
<td align="center">0&nbsp;.&nbsp;6&nbsp;2&nbsp;±&nbsp;1&nbsp;.&nbsp;0&nbsp;4</td>
<td align="center">0&nbsp;.&nbsp;8&nbsp;5&nbsp;±&nbsp;2&nbsp;.&nbsp;1&nbsp;2</td>
<td align="center">0.548</td>
</tr>
<tr>
<td align="left"><i>Estrone (pg/mL)</i></td>
<td align="center">2&nbsp;5&nbsp;.&nbsp;1&nbsp;±&nbsp;1&nbsp;3&nbsp;.&nbsp;6</td>
<td align="center">2&nbsp;1&nbsp;.&nbsp;6&nbsp;±&nbsp;1&nbsp;1&nbsp;.&nbsp;5</td>
<td align="center">0.166</td>
</tr>
<tr class="table-tr">
<td colspan="4">
<hr class="tbody-hr">
</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr class="table-fn">
<td>SBP: systolic blood pressure; DBP: diastolic blood pressure.</td>
</tr>
</tbody>
</table>
</div>
<p>&nbsp;</p>
<h2>Table 3</h2>
<div class="floats-full-page-caption" bis_skin_checked="1">Baseline clinical characteristics and comparison of 246 patients by survival status (32 deaths).</div>
<div class="floats-full-page-content" bis_skin_checked="1">
<table id="tab3" class="table-group">
<tbody>
<tr>
<td>
<table class="table">
<tbody>
<tr>
<td class="thead-hr" colspan="4">
<hr>
</td>
</tr>
<tr class="thead">
<td align="left"></td>
<td align="center">Alive&nbsp;(&nbsp;𝑁&nbsp;=&nbsp;2&nbsp;1&nbsp;4&nbsp;)</td>
<td align="center">Death&nbsp;(&nbsp;𝑁&nbsp;=&nbsp;3&nbsp;2&nbsp;)</td>
<td align="center">𝑃</td>
</tr>
<tr>
<td class="thead-hr" colspan="4">
<hr>
</td>
</tr>
<tr>
<td align="left">Age (years)</td>
<td align="center">6&nbsp;9&nbsp;.&nbsp;2&nbsp;±&nbsp;6&nbsp;.&nbsp;9</td>
<td align="center">7&nbsp;2&nbsp;.&nbsp;6&nbsp;±&nbsp;7&nbsp;.&nbsp;2</td>
<td align="center">0.010</td>
</tr>
<tr>
<td align="left">Body mass index</td>
<td align="center">2&nbsp;9&nbsp;.&nbsp;7&nbsp;±&nbsp;5&nbsp;.&nbsp;2</td>
<td align="center">2&nbsp;8&nbsp;.&nbsp;3&nbsp;±&nbsp;5&nbsp;.&nbsp;7</td>
<td align="center">0.157</td>
</tr>
<tr>
<td align="left">Hypertension</td>
<td align="center">205 (96)</td>
<td align="center">28 (88)</td>
<td align="center">0.051</td>
</tr>
<tr>
<td align="left">Diabetes</td>
<td align="center">93 (43)</td>
<td align="center">13 (41)</td>
<td align="center">0.763</td>
</tr>
<tr>
<td align="left">Dyslipidemia</td>
<td align="center">200 (93)</td>
<td align="center">28 (88)</td>
<td align="center">0.227</td>
</tr>
<tr>
<td align="left">Coronary artery disease</td>
<td align="center">54 (25)</td>
<td align="center">6 (19)</td>
<td align="center">0.426</td>
</tr>
<tr>
<td align="left">Family history</td>
<td align="center">151 (71)</td>
<td align="center">19 (59)</td>
<td align="center">0.202</td>
</tr>
<tr>
<td align="left">Smoking</td>
<td align="center">23 (11)</td>
<td align="center">2 (6)</td>
<td align="center">0.432</td>
</tr>
<tr>
<td align="left">SBP (mm Hg)</td>
<td align="center">1&nbsp;4&nbsp;1&nbsp;.&nbsp;4&nbsp;±&nbsp;1&nbsp;8&nbsp;.&nbsp;2</td>
<td align="center">1&nbsp;4&nbsp;3&nbsp;.&nbsp;1&nbsp;±&nbsp;1&nbsp;9&nbsp;.&nbsp;7</td>
<td align="center">0.612</td>
</tr>
<tr>
<td align="left">DBP (mm Hg)</td>
<td align="center">8&nbsp;2&nbsp;.&nbsp;9&nbsp;±&nbsp;9&nbsp;.&nbsp;8</td>
<td align="center">8&nbsp;2&nbsp;.&nbsp;8&nbsp;±&nbsp;1&nbsp;0&nbsp;.&nbsp;2</td>
<td align="center">0.938</td>
</tr>
<tr>
<td align="left">Triglycerides (mg/dL)</td>
<td align="center">1&nbsp;7&nbsp;2&nbsp;.&nbsp;2&nbsp;±&nbsp;1&nbsp;1&nbsp;9</td>
<td align="center">1&nbsp;7&nbsp;0&nbsp;.&nbsp;6&nbsp;±&nbsp;1&nbsp;0&nbsp;1</td>
<td align="center">0.908</td>
</tr>
<tr>
<td align="left">Total cholesterol (mg/dL)</td>
<td align="center">1&nbsp;9&nbsp;8&nbsp;.&nbsp;4&nbsp;±&nbsp;4&nbsp;1&nbsp;.&nbsp;9</td>
<td align="center">2&nbsp;0&nbsp;4&nbsp;±&nbsp;3&nbsp;3&nbsp;.&nbsp;9</td>
<td align="center">0.468</td>
</tr>
<tr>
<td align="left">HDL cholesterol (mg/dL)</td>
<td align="center">5&nbsp;3&nbsp;.&nbsp;3&nbsp;±&nbsp;1&nbsp;2&nbsp;.&nbsp;8</td>
<td align="center">5&nbsp;0&nbsp;.&nbsp;6&nbsp;±&nbsp;1&nbsp;0&nbsp;.&nbsp;7</td>
<td align="center">0.251</td>
</tr>
<tr>
<td align="left">LDL cholesterol (mg/dL)</td>
<td align="center">1&nbsp;1&nbsp;1&nbsp;.&nbsp;2&nbsp;±&nbsp;3&nbsp;7&nbsp;.&nbsp;1</td>
<td align="center">1&nbsp;2&nbsp;1&nbsp;.&nbsp;3&nbsp;±&nbsp;2&nbsp;5&nbsp;.&nbsp;2</td>
<td align="center">0.054</td>
</tr>
<tr>
<td align="left">Glucose (mg/dL)</td>
<td align="center">1&nbsp;3&nbsp;2&nbsp;.&nbsp;6&nbsp;±&nbsp;5&nbsp;6&nbsp;.&nbsp;4</td>
<td align="center">1&nbsp;3&nbsp;1&nbsp;.&nbsp;3&nbsp;±&nbsp;6&nbsp;4&nbsp;.&nbsp;5</td>
<td align="center">0.904</td>
</tr>
<tr>
<td align="left">C reactive protein (mg/dL)</td>
<td align="center">0&nbsp;.&nbsp;6&nbsp;2&nbsp;±&nbsp;1&nbsp;.&nbsp;0&nbsp;4</td>
<td align="center">0&nbsp;.&nbsp;8&nbsp;5&nbsp;±&nbsp;2&nbsp;.&nbsp;1&nbsp;2</td>
<td align="center">0.548</td>
</tr>
<tr>
<td align="left"><i>Estrone (pg/mL)</i></td>
<td align="center">2&nbsp;5&nbsp;.&nbsp;1&nbsp;±&nbsp;1&nbsp;3&nbsp;.&nbsp;6</td>
<td align="center">2&nbsp;1&nbsp;.&nbsp;6&nbsp;±&nbsp;1&nbsp;1&nbsp;.&nbsp;5</td>
<td align="center">0.166</td>
</tr>
<tr class="table-tr">
<td colspan="4">
<hr class="tbody-hr">
</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr class="table-fn">
<td>SBP: systolic blood pressure; DBP: diastolic blood pressure.<p></p>
<p>&nbsp;</p></td>
</tr>
</tbody>
</table>
</div>
<p>&nbsp;</p>
<h2>Table 4</h2>
<div class="floats-full-page-caption" bis_skin_checked="1">Cox regression multivariate analysis for different models of variable adjustments.</div>
<div class="floats-full-page-content" bis_skin_checked="1">
<table id="tab4" class="table-group">
<tbody>
<tr>
<td>
<table class="table">
<tbody>
<tr>
<td class="thead-hr" colspan="5">
<hr>
</td>
</tr>
<tr class="thead">
<td align="left">Model</td>
<td align="center">Variable</td>
<td align="center">Hazard ratio</td>
<td align="center">95% Confidence interval</td>
<td align="center">𝑃</td>
</tr>
<tr>
<td class="thead-hr" colspan="5">
<hr>
</td>
</tr>
<tr>
<td align="left">1</td>
<td align="center">Age</td>
<td align="center">1.05</td>
<td align="center">1.00–1.11</td>
<td align="center">0.016</td>
</tr>
<tr>
<td align="left">2</td>
<td align="center">Hypertension</td>
<td align="center">2.44</td>
<td align="center">0.83–7.20</td>
<td align="center">0.030</td>
</tr>
<tr>
<td align="left">3</td>
<td align="center">Estrone</td>
<td align="center">0.45</td>
<td align="center">0.21–0.95</td>
<td align="center">0.038</td>
</tr>
<tr class="table-tr">
<td colspan="5">
<hr class="tbody-hr">
</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr class="table-fn">
<td>Model 1: adjusted for age, body mass index, hypertension, diabetes, dyslipidemia, family history, and estrone; 2: adjusted for body mass index, hypertension, diabetes, dyslipidemia, family history, and estrone; 3: adjusted for body mass index, diabetes, dyslipidemia, family history, and estrone.</td>
</tr>
</tbody>
</table>
</div>
<p>&nbsp;</p>
<p><img src="https://static-01.hindawi.com/articles/tswj/volume-2012/363595/figures/363595.fig.001.jpg" class="lazyloaded" data-ll-status="loaded"><noscript><img src="https://static-01.hindawi.com/articles/tswj/volume-2012/363595/figures/363595.fig.001.jpg" /></noscript></p>
<div class="floats-partial-caption" bis_skin_checked="1"><span class="caption-text">Figure 1</span><a class="caption-partial-url" title="full view" href="https://www.hindawi.com/journals/tswj/2012/363595/fig1/" target="_blank" rel="noopener" aria-label="full view">&nbsp;</a></div>
<div class="floats-partial-caption-text" bis_skin_checked="1">Histogram of estrone plasma levels.</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"><img src="https://static-01.hindawi.com/articles/tswj/volume-2012/363595/figures/363595.fig.002.jpg" class="lazyloaded" data-ll-status="loaded"><noscript><img src="https://static-01.hindawi.com/articles/tswj/volume-2012/363595/figures/363595.fig.002.jpg" /></noscript></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<div class="floats-partial-caption" bis_skin_checked="1"><span class="caption-text">Figure 2</span></div>
<div class="floats-partial-caption-text" bis_skin_checked="1">Kaplan-Meier curve for all causes of deaths according to estrone levels (&lt;15 pg/mL versus ≥15 pg/mL).</div>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h4 id="discussion">4. Discussion</h4>
<hr>
</div>
<p>&nbsp;</p>
<p>This study of long-term followup showed that serum estrone level &lt;15 pg/mL was an independent risk factor for increased mortality from all causes in postmenopausal women with CHD or at high risk for CAD. Almost all deaths (84%) were from cardiovascular origin and from myocardial infarction. The current study confirmed the possible beneficial effects of estrone suggested by our previous study of short-term followup in the same population [<a class="refAnchor">9</a>]. However, the association of estrone and CAD is unknown. Few studies have analyzed this association, and they have not shown any correlation between estrone plasma levels and CAD [<a class="refAnchor">16</a>–<a class="refAnchor">18</a>]. In a recent nested case-control study, estrone levels did not correlate with the incidence of CAD [<a class="refAnchor">19</a>].</p>
<p>Estrone is the main endogenous estrogen in postmenopausal women. Nevertheless, estrone effects on the vascular system are significantly lower than estradiol mainly present in the premenopausal period [<a class="refAnchor">20</a>]. Appropriate physiological levels of estrone in postmenopausal women may therefore bring additional benefits in cardiovascular protection. In postmenopausal women, a reduction occurs in the number and activity of estrogen receptors in tissues, and therefore more potent endogenous or exogenous estrogens are not necessary in this period. Likewise, the doses of exogenous estrogens are not physiological and are generally above the baseline needs. Estrogen therapy significantly increases the serum levels of estrone far above the levels observed in postmenopausal women. Estrone is also the main precursor of the small amount of estradiol still present in postmenopausal women. Estrone can then be the most suitable endogenous estrogen during the postmenopausal period for maintenance of basic physiological needs at this time. The estrone in postmenopausal women is produced mainly in adipose tissue, and obese women have higher serum estrone. However, obesity is associated with metabolic syndrome characterized by alterations in glucose metabolism, lipids, and presence of hypertension [<a class="refAnchor">21</a>]. Inflammatory markers, such as CRP and leptin, are also increased in obese individuals. CRP is also increased in postmenopausal women who use hormone replacement therapy. In our study, we observed increased serum levels of CRP in the group of women with estrone ≥15 pg/mL. However, this increase may be due to the higher prevalence of hypertension, diabetes, serum triglycerides, and glucose in this group, suggesting a pattern of metabolic syndrome that is known to increase CRP. Being estrone protective of the cardiovascular system, the increased production of estrone in obese women may be a feedback mechanism for protecting the cardiovascular system in this population. In our study, estrone ≥15 pg/mL may be a factor to explain the lower mortality despite the high risk profile for cardiovascular patients. Higher estrone levels remained an independent variable even after adjustment for body mass index and prevalence of diabetes and dyslipidemia. The action of estrone in the metabolism of glucose and lipid is still controversial [<a class="refAnchor">22</a>–<a class="refAnchor">25</a>], but direct and indirect beneficial effects similar to those observed for estradiol, but of lesser intensity, may also occur with estrone in these 2 pathways. The prevalence of risk factors for CAD was significantly higher in our population. Diabetes was more prevalent in women with estrone levels ≥15 pg/mL (62% versus 37%, P=0.003), but even with a worse cardiovascular risk profile [<a class="refAnchor">26</a>], this was the group that had fewer deaths. In conclusion, serum estrone levels ≥15 pg/mL were associated with lower mortality from all causes in postmenopausal women with CHD or at high risk for CAD. Therefore, we hypothesized that the better prognosis was due to the possible protective effects of increased physiological levels of estrone. Nevertheless, this hypothesis should be validated by a large prospective study.</p>
<h4 id="authors’-contributions">Authors’ Contributions</h4>
<hr>
<p>&nbsp;</p>
<p>A. P. Mansur, T. C. B. F. Silva, J. Y. Takada, and S. D. Avakian made substantial contributions to conception, design, analysis and interpretation of data. C. M. C. Strunz, L. A. M. César, J. M. Aldrighi and J. A. F. Ramires made substantial contributions to the design of the study and drafted the first version of the paper. All authors were involved in revising the drafts critically for important intellectual content and gave final approval of the version to be published.</p>
<p>&nbsp;</p>
<h4 id="acknowledgment">Acknowledgment</h4>
<hr>
<p>&nbsp;</p>
<p>The authors acknowledge the financial support provided by “Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)” number 03/127152.</p>
<p>&nbsp;</p>
<h4 id="references" class="references">References</h4>
<hr>
<p>&nbsp;</p>
<p>D. Xing, S. Nozell, Y. F. Chen, F. Hage, and S. Oparil, “Estrogen and mechanisms of vascular protection,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 3, pp. 289–295, 2009.</p>
<p>S. Nilsson, S. Mäkelä, E. Treuter et al., “Mechanisms of estrogen action,” Physiological Reviews, vol. 81, no. 4, pp. 1535–1565, 2001.</p>
<p>E. Murphy and C. Steenbergen, “Gender-based differences in mechanisms of protection in myocardial ischemia-reperfusion injury,” Cardiovascular Research, vol. 75, no. 3, pp. 478–486, 2007.</p>
<p>S. Hulley, D. Grady, T. Bush et al., “Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women,” Journal of the American Medical Association, vol. 280, no. 7, pp. 605–613, 1998.</p>
<p>Writing Group for the Women’s Health Initiative Investigators, “Risks and benefits of estrogen plus progestin in healthy postmenopausal women,” Journal of the American Medical Association, vol. 288, pp. 321–333, 2002.</p>
<p>S. M. Harman, E. Vittinghoff, E. A. Brinton et al., “Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes,” American Journal of Medicine, vol. 124, no. 3, pp. 199–205, 2011.</p>
<p>C. J. Gruber, W. Tschugguel, C. Schneeberger, and J. C. Huber, “Mechanisms of disease: Production and actions of estrogens,” New England Journal of Medicine, vol. 346, no. 5, pp. 340–352, 2002.</p>
<p>A. Lukanova, E. Lundin, A. Zeleniuch-Jacquotte et al., “Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women,” European Journal of Endocrinology, vol. 150, no. 2, pp. 161–171, 2004.</p>
<p>T. C. B. F. Silva, E. Barrett-Connor, J. A. F. Ramires, and A. P. Mansur, “Obesity, estrone, and coronary artery disease in postmenopausal women,” Maturitas, vol. 59, no. 3, pp. 242–248, 2008.</p>
<p>L. Mosca, E. Barrett-Connor, N. K. Wenger et al., “Design and methods of the Raloxifene Use for The Heart (RUTH) study,” American Journal of Cardiology, vol. 88, no. 4, pp. 392–395, 2001.</p>
<p>American Diabetes Association, “Diagnosis and classification of diabetes mellitus 2006,” Diabetes Care, vol. 29, no. Suppl S), pp. S43–S48, 2006.</p>
<p>“The Seventh Report of the Joint National Committee on Prevention, Detection, evaluation and treatment of high blood pressure,” Journal of the American Medical Association, vol. 289, pp. 2560–2572, 2003.</p>
<p>“III Diretrizes Brasileiras Sobre Dislipidemias e Diretriz de Prevenção da Aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia,” Arquivos Brasileiros de Cardiologia, vol. 77, pp. 4–8, 2001.</p>
<p>World Health Organization, Guidelines for the conduct of the tobacco smoking surveys of the general population: report of a meeting, WHO, Geneva, Switzerland, 1992.<br>
Obesity: Preventing and managing the global epidemic. Report of a WHO Consultation, Technical Report Series, no. 894, World Health Organization, Geneva, Switzerland, 2000.<br>
J. A. Cauley, J. P. Gutai, N. W. Glynn, M. Paternostro-Bayles, E. Cottington, and L. H. Kuller, “Serum estrone concentrations and coronary artery disease in postmenopausal women,” Arteriosclerosis and Thrombosis, vol. 14, no. 1, pp. 14–18, 1994.</p>
<p>E. Barrett-Connor and D. Goodman-Gruen, “Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women,” British Medical Journal, vol. 311, no. 7014, pp. 1193–1196, 1995.</p>
<p>K. M. Rexrode, J. E. Manson, I. M. Lee et al., “Sex hormone levels and risk of cardiovascular events in postmenopausal women,” Circulation, vol. 108, no. 14, pp. 1688–1693, 2003.</p>
<p>Y. Chen, A. Zeleniuch-Jacquotte, A. A. Arslan et al., “Endogenous hormones and coronary heart disease in postmenopausal women,” Atherosclerosis, vol. 216, no. 2, pp. 414–419, 2011.</p>
<p>G. G. J. M. Kuiper, B. Carlsson, K. Grandien et al., “Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors and α and β,” Endocrinology, vol. 138, no. 3, pp. 863–870, 1997.</p>
<p>S. M. Grundy, B. Hansen, S. C. Smith, J. I. Cleeman, and R. A. Kahn, “Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management.,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 2, pp. e19–e24, 2004.</p>
<p>R. H. Knopp, X. Zhu, and B. Bonet, “Effects of estrogens on lipoprotein metabolism and cardiovascular disease in women,” Atherosclerosis, vol. 110, pp. S83–S91, 1994.</p>
<p>E. L. Ding, Y. Song, V. S. Malik, and S. Liu, “Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysis,” Journal of the American Medical Association, vol. 295, no. 11, pp. 1288–1299, 2006.</p>
<p>I. Lambrinoudaki, G. Christodoulakos, D. Rizos et al., “Endogenous sex hormones and risk factors atherosclerosis in healthy Greek postmenopausal women,” European Journal of Endocrinology, vol. 154, no. 6, pp. 907–916, 2006.</p>
<p>J. Hsia, J. D. Otvos, J. E. Rossouw et al., “Lipoprotein particle concentrations may explain the absence of coronary protection in the women’s health initiative hormone trials,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, pp. 1666–1671, 2008.</p>
<p>C. Walton, I. F. Godsland, A. J. Proudler, V. Wynn, and J. C. Stevenson, “The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women,” European Journal of Clinical Investigation, vol. 23, no. 8, pp. 466–473, 1993.</p>
<p>&nbsp;</p>
<h2>Source:</h2>
<hr>
<p>&nbsp;</p>
<p>https://www.hindawi.com/journals/tswj/2012/363595/</p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/06/14/long-term-prospective-study-of-the-influence-of-estrone-levels-on-events-in-postmenopausal-women-with-or-at-high-risk-for-coronary-artery-disease/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/06/14/long-term-prospective-study-of-the-influence-of-estrone-levels-on-events-in-postmenopausal-women-with-or-at-high-risk-for-coronary-artery-disease/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5216 post type-post status-publish format-standard hentry category-articles animated"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g" class="avatar avatar-144 photo lazyloaded" height="144" width="144" srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" data-ll-status="loaded"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>04.06.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/06/04/estradiol-cypionate-medroxyprogesterone-contraceptive-injection/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/06/04/estradiol-cypionate-medroxyprogesterone-contraceptive-injection/">Estradiol Cypionate; Medroxyprogesterone contraceptive injection</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><div bis_skin_checked="1">
<div class="buct121" dir="" data-kswid="articleContent" bis_skin_checked="1">
<div class="Page" bis_skin_checked="1">
<div class="SectionIndentOne" bis_skin_checked="1">
<h2>What is this medicine?</h2>
<hr>
<p>&nbsp;</p>
<p>ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE (es tra DYE ole sip EYE oh nate; me DROX ee proe JES te rone) is a birth-control method to prevent an unwanted pregnancy. Each injection provides birth control for 1 month (30 days).</p>
<p>NOTE: This drug is discontinued in the United States.</p>
</div>
<div class="SectionIndentOne" bis_skin_checked="1">
<h2>How should I use this medicine?</h2>
<hr>
<p>&nbsp;</p>
<p>This medicine is for injection into a muscle. It is given by a health-care professional. The first injection is usually given during the first 5 days after the start of a menstrual period. This medicine will provide birth control for roughly 28 to 30 days.</p>
<p>Talk to your pediatrician regarding the use of this medicine in children. Special care may be needed. This medicine has been used in female children who have started having menstrual periods.</p>
<p>A patient package insert for the product will be given with each prescription and refill. Read this sheet carefully each time. The sheet may change frequently.</p>
</div>
<div class="SectionIndentOne" bis_skin_checked="1">
<h2>What side effects may I notice from receiving this medicine?</h2>
<hr>
<p>&nbsp;</p>
<p>Side effects that you should report to your doctor or health care professional as soon as possible:</p>
<ul class="">
<li>allergic reactions like skin rash, itching or hives, swelling of the face, lips, or tongue</li>
<li>breast tissue changes or discharge</li>
<li>changes in vision</li>
<li>chest pain</li>
<li>confusion, trouble speaking or understanding</li>
<li>dark urine</li>
<li>general ill feeling or flu-like symptoms</li>
<li>light-colored stools</li>
<li>nausea, vomiting</li>
<li>pain, swelling, warmth in the leg</li>
<li>right upper belly pain</li>
<li>severe headaches</li>
<li>shortness of breath</li>
<li>sudden numbness or weakness of the face, arm or leg</li>
<li>trouble walking, dizziness, loss of balance or coordination</li>
<li>unusual vaginal bleeding</li>
<li>yellowing of the eyes or skin</li>
</ul>
<p>Side effects that usually do not require medical attention (report to your doctor or health care professional if they continue or are bothersome):</p>
<ul class="">
<li>back pain</li>
<li>breast tenderness</li>
<li>depressed mood or mood swings</li>
<li>hair loss</li>
<li>increased hunger or thirst</li>
<li>increased urination</li>
<li>fluid retention and swelling</li>
<li>stomach cramps or bloating</li>
<li>symptoms of vaginal infection like itching, irritation or unusual discharge</li>
<li>unusually weak or tired</li>
</ul>
</div>
<div class="SectionIndentOne" bis_skin_checked="1">
<h2>What may interact with this medicine?</h2>
<hr>
<p>&nbsp;</p>
<p>&nbsp;</p>
<ul>
<li>acetaminophen</li>
<li>antibiotics or medicines for infections, especially rifampin, rifabutin, rifapentine, and griseofulvin, and possibly penicillins or tetracyclines</li>
<li>aprepitant</li>
<li>ascorbic acid (vitamin C)</li>
<li>atorvastatin</li>
<li>barbiturate medicines, such as phenobarbital</li>
<li>bosentan</li>
<li>carbamazepine</li>
<li>caffeine</li>
<li>clofibrate</li>
<li>cyclosporine</li>
<li>dantrolene</li>
<li>doxercalciferol</li>
<li>felbamate</li>
<li>grapefruit juice</li>
<li>hydrocortisone</li>
<li>medicines for anxiety or sleeping problems, such as diazepam or temazepam</li>
<li>medicines for diabetes, including pioglitazone</li>
<li>mineral oil</li>
<li>modafinil</li>
<li>mycophenolate</li>
<li>nefazodone</li>
<li>oxcarbazepine</li>
<li>phenytoin</li>
<li>prednisolone</li>
<li>ritonavir or other medicines for HIV infection or AIDS</li>
<li>rosuvastatin</li>
<li>selegiline</li>
<li>soy isoflavones supplements</li>
<li>St. John’s wort</li>
<li>tamoxifen or raloxifene</li>
<li>theophylline</li>
<li>thyroid hormones</li>
<li>topiramate</li>
<li>warfarin</li>
</ul>
</div>
<div class="SectionIndentOne" bis_skin_checked="1">
<h2>What if I miss a dose?</h2>
<hr>
<p>&nbsp;</p>
<p>Try not to miss a dose. You will need an injection once per month in order to maintain birth control. If you cannot keep an appointment call to reschedule. If it has been more than 4 weeks (33 days) since your last injection, you will need to have a pregnancy test before you can have another injection.</p>
</div>
<div class="SectionIndentOne" bis_skin_checked="1">
<h2>Where should I keep my medicine?</h2>
<hr>
<p>&nbsp;</p>
<p>This drug is given in a hospital or clinic and will not be stored at home.</p>
</div>
<div class="SectionIndentOne" bis_skin_checked="1">
<h2>What should I tell my health care provider before I take this medicine?</h2>
<hr>
<p>&nbsp;</p>
<p>They need to know if you have or ever had any of these conditions:</p>
<ul class="">
<li>abnormal vaginal bleeding</li>
<li>blood vessel disease or blood clots</li>
<li>breast, cervical, endometrial, ovarian, liver, or uterine cancer</li>
<li>diabetes</li>
<li>gallbladder disease</li>
<li>heart disease or recent heart attack</li>
<li>high blood pressure</li>
<li>high cholesterol</li>
<li>kidney disease</li>
<li>liver disease</li>
<li>migraine headaches</li>
<li>stroke</li>
<li>systemic lupus erythematosus (SLE)</li>
<li>tobacco smoker</li>
<li>an unusual or allergic reaction to estrogens, progestins, or other medicines, foods, dyes, or preservatives</li>
<li>pregnant or trying to get pregnant</li>
<li>breast-feeding</li>
</ul>
</div>
<div class="SectionIndentOne" bis_skin_checked="1">
<h2>What should I watch for while using this medicine?</h2>
<hr>
<p>&nbsp;</p>
<p>Visit your doctor or health care professional for regular checks on your progress. You will need a regular breast and pelvic exam and Pap smear while on this medicine.</p>
<p>Smoking increases the risk of getting a blood clot or having a stroke while you are taking hormonal birth control, especially if you are more than 35 years old. You are strongly advised not to smoke.</p>
<p>Use of this product may cause you to lose calcium from your bones. Loss of calcium may cause weak bones (osteoporosis). Only use this product for more than 2 years if other forms of birth control are not right for you. Ask your health care professional how you can keep strong bones.</p>
<p>If you have received your injections on time, your chance of being pregnant is very low. If you think you may be pregnant, see your health care professional as soon as possible.</p>
<p>Tell your health care professional if you want to get pregnant within the next year. Another form of birth control may be a better choice.</p>
<p>If you are going to have elective surgery, you may need to stop taking this medicine before the surgery. Consult your health care professional for advice.</p>
<p>This medicine does not protect you against HIV infection (AIDS) or any other sexually transmitted diseases.</p>
</div>
</div>
</div>
<hr>
</div>
<div id="drugDisclaimer" bis_skin_checked="1">
<p>&nbsp;</p>
<p><strong>NOTE:</strong>&nbsp;This sheet is a summary. It may not cover all possible information. If you have questions about this medicine, talk to your doctor, pharmacist, or health care provider.</p>
<p><strong>NOTE:</strong>&nbsp;This information is not intended to cover all possible uses, precautions, interactions, or adverse effects for this drug. If you have questions about the drug(s) you are taking, check with your health care professional.</p>
</div>
<p>&nbsp;</p>
<h2>Source:</h2>
<p>https://www.veteranshealthlibrary.va.gov/121,1385</p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/06/04/estradiol-cypionate-medroxyprogesterone-contraceptive-injection/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/06/04/estradiol-cypionate-medroxyprogesterone-contraceptive-injection/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5214 post type-post status-publish format-standard hentry category-articles animated"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g" class="avatar avatar-144 photo lazyloaded" height="144" width="144" srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" data-ll-status="loaded"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>01.06.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/06/01/7-keto-dhea-benefits-side-effects-dosage-reviews/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/06/01/7-keto-dhea-benefits-side-effects-dosage-reviews/">7-Keto DHEA Benefits, Side Effects, Dosage &amp; Reviews</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><p>7-Keto DHEA is a hormone produced in the brain, kidneys, and reproductive organs. Although similar to its cousin, DHEA, 7-keto acts differently in the body. As a supplement, it may help burn fat and protect the brain, but the clinical research is scarce. Read on to learn more about the potential benefits, side effects, and dosage.</p>
<h2><span id="What_is_7-Keto_DHEA"><b>What is 7-Keto DHEA?</b></span></h2>
<hr>
<p>&nbsp;</p>
<p>Adrenals, located at the top of the kidneys, produce hormones that play diverse roles in the body. One of these hormones is<b>&nbsp;DHEA,&nbsp;</b>which is the most abundant steroid in our bodies. DHEA and its derivatives are also produced in the<b>&nbsp;reproductive organs, and brain from</b>&nbsp;<a href="https://selfhacked.com/blog/cholesterol/"><b>cholesterol</b></a>&nbsp;[1,&nbsp;2].</p>
<p>DHEA is used in the body to make other hormones: weak estrogens (androstenediol) and powerful androgens. DHEA is also used to make 7-Keto DHEA [1,&nbsp;3].</p>
<p>People use 7-keto DHEA to boost immunity and mental health, reduce the signs of aging, and more.</p>
<h3><span id="7-Keto_DHEA_vs_DHEA"><b>7-Keto DHEA vs. DHEA</b></span></h3>
<p>Although 7-Keto DHEA and DHEA are similar, they can have different effects. 7-Keto may have more psychological effects than DHEA,<b>&nbsp;without influencing sex hormones</b>.</p>
<p>DHEA, on the other hand, achieves many effects by being converted to sex hormones – androgens. The research on both is still limited [4,&nbsp;5].</p>
<h3><span id="Mechanism_of_Action"><b>Mechanism of Action</b></span></h3>
<p>Are there specific “receptors” in the body DHEA binds to? For over 20 years scientists have tried to answer this question, which is still largely a mystery. There are components in the liver (<a href="https://selfhacked.com/blog/about-ppar-alpha-and-natural-ways-to-activate-it/">PPAR-alpha</a>, estrogen, and<a href="https://selfhacked.com/blog/natural-ways-to-increase-gaba/">&nbsp;GABA</a>) that bind to DHEA, but not much more is known [4].</p>
<p>Since DHEA and sex hormones decline with aging, many have referred to DHEA as the “fountain of youth.” But unlike DHEA, 7-keto cannot be used in the body to make sex hormones. Instead,&nbsp;<b>7-Keto is used for cell metabolism and brain functions.&nbsp;</b>Other 7-keto effects are different, too [6,&nbsp;7]:</p>
<h4><b>PPAR-alpha</b></h4>
<p>PPAR-alpha is a protein that helps make peroxisomes, burn fat, and boosts weight loss [8,&nbsp;9].</p>
<p>DHEA and its derivatives activate&nbsp;<a href="https://selfhacked.com/blog/about-ppar-alpha-and-natural-ways-to-activate-it/">PPAR alpha</a>. In one study mice with inactive PPAR-alpha gene took DHEA and were able to produce peroxisomes. It turns out that DHEA and its derivatives like 7-keto can all “turn on” the PPAR-alpha gene [9,&nbsp;10,&nbsp;11].</p>
<h4><b>Estrogen</b></h4>
<p>Unlike DHEA, 7-Keto has a very weak effect on estrogen receptors. DHEA has a much stronger effect, but both may boost the growth of estrogen-sensitive cells [12,&nbsp;13].</p>
<h4><b>GABA</b></h4>
<p>7-Keto, like many drugs, as well as alcohol, can alter GABA activity. 7-keto may<b>&nbsp;reduce the reinforcing effects of drinking alcohol,&nbsp;</b>possibly helping with alcohol dependence and abuse [14,&nbsp;15].</p>
<p>&nbsp;</p>
<h2><span id="Benefits_of_7-Keto_DHEA"><b>Benefits of 7-Keto DHEA</b></span></h2>
<hr>
<p>&nbsp;</p>
<h3><span id="Insufficient_Evidence">Insufficient Evidence:</span></h3>
<p><i>No valid clinical evidence supports the use of 7-keto DHEA for any of the conditions in this section. Below is a summary of up-to-date animal studies, cell-based research, or low-quality clinical trials which should spark further investigation. However, you shouldn’t interpret them as supportive of any health benefit.</i></p>
<h3><span id="1_Fat_Burning"><b>1) Fat Burning</b></span></h3>
<p>In one study, 33 overweight adults received 7-Keto DHEA supplements (200 mg/day) for 8 weeks. 7-keto, along with diet and&nbsp;<a href="https://selfhacked.com/blog/top-14-proven-health-benefits-exercise-references-mechanisms/">exercise</a>, reduced weight more than diet and exercise alone with no adverse effects [16].</p>
<p>7-Keto may benefit inactive overweight people. In a study of 40 subjects, 7-keto was used both alone and in combination with other supplements (<a href="https://selfhacked.com/blog/green-tea/">green tea</a>&nbsp;extract,&nbsp;<a href="https://selfhacked.com/blog/need-know-vitamin-c-32-science-based-health-benefits/">vitamin C</a>,<a href="https://selfhacked.com/blog/chromium/">&nbsp;chromium</a>, and&nbsp;<a href="https://selfhacked.com/blog/35proven-health-benefits-vitamin-d-part-1/">vitamin D</a><a href="https://selfhacked.com/blog/35proven-health-benefits-vitamin-d-part-1/">3</a>). Both options increased the metabolic rate, helping to burn more calories. The overweight patients were also on a calorie-restricted diet [17].</p>
<p>In mice, 7-Keto stimulated weight loss in fully grown mice; it reduced appetite, which is crucial for weight loss [18].</p>
<p><b>More research is needed to evaluate the effects of 7-keto DHEA on fat metabolism and weight control.</b></p>
<h3><span id="2_Cortisol_Reduction_and_Heart_Health"><b>2) Cortisol Reduction and Heart Health</b></span></h3>
<p><a href="https://selfhacked.com/blog/need-know-cortisol-health-effects/">Cortisol</a>&nbsp;levels will increase after a short period of<a href="https://selfhacked.com/blog/63-factors-raising-stress-cortisol-level-backed-science/">&nbsp;stress</a>, but may rapidly fall if the stress is prolonged. In one study, 7-Keto (25 mg single doses) gel was applied to the skin of 10 healthy men. After five days the cortisol levels decreased by 7.4% [19].</p>
<p>in the same study, 7-keto also increased<a href="https://selfhacked.com/blog/hdl-cholesterol/">&nbsp;HDL</a>-cholesterol, and apolipoprotein A-I, reducing the risk for clogged arteries and heart disease, especially in older men. It didn’t have any hormonal side effects, making it a potentially safe alternative to DHEA [19].</p>
<p><b>However, we can’t draw any reliable conclusions from a single small clinical trial such as this one.</b></p>
<h3><span id="3_PTSD"><b>3) PTSD</b></span></h3>
<p>In one study of 5 women with treatment-resistant PTSD, 7-keto DHEA (25-150 mg/day) rapidly improved PTSD symptoms [2,&nbsp;20].</p>
<p><b>Despite the promising initial findings, much more research is required.</b></p>
<h3><span id="Animal_and_Cellular_Research_Lacking_Evidence">Animal and Cellular Research (Lacking Evidence)</span></h3>
<p><i>No clinical evidence supports the use of 7-keto DHEA for any of the conditions listed in this section. Below is a summary of the existing animal and cell-based research, which should guide further investigational efforts. However, the studies listed below should not be interpreted as supportive of any health benefit.</i></p>
<h3><span id="4_Memory_Improvement"><b>4) Memory Improvement</b></span></h3>
<p>In one study, scientists observed the potential of 7-Keto to improve memory in both young and old mice with memory impairment. The effect was much stronger in young mice, in which 7-Keto completely reversed memory loss [21].</p>
<h3><span id="5_Depression_and_Thyroid_Function"><b>5) Depression and Thyroid Function</b></span></h3>
<p>In one study, chronic mild stress reduced&nbsp;<a href="https://selfhacked.com/blog/thyroid-hormones-t4t3/">thyroid hormones</a>&nbsp;and immune response (T cells) in mice with induced depression. Scientists observed the potential of 7-keto DHEA to reduce depressive symptoms and restore thyroid hormones and immune cell levels to normal [22].</p>
<h3><span id="6_Alcohol_Abuse"><b>6) Alcohol Abuse</b></span></h3>
<p>In one study, 7-Keto DHEA reduced the alcohol-seeking behavior and alcohol blood levels in mice [23].</p>
<p>In another rat study, it reduced alcohol intake. It had a stronger effect than DHEA at the same doses [24].</p>
<p><b>Once again, the discussed animal research looks promising, but we can’t draw any reliable conclusions until clinical trials confirm the results.</b></p>
<h3><span id="Limitations_and_Caveats"><b>Limitations and Caveats</b></span></h3>
<p>The biological functions, role in disease, and mechanism of action of 7-Keto DHEA are still under investigation. Clinical trials on 7-Keto DHEA are scant and have not studied its long-term use. Studies done on rats and mice may not continue to hold true in humans [2].</p>
<p>&nbsp;</p>
<h2><span id="7-Keto_DHEA_Side_Effects">7-Keto DHEA Side Effects</span></h2>
<hr>
<p>&nbsp;</p>
<p><i>Keep in mind that the safety profile of 7-keto DHEA is relatively unknown, given the lack of well-designed clinical studies. The list of side effects below is not a definite one, and you should consult your doctor about other potential side effects, based on your health condition and possible drug or supplement interactions.</i></p>
<p>7-Keto was found safe and well tolerated in preliminary clinical trials. In some patients, it caused mild side effects such as [25,&nbsp;26]:</p>
<ul>
<li>Nausea</li>
<li>Dizziness</li>
<li>Reduced blood pressure</li>
</ul>
<p><b>Pregnant women and children should avoid it due to the lack of safety data in these sensitive groups.</b></p>
<p>&nbsp;</p>
<h2><span id="7-Keto_DHEA_Supplements_and_Dosage"><b>7-Keto DHEA Supplements and Dosage</b></span></h2>
<hr>
<p>&nbsp;</p>
<p><i>7-Keto DHEA supplements have not been approved by the FDA for medical use. In general, regulatory bodies aren’t assuring the quality, safety, and efficacy of supplements. Speak with your doctor before supplementing.</i></p>
<h3><span id="Forms_of_Supplementation"><b>Forms of Supplementation</b></span></h3>
<p>7-keto is commonly sold in 100 mg and 25 mg pills. It can also be found in a powder supplement form, or as a topical gel – alone or combined with other ingredients.</p>
<h3><span id="Dosage"><b>Dosage</b></span></h3>
<p><i>The below doses may not apply to you personally. If your doctor suggests using 7-keto DHEA, work with them to find the optimal dosage according to your health condition and other factors.</i></p>
<p>The dosage of<b>&nbsp;200 mg per day</b>&nbsp;for 4-8 weeks was safe and produced mild benefits [25,&nbsp;16].</p>
<p>Older men received&nbsp;<b>25 mg</b>&nbsp;of 7-keto daily in the form of a gel applied to the skin [27].</p>
<p><b>25-150 mg</b>&nbsp;of 7-keto per day was safe and moderately effective in women with PTSD [2,&nbsp;20].</p>
<h3><span id="Reviews">Reviews</span></h3>
<p><i>The opinions expressed in this section are solely from the users who may or may not have a medical background. SelfDecode does not endorse any specific product, service, or treatment. Do not consider user experiences as medical advice. Never delay or disregard seeking professional medical advice because of something you have read on SelfDecode.</i></p>
<p>Many users praise the ability of 7-keto to boost weight loss. One user said that it was the fastest and easiest way that they have found to&nbsp;<a href="https://selfhacked.com/blog/a-comprehensive-list-of-effective-ways-to-lose-weight/">lose weight</a>&nbsp;– they were unable to exercise, but ate healthily and lost weight after taking 7-Keto.</p>
<p>One user had chest<a href="https://selfhacked.com/blog/23-ways-to-combat-pain-naturally-by-increasing-your-opioids/">&nbsp;pain</a>&nbsp;from 7-keto DHEA, leading him to stop taking the supplement and go to the ER. Many users complained about hair loss and<a href="https://selfhacked.com/blog/natural-treatment-migraines/">&nbsp;headaches</a>.</p>
<p>Reviewers say that 7-keto is a more effective supplement for&nbsp;<a href="https://selfhacked.com/blog/a-comprehensive-list-of-effective-ways-to-lose-weight/">weight loss</a>, while DHEA is more effective at reducing menopause symptoms and aging.</p>
<p>&nbsp;</p>
<h3>About the Author</h3>
<hr>
<p>&nbsp;</p>
<h4 class="name">Aleksa Ristic</h4>
<div class="credentials" bis_skin_checked="1">MS (PHARMACY)</div>
<div class="summary" bis_skin_checked="1">Aleksa received his MS in Pharmacy from the University of Belgrade, his master thesis focusing on protein sources in plant-based diets.</div>
<div class="biography" bis_skin_checked="1">Aleksa is passionate about herbal pharmacy, nutrition, and functional medicine. He found a way to merge his two biggest passions—writing and health—and use them for noble purposes. His mission is to bridge the gap between science and everyday life, helping readers improve their health and feel better.</div>
<h2></h2>
<h2>Source</h2>
<hr>
<p>&nbsp;</p>
<p>https://selfhacked.com/blog/7-keto-dhea/</p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/06/01/7-keto-dhea-benefits-side-effects-dosage-reviews/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/06/01/7-keto-dhea-benefits-side-effects-dosage-reviews/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5211 post type-post status-publish format-standard hentry category-articles animated"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g" class="avatar avatar-144 photo lazyloaded" height="144" width="144" srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" data-ll-status="loaded"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>30.05.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/05/30/6p-hydroxylation-of-steroids-by-extracts-of-aspergillus-niger/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/05/30/6p-hydroxylation-of-steroids-by-extracts-of-aspergillus-niger/">6P-Hydroxylation of Steroids by Extracts of Aspergillus niger</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><p>By I. A. EL-KADY<br>
Department of Botany, Faculty of Science, Assiut University, Assiut, Egypt<br>
(Received 28 August 1981 ; revised 19 January 1982)</p>
<p>Growing cultures of Aspergillus niger hydroxylate progesterone at the 6P and 1 la positions. The properties of the 6p-hydroxylase activity were studied in extracts of this organism using llahydroxyprogesterone as substrate. Maximum 6P-hydroxylase activity was obtained at pH 6.5. EDTA and thiophenol inhibited hydroxylation, while NADPH, 2-oxoglutarate and pyruvate stimulated it. Cobalt and cadmium ions inhibited the 6P-hydroxylase activity. The feasibility of introducing a hydroxyl group into the 6P-position of various steroid compounds was tested : the 3-0X0-A4 configuration appeared to exert a directional effect for 6p-hydroxylation, while an 118-<br>
hydroxyl group exerted some kind of steric hindrance against 6p-hydroxylation.</p>
<p>&nbsp;</p>
<h2>INTRODUCTION</h2>
<hr>
<p>&nbsp;</p>
<p>The important discovery by Peterson &amp; Murray (1952) of the microbiological 1 la-hydroxylation of progesterone and other steroids led to the use of a variety of micro-organisms for hdyroxylating every position in the steroid nucleus. However, steroid hydroxylation by extracts of micro-organisms has been described in only a few instances. Zuidweg et al. (1962) prepared an extract from Curvularia Zunata capable of catalysing the hydroxylation of Reichstein’s compound S to hydrocortisone. A 9a-hydroxylase activity was demonstrated in extracts of Nocardia restrictus by Chang &amp; Sih (1964). Wilson &amp; Vestling (1965) obtained an extract from Bacillus megaterium KM able to hydroxylate deoxycorticosterone mainly at the 15p position. Zuidweg (1968), using extracts of C. Zunata, studied the nature of the hydroxylation of Reichstein’s compound S at the 1lP and 14a positions. Sallam et al. (1971), using a cell homogenate of Rhizopus nigricans REF 129, studied the hydroxylation of progesterone at the 1 la, 17a and 21 positions. Nguyen-Dang-Tam et al. (1971) showed that extracts of Aspergillus niger catalysed the hydroxylation of progesterone at the 1 la position. Previously, I have studied the hydroxylation of progesterone at the 1 la and 17a positions by extracts of Rhizopusnigricans NRRL 1477 (El-Kady &amp; Allam, 1973; Allam &amp; El-Kady, 1975). In this report, I describe an investigation of the 6P-hydroxylation of progesterone and 1 la-hydroxyprogesterone by extracts of Aspergillus niger.</p>
<p>&nbsp;</p>
<h2>METHODS</h2>
<hr>
<p>&nbsp;</p>
<p>Cultures. Aspergillus niger isolate no. 58 (from the Culture Collection of the Mycological Laboratory, Botany Department, Assiut University, Egypt) was cultivated in 250 ml Erlenmeyer flasks which contained 50 ml of the medium described by Capek et al. (1964). The pH was adjusted to 5.6. After sterilization, each flask was inoculated with 2ml of a spore suspension made from a 1-week old culture. The inoculated flasks were agitated on a reciprocating shaker at 28 “C. After 24 h growth, the cultures were activated by the addition of 5 mg progesterone per flask and reagitated for another 24 h.<br>
Preparation of extracts. Mycelium was harvested by filtration, washed, thoroughly with 0.5 % (w/v) NaCl solution, followed by distilled water, and blotted dry with absorbent paper. This mycelium (1 5 g) was then ground with cold sand and extracted with 100 ml cold water or 0.1 M-pOtaSSiUm phosphate buffer, pH 6-5. The slurry obtained was centrifuged at 4000 rev. min-‘ for 15 min and the supernatant was used as the enzyme source.<br>
Assay of6P-hydroxylating activity in extracts. To 5 ml portions of the extracts in 25 ml Erlenmeyer flasks were added 5 mg 1 la-hydroxyprogesterone in 0-1 ml ethanol. The contents were mixed immediately and the flasks were agitated on a reciprocating shaker for 5 h at 30°C. At the end of this period the contents of each flask were extracted with 10 ml chloroform. Extraction was repeated three times and the combined chloroform extracts were then treated with 0.5 vol. of 5% (w/v) sodium bicarbonate solution followed by an equal volume of distilled water. The residue was dissolved in a measured volume of chloroform/methanol (1 : 1, by vol.). Determination of reaction products. The hydroxylated product in the prepared residue was first identified by conventional thin-layer chromatography with an authentic sample, using cyclohexane/acetone/chloroform (75 : 25 : 20, by vol.) as solvent. The amounts of the product and residual substrate were determined by preparative thin-layer chromatography with the same solvent. The bands containing the compounds were scraped off and eluted with ethanol. The concentration of each was then determined by U.V. spectrophotometric measurement.</p>
<p>&nbsp;</p>
<h2>RESULTS AND DISCUSSION</h2>
<hr>
<p>&nbsp;</p>
<p>Out of 40 different isolates from five genera (Rhizopus, Mucor, Cunninghamella, Cladosporium and Aspergillus) tested for 61-hydroxylation activity, Aspergillus niger isolate no. 58 was the most active and was chosen for further study. Growing cultures of this organism converted 80% of added progesterone (50 mg per 50 ml medium) to 1 la-hydroxyprogesterone (10 mg) and 6p,1 ladihydroxyprogesterone (30 mg) within 48 h. Using 1 la-hydroxyprogesterone as a substrate, the stability of the 6P-hydroxylating activity was tested in extracts stored at 5 and – 10 “C. Extracts kept at 5 “C lost 90% of their activity in 24 h and those kept at – 10 “C lost 60% of their activity in the same period. After 48 h at either temperature all activity was lost. In earlier studies (Chang &amp; Sih, 1964; El-Kady &amp; Allam, 1973) microbial steroid-hydroxylating systems were shown to be unstable.<br>
Efect of pH. The effect of different pH values on the 6P-hydroxylating activity was studied. Portions (4 ml) of the extract in distilled water were adjusted to pH values ranging from 5-5 to 9 using phosphate or Tris buffers (500 pmol). Hydroxylation at the 6P position increased with increase in pH, reaching a maximum at pH 6-5. At this pH, 42% of the added 1 la-hydroxyprogesterone was converted to 6p, 1 la-dihydroxyprogesterone. At pH values between 7 and 9, the 6P-hydroxylase activity decreased linearly with pH.<br>
Efect of EDTA. EDTA has been used in most studies of the hydroxylation of steroids by extracts of micro-organisms (Zuidweg et al., 1962; Chang &amp; Sih, 1964; Zuidweg, 1968; Sallam et al., 1971 ; El-Kady &amp; Allam, 1973). The effect of different concentrations of this compound on the 6P-hydroxylating activity was tested. The presence of EDTA at a concentration as low as 5 mM inhibited about 30% of the 6P-hydroxylase activity. Higher concentrations of EDTA were more inhibitory (data not presented). This suggests that a metal cation is involved in the hydroxylation.<br>
Eflect of some external electron carriers and thiol compounds. A marked stimulation of 6phydroxylase activity was observed in the presence of NADPH (Table 1). 2-Oxoglutarate and pyruvate had a similar effect, but ascorbate, fumarate and succinate were completely inactive. These results are consistent with earlier reports that 2-oxoglutarate stimulates different hydroxylation reactions (Hayaishi, 1969), and that pyruvate can replace 2-oxoglutarate in some enzymic hydroxylation reactions (Hayaishi, 1969).<br>
The effect of some thiol compounds was also studied (Table 2). Glutathione, at a concentration of 5 mM, stimulated 6P-hydroxylase activity, while 2-mercaptoethanol, sodium thioglycolate and cysteine.HC1 had no effect. On the other hand, thiophenol, at the same concentration, caused some inhibition.<br>
Efect of some metal ions. The 6P-hydroxylase activity was sensitive to Co2+ and Cd2+ which inhibited 80% and 60% of the 6P-hydroxylase activity, respectively (Table 3). Previous reports (El-Kady &amp; Allam, 1973) showed that Co2+ completely inhibited both 1 la- and 17a-hydroxylase activities.<br>
Substrate specijicity. The feasibility of introducing a hydroxyl group into the 68 position of some steroid compounds was tested. The following compounds were equally active as substrates for the 6P-hydroxylase : progesterone, 1 1 a-hydroxyprogesterone, 17a-hydroxyprogesterone, 21 – hydroxyprogesterone, 1 1 a, 17a-dihydroxyprogesterone, epicortisol, testosterone, 1 1 a hydroxytestosterone and androst-4-ene-3,17-dione. In contrast, the following compounds were found to be inactive for the 6p-hydroxylase : 1 1 p-hydroxyprogesterone, 1 1 or-hydroxy-5a-pregnane-3,20-dione, 17a-hydroxy-5a-pregnane-3,20-dione, 5a-pregnane-3p, 17a,21-triol-2O-one, 1 1/3,21-dihydroxyprogesterone, cortisol, cholesterol and ergosterol. It was noted that all the active substrates contained the 3-oxo-A4 configuration. Hence, this configuration probably exerts a directional effect for 6Q-hydroxylation. The inactive compounds lack at least one of these two functional groups (3-oxo-A4-), except 1 1 p-hydroxyprogesterone, 1 1p,2 1 -dihydroxyprogesterone and cortisol which contain the 3-oxo-A4 configuration but also possess an 1 1 P-hydroxyl group. Thus, it appears that an 1 lp-hydroxyl group exerts some kind of’ steric hindrance against 6phydroxylat ion.</p>
<p>Table 1. Efect of some electron carriers on 6P-hydroxylation</p>
<p><img class="alignnone size-medium wp-image-5212" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20640%20722'%3E%3C/svg%3E" alt="" width="640" height="722" data-lazy-srcset="/../../../../wp-content/uploads/2021/01/tables-123-640x722.jpg 640w, //ikigaicorporation.com/wp-content/uploads/2021/01/tables-123-320x361.jpg 320w, //ikigaicorporation.com/wp-content/uploads/2021/01/tables-123.jpg 718w" data-lazy-sizes="(max-width: 640px) 100vw, 640px" data-lazy-src="/../../../../wp-content/uploads/2021/01/tables-123-640x722.jpg"><noscript><img class="alignnone size-medium wp-image-5212" src="/../../../../wp-content/uploads/2021/01/tables-123-640x722.jpg" alt="" width="640" height="722" srcset="/../../../../wp-content/uploads/2021/01/tables-123-640x722.jpg 640w, //ikigaicorporation.com/wp-content/uploads/2021/01/tables-123-320x361.jpg 320w, //ikigaicorporation.com/wp-content/uploads/2021/01/tables-123.jpg 718w" sizes="(max-width: 640px) 100vw, 640px" /></noscript></p>
<p>&nbsp;</p>
<h2>REFERENCES</h2>
<hr>
<p>&nbsp;</p>
<p>ALLAM, A. M. &amp; EL-KADY, I. A. (1975). The lla- and 17a-progesterone hydroxylases of Rhizopus nigricans NRRL 1477. Acta microbwlogica polonica, Series A7(24), 41-44.<br>
CAPEK, A., TADRA, M. &amp; TUMA, J. (1964). Separation of androst- 1 7-hydroxy-epimers. Folia microbiologica<br>
CHANG, F. N. &amp; SIH, C. J. (1964). Mechanisms of steroid oxidation by microorganisms. VII. Properties of the 9a-hydroxylase. Biochemistry 3, 1551-1557.<br>
EL-KADY, I. A. &amp; ALLAM, A. M. (1973). Hydroxylation of progesterone by extracts of Rhizopus nigricans NRRL 1477. Journal of General Microbwlogy 77, 465-469.<br>
HAYAISHI, 0. (1969). Enzymic hydroxylation. Annual Review of Biochemistry 38, 21-44.<br>
NGUYEN-DANG-TAM, MAYER, M. &amp; JANOT, M. M.(1971). Hydroxylation of progesterone by cell-free extract of Aspergillus niger. Compte rendu hebdomadaire des dances de I’Acadkmie des sciences D272, 9, 380-382. 2032-2033.</p>
<p>PETERSON, D. H. &amp; MURRAY, H. C. (1952). Microbiological oxygenation of steroids at carbon 1 1. Journal of the American Chemical Society 74, 1871-1872.<br>
SALLAM, L.A. R., EL-REFAI, A. H. &amp; EL-KADY, I. A. (1971). The in vitro transformation of progesterone by Rhizopus nigricans REF 129. Zeitschrifr fur allgemeine Mikrobiologie 11, 325-330.<br>
WILSON, J. A. &amp; VESTLING, C. S. (1965). A cell-free steroid hydroxylating system from Bacillus megaterium, strain KM. Archives of Biochemistry and Bwphysics 110, 401-403.<br>
ZUIDWEG, M. H. J. (1968). Hydroxylation of Reichstein’s compound S with cell-free preparation from Curvularia lunata. Bwchimica et bwphysica acta 152, 144.<br>
ZUIDWEG, M. H. J., VAN DER WAARD, W. F. &amp; DE FLINES, J.(1962). Formation of hydrocortisone by hydroxylation of Reichstein’s compound S with an enzyme preparation from Curvularia lunata. Biochimica et biophysica acta 58, 131-133.</p>
<p>&nbsp;</p>
<h2>Source:</h2>
<hr>
<p>&nbsp;</p>
<p>https://www.microbiologyresearch.org/content/journal/micro/10.1099/00221287-128-11-2511;jsessionid=6koy8LppgxEyfoteJePlodIp.mbslive-10-240-10-165</p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/05/30/6p-hydroxylation-of-steroids-by-extracts-of-aspergillus-niger/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/05/30/6p-hydroxylation-of-steroids-by-extracts-of-aspergillus-niger/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5207 post type-post status-publish format-standard hentry category-articles animated"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20144%20144'%3E%3C/svg%3E" data-lazy-srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" class="avatar avatar-144 photo" height="144" width="144" data-lazy-src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>16.05.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/05/16/steroid-transformation-by-dactylium-dendroides-bulliard-fries/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/05/16/steroid-transformation-by-dactylium-dendroides-bulliard-fries/">Steroid Transformation by Dactylium dendroides (Bulliard) Fries</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><p>EUGENE L. DULANEY, W. J. McALEER, H. R. BARKEMEYER and CHARLES HLAVAC<br>
Research Laboratories, Chemical Division, Merck &amp; Co., Inc., Rahway, New Jersey Received for publication July 18, 1955</p>
<p>The transformation of 17-desoxysteroid to 17ahydroxysteroid has been reported recently by Meystre et al. (1954) and Meister et al. (1954). Trichothecium roseum Cda. was the organism used in both instances. Transformation of progesterone to 1 la, 17a-dihydroxyprogesterone by T. roseum has been obtained also in these laboratories. The present communication reports<br>
steroid hydroxylation, including the introduction of 17a-hydroxyl, by Dactylium dendroides.</p>
<p>&nbsp;</p>
<h2>MATERIALS AND METHODS</h2>
<hr>
<p>&nbsp;</p>
<p>Two cultures of Dactylium dendroides obtained from the Quartermaster Corps Culture Collection were studied. Both exhibited similar steroid transformation patterns on preliminary investigation and one was<br>
selected for further study. Two media were used in these studies. A synthetic medium of the following composition was employed<br>
for large scale growth from which 1 la, 17a-dihydroxyprogesterone was isolated: dextrose 50 g, (NH4)2HP04 7.5 g, K2HP04 1 g, KCI 0.5 g, MgS04*7H20 0.5 g, FeS04*7H20 0.01 g, ZnS04*7H20 0.01 g, and distilled H20 to 1 liter. For growth and steroid transformation studies in shaken Erlenmeyer flasks, the following medium was used: cerelose 50 g, edamine 20 g, corn steep liquor 5 ml, and H20 to 1 liter (Murray and Peterson, 1952). The pH was adjusted to 6.5 before sterilization. Vegetative growth, developed in the latter medium, was used for inoculum in all experiments.</p>
<p>In the shaken flask experiments 50 ml of medium was dispensed in 250-ml Erlenmeyer flasks and sterilized by autoclaving at 15 lb pressure for 17 minutes. These were inoculated with 5 ml of vegetative growth. The inoculated flasks were incubated at 28 C on rotary shakers moving at 220 rpm and describing a circle 1.5 inches in diameter. After 48 to 72 hours growth, the flasks were charged with 20 mg of steroid in 0.5 ml of dimethylformamide. The charged flasks were incubated further, individual flasks being removed at the desiredtime for assay. For assay, the contents of a flask were homogenized in a Waring blender in 100 ml of ethyl acetate for 10 minutes. The solvent was separated from the homogenized growvth by filtration and the filtrate extracted with three other 100-ml portions of ethyl acetate. The ethyl acetate extracts were combined, evaporated under reduced pressure to a volume of 12 ml and spotted on strips of Whatman No. 1 filter paper. Papergrams were developed using the solvent systems of Zaffaroni and associates (Zaffaroni et al., 1950; Burton et al., 1951; and Zaffaroni and Burton, 1951). The steroids were located by means of an ultraviolet light scanner (Haines and Drake, 1950), eluted in pure methanol, and the per cent transformations calculated from optical densities determined at 2400 A. The introduction of 1 a- and 17a-hydroxyls by Dactylium dendroides was confirmed by isolation and<br>
characterization of 11a, 17a-dihydroxyprogesterone from conversions in synthetic medium. Approximately 28 liters of growth were incubated 78 hours following the addition of 24.4 g of progesterone. The broth and mycelium were extracted with portions of ethyl acetate. The 25 liters of ethyl acetate extract were reduced to 6 liters, washed well with saturated aqueous NaHCO3 and distilled H20, then further evaporated to a volume of 150 ml. This was shaken with 50 ml of acetone and placed at 4 C overnight after which 2 g of solids were removed by filtration. The filtrate was concentrated to near dryness and partitioned between 50 per cent<br>
aqueous methanol and petroleum ether. The methanol fraction then was evaporated and extracted with ethyl acetate. The ethyl acetate fraction was further evaporated and placed at 4 C overnight. Papergrams of the crude crystals thus obtained showed la, 17adihydroxyprogesterone to be present along with progesterone, lca-hydroxyprogesterone, and a product near the mobility of 6# , 11a-dihydroxyprogesterone. The ethyl acetate solution of these crude crystals was streaked on sheets of Whatman No. 4 paper and</p>
<p>TABLE 1. Qualitative test of steroid transformation by Dactylium dendroides papergrams developed to separate the 1 la, 17adihydroxyprogesterone bands. These bands were cut out, eluted with methanol, the methanol removed, and the residue partitioned between ethyl acetate and H20. The ethyl acetate layer was treated with anhydrous Na2SO4, filtered, and the filtrate concentrated. The crystals thus obtained were recrystallized from ethyl acetate. This crystalline product was compared with an authentic reference sample of 1 la, 17a-dihydroxyprogesterone.</p>
<p><img class="alignnone size-full wp-image-5208" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20497%20376'%3E%3C/svg%3E" alt="" width="497" height="376" data-lazy-srcset="/../../../../wp-content/uploads/2021/01/table-1-steroid.jpg 497w, //ikigaicorporation.com/wp-content/uploads/2021/01/table-1-steroid-320x242.jpg 320w" data-lazy-sizes="(max-width: 497px) 100vw, 497px" data-lazy-src="/../../../../wp-content/uploads/2021/01/table-1-steroid.jpg"><noscript><img class="alignnone size-full wp-image-5208" src="/../../../../wp-content/uploads/2021/01/table-1-steroid.jpg" alt="" width="497" height="376" srcset="/../../../../wp-content/uploads/2021/01/table-1-steroid.jpg 497w, //ikigaicorporation.com/wp-content/uploads/2021/01/table-1-steroid-320x242.jpg 320w" sizes="(max-width: 497px) 100vw, 497px" /></noscript></p>
<p>TABLE 2. Quantitative assay of steroid transformation by Dactylium dendroides</p>
<p><img class="alignnone size-medium wp-image-5209" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20640%20229'%3E%3C/svg%3E" alt="" width="640" height="229" data-lazy-srcset="/../../../../wp-content/uploads/2021/01/table-2-steroid-640x229.jpg 640w, //ikigaicorporation.com/wp-content/uploads/2021/01/table-2-steroid-320x115.jpg 320w, //ikigaicorporation.com/wp-content/uploads/2021/01/table-2-steroid.jpg 1020w" data-lazy-sizes="(max-width: 640px) 100vw, 640px" data-lazy-src="/../../../../wp-content/uploads/2021/01/table-2-steroid-640x229.jpg"><noscript><img class="alignnone size-medium wp-image-5209" src="/../../../../wp-content/uploads/2021/01/table-2-steroid-640x229.jpg" alt="" width="640" height="229" srcset="/../../../../wp-content/uploads/2021/01/table-2-steroid-640x229.jpg 640w, //ikigaicorporation.com/wp-content/uploads/2021/01/table-2-steroid-320x115.jpg 320w, //ikigaicorporation.com/wp-content/uploads/2021/01/table-2-steroid.jpg 1020w" sizes="(max-width: 640px) 100vw, 640px" /></noscript></p>
<p>&nbsp;</p>
<h2>RESULTS AND DISCUSSION</h2>
<hr>
<p>&nbsp;</p>
<p>Results of a study of transformation of six steroids by Dactylium dendroides are summarized in table 1. In this experiment, individual shaken Erlenmeyer flasks were incubated for 24 and 72 hours following steroid charge then pooled and assayed qualitatively.<br>
The addition of an Ila or a 17a-hydroxyl to various steroids is indicated quite clearly. Apparently both the lla- and 17a-hydroxyls are added to progesterone and 11-desoxycorticosterone. The transformation of progesterone to 1la, 17a-dihydroxyprogesterone was proved conclusively by isolation of the 1la, 17a-dihydroxy derivative and comparing it with an authentic reference<br>
sample of hla, 17a-dihydroxyprogesterone. The following comparisons show the isolated product and the reference la, 17a-diol to be identical: Mixed chromatograms: The isolation product could not be separated from the reference 1 la, 17adihydroxyprogesterone in&nbsp; mixed papergrams. Sulfuric acid chromogen: That of the isolated product is identical with that of the reference 1la, 17adiol.<br>
Melting point: Isolated product, 224-227 C; remelts 248-251 C; reference hla, 17a-diol, 225-227 C; remelts 249-252 C.<br>
Ultraviolet absorption spectrum: Isolated product, XH2804 290 m,u, 370 m,u, 450 m,i, identical with that of reference 1la, 17a-diol.</p>
<p>Infra-red spectrum: Isolated product, ‘X .., 2.93 I,¾ 5.82 l,u 6.02 IA, 6.18 Iu; reference 1la,17a- diol, nujol 295 I,u 5.91 A), 6.0 ,g, 6.20 u. Specific rotation: Isolated products = [a]14 + 74 (C = 1.0 in methanol) The above results show the ability of Daclylium dendroides to introduce lla- or 17a-hydroxyl into various steroids. Some of these transformations have been measured quantitatively with the results given in table 2. The results in tables 1 and 2 reveal the effect of substrate specificity. It appears that under the limited<br>
experitnental conditions employed, that substrates containing an 1 1a-hydroxyl are more easily transformed by the addition of a 17a-hydroxyl. The data supporting this thesis are not extensive. Steroid transformation has iiot been studied under a wide variety of conditions. Moreover, the number of steroids used as substrate is limited. Transformations of 11-keto steroids are not reported and a small number of substrates containing 1 13-hydroxyls were charged. The presence of a hydroxyl at carbon-21 has no effect on the further direction of hydroxylation. When 11, 17-desoxy steroids are charged, however, the 1 Iahydroxyl appears to be added first followed by the 17ahydroxyl. Thus, with progesterone as the substrate, one can detect i la-hydroxyprogesterone and 1ha, 17a, dihydroxyprogesterone as transformation products. This would indicate the transformation of progesterone to 1 la-hydroxyprogesterone and further conversion of this derivative to 1la, 17a-dihydroxyprogesterone. In table 2, progesterone is reported to be transformed to lca-hydroxyprogesterone in 30 per cent yield. If one assumes, however, that all of the 1ha, 17a-dihydroxyprogesterone was formed via lla-hydroxyprogesterone, then approximately 45 per cent of the charged progesterone must have been converted to lc1a-hydroxyprogesterone. Conversely, it might be argued that progesterone is also transformed to 17a-hydroxyprogesterone and this derivative transformed immediately to l la,17adihydroxyprogesterone. Thus formation of 17a-hydroxyprogesterone would be rate limiting and the 17ahydroxyprogesterone would be difficult to detect. The lla, 17a-dihydroxyprogesterone would be formed, simultaneously via the 1 la- and 17a-hydroxyprogesterone.</p>
<p>Transformation of 11-desoxycorticosterone, also, shows the presence of an 1la-hydroxyl favors 17ahydroxylation. The 11-desoxycorticosterone is transformed to epi-corticosterone. This derivative apparently is converted to compound epi F although this<br>
latter product is present in low yield. Failure to detect 11-desoxy-17a-hydroxycorticosterone from charged 11- desoxycorticosterone and 17a-hydroxycorticosterone from corticosterone would indicate the addition of a 17a-hydroxyl to these substrates must occur at a low level, if at all under these conditions.</p>
<h2>SUMMARY</h2>
<hr>
<p>&nbsp;</p>
<p>Dactylium dendroides is capable of introducing an 1la-hydroxyl and/or a 17a-hydroxyl to a number of steroid substrates. The transformation pattern is determined by the steroid substrate. The presence of a hydroxyl at carboni-21 had no observed effect on the route of transformation. The presence of a hydroxyl with the a-configuration at carbon-il appears to favor<br>
17a-hydroxylation under the experimental conditions employed. The 11 desoxy steroids, progesterone, 1 1-desoxycorticosterone, and 17a-hydroxyprogesterone, were converted to the lla-hydroxy derivatives.</p>
<p>&nbsp;</p>
<h2>REFERENCES</h2>
<hr>
<p>&nbsp;</p>
<p>BURTON, R. B., ZAFFARONI, A., AND KEUTMANN, E. H. 1951<br>
Paper chromatography of steroids. II. Corticosteroids and related compounds. J. Biol. Chem., 188, 763-771.<br>
HAINES, W. J., AND DRAKE, N. A. 1950 Fluorescence scanner for evaluation of papergrams of cortical hormones. Federation Proc., 9, 180.<br>
MEISTER, P. D., REINEKE, L. M., MEEKS, R. C., MURRAY, H.<br>
C., EPPSTEIN, S. H., LEIGH OSBORN, H. M., WEINTRAUB, A., AND PETERSON, D. H. 1954 Microbiological transformation of steroids. XII. 17a-hydroxylation. J. Am.<br>
Chem. Soc., 76, 4050-4051.<br>
MEYSTRE, C., VISCHER, E., AND WETTSTEIN, A. 1954 Microbiological hydroxylation of steroids in the 17a and 21- positions. Microbiological reactions, fourth communication. Helv. Chim. Acta, 37, 1548-1553.<br>
MURRAY, H. C., AND PETERSON, D. H. 1952 Oxygenation of steroids by mucorales fungi. U. S. Patent 2,602,769.<br>
July 8.<br>
ZAFFARONI, A., BURTON, R. B., AND KEUTMANN, E. H. 1950<br>
Adrenal cortical hormones; analysis by paper partition chromatography and occurrence in the urine of normal persons. Science, 111, 6-8.<br>
ZAFFARONI, A., AND BURTON, R. B. 1951 Identification of corticosteroids of beef adrenal extracts by paper chromatography. J. Biol. Chem., 193, 749-767.</p>
<p>&nbsp;</p>
<h2>Source:</h2>
<p>https://aem.asm.org/content/aem/3/6/372.full.pdf?ck=nck</p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/05/16/steroid-transformation-by-dactylium-dendroides-bulliard-fries/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/05/16/steroid-transformation-by-dactylium-dendroides-bulliard-fries/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5202 post type-post status-publish format-standard hentry category-articles animated"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20144%20144'%3E%3C/svg%3E" data-lazy-srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" class="avatar avatar-144 photo" height="144" width="144" data-lazy-src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>02.05.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/05/02/development-of-a-chemoenzymatic-process-for-dehydroepiandrosterone-acetate-synthesis/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/05/02/development-of-a-chemoenzymatic-process-for-dehydroepiandrosterone-acetate-synthesis/">Development of a Chemoenzymatic Process for Dehydroepiandrosterone Acetate Synthesis</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><p><span class="hlFld-ContribAuthor">Anna Fryszkowska, </span>Justine Peterson, Nichola L. Davies, Colin Dewar, George Evans, Matthew Bycroft, Neil Triggs, Toni Fleming, Srikanth Sarat Chandra Gorantla, Garrett Hoge, <span class="hlFld-ContribAuthor">Michael Quirmbach, </span>Upadhya Timmanna,Srinivas Reddy Poreddy, D. Naresh Kumar Reddy, <span class="hlFld-ContribAuthor">Vilas Dahanukar</span>,&nbsp;and&nbsp;<span class="hlFld-ContribAuthor">Karen E. Holt-Tiffin</span><span class="author-xref-symbol "><sup>*</sup></span></p>
<h2 id="Abstract" class="article_abstract-title">Abstract</h2>
<hr>
<p>&nbsp;</p>
<p>Dehydroepiandrosterone (DHEA,&nbsp;<b>2</b>) is an important endogenous steroid hormone in mammals used in the treatment of a variety of dysfunctions in female and male health,1 as well as an intermediate in the synthesis of steroidal drugs, such as abiraterone acetate which is used for the treatment of prostate cancer.2−4 In this manuscript we describe a novel, concise, and cost-efficient route toward DHEA (<b>2</b>) and DHEA acetate (<b>3</b>) from 4-androstene-3,17-dione (4-AD,&nbsp;<b>1</b>). Crucial to success was the identification of a ketoreductase from&nbsp;<i>Sphingomonas wittichii</i>&nbsp;for the highly regio- and stereoselective reduction of the C3-carbonyl group of 5-androstene-3,17-dione (<b>5</b>) to the required 3β-alcohol (<b>2</b>, &gt;99% de). The enzyme displayed excellent robustness and solvent stability under high substrate concentrations (up to 150 g/L).</p>
<p><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" data-lazy-src="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/oprdfk/2016/oprdfk.2016.20.issue-8/acs.oprd.6b00215/20160815/images/medium/op-2016-00215r_0006.gif"><noscript><img src="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/oprdfk/2016/oprdfk.2016.20.issue-8/acs.oprd.6b00215/20160815/images/medium/op-2016-00215r_0006.gif" /></noscript></p>
<p>&nbsp;</p>
<h2 id="_i1">1 Introduction</h2>
<hr>
<p>&nbsp;</p>
<div class="NLM_p" bis_skin_checked="1">3β-Hydroxyandrost-5-en-17-one (<b>2</b>), also known as dehydroepiandrosterone (DHEA) or prasterone, is an important endogenous steroid hormone<a class="ref ref1">(1)</a>&nbsp;and a precursor in the synthesis of other steroidal drugs such as abiraterone acetate (Zytiga), a drug developed for the treatment of castration-resistant prostate cancer.<a class="ref ref2 ref3 ref4">(2-4)</a>&nbsp;Current routes toward DHEA (<b>2</b>) and DHEA acetate (<b>3</b>) are typically based on the selective degradation of yam-derived diosgenin to 16-dehydropregnenolone acetate (<b>29</b>),<a class="ref ref5 ref6">(5, 6)</a>&nbsp;followed by oxime formation and rearrangement (Scheme 1).<a class="ref ref5 ref6 ref7 ref8">(5-8)</a></div>
<div bis_skin_checked="1"></div>
<p class="NLM_p"><strong>Scheme 1</strong></p>
<p><img src="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/oprdfk/2016/oprdfk.2016.20.issue-8/acs.oprd.6b00215/20160815/images/medium/op-2016-00215r_0001.gif" class="lazyloaded" data-ll-status="loaded"><noscript><img src="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/oprdfk/2016/oprdfk.2016.20.issue-8/acs.oprd.6b00215/20160815/images/medium/op-2016-00215r_0001.gif" /></noscript></p>
<p>&nbsp;</p>
<figure id="sch1" class="article__inlineFigure" data-index="1"><figcaption>
<div class="hlFld-FigureCaption caption" bis_skin_checked="1">
<div class="title2" bis_skin_checked="1">Scheme 1. Diosegenin (<b>28</b>) and Stigmasterol (<b>31</b>) as Precursors for DHEA Acetate (<b>3</b>) Synthesis</div>
</div>
</figcaption></figure>
<div class="NLM_p" bis_skin_checked="1">Dependence on raw materials with variable availability often drives the development of alternative processes for steroid drug manufacture.<a class="ref ref5">(5)</a>&nbsp;Here, we aimed to develop a novel and scalable route to DHEA acetate (<b>3</b>) from 4-androstene-3,17-dione (4-AD,&nbsp;<b>1</b>), which is derived from phytosterols obtained from soybeans (e.g., stigmasterol,&nbsp;<b>31</b>;&nbsp;<a class="ref internalNav" href="https://pubs.acs.org/doi/10.1021/acs.oprd.6b00215#sch1" aria-label="Scheme 1">Scheme 1</a>).<a class="ref ref5 ref9 ref10 ref11">(5, 9-11)</a></div>
<div class="NLM_p" bis_skin_checked="1">Nature offers a vast array of enzymes that can be used to access the structural and functional diversity of steroids<a class="ref ref10 ref11">(10, 11)</a>and they often display high substrate specificity, as well as remarkable regio- and stereoselectivity. During the initial phase of route scouting for possible ways to make dehydroepiandrosterone acetate (<b>3</b>) from 4-AD (<b>1</b>), we considered several possible chemoenzymatic approaches, including routes A and B depicted in&nbsp;Scheme 2.</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"><strong>Scheme 2</strong></div>
<div bis_skin_checked="1"><img src="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/oprdfk/2016/oprdfk.2016.20.issue-8/acs.oprd.6b00215/20160815/images/medium/op-2016-00215r_0002.gif" class="lazyloaded" data-ll-status="loaded"><noscript><img src="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/oprdfk/2016/oprdfk.2016.20.issue-8/acs.oprd.6b00215/20160815/images/medium/op-2016-00215r_0002.gif" /></noscript></div>
<div bis_skin_checked="1">
<figure id="sch2" class="article__inlineFigure" data-index="2"><figcaption>
<div class="hlFld-FigureCaption caption" bis_skin_checked="1">
<div class="title2" bis_skin_checked="1">Scheme 2. Proposed Synthetic Strategies To Convert 4-AD (<b>1</b>) to DHEA Acetate (<b>3</b>)</div>
</div>
</figcaption></figure>
<div class="NLM_p last" bis_skin_checked="1">Although hydrolases can be used for the regioselective esterification of polyhydroxylated steroid derivatives,<a class="ref ref12 ref13">(12, 13)</a>&nbsp;our initial trials with 5-androstene-3,17-diol (5-AD-diol,&nbsp;<b>6</b>,&nbsp;Scheme 2, Route A) indicated that with Novozyme 435 (<i>Candida antarctica</i>&nbsp;Lipase B) the reaction progressed slowly and required high enzyme loading (60h, 100% w/w enzyme, complete conversion to&nbsp;<b>28</b>). Inspired by natural metabolic pathways for androgens, we turned our attention to oxidoreductases (Route B,&nbsp;Scheme 2).<a class="ref ref14 ref15 ref16 ref17 ref18 ref19 ref20">(14-20)</a>&nbsp;In mammals 4-AD (<b>4</b>) is synthesized from DHEA (<b>2</b>) by the action of two enzymes: 3β-hydroxysteroid dehydrogenase (3β-HSD) catalyzing its oxidation to 5-androstene-3,17-dione (5-AD,&nbsp;<b>5</b>)<a class="ref ref14 ref21 ref22 ref23 ref24 ref25 ref26">(14, 21-26)</a>&nbsp;and ketosteroid isomerase (KSI), which catalyzes the thermodynamically favored isomerization of the double bond to the conjugated α,β-unsaturated ketone&nbsp;<b>1</b>&nbsp;(<i>K</i><sub>eq</sub>&nbsp;= 2400).<a class="ref ref20 ref27 ref28 ref29 ref30">(20, 27-30)</a>&nbsp;Thus, we hoped to take advantage of the reversibility of biooxidation and use an enzyme for the stereo- and regioselective reduction of the C3-carbonyl group—a reverse sequence to the natural mammalian metabolic pathway. Ultimately, this proved successful, and the results are described hereafter.</div>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h2 id="_i4">2 Results and Discussion</h2>
<hr>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">In order to successfully convert 4-AD (<b>1</b>) into DHEA acetate (<b>3</b>), we envisaged a three-step process. First, we planned to convert 4-AD to 5-AD (<b>5</b>) through a selective Δ<sup>4</sup>–Δ<sup>5</sup>&nbsp;isomerization.<a class="ref ref31 ref32 ref33">(31-33)</a>&nbsp;Second, we needed to identify a highly stereoselective ketoreductase with appropriate industrial properties to selectively reduce 5-AD (<b>5</b>) to DHEA (<b>2</b>), which was the key to success of this project. As ketoreductases and hydroxysteroid dehydrogenases may display vastly different degrees of regioselectivity (3 vs 17 positions) and stereoselectivity (α vs β),<a class="ref ref14 ref21 ref22 ref23 ref24 ref25 ref26">(14, 21-26)</a>&nbsp;finding the enzyme with exclusive 3β-stereoselectivity was crucial. Finally, we planned to convert DHEA (<b>2</b>) into DHEA acetate (<b>3</b>) and to develop an efficient acetylation and crystallization to provide the material with the required purity (≥99.5% by HPLC area).</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h3 id="_i5" class="article-section__title">2.1 Isomerization</h3>
<p>Several approaches to prepare 5-AD (<b>5</b>) are described in the literature;<a class="ref ref19 ref34 ref35">(19, 34, 35)</a>&nbsp;however, these were considered suboptimal for our process requirements, as they required multistep syntheses. Our attention was drawn by short communications on deconjugation of α,β-unsaturated ketones,<a class="ref ref31 ref32 ref33">(31-33)</a>&nbsp;including an example of a low-yielding potassium hydroxide-catalyzed isomerization of 4-AD (<b>1</b>).<a class="ref ref32">(32)</a>&nbsp;After an initial screen, we were able to identify a promising initial set of reaction conditions that afforded 5-AD (<b>5</b>) in &gt;80% yield (<a class="ref internalNav" href="https://pubs.acs.org/doi/10.1021/acs.oprd.6b00215#sch3" aria-label="Scheme 3">Scheme 3</a>). Treatment of 4-AD (<b>1</b>) with 10 equiv of potassium&nbsp;<i>tert</i>-butoxide in&nbsp;<i>tert</i>-butanol for 90 min, followed by the kinetic quench of the extended enolate (<b>32</b>) into 10% (v/v) aqueous acetic acid, allowed precipitation of the product&nbsp;<b>5</b>, which was then isolated by filtration.</p>
</div>
<p><strong>Scheme 3</strong></p>
<p><img src="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/oprdfk/2016/oprdfk.2016.20.issue-8/acs.oprd.6b00215/20160815/images/medium/op-2016-00215r_0003.gif" class="lazyloaded" data-ll-status="loaded"><noscript><img src="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/oprdfk/2016/oprdfk.2016.20.issue-8/acs.oprd.6b00215/20160815/images/medium/op-2016-00215r_0003.gif" /></noscript></p>
<p>&nbsp;</p>
<figure id="sch3" class="article__inlineFigure" data-index="3"><figcaption>
<div class="hlFld-FigureCaption caption" bis_skin_checked="1">
<div class="title2" bis_skin_checked="1">Scheme 3. Isomerization of 4-AD (<b>1</b>) to 5-AD (<b>5</b>)</div>
</div>
</figcaption></figure>
<div class="NLM_p" bis_skin_checked="1">Encouraged by these results, we proceeded to develop the process further. Initially, we observed great variability in the reaction outcome, with the relative amount of the desired 5-AD (<b>5</b>) varying from 50 to 95% (by HPLC area %). From consideration of the isomerization mechanism (Scheme 3), the root cause of this problem became evident. The initial formation of the dianion&nbsp;<b>32</b>&nbsp;occurs readily (&lt;30 min) using 2.0–2.5 equiv of potassium&nbsp;<i>tert</i>-butoxide. (Note: while we have drawn this as the dianion, this is purely based on mechanism proposed in the literature<a class="ref ref31">(31)</a>&nbsp;and the observation that we required &gt;2 eq of base, and we did not obtain any additional confirmation of the structure). The subsequent kinetic protonation results in the desired 5-AD (<b>5</b>) isomer, which is sensitive to even mildly basic conditions and readily isomerizes back to 4-AD (<b>1</b>). Fortunately, the exposure of the 5-AD (<b>5</b>) to basic conditions could be minimized by quenching the enolate into an excess of acetic acid, rather than by adding the acid to the reaction mass. The addition rate, efficient mixing and temperature (&lt;30 °C) have to be carefully controlled to achieve high yields and to prevent localized high pH “hotspots” during the quench. Failure to control these physical parameters leads to significant isomerization and apparent poor conversion. Moreover, 5-AD (<b>5</b>) quenched this way precipitated from the solution and could be readily isolated by filtration, which is a significant process advantage.</div>
<div class="NLM_p" bis_skin_checked="1">While the controlled quench addressed one of the issues with the reaction, we observed formation of several other impurities, as evidenced by additional peaks in the HPLC chromatogram and NMR spectra. The levels of these impurities varied from batch to batch, and their content changed upon storage of the 5-AD (<b>5</b>). Moreover, the formation of the same impurities was then also observed during the bioreduction step (vide infra, see&nbsp;Scheme 4).</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"><strong>Scheme 4</strong></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" data-lazy-src="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/oprdfk/2016/oprdfk.2016.20.issue-8/acs.oprd.6b00215/20160815/images/medium/op-2016-00215r_0004.gif"><noscript><img src="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/oprdfk/2016/oprdfk.2016.20.issue-8/acs.oprd.6b00215/20160815/images/medium/op-2016-00215r_0004.gif" /></noscript></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<div id="sec2_1" class="NLM_sec NLM_sec_level_2" bis_skin_checked="1">
<figure id="sch4" class="article__inlineFigure" data-index="4"><figcaption>
<div class="hlFld-FigureCaption caption" bis_skin_checked="1">
<div class="title2" bis_skin_checked="1">Scheme 4. Impurities Generated during Isomerization of 4-AD (<b>1</b>) to 5-AD (<b>5</b>)</div>
</div>
</figcaption></figure>
<div class="NLM_p" bis_skin_checked="1">The main impurities were isolated chromatographically and characterized by NMR and MS (see&nbsp;<a class="ext-link" href="https://pubs.acs.org/doi/suppl/10.1021/acs.oprd.6b00215/suppl_file/op6b00215_si_001.pdf">Supporting Information</a>&nbsp;for details). The spectroscopic data obtained for one of the main side products were in agreement with the structure of androst-4-ene-3,6,17-trione (<b>19</b>,&nbsp;<i>m</i>/<i>z</i>&nbsp;301 [<i>M</i>&nbsp;+ 1]<sup>+</sup>). This oxygenated impurity was reported previously by Pollack et al. and its formation ascribed to autoxidation of the steroid backbone by molecular oxygen present in the reaction.<a class="ref ref19">(19)</a>&nbsp;We identified two further impurities, 6β- and 6α-hydroxyandrost-4-ene-3,17-dione (<b>22</b>&nbsp;and&nbsp;<b>23</b>, respectively,&nbsp;<i>m</i>/<i>z</i>&nbsp;303 [<i>M</i>&nbsp;+ 1]<sup>+</sup>).<a class="ref ref36">(36)</a>&nbsp;In addition we were able to isolate small quantities of two further compounds, which proved unstable, and we observed their conversion to trione&nbsp;<b>19</b>&nbsp;over the course of the NMR experiments. Based on the similarity of their&nbsp;<sup>1</sup>H NMR spectra to the isomeric 6-hydroxyandrost-4-ene-3,17-diones (<b>22</b>&nbsp;and&nbsp;<b>23</b>) and mass spectrometry data (both had&nbsp;<i>m</i>/<i>z</i>&nbsp;of 319), these compounds were tentatively assigned as 6β- and 6α-perhydroxyandrost-4-ene-3,17-diones (<b>20</b>&nbsp;and&nbsp;<b>21</b>), respectively. Their presence would be in agreement with the involvement of oxygen in the side-product formation; however, no further elucidation of the mechanism of autoxidation and possible interconversion between the compounds&nbsp;<b>19</b>–<b>23</b>&nbsp;was performed. Nevertheless, this highlighted the need to carry out the isomerization under oxygen-free conditions. Thus, the introduction of a rigorous nitrogen sparging protocol during the reactions reduced the levels of these impurities sufficiently; on a 300 g scale we were able to prepare crude 5-AD (<b>5</b>) of acceptable purity: typically 89–93% by HPLC area, containing 3–5% of 4-AD (<b>1</b>) and 3–4% oxygenated impurities&nbsp;<b>19</b>–<b>23</b>.</div>
<div class="NLM_p last" bis_skin_checked="1">In summary, our efforts resulted in an efficient 4-AD (<b>1</b>) isomerization procedure, giving 5-AD (<b>5</b>) in approximately 80% yield and acceptable purity. We reduced the base requirement from 10 to 2 equiv of potassium&nbsp;<i>tert</i>-butoxide, providing significant cost reduction for this step. The material generated under the optimized conditions was used directly in the subsequent biocatalytic step, as it was not suitable for prolonged storage.</div>
</div>
<div id="sec2_2" class="NLM_sec NLM_sec_level_2" bis_skin_checked="1">
<div id="ac_i8" class="anchor-spacer" bis_skin_checked="1"></div>
<h3 id="_i8" class="article-section__title">2.2 Development of the Enzymatic Step</h3>
<div id="sec2_2_1" class="NLM_sec NLM_sec_level_3" bis_skin_checked="1">
<div id="ac_i9" class="anchor-spacer" bis_skin_checked="1"></div>
<h4 id="_i9" class="article-section__title">2.2.1 Ketoreductase Screening</h4>
<div class="NLM_p" bis_skin_checked="1">The key step of our proposed route relied on identifying a highly regio- and stereoselective ketoreductase enzyme to convert 5-AD (<b>5</b>) to the desired 3β-hydroxyandrost-5-ene-17-one (DHEA,&nbsp;<b>2</b>) exclusively. The bioreduction of diketone&nbsp;<b>5</b>&nbsp;could theoretically result in up to 16 possible products: four possible diastereoisomers of monohydroxysteroids (C3-OH or C17-OH) and further four possible diols (<b>6</b>). An additional eight isomeric products could be expected, if the double bond moves back to C4. The complexity of the chromatographic analysis of such a mixture and lack of commercially available reference materials added to the challenging nature of the enzymatic screen. Therefore, to simplify and accelerate the identification of regioselective enzymes, we took advantage of the reversibility of the ketoreductase-catalyzed reactions. Specifically, we screened the enzyme libraries toward the oxidation of hydroxysteroids as depicted in&nbsp;<a class="ref internalNav" href="https://pubs.acs.org/doi/10.1021/acs.oprd.6b00215#fig1" aria-label="Figure 1">Figure 1</a>. The screen was performed using a routine colorimetric formazan-linked assay, which detects reduced NAD(P)H cofactor, formed during the biooxidation.<a class="ref ref37">(37)</a>&nbsp;In parallel, we tested ketoreductases for the oxidation of commercially available DHEA (<b>2</b>), testosterone (<b>9</b>), and androst-5-ene-3β,17β-diol (5-AD-diol,&nbsp;<b>6</b>), observing red coloration in the wells with biocatalyst active toward individual compounds after 60 min at 30 °C (the low substrate solubility in aqueous media did not allow monitoring of the reactions spectrophotometrically and the plates were inspected visually).</div>
</div>
</div>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"><strong>Figure1</strong></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" data-lazy-src="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/oprdfk/2016/oprdfk.2016.20.issue-8/acs.oprd.6b00215/20160815/images/medium/op-2016-00215r_0008.gif"><noscript><img src="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/oprdfk/2016/oprdfk.2016.20.issue-8/acs.oprd.6b00215/20160815/images/medium/op-2016-00215r_0008.gif" /></noscript></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<div id="sec2_2_1" class="NLM_sec NLM_sec_level_3" bis_skin_checked="1">
<figure id="fig1" class="article__inlineFigure" data-index="5"><figcaption>
<div class="hlFld-FigureCaption caption" bis_skin_checked="1">
<p class="first last">Figure 1. Principle of screening for regioselective ketoreductases in the oxidative direction using a NAD(P)H-linked colorimetric assay.</p>
</div>
</figcaption></figure>
<div class="NLM_p" bis_skin_checked="1">The pictures show snapshots of typical screening plates tested with three different hydroxysteroids: top panel—DHEA (<b>2</b>); middle panel—5-AD-diol (<b>6</b>); bottom panel—testosterone (<b>9</b>). NAD(P)H cofactor formed in the oxidation in the presence of tetrazolium (2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2<i>H</i>-tetrazolium chloride—INT) and diaphorase causes red coloration of the wells with an active enzyme. Colors were as follows: highlighted in blue circles—an enzyme with exclusive activity toward C3β-hydroxyl group; in red circles—an enzyme with exclusive activity toward C17β-hydroxyl group; in gray circles—enzymes active toward both C17- and C3-hydroxyl groups (nonselective).</div>
<div class="NLM_p" bis_skin_checked="1">Using this screening strategy we quickly discriminated between the enzymes displaying 3β- versus 17β-regioselectivity (see&nbsp;<a class="ref internalNav" href="https://pubs.acs.org/doi/10.1021/acs.oprd.6b00215#fig1" aria-label="Figure 1">Figure 1</a>, top vs bottom panel). Androst-5-ene-3β,17β-diol (<b>6</b>,&nbsp;<a class="ref internalNav" href="https://pubs.acs.org/doi/10.1021/acs.oprd.6b00215#fig1" aria-label="Figure 1">Figure 1</a>, middle panel) was added to the screening program as a control to confirm the regioselectivity toward C3 and C17 hydroxyl groups.</div>
<div class="NLM_p last" bis_skin_checked="1">The colorimetric screening strategy simplified and accelerated the screening for regioselective enzymes, without the need to put effort into complex and lengthy chromatographic analysis. We efficiently tested a collection of almost 400 proprietary and commercial ketoreductases to identify a short-chain dehydrogenase/reductase from&nbsp;<i>Sphingomonas wittichii</i><a class="ref ref38">(38)</a>&nbsp;as&nbsp;<b>the sole enzyme</b>&nbsp;with the desired 3β-stereoselectivity. Subsequent studies on the enzymatic reduction of 5-AD (<b>5</b>) demonstrated that the&nbsp;<i>Sphingomonas wittichii</i>&nbsp;ketoreductase catalyzed formation of DHEA with high diastereoselectivity (<b>2</b>, &gt;99% de)—spiking experiments showed no detectable formation of 3α-epimer&nbsp;<b>13</b>&nbsp;by HPLC. Moreover, the enzyme showed almost no activity toward the isomer 4-AD (<b>1</b>).</div>
</div>
<div id="sec2_2_2" class="NLM_sec NLM_sec_level_3" bis_skin_checked="1">
<div id="ac_i10" class="anchor-spacer" bis_skin_checked="1"></div>
<h4 id="_i10" class="article-section__title">2.2.2 Reaction Optimization</h4>
<div class="NLM_p" bis_skin_checked="1">We optimized process parameters, such as substrate and ketoreductase loading, cosolvent, phase ratio, pH, and temperature in a series of experiments (details are shown in&nbsp;<a class="ref internalNav" href="https://pubs.acs.org/doi/10.1021/acs.oprd.6b00215#tbl1" aria-label="Table 1">Table 1</a>). We aimed to maximize the substrate concentration and to minimize the enzyme loading in order to improve the volumetric efficiency and the cost of the process. In parallel, we also improved the gene and the protein expression of the ketoreductase to minimize the fermentation requirement (vide infra).</div>
<div id="tbl1" class="NLM_table-wrap" bis_skin_checked="1">
<div class="hlFld-FigureCaption" bis_skin_checked="1">
<div id="" class="NLM_caption" bis_skin_checked="1">
<div class="title2" bis_skin_checked="1">Table 1. Optimization Studies of 5-AD (<b>5</b>) Bioreduction</div>
</div>
</div>
</div>
</div>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<div style="box-sizing: border-box; outline: none; font-variant-ligatures: normal; font-variant-caps: normal; orphans: 2; text-align: start; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;" bis_skin_checked="1">
<table style="border-collapse: collapse; width: 815px; height: 734px;" border="0" width="192" cellspacing="0" cellpadding="0">
<tbody>
<tr style="height: 15.0pt;">
<td class="xl64" style="height: 15.0pt; width: 48pt;" width="64" height="20">
<div style="box-sizing: border-box; outline: none; overflow-x: auto;" bis_skin_checked="1">parameter</div>
</td>
<td class="xl64" style="width: 48pt;" width="64">evaluated range</td>
<td class="xl64" style="width: 48pt;" width="64">set value</td>
</tr>
<tr style="height: 15.0pt; box-sizing: border-box; outline: none;">
<td class="xl65" style="height: 15.0pt; border-top: none; box-sizing: border-box; outline: none;" height="20">cofactor</td>
<td class="xl65" style="border-top: none; box-sizing: border-box; outline: none;">NAD<span class="font6">+</span><span class="font5">/NADP</span><span class="font6">+</span></td>
<td class="xl65" style="border-top: none; box-sizing: border-box; outline: none;">NAD<span class="font6">+</span></td>
</tr>
<tr style="height: 15.0pt; box-sizing: border-box; outline: none;">
<td class="xl65" style="height: 15.0pt; border-top: none; box-sizing: border-box; outline: none;" height="20">pH</td>
<td class="xl65" style="border-top: none; box-sizing: border-box; outline: none;">6.0–8.0</td>
<td class="xl65" style="border-top: none; box-sizing: border-box; outline: none;">6.3</td>
</tr>
<tr style="height: 15.0pt; box-sizing: border-box; outline: none;">
<td class="xl67" style="border-bottom: 1.0pt solid #A7A9AC; height: 45.0pt; border-top: none; box-sizing: border-box; outline: none;" rowspan="3" height="60">enzyme loading and form&nbsp;enzyme&nbsp;addition</td>
<td class="xl67" style="border-bottom: 1.0pt solid #A7A9AC; border-top: none; box-sizing: border-box; outline: none;" rowspan="3">0.25–10% (w/w or v/w) one batch vs multiple additions</td>
<td class="xl66" style="border-top: none; box-sizing: border-box; outline: none;"><a style="box-sizing: border-box; outline: none; transition: color 0.3s ease 0s; overflow-wrap: break-word; word-break: break-word;" href="https://pubs.acs.org/doi/10.1021/acs.oprd.6b00215#t1fn1" aria-label="a">first generation ketoreductase: 3%&nbsp;w/w (powder, 1&nbsp;batch)a</a></td>
</tr>
<tr style="height: 15.0pt;">
<td class="xl66" style="height: 15.0pt; border-top: none;" height="20"><a style="box-sizing: border-box; outline: none; transition: color 0.3s ease 0s; overflow-wrap: break-word; word-break: break-word;" href="https://pubs.acs.org/doi/10.1021/acs.oprd.6b00215#t1fn1" aria-label="a">second generation ketoreductase: 5%&nbsp;v/w (liquid, 4&nbsp;batches)a</a></td>
</tr>
<tr style="height: 15.0pt;">
<td class="xl66" style="height: 15.0pt; border-top: none;" height="20"><a style="box-sizing: border-box; outline: none; transition: color 0.3s ease 0s; overflow-wrap: break-word; word-break: break-word;" href="https://pubs.acs.org/doi/10.1021/acs.oprd.6b00215#t1fn2" aria-label="b">third generation ketoreductase: 0.25%&nbsp;w/w (powder, 1&nbsp;batch)b</a></td>
</tr>
<tr style="height: 15.0pt; box-sizing: border-box; outline: none;">
<td class="xl65" style="height: 15.0pt; border-top: none; box-sizing: border-box; outline: none;" height="20">temperature</td>
<td class="xl65" style="border-top: none; box-sizing: border-box; outline: none;">20–50&nbsp;°C</td>
<td class="xl65" style="border-top: none; box-sizing: border-box; outline: none;">33&nbsp;°C</td>
</tr>
<tr style="height: 15.0pt; box-sizing: border-box; outline: none;">
<td class="xl66" style="height: 15.0pt; border-top: none; box-sizing: border-box; outline: none;" height="20"><a style="box-sizing: border-box; outline: none; transition: color 0.3s ease 0s; overflow-wrap: break-word; word-break: break-word;" href="https://pubs.acs.org/doi/10.1021/acs.oprd.6b00215#t1fn3" aria-label="c">cosolventc</a></td>
<td class="xl65" style="border-top: none; box-sizing: border-box; outline: none;">2-MeTHF, EtOAc, MTBE, DIIPE, BuOAc, toluene,&nbsp;<span class="font7">n</span><span class="font5">-BuOH, THF, DMSO, DMF</span></td>
<td class="xl65" style="border-top: none; box-sizing: border-box; outline: none;">2-MeTHF, EtOAc</td>
</tr>
<tr style="height: 15.0pt; box-sizing: border-box; outline: none;">
<td class="xl65" style="height: 15.0pt; border-top: none; box-sizing: border-box; outline: none;" height="20">cosolvent volume</td>
<td class="xl65" style="border-top: none; box-sizing: border-box; outline: none;">0–66%&nbsp;v/v</td>
<td class="xl65" style="border-top: none; box-sizing: border-box; outline: none;">50–60%&nbsp;v/v</td>
</tr>
<tr style="height: 15.0pt; box-sizing: border-box; outline: none;">
<td class="xl65" style="height: 15.0pt; border-top: none; box-sizing: border-box; outline: none;" height="20">buffer</td>
<td class="xl65" style="border-top: none; box-sizing: border-box; outline: none;">TRIS, phosphate</td>
<td class="xl65" style="border-top: none; box-sizing: border-box; outline: none;">phosphate</td>
</tr>
<tr style="height: 15.0pt; box-sizing: border-box; outline: none;">
<td class="xl65" style="height: 15.0pt; border-top: none; box-sizing: border-box; outline: none;" height="20">substrate conc.</td>
<td class="xl65" style="border-top: none; box-sizing: border-box; outline: none;">3–150&nbsp;g/L</td>
<td class="xl65" style="border-top: none; box-sizing: border-box; outline: none;">100&nbsp;g/L</td>
</tr>
<tr style="height: 15.0pt; box-sizing: border-box; outline: none;">
<td class="xl66" style="height: 15.0pt; border-top: none; box-sizing: border-box; outline: none;" height="20"><a style="box-sizing: border-box; outline: none; transition: color 0.3s ease 0s; overflow-wrap: break-word; word-break: break-word;" href="https://pubs.acs.org/doi/10.1021/acs.oprd.6b00215#t1fn4" aria-label="d">MgCl2d</a></td>
<td class="xl65" style="border-top: none; box-sizing: border-box; outline: none;">0–5&nbsp;mM</td>
<td class="xl65" style="border-top: none; box-sizing: border-box; outline: none;">0&nbsp;mM</td>
</tr>
<tr style="height: 15.0pt; box-sizing: border-box; outline: none;">
<td class="xl65" style="height: 15.0pt; border-top: none; box-sizing: border-box; outline: none;" height="20">base</td>
<td class="xl65" style="border-top: none; box-sizing: border-box; outline: none;">2.0 M NaOH, 1.7 M Na<span class="font6">2</span><span class="font5">CO</span><span class="font6">3</span><span class="font5">, 1.5&nbsp;M&nbsp;K</span><span class="font6">2</span><span class="font5">CO</span><span class="font6">3</span></td>
<td class="xl65" style="border-top: none; box-sizing: border-box; outline: none;">1.5&nbsp;M&nbsp;K<span class="font6">2</span><span class="font5">CO</span><span class="font6">3</span></td>
</tr>
</tbody>
</table>
</div>
</div>
<p>&nbsp;</p>
<div id="t1fn1" class="footnote" bis_skin_checked="1"><sup>a</sup>Used for the &gt;200 g scale campaign.</div>
<div id="t1fn2" class="footnote" bis_skin_checked="1"><sup>b</sup>Loading for the optimized enzyme powder.</div>
<div id="t1fn3" class="footnote" bis_skin_checked="1"><sup>c</sup>Optimized water immiscible cosolvents were initially tested at 30% v/v, while water miscible ones were at 6% v/v.</div>
<div id="t1fn4" class="footnote" bis_skin_checked="1"><sup>d</sup>Magnesium chloride was added to see if it would improve the protein stability/activity under the reaction conditions; however, no difference was observed.</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<div id="sec2_2" class="NLM_sec NLM_sec_level_2" bis_skin_checked="1">
<div id="sec2_2_2" class="NLM_sec NLM_sec_level_3" bis_skin_checked="1">
<div class="NLM_p" bis_skin_checked="1">All of the bioreductions were conducted in a Multimax system, using 50 mL reactors with overhead stirring, temperature control, and pH control. We used glucose and glucose dehydrogenase to recycle the NAD(P)H cofactors, adjusting the pH with a base (2.0 M NaOH or 1.7 M Na<sub>2</sub>CO<sub>3</sub>). The best conversions were obtained at 25–35 °C and pH 6.0–7.0. Very early into the process development, we concluded that biotransformations proceeded more efficiently under biphasic reaction conditions, using 2-MeTHF or EtOAc—this increased the substrate solubility in the reaction media and allowed much higher conversions and substrate loadings than the addition of water miscible cosolvents. Consequently we were able to run &gt;200 g scale batches at concentrations up to 150 g/L, achieving full conversion. EtOAc was selected as the best solvent overall, since it was significantly cheaper, although it required 10–20% higher enzyme loadings. Moreover, EtOAc offered a process safety advantage, as 2-MeTHF may form explosive peroxides. We replaced 2 M NaOH with 1.7 M Na<sub>2</sub>CO<sub>3</sub>&nbsp;to avoid localized high pH “hotspots” leading to side-product formation. Ultimately, we preferred 1.4 M K<sub>2</sub>CO<sub>3</sub>&nbsp;solution as a base, as it possesses higher solubility in water in comparison to Na<sub>2</sub>CO<sub>3</sub>&nbsp;(112 g/100 mL versus 21.5 g/100 mL at 20 °C), which improved process reproducibility and eliminated the risk of line blockage in the pH control apparatus seen occasionally with saturated sodium carbonate solutions.</div>
<div class="NLM_p" bis_skin_checked="1">Under the optimized conditions &gt;200 g scale enzymatic reductions proceeded efficiently using our second generation biocatalyst (liquid cell-free extract of the gene and expression optimized ketoreductase). Such biotransformations reached full conversions in 24–28 h, giving crude DHEA (<b>2</b>) in 88–90% purity by HPLC. Further improvements of biocatalyst form (powder, third generation enzyme) further reduced the time required to reach &gt;95% conversion to 6–8 h at 0.25–0.30% w/w enzyme loading.</div>
<div class="NLM_p" bis_skin_checked="1">During these bioreductions, we observed the formation of similar impurities to the isomerization step. Unsurprisingly, their content increased significantly at elevated temperatures (&gt;40 °C). Under such conditions, at pH 7.5 and in the presence of air, 5-AD (<b>5</b>) decomposed almost completely over 3 days. The most prominent impurities were 4-AD (<b>1</b>) and trione (<b>19</b>) as well as hydroxy- and perhydroxysteroids&nbsp;<b>20</b>–<b>23</b>. Nevertheless, maintaining the pH at 6–7 and temperature &lt;35 °C ensured an efficient biotransformation and minimized the reverse isomerization. The content of 4-AD (<b>1</b>) present in starting 5-AD (<b>5</b>) material did not increase by more than 2–3%. Sparging of the bioreduction solutions with nitrogen was necessary to keep the level of the oxygenated impurities below 8% from the initial 4–6% present in the input crude 5-AD (<b>5</b>).</div>
<div class="NLM_p last" bis_skin_checked="1">In addition, we observed the formation of some impurities specific to the bioreduction itself. We detected low levels of 5-AD-diol (<b>6</b>, &lt; 0.5% by HPLC area), possibly arising from reduction at C17 catalyzed by the&nbsp;<i>Sphingomonas wittichii</i>&nbsp;ketoreductase and/or other endogenous, nonselective&nbsp;<i>E. coli</i>&nbsp;derived ketoreductase enzymes present in either the ketoreductase or glucose dehydrogenase preparations. This impurity could be minimized by monitoring conversion and stopping the reaction as soon as it reached completion.</div>
</div>
<div id="sec2_2_3" class="NLM_sec NLM_sec_level_3" bis_skin_checked="1">
<div id="ac_i12" class="anchor-spacer" bis_skin_checked="1"></div>
<h4 id="_i12" class="article-section__title">2.2.3 Molecular Biology and Fermentation</h4>
<div class="NLM_p" bis_skin_checked="1">The first generation ketoreductase preparation used in the screen and the initial process development had relatively low activity, 17–35 U/g of enzyme powder, as it contained a large amount of insolubly expressed protein. Consequently, high enzyme loadings (3–5% w/w, 2U per g of substrate) were required to achieve full conversion of 5-AD (<b>5</b>). Therefore, we decided to improve the protein expression, fermentation and downstream processing of the enzyme. This resulted in 10–15 fold improved enzyme productivity, lowering enzyme loadings, which also resulted in better process parameters (elimination of the emulsions we observed with the first generation enzyme preparations). It is worth noting that such improvements in biocatalyst production can be very effective in improving the efficiency of a biotransformation and are rapidly implemented.<a class="ref ref39">(39)</a></div>
<div class="NLM_p" bis_skin_checked="1">First, we optimized the gene encoding the ketoreductase for heterologous expression in a phage-resistant&nbsp;<i>E. coli</i>&nbsp;BL21(DE3) strain containing pET26b vector. This afforded an isopropyl β-<span class="smallcaps smallerCapital">d</span>-1-thiogalactopyranoside (IPTG) inducible&nbsp;<i>E. coli</i>&nbsp;strain, in which 90% of the ketoreductase was solubly expressed. Second, we developed high optical density fermentation (20 L, glucose feed, 176 OD, see&nbsp;<a class="ext-link" href="https://pubs.acs.org/doi/suppl/10.1021/acs.oprd.6b00215/suppl_file/op6b00215_si_001.pdf">Supporting Information</a>&nbsp;for details), which after clarification and ultrafiltration (10 kDa membrane) resulted in second-generation enzyme produced as liquid cell free extract of 39 U/mL activity.</div>
<div class="NLM_p last" bis_skin_checked="1">Unfortunately, upon storage for 1 month at 2–8 °C, we observed that the enzyme preparation lost 75% of its activity and the later batches of the bioreduction required higher than expected enzyme loading. We discovered that lyophilization improved its storage and stability over time. Consequently, later batches of the enzyme were lyophilized to give third generation ketoreductase powder with 400–500 U/g activity. This represented an overall 10–15 fold improvement in comparison to the first generation biocatalyst (17–35 U/g), and it allowed a decrease in the enzyme loading from 3 to 5% to 0.25–0.30% w/w to achieve 95–99% conversion in 6h. Not only did the reduction in biocatalyst loading lower the cost of the biocatalyst, but it improved the ease of the workup, as quick phase separation was observed after the biotransformation.</div>
</div>
<div id="sec2_2_4" class="NLM_sec NLM_sec_level_3" bis_skin_checked="1">
<div id="ac_i13" class="anchor-spacer" bis_skin_checked="1"></div>
<h4 id="_i13" class="article-section__title">2.2.4 Purification of DHEA</h4>
<div class="NLM_p last" bis_skin_checked="1">Initially we intended to develop an efficient crystallization of crude DHEA (<b>2</b>) after the biotransformation step (79–91% purity by HPLC). A literature evaluation indicated that five polymorphs of DHEA (<b>2</b>) are known (forms I–V), as well as three monohydrate polymorphs and numerous solvates with solvents like alcohols and ethers.<a class="ref ref40 ref41">(40, 41)</a>&nbsp;Crystallization studies of the crude DHEA (<b>2</b>) isolated from the biotransformation gave a product of &gt;98% purity using a variety of solvents, but the recoveries were low (10–55%, results not shown). Therefore, we decided to telescope the crude DHEA to the subsequent acetylation step and focus on developing an efficient crystallization of DHEA acetate (<b>3</b>) instead.</div>
</div>
</div>
<div id="sec2_3" class="NLM_sec NLM_sec_level_2" bis_skin_checked="1">
<div id="ac_i14" class="anchor-spacer" bis_skin_checked="1"></div>
<h3 id="_i14" class="article-section__title">2.3 Acetylation and Final Crystallization</h3>
<div class="NLM_p" bis_skin_checked="1">The acetylation of DHEA (<b>2</b>) to its acetate (<b>3</b>) proved to be a facile reaction and proceeded quantitatively under a variety of reaction conditions tested. Successful reaction conditions included: (i) dichloromethane/acetic anhydride/pyridine/DMAP; (ii) dichloromethane/acetic anhydride/boron trifluoride diethyl etherate; (iii) acetic acid/acetic anhydride/sodium acetate; (iv) toluene/acetic anhydride/triethylamine/DMAP (details not shown). In the early stages of development DHEA acetate (<b>3</b>) was prepared using acetic anhydride, triethylamine with catalytic DMAP in toluene.<a class="ref ref38">(38)</a>&nbsp;These conditions gave a fast, robust reaction with low-cost raw materials, and acetate (<b>3</b>) was obtained in &gt;98% purity (by HPLC) as 2 crops in 85–87% yield.</div>
<div class="NLM_p" bis_skin_checked="1">During further process development and optimization work, we aimed to reduce the number of unit operations and to develop a facile acetylation procedure that could be telescoped into the final crystallization process. After some further optimization we achieved full conversion of DHEA (<b>2</b>) using acetic anhydride in the presence of sodium acetate in acetic acid over 16 h (<a class="ref internalNav" href="https://pubs.acs.org/doi/10.1021/acs.oprd.6b00215#sch5" aria-label="Scheme 5">Scheme 5</a>). Quenching the reaction into a mixture of water and methanol (9:1, 1.5 vol) precipitated crude DHEA acetate (<b>3</b>) in 88% yield and 98% purity. This material was subsequently recrystallized from methanol (4 vol), affording final product&nbsp;<b>3</b>&nbsp;in 74% yield and &gt;99.5% purity (by HPLC), meeting the product specifications. These modifications considerably simplified the process and provided both cost and operational benefits.</div>
<div bis_skin_checked="1"></div>
</div>
</div>
<div bis_skin_checked="1"><strong>Schema 5</strong></div>
<div bis_skin_checked="1"><img src="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/oprdfk/2016/oprdfk.2016.20.issue-8/acs.oprd.6b00215/20160815/images/medium/op-2016-00215r_0005.gif" class="lazyloaded" data-ll-status="loaded"><noscript><img src="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/oprdfk/2016/oprdfk.2016.20.issue-8/acs.oprd.6b00215/20160815/images/medium/op-2016-00215r_0005.gif" /></noscript></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<div class="hlFld-FigureCaption caption" bis_skin_checked="1">
<div class="title2" bis_skin_checked="1">Scheme 5. Optimized Conditions for the &gt;200 g Scale Process to Convert 4-AD (<b>1</b>) to DHEA Acetate (<b>3</b>)<sup>a</sup></div>
</div>
<p class="last"><span class="fn-label">Scheme a</span>(i)&nbsp;<i>t</i>-BuOK (2.1 equiv),&nbsp;<i>t</i>-BuOH (6 vol), 30–35 °C, N<sub>2</sub>, 20 min; (ii) 2.5% AcOH in water (20 vol), 20–30 °C, N<sub>2</sub>, 60 min, 94% yield, 93% pure; (iii) 100 g/L, EtOAc–phosphate buffer (40 mM, pH 6.5) 60:40 v/v, NAD<sup>+</sup>&nbsp;(0.075% w/w), glucose (1.1 equiv), glucose dehydrogenase (0.044% w/w), ketoreductase from&nbsp;<i>Sphingomonas wittichii</i>&nbsp;(liquid preparation, 2 U per g of 5-AD), temp. 33 °C, 29 h, N<sub>2</sub>, &gt;99% conversion, 91% purity; (iv) 2.0 equiv of Ac<sub>2</sub>O, AcOH (3 vol), NaOAc (1.25 equiv), 60 °C, N<sub>2</sub>, 16 h, quench with MeOH–water (1.5 vol); (v) crystallization from hot MeOH (4 vol), 74%, purity &gt;99.5% (by HPLC). 64% overall yield.</p>
</div>
<p>&nbsp;</p>
<h2 id="_i16">3 Summary</h2>
<hr>
<p>&nbsp;</p>
<p>We developed a novel, high yielding chemoenzymatic route to DHEA acetate (<b>3</b>) from 4-AD (<b>1</b>). The key enabling reaction of this process was a highly regio- and stereoselective bioreduction of 5-AD (<b>5</b>) to DHEA (<b>2</b>). A fast colorimetric assay was crucial in the identification of a short-chain dehydrogenase from&nbsp;<i>Sphingomonas wittichii</i>, which possessed the desired selectivity. The enzyme displayed good robustness and performance under the biphasic reaction conditions,<a class="ref ref38">(38)</a>&nbsp;which enabled the biotransformations to be conducted at high substrate concentrations (up to 150 g/L). Optimization of the gene expression as well as the fermentation conditions of an&nbsp;<i>E. coli</i>&nbsp;host strain resulted in 10–15 fold improvement of the enzyme productivity and gave us access to a cost-effective biocatalyst. Development of both the 4-AD to 5-AD isomerization and the final acetylation and purification provided a robust process, suitable for further scale-up. Identification of the impurities generated in the process enabled the development of control strategies and was crucial to obtain high purity final product.</p>
<p>&nbsp;</p>
<h2 id="_i17">4 Experimental Section</h2>
<hr>
<p>&nbsp;</p>
<div id="sec4_1" class="NLM_sec NLM_sec_level_2" bis_skin_checked="1">
<h3 id="_i18" class="article-section__title">4.1 Materials and Methods</h3>
<div class="NLM_p last" bis_skin_checked="1">4-AD (<b>1</b>) was supplied by Dr. Reddy’s de Mexico, Cuernavaca-Cuautla, 62578 Civac Jiutepec Morelos, Mexico. Testosterone (<b>9</b>) was obtained from Sigma. Epitestosterone (<b>10</b>) was obtained from LGC Standards, Queens Road, Teddington, Middlesex, TW11 0LY, UK. 3β,17β-5-AD-diol (<b>6</b>) was provided by Dr. Reddy’s Laboratories Ltd., Custom Pharmaceutical Services, TDC-1 Bollaram Road, Miyapur, Hyderabad 500049, Telangana, India. 3α-DHEA acetate (<b>14</b>) was obtained from Bujno Synthesis, Dorodna 16, Warsaw, Poland. 3α-DHEA (<b>13</b>) and 3α-DHEA acetate (<b>14</b>) were also synthesized from 3β-DHEA (<b>2</b>) using a Mitsunobu reaction sequence according to a previously reported method<a class="ref ref42">(42)</a>&nbsp;(see&nbsp;<a class="ext-link" href="https://pubs.acs.org/doi/suppl/10.1021/acs.oprd.6b00215/suppl_file/op6b00215_si_001.pdf">Supporting Information</a>&nbsp;for details). All enzymes used in the screen were proprietary to Dr. Reddy’s Laboratories or obtained from commercial suppliers (Almac, Codexis, Daicel, Evocatal, Johnson Matthey, Prozomix and Syncore). Glucose dehydrogenase GDH CDX-901 (66 U/mg) was supplied by Codexis. Nicotinamide cofactors NAD<sup>+</sup>&nbsp;and NADP<sup>+</sup>&nbsp;were obtained from Europa Bioproducts. Routine NMR spectra were recorded on a Bruker DRX 400 MHz spectrometer and chemical shifts for&nbsp;<sup>1</sup>H spectra were referenced relative to internal tetramethylsilane or residual solvent peaks. If additional resolution and sensitivity was required, compounds were analyzed on a 700 and 500 MHz NMR instrument with a cryoprobe, School of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.</div>
</div>
<div id="sec4_2" class="NLM_sec NLM_sec_level_2" bis_skin_checked="1">
<div id="ac_i19" class="anchor-spacer" bis_skin_checked="1"></div>
<h3 id="_i19" class="article-section__title">4.2 Biology and Fermentation</h3>
<div class="NLM_p" bis_skin_checked="1">For detailed information on the methods, please see the&nbsp;<a class="ext-link" href="https://pubs.acs.org/doi/suppl/10.1021/acs.oprd.6b00215/suppl_file/op6b00215_si_001.pdf">Supporting Information</a>.</div>
<div id="sec4_2_1" class="NLM_sec NLM_sec_level_3" bis_skin_checked="1">
<div id="ac_i20" class="anchor-spacer" bis_skin_checked="1"></div>
<h4 id="_i20" class="article-section__title">4.2.1 Analytical Methods</h4>
<div class="NLM_p" bis_skin_checked="1">The isomerization and biotransformations were monitored by HPLC: Method A using ELSD and UV (λ = 200 nm) detectors and Luna C18 column 150 × 4.6 mm, column temp. 50 °C, flow 1 mL/min, MP 50:50 A:B, A: water, B: MeOH–MeCN 30:70, inj. vol: 10 μL. The progress of the biotransformation reactions was also monitored by the base consumption as well as by&nbsp;<sup>1</sup>H NMR spectroscopy. LC-MS data were collected using ESI(+) ion detector and HPLC method A, where 0.1% v/v was added to water.</div>
<div class="NLM_p" bis_skin_checked="1">The purity of the DHEA acetate (<b>3</b>) was determined by HPLC: Method B using UV detector (λ = 205 nm) and Kinetex C8 column 2.6 μm 100 Å 150 × 4.6 mm, flow 1 mL/min, column temp. 40 °C, using mobile phase gradient (A = 80:20 water–MeCN, B = MeCN, see&nbsp;<a class="ref internalNav" href="https://pubs.acs.org/doi/10.1021/acs.oprd.6b00215#tbl2" aria-label="Table 2">Table 2</a>), inj. vol: 10 μL.</div>
<div id="tbl2" class="NLM_table-wrap" bis_skin_checked="1">
<div class="hlFld-FigureCaption" bis_skin_checked="1">
<div id="" class="NLM_caption" bis_skin_checked="1">
<div class="title2" bis_skin_checked="1">Table 2. Mobile Phase Gradient for HPLC Analysis of DHEA Acetate (<b>3</b>) Using the Kinetex C8 Column (Method B)</div>
</div>
</div>
<div class="scrollable-table-wrap" bis_skin_checked="1">
<table class="table" border="0">
<colgroup>
<col align="left">
<col align="left">
<col align="left">
<col align="left">
<col align="left">
<col align="left">
<col align="left">
<col align="left">
<col align="left"></colgroup>
<tbody>
<tr class="colsep0" valign="top">
<td class="colsep0 rowsep0" align="left">time (min)</td>
<td class="colsep0 rowsep0" align="left">0</td>
<td class="colsep0 rowsep0" align="left">5</td>
<td class="colsep0 rowsep0" align="left">20</td>
<td class="colsep0 rowsep0" align="left">25</td>
<td class="colsep0 rowsep0" align="left">35</td>
<td class="colsep0 rowsep0" align="left">50</td>
<td class="colsep0 rowsep0" align="left">55</td>
<td class="colsep0 rowsep0" align="left">60</td>
</tr>
<tr class="colsep0" valign="top">
<td class="colsep0 rowsep0" align="left">mobile phase&nbsp;A</td>
<td class="colsep0 rowsep0" align="left">65</td>
<td class="colsep0 rowsep0" align="left">65</td>
<td class="colsep0 rowsep0" align="left">35</td>
<td class="colsep0 rowsep0" align="left">10</td>
<td class="colsep0 rowsep0" align="left">5</td>
<td class="colsep0 rowsep0" align="left">5</td>
<td class="colsep0 rowsep0" align="left">65</td>
<td class="colsep0 rowsep0" align="left">65</td>
</tr>
<tr class="colsep0" valign="top">
<td class="colsep0 rowsep0" align="left">mobile phase&nbsp;B</td>
<td class="colsep0 rowsep0" align="left">35</td>
<td class="colsep0 rowsep0" align="left">35</td>
<td class="colsep0 rowsep0" align="left">65</td>
<td class="colsep0 rowsep0" align="left">90</td>
<td class="colsep0 rowsep0" align="left">95</td>
<td class="colsep0 rowsep0" align="left">95</td>
<td class="colsep0 rowsep0" align="left">35</td>
<td class="colsep0 rowsep0" align="left">35</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div id="sec4_2_2" class="NLM_sec NLM_sec_level_3" bis_skin_checked="1">
<div id="ac_i22" class="anchor-spacer" bis_skin_checked="1"></div>
<h4 id="_i22" class="article-section__title">4.2.2 Enzyme Activity Assay</h4>
<div class="NLM_p last" bis_skin_checked="1">The activity of the ketoreductase from&nbsp;<i>Sphingomonas wittichii</i>&nbsp;was determined in 5 g use tests or spectrophotometrically using 4-heptanol as a substrate, by following its oxidation at 340 nm, monitoring the conversion of the NAD(P)<sup>+</sup>&nbsp;cofactor to NAD(P)H. One unit of activity is defined as sufficient enzyme to catalyze the oxidation of 1 μmol/min of 4-heptanol under the assay conditions (see the&nbsp;<a class="ext-link" href="https://pubs.acs.org/doi/suppl/10.1021/acs.oprd.6b00215/suppl_file/op6b00215_si_001.pdf">Supporting Information</a>&nbsp;for details).</div>
</div>
<div id="sec4_2_3" class="NLM_sec NLM_sec_level_3" bis_skin_checked="1">
<div id="ac_i23" class="anchor-spacer" bis_skin_checked="1"></div>
<h4 id="_i23" class="article-section__title">4.2.3 Colorimetric Enzyme Screening Using INT/Diaphorase</h4>
<div class="NLM_p last" bis_skin_checked="1">In a spectrophotometric 96-well plate ketoreductase (0.1–0.6 mg/mL), diaphorase (0.1–0.6 mg/mL), NAD<sup>+</sup>&nbsp;(0.4 mg/mL), and NADP<sup>+</sup>&nbsp;(0.4 mg/mL) were rehydrated with a solution of INT in deionized water (1 mg/mL, 190 μL). A sample of 10 μL of a DMSO solution of the respective hydroxysteroid (20 mg/mL stock solution of&nbsp;<b>2</b>,&nbsp;<b>6</b>, or&nbsp;<b>9</b>) was added to commence the reaction. The plates were sealed and incubated in a Heidolph shaker at 30 °C, 750 rpm, and they were visually inspected after 1, 5, and 24 h.</div>
</div>
<div id="sec4_2_4" class="NLM_sec NLM_sec_level_3" bis_skin_checked="1">
<div id="ac_i24" class="anchor-spacer" bis_skin_checked="1"></div>
<h4 id="_i24" class="article-section__title">4.2.4 Biotransformation Reactions (Optimization Studies): General Procedure</h4>
<div class="NLM_p last" bis_skin_checked="1">In a Multimax reactor vessel 5-AD (<b>5</b>, 0.3–3.0 g) was predissolved in water immiscible cosolvent (5–25 mL, MTBE, 2-MeTHF, EtOAc). Buffer cocktail (10–25 mL) containing ketoreductase (1–3% w/w), glucose (1.1–2.0 equiv), NAD<sup>+</sup>&nbsp;(7–10 mg), and NADP<sup>+</sup>&nbsp;(7–10 mg) and glucose dehydrogenase (CDX-901, 3–10 mg, 66 U/mg) in phosphate buffer (50 mM, 10–25 mL) was added, and the reaction mixtures were stirred for 21 h at 20–50 °C. The reaction pH (5.5–8.5) was maintained by autotitration with 2 M NaOH or 1.7 M sodium carbonate solution. The products were analyzed by HPLC and NMR spectroscopy.</div>
</div>
<div id="sec4_2_5" class="NLM_sec NLM_sec_level_3" bis_skin_checked="1">
<div id="ac_i25" class="anchor-spacer" bis_skin_checked="1"></div>
<h4 id="_i25" class="article-section__title">4.2.5 Chemistry</h4>
<div class="NLM_p" bis_skin_checked="1">The initial reaction conditions were performed as described previously.<a class="ref ref38">(38)</a>&nbsp;The optimized process was performed as described below.</div>
<div id="sec4_2_5_1" class="NLM_sec NLM_sec_level_4" bis_skin_checked="1">
<div id="ac_i26" class="anchor-spacer" bis_skin_checked="1"></div>
<h5 id="_i26" class="article-section__title">4.2.5.1 Preparation of 5-Androsten-3,17-dione (<b>5</b>)</h5>
<div class="NLM_p last" bis_skin_checked="1"><i>tert</i>-Butanol (2.00 L) was sparged with nitrogen for 90 min at 30–35 °C. Potassium&nbsp;<i>tert</i>-butoxide (235 g, 2.09 mol) was added, and the mixture was stirred with nitrogen sparging for a further 90 min at 30–35 °C. 4-AD (<b>1</b>, 300 g, 1.00 mol) was added, and the reaction was stirred for a further 1 h with nitrogen sparging. Separately, acetic acid (150 mL) was added to a 20 L vessel containing water (6.00 L) that had been sparged with nitrogen for 24 h, and the mixture was stirred at 20 °C under nitrogen. The reaction mixture was then slowly added to the acetic acid solution via cannula over 10–15 min. Once the addition was complete, the mixture was cooled to 12 °C and stirred for 1 h. The precipitate obtained was filtered, washed with water (3 × 2.00 L), and dried under vacuum at 40 °C. The product is obtained as a free-flowing white powder (283 g, 94% yield), purity by HPLC: 93%, 4-AD (<b>1</b>), 3%; oxygenated impurities (<b>19</b>–<b>23</b>), 4%.&nbsp;<sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 5.38 (d, 1H), 3.28–3.33 (m, 1H), 2.86 (dd, 1H), 2.45–2.50 (2H), 1.05–2.60 (m, 15H), 1.22 (s, 3H), 0.92 (s, 3H).</div>
</div>
<div id="sec4_2_5_2" class="NLM_sec NLM_sec_level_4" bis_skin_checked="1">
<div id="ac_i27" class="anchor-spacer" bis_skin_checked="1"></div>
<h5 id="_i27" class="article-section__title">4.2.5.2 Preparation of Dehydroepiandrosterone (<b>2</b>)</h5>
<div class="NLM_p last" bis_skin_checked="1">5-AD (<b>5</b>, 8.0 g, 27.9 mmol, 94% pure by HPLC, 2% 4-AD, 4% impurities&nbsp;<b>19</b>–<b>23</b>) was dissolved in EtOAc (40 mL) at 33 °C under nitrogen atmosphere and stirred vigorously. To this was added a solution of phosphate buffer (50 mM, 40 mL, pH 6.3) containing glucose (6.0 g, 33.3 mmol, 1.2 equiv), NAD<sup>+</sup>&nbsp;(15 mg), glucose dehydrogenase (CDX-901, 8 mg, 528 U), and ketoreductase powder (3rd generation, 20 mg, 0.25% w/w, 9 U) was added. The reaction temperature was maintained at 32.5 °C (jacket temp 33 °C), while the pH 6.3–6.5 was kept constant by addition of 1.5 M K<sub>2</sub>CO<sub>3</sub>&nbsp;solution in water. The reaction conversion was monitored by base consumption as well as by HPLC and&nbsp;<sup>1</sup>H NMR spectroscopy. After 6 h the reaction reached ∼95% conversion. It was stirred for a total of 21 h to give &gt;99% conversion. The mixture was warmed up to 70 °C to fully dissolve partially precipitated DHEA, and the phases were separated. The separated organic layer was dried over magnesium sulfate and evaporated to give crude DHEA as solid residue (7.2 g, 24.2 mmol, 90% yield). Purity by HPLC: 93% [5-AD (<b>5</b>, 0.5%), 4-AD (<b>1</b>, 1.9%), 5-AD-diol (<b>6</b>, 0.5%)].&nbsp;<sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 mHz) δ 5.38 (d, 1 H), 3.50–3.58 (m, 1 H), 2.47 (dd, 1 H), 2.22–2.39 (m, 2H), 2.04–2.12 (m, 2H), 1.92–1.98 (m, 1 H), 1.83–1 0.89 (m, 3H), 1 0.44–1 0.71 (m, 6H), 1.22–1.29 (m, 2H), 0.97–1.14 (m, 2H), 1.04 (s, 3H), 0.89 (s, 3H).</div>
</div>
<div id="sec4_2_5_3" class="NLM_sec NLM_sec_level_4" bis_skin_checked="1">
<div id="ac_i28" class="anchor-spacer" bis_skin_checked="1"></div>
<h5 id="_i28" class="article-section__title">4.2.5.3 Preparation of DHEA Acetate (<b>3</b>) from 5-AD (<b>5</b>) on 200 g Scale (Telescoped Process)</h5>
<div class="NLM_p last" bis_skin_checked="1">5-AD (<b>5</b>, 235 g, 0.82 mol) was loaded into a 5 L reactor and sparged with nitrogen for 30 min upon gentle stirring. EtOAc (1.15 L) was added, and the mixture was stirred at 33 °C under nitrogen until the substrate was fully dissolved. In a separate flask KH<sub>2</sub>PO<sub>4</sub>&nbsp;(7.85 g) and glucose (162 g, 0.90 mol) were dissolved in 1.65 L of deionized water at 20 °C, and the pH was adjusted to 6.3 using solid KOH (1.40 g, ≥85% assay). The solution was sparged with nitrogen for 2–5 h. NAD<sup>+</sup>&nbsp;(0.20 g), glucose dehydrogenase (CDX-901, 165 mg, 10.9 kU), and ketoreductase cell free extract (second generation, 4.0 mL, 40 U) were added and stirred until fully dissolved. The buffer solution of enzymes was added to the vigorously stirred solution of 5-AD in EtOAc at 32.5 °C. The reaction was stirred at 32.5 °C, and pH 6.3–6.5 was maintained by autotitration with 1.7 M Na<sub>2</sub>CO<sub>3</sub>&nbsp;solution in water. The reaction conversion was monitored by base consumption as well as by&nbsp;<sup>1</sup>H NMR spectroscopy. After 4 h, the reaction reached 43% conversion, and additional portions of ketoreductase (3 mL, 30 U), NAD<sup>+</sup>&nbsp;(300 mg) and GDH (160 mg, 10.9 kU) were added; after 8 h more ketoreductase (4 mL, 40 U), NAD<sup>+</sup>&nbsp;(300 mg), and GDH (160 mg, 10.9 kU) were added. The mixture was stirred for 22 h and reached full conversion. The reaction mixture was warmed up to 55 °C to fully dissolve the partially precipitated DHEA, and the phases were separated. The aqueous layer was extracted with EtOAc (1 L) at 55 °C. The combined organic layers were washed with brine (0.4 L) and water (0.4 L) and passed through a magnesium sulfate plug, washed with additional EtOAc (0.4 L). The solvent was partially evaporated under vacuum (100 mbar/50 °C water baths) to give 643 g of DHEA (<b>2</b>) in EtOAc, which solidified. Sample analysis indicated 36% potency by HPLC, equivalent to 0.80 mol, yield 97% (91% purity by HPLC, 4-AD, 7%; oxygenated impurities, 2%). This material was suspended in acetic acid (400 mL), and the residual EtOAc was removed under reduced pressure. Additional 320 mL of acetic acid were added (720 mL total, 3 vols), acetic anhydride (150 mL, 1.60 mol), and sodium acetate (80.0 g, 0.98 mol). The reaction was stirred at 60 °C for 16 h under a nitrogen atmosphere. Upon completion (by&nbsp;<sup>1</sup>H NMR), the reaction was cooled to 25 °C; a mixture of water (1125 mL) and methanol (125 mL) was added to the reaction mixture over 10 min, and it was stirred for 1 h. The precipitate was filtered and washed with further 3:1 water/methanol solution (1000 mL). The wet cake (320 g) was dissolved in hot methanol (1000 mL), and this solution was allowed to cool to 20 °C, then cooled further in an ice bath. The solid was collected and washed with additional methanol–water mixture (1:2, 300 mL). The solid was placed in a drying oven at 40 °C overnight to give DHEA acetate (<b>3</b>) as a white solid (171.4 g, 74% yield for 2 steps, and purity 99.5% by HPLC).&nbsp;<sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 5.41 (d, 1H), 4.57–3.65 (m, 1H), 2.46 (dd, 1H), 2.28–2.36 (m, 2H), 2.04 (s, 3H), 1.80–2.20 (m, 6H), 0.95–1.75 (m, 10), 1.05 (s, 3H), 0.89 (s, 3H).</div>
</div>
</div>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<h2 id="_i29"><a href="https://pubs.acs.org/doi/suppl/10.1021/acs.oprd.6b00215">Supporting Information</a></h2>
<hr>
</div>
<p>&nbsp;</p>
<p class="last">The Supporting Information is available free of charge on the&nbsp;<a class="ext-link" href="https://pubs.acs.org/">ACS Publications website</a>&nbsp;at DOI:&nbsp;<a class="ext-link" href="https://pubs.acs.org/doi/abs/10.1021/acs.oprd.6b00215">10.1021/acs.oprd.6b00215</a>.</p>
<ul id="silist" class="NLM_list-list_type-label">
<li>
<p class="inline">Synthesis and characterization of the main process impurities; structural assignment data for the oxygenated compounds&nbsp;<b>19</b>–<b>23</b>; experimental for molecular biology and fermentation; enzyme activity assay and sample chromatograms</p>
</li>
</ul>
<p>&nbsp;</p>
<h2 id="authorInformationSection">Author Information</h2>
<hr>
<p>&nbsp;</p>
<ul>
<li><span class="author-information-subsection-header">Corresponding Author</span>
<ul>
<li>
<div class="authorItemInformation" bis_skin_checked="1"><span class="hlFld-ContribAuthor strong">Karen E. Holt-Tiffin</span>&nbsp;–&nbsp;<span class="hlFld-Affiliation affiliation">Chirotech Technology Centre, Dr. Reddy’s Laboratories EU Ltd., 410 Cambridge Science Park, Cambridge CB4 0PE, United Kingdom</span>;&nbsp;&nbsp;<span class="author-email">Email:&nbsp;<a href="mailto:keholt.tiffin@drreddys.com">keholt.tiffin@drreddys.com</a></span></div>
</li>
</ul>
</li>
<li><span class="author-information-subsection-header">Authors</span>
<ul>
<li>
<div class="authorItemInformation" bis_skin_checked="1"><span class="hlFld-ContribAuthor strong">Anna Fryszkowska</span>&nbsp;–&nbsp;<span class="hlFld-Affiliation affiliation">Chirotech Technology Centre, Dr. Reddy’s Laboratories EU Ltd., 410 Cambridge Science Park, Cambridge CB4 0PE, United Kingdom</span></div>
</li>
<li>
<div class="authorItemInformation" bis_skin_checked="1"><span class="hlFld-ContribAuthor strong">Justine Peterson</span>&nbsp;–&nbsp;<span class="hlFld-Affiliation affiliation">Chirotech Technology Centre, Dr. Reddy’s Laboratories EU Ltd., 410 Cambridge Science Park, Cambridge CB4 0PE, United Kingdom</span></div>
</li>
<li>
<div class="authorItemInformation" bis_skin_checked="1"><span class="hlFld-ContribAuthor strong">Nichola L. Davies</span>&nbsp;–&nbsp;<span class="hlFld-Affiliation affiliation">Chirotech Technology Centre, Dr. Reddy’s Laboratories EU Ltd., 410 Cambridge Science Park, Cambridge CB4 0PE, United Kingdom</span></div>
</li>
<li>
<div class="authorItemInformation" bis_skin_checked="1"><span class="hlFld-ContribAuthor strong">Colin Dewar</span>&nbsp;–&nbsp;<span class="hlFld-Affiliation affiliation">Chirotech Technology Centre, Dr. Reddy’s Laboratories EU Ltd., 410 Cambridge Science Park, Cambridge CB4 0PE, United Kingdom</span></div>
</li>
<li>
<div class="authorItemInformation" bis_skin_checked="1"><span class="hlFld-ContribAuthor strong">George Evans</span>&nbsp;–&nbsp;<span class="hlFld-Affiliation affiliation">Chirotech Technology Centre, Dr. Reddy’s Laboratories EU Ltd., 410 Cambridge Science Park, Cambridge CB4 0PE, United Kingdom</span></div>
</li>
<li>
<div class="authorItemInformation" bis_skin_checked="1"><span class="hlFld-ContribAuthor strong">Matthew Bycroft</span>&nbsp;–&nbsp;<span class="hlFld-Affiliation affiliation">Chirotech Technology Centre, Dr. Reddy’s Laboratories EU Ltd., 410 Cambridge Science Park, Cambridge CB4 0PE, United Kingdom</span></div>
</li>
<li>
<div class="authorItemInformation" bis_skin_checked="1"><span class="hlFld-ContribAuthor strong">Neil Triggs</span>&nbsp;–&nbsp;<span class="hlFld-Affiliation affiliation">Chirotech Technology Centre, Dr. Reddy’s Laboratories EU Ltd., 410 Cambridge Science Park, Cambridge CB4 0PE, United Kingdom</span></div>
</li>
<li>
<div class="authorItemInformation" bis_skin_checked="1"><span class="hlFld-ContribAuthor strong">Toni Fleming</span>&nbsp;–&nbsp;<span class="hlFld-Affiliation affiliation">Chirotech Technology Centre, Dr. Reddy’s Laboratories EU Ltd., 410 Cambridge Science Park, Cambridge CB4 0PE, United Kingdom</span></div>
</li>
<li>
<div class="authorItemInformation" bis_skin_checked="1"><span class="hlFld-ContribAuthor strong">Srikanth Sarat Chandra Gorantla</span>&nbsp;–&nbsp;<span class="hlFld-Affiliation affiliation">Custom Pharmaceutical Services, Dr. Reddy’s Laboratories Ltd, Bollaram Road, Miyapur, Hyderabad 500049, India</span></div>
</li>
<li>
<div class="authorItemInformation" bis_skin_checked="1"><span class="hlFld-ContribAuthor strong">Garrett Hoge</span>&nbsp;–&nbsp;<span class="hlFld-Affiliation affiliation">Chirotech Technology Centre, Dr. Reddy’s Laboratories EU Ltd., 410 Cambridge Science Park, Cambridge CB4 0PE, United Kingdom</span></div>
</li>
<li>
<div class="authorItemInformation" bis_skin_checked="1"><span class="hlFld-ContribAuthor strong">Michael Quirmbach</span>&nbsp;–&nbsp;<span class="hlFld-Affiliation affiliation">Dr. Reddy’s Laboratories SA Elisabethenanlage, 11CH-4051 Basel, Switzerland</span></div>
</li>
<li>
<div class="authorItemInformation" bis_skin_checked="1"><span class="hlFld-ContribAuthor strong">Upadhya Timmanna</span>&nbsp;–&nbsp;<span class="hlFld-Affiliation affiliation">Custom Pharmaceutical Services, Dr. Reddy’s Laboratories Ltd, Bollaram Road, Miyapur, Hyderabad 500049, India</span></div>
</li>
<li>
<div class="authorItemInformation" bis_skin_checked="1"><span class="hlFld-ContribAuthor strong">Srinivas Reddy Poreddy</span>&nbsp;–&nbsp;<span class="hlFld-Affiliation affiliation">Custom Pharmaceutical Services, Dr. Reddy’s Laboratories Ltd, Bollaram Road, Miyapur, Hyderabad 500049, India</span></div>
</li>
<li>
<div class="authorItemInformation" bis_skin_checked="1"><span class="hlFld-ContribAuthor strong">D. Naresh Kumar Reddy</span>&nbsp;–&nbsp;<span class="hlFld-Affiliation affiliation">Custom Pharmaceutical Services, Dr. Reddy’s Laboratories Ltd, Bollaram Road, Miyapur, Hyderabad 500049, India</span></div>
</li>
<li>
<div class="authorItemInformation" bis_skin_checked="1"><span class="hlFld-ContribAuthor strong">Vilas Dahanukar</span>&nbsp;–&nbsp;<span class="hlFld-Affiliation affiliation">Custom Pharmaceutical Services, Dr. Reddy’s Laboratories Ltd, Bollaram Road, Miyapur, Hyderabad 500049, India</span></div>
</li>
</ul>
</li>
<li><span class="author-information-subsection-header">Author Contributions</span>The manuscript was written by Anna Fryszkowska through equal contributions of all authors. All authors have given approval to the final version of the manuscript.</li>
<li><span class="author-information-subsection-header">Notes</span>The authors declare no competing financial interest.</li>
</ul>
<p>&nbsp;</p>
<div class="article_content-title" bis_skin_checked="1">
<h2 id="_i37">Acknowledgment</h2>
<hr>
</div>
<p>&nbsp;</p>
<div id="ACK-d55e1635-autogenerated" class="ack" bis_skin_checked="1">
<p class="last">We acknowledge Pieter de Koning for invaluable discussions and his help in preparation of this manuscript.</p>
</div>
<div id="" class="NLM_sec NLM_sec_level_1" bis_skin_checked="1">
<div id="ac_i38" class="anchor-spacer" bis_skin_checked="1"></div>
<h2 id="_i38" class="article-section__title section__title"></h2>
<div class="NLM_p last" bis_skin_checked="1">
<div id="ac_i39" class="anchor-spacer" bis_skin_checked="1"></div>
<h2 id="_i39" class="article-section__title section__title">Abbreviations</h2>
<table id="dl1" class="NLM_def-list" summary="">
<tbody>
<tr>
<td class="NLM_term">DHEA</td>
<td class="NLM_def">
<p class="first last">dehydroepiandrosterone</p>
</td>
</tr>
<tr>
<td class="NLM_term">5-AD</td>
<td class="NLM_def">
<p class="first last">androst-5-ene-3,17-dione</p>
</td>
</tr>
<tr>
<td class="NLM_term">4-AD</td>
<td class="NLM_def">
<p class="first last">androst-4-ene-3,17-dione</p>
</td>
</tr>
<tr>
<td class="NLM_term">HSD</td>
<td class="NLM_def">
<p class="first last">hydroxysteroid dehydrogenase</p>
</td>
</tr>
<tr>
<td class="NLM_term">KSI</td>
<td class="NLM_def">
<p class="first last">ketosteroid isomerase</p>
</td>
</tr>
<tr>
<td class="NLM_term">NAD<sup>+</sup></td>
<td class="NLM_def">
<p class="first last">nicotinamide adenine dinucleotide (oxidized form)</p>
</td>
</tr>
<tr>
<td class="NLM_term">NADH</td>
<td class="NLM_def">
<p class="first last">nicotinamide adenine dinucleotide (reduced form)</p>
</td>
</tr>
<tr>
<td class="NLM_term">NADP<sup>+</sup></td>
<td class="NLM_def">
<p class="first last">nicotinamide adenine dinucleotide phosphate (oxidized form)</p>
</td>
</tr>
<tr>
<td class="NLM_term">NADPH</td>
<td class="NLM_def">
<p class="first last">nicotinamide adenine dinucleotide phosphate (reduced form)</p>
</td>
</tr>
<tr>
<td class="NLM_term">GDH</td>
<td class="NLM_def">
<p class="first last">glucose dehydrogenase</p>
</td>
</tr>
<tr>
<td class="NLM_term">IPTG</td>
<td class="NLM_def">
<p class="first last">isopropyl β-<span class="smallcaps smallerCapital">d</span>-1-thiogalactopyranoside</p>
<p>&nbsp;</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<h2 id="_i40">References</h2>
<hr>
<p>&nbsp;</p>
<p>This article references 42 other publications.</p>
<p>1Mo, Q.; Lu, S. F.; Simon, N. G. J. Steroid Biochem. Mol. Biol. 2006, 99, 50– 58 DOI: 10.1016/j.jsbmb.2005.11.011<br>
2Potter, G. A.; Barrie, S. E.; Jarman, M.; Rowlands, M. G. J. Med. Chem. 1995, 38, 2463– 2471 DOI: 10.1021/jm00013a022 [ACS Full Text ACS Full Text],<br>
3Barrie, S. E.; Jarman, M.; Potter, G. A. 17-Substituted steroids useful in cancer treatment. WO1993020097 A1, 1993.<br>
4Ding, H. X.; Liu, K. K.-C.; Sakya, S. M.; O’Donnell, C. J.; Flick, A. C.; Li, J. Bioorg. Med. Chem. 2011, 19, 1136– 1154 DOI: 10.1016/j.bmc.2010.12.038 , ,<br>
5Al Jasem, Y. Al; Khan, M.; Taha, A.; Thiemann, T. Mediterr. J. Chem. 2014, 3, 796– 830 DOI: 10.13171/mjc.3.2.2014.18.04.15 ,<br>
6Marker, R. E.; Krueger, J. J. Am. Chem. Soc. 1940, 62, 3349– 3350 DOI: 10.1021/ja01869a023 [ACS Full Text ACS Full Text],<br>
7Rosenkranz, G. Steroids 1992, 57, 409– 418 DOI: 10.1016/0039-128X(92)90085-N<br>
8Xi, Z.; Zhang, G.; Wang, Y. Method for preparation of dehydroepiandrosterone (DHEA). CN 102603839 A1, 2012.<br>
9Wang, X.-L.; Kim, H.-J.; Kang, S.-I.; Kim, S.-I.; Hur, H.-G. Arch. Microbiol. 2007, 187, 155– 160 DOI: 10.1007/s00203-006-0183-8<br>
10Donova, M. V.; Egorova, O. V. Appl. Microbiol. Biotechnol. 2012, 94, 1423– 1447 DOI: 10.1007/s00253-012-4078-0<br>
11Bhatti, H. N.; Khera, R. A. Steroids 2012, 77, 1267– 1290 DOI: 10.1016/j.steroids.2012.07.018<br>
12Cruz Silva, M. M.; Riva, S.; Sá E Melo, M. L. Tetrahedron 2005, 61, 3065– 3073 DOI: 10.1016/j.tet.2005.01.104 ,<br>
13Cruz Silva, M. M.; Riva, S.; Sá E Melo, M. L. Tetrahedron: Asymmetry 2004, 15, 1173– 1179 DOI: 10.1016/j.tetasy.2004.02.010 ,<br>
14Thomas, J. L.; Strickler, R. C.; Myers, R. P.; Covey, D. F. Biochemistry 1992, 31, 5522– 5527 DOI: 10.1021/bi00139a014 [ACS Full Text ACS Full Text],<br>
15Thomas, J. L.; Mason, J. I.; Brandt, S.; Spencer, B. R.; Norris, W. J. Biol. Chem. 2002, 277, 42795– 42801 DOI: 10.1074/jbc.M208537200<br>
16Rajapaksha, M.; Thomas, J. L.; Streeter, M.; Prasad, M.; Whittal, R. M.; Bell, J. D.; Bose, H. S. Biochemistry 2011, 50, 11015– 11024 DOI: 10.1021/bi2016102 [ACS Full Text ACS Full Text],<br>
17Bertolino, A.; Benson, A. M.; Talalay, P. Biochem. Biophys. Res. Commun. 1979, 88, 1158– 1166 DOI: 10.1016/0006-291X(79)91530-4<br>
18Benson, A. M.; Talalay, P. Biochem. Biophys. Res. Commun. 1976, 69, 1073– 1079 DOI: 10.1016/0006-291X(76)90482-4<br>
19Wilde, T. C.; Blotny, G.; Pollack, R. M. J. Am. Chem. Soc. 2008, 130, 6577– 6585 DOI: 10.1021/ja0732330 [ACS Full Text ACS Full Text],<br>
20Pollack, R. M. Bioorg. Chem. 2004, 32, 341– 353 DOI: 10.1016/j.bioorg.2004.06.005<br>
21Oppermann, U. C.; Filling, C.; Berndt, K. D.; Persson, B.; Benach, J.; Ladenstein, R.; Jörnvall, H. Biochemistry 1997, 36, 34– 40 DOI: 10.1021/bi961803v [ACS Full Text ACS Full Text],<br>
22Han, Q.; Campbell, R. L.; Gangloff, A.; Huang, Y.; Lin, S. J. Biol. Chem. 2000, 275, 1105– 1111 DOI: 10.1074/jbc.275.2.1105<br>
23Benach, J.; Filling, C.; Oppermann, U. C. T.; Roversi, P.; Berndt, K. D.; Jornvall, H.; Ladenstein, R. Biochemistry 2002, 41, 14659– 14668 DOI: 10.1021/bi0203684 [ACS Full Text ACS Full Text],<br>
24Grimm, C.; Maser, E.; Möbus, E.; Klebe, G.; Reuter, K.; Ficner, R. J. Biol. Chem. 2000, 275, 41333– 41339 DOI: 10.1074/jbc.M007559200<br>
25Kochakian, C. D. J. Steroid Biochem. 1982, 17, 541– 546 DOI: 10.1016/0022-4731(82)90013-9<br>
26Fogal, S.; Bergantino, E.; Motterle, R.; Castellin, A.; Arvotti, G. Process for the Preparation of Testosterone. US 20110207172 A1, 2011.<br>
27Pollack, R. M.; Zeng, B.; Mack, J. P. G.; Eldin, S. J. Am. Chem. Soc. 1989, 111, 6419– 6423 DOI: 10.1021/ja00198a066 [ACS Full Text ACS Full Text],<br>
28Pollack, R. M.; Thornburg, L. D.; Wu, Z. R.; Summers, M. F. Arch. Biochem. Biophys. 1999, 370, 9– 15 DOI: 10.1006/abbi.1999.1384<br>
29Wu, Z. R.; Ebrahimian, S.; Zawrotny, M. E.; Thornburg, L. D.; Perez-Alvarado, G. C.; Brothers, P.; Pollack, R. M.; Summers, M. F. Science 1997, 276, 415– 418 DOI: 10.1126/science.276.5311.415<br>
30Ha, N. C.; Choi, G.; Choi, K. Y.; Oh, B. H. Curr. Opin. Struct. Biol. 2001, 11, 674– 678 DOI: 10.1016/S0959-440X(01)00268-8<br>
31Ringold, H. J.; Malhotra, S. K. Tetrahedron Lett. 1962, 15, 669– 672 DOI: 10.1016/S0040-4039(00)70930-0 ,<br>
32D’Incan, E.; Viout, P. Tetrahedron 1984, 40, 3421– 3424 DOI: 10.1016/S0040-4020(01)91490-5 ,<br>
33Amar, D.; Permutti, V.; Mazur, Y. Tetrahedron 1969, 25, 1717– 1726 DOI: 10.1016/S0040-4020(01)82744-7 ,<br>
34Morton, D.; Dick, A. R.; Ghosh, D.; Davies, H. M. L. Chem. Commun. 2012, 48, 5838– 5840 DOI: 10.1039/c2cc31973j<br>
35Davies, H.; Ghosh, D.; Morton, D. Substituted androst-4-ene diones. WO2011127232 A2, 2011.<br>
36Kollerov, V. V.; Shutov, A. A.; Fokina, V. V.; Sukhodol’skaya, G. V.; Donova, M. V. J. Mol. Catal. B: Enzym. 2008, 55, 61– 68 DOI: 10.1016/j.molcatb.2008.01.009 , [CAS],<br>
37 Enzyme Assays. Hight-throughput Screening, Genetic Selection and Fingerprinting; Reymond, J.-L., Ed.; Wiley-VCH, 2006.<br>
38Fryszkowska, A.; Quirmbach, M. S.; Gorantla, S. S. C.; Alieti, S. R.; Poreddy, S. R.; Dinn, N. K. R.; Timmanna, U.; Dahanukar, V. Process for the preparation of dehydroepiandrosterone and its intermediates. WO2014188353 A2, 2014.<br>
39Bornscheuer, U. T.; Huisman, G. W.; Kazlauskas, R. J.; Lutz, S.; Moore, J. C.; Robins, K. Nature 2012, 485, 185– 194 DOI: 10.1038/nature11117<br>
40Chang, L. C.; Caira, M. R.; Guillory, J. K. J. Pharm. Sci. 1995, 84, 1169– 1179 DOI: 10.1002/jps.2600841007<br>
41Parasrampuriar, J.; Yonker, M. B.; Schwartz, K. E.; Gurwith, M. J. DHEA composition and method. US 7045513 B1, 2006.<br>
42Ge, Y.; Huang, Y.; White, S. K. Methods and compounds for preparing 3alpha-oxygen substituted steroids. WO 2012083090 A2, 2012.</p>
<p>&nbsp;</p>
<h2>Source:</h2>
<hr>
<p>&nbsp;</p>
<p>https://pubs.acs.org/doi/10.1021/acs.oprd.6b00215</p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/05/02/development-of-a-chemoenzymatic-process-for-dehydroepiandrosterone-acetate-synthesis/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/05/02/development-of-a-chemoenzymatic-process-for-dehydroepiandrosterone-acetate-synthesis/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5200 post type-post status-publish format-standard hentry category-articles animated"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20144%20144'%3E%3C/svg%3E" data-lazy-srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" class="avatar avatar-144 photo" height="144" width="144" data-lazy-src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>28.04.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/04/28/effect-of-oral-prednisolone-on-symptom-duration-and-severity-in-nonasthmatic-adults-with-acute-lower-respiratory-tract-infection-a-randomized-clinical-trial/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/04/28/effect-of-oral-prednisolone-on-symptom-duration-and-severity-in-nonasthmatic-adults-with-acute-lower-respiratory-tract-infection-a-randomized-clinical-trial/">Effect of Oral Prednisolone on Symptom Duration and Severity in Nonasthmatic Adults With Acute Lower Respiratory Tract Infection A Randomized Clinical Trial</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><p><span class="meta-authors--limited"><span class="wi-fullname brand-fg">D. Hay, FRCGP<sup>1</sup></span><span class="al-author-delim">;&nbsp;</span><span class="wi-fullname brand-fg">Paul&nbsp;Little,&nbsp;FMedSci<sup>2</sup></span><span class="al-author-delim">;&nbsp;</span><span class="wi-fullname brand-fg">Anthony&nbsp;Harnden,&nbsp;FRCGP<sup>3</sup></span>;&nbsp;</span><span class="meta-authors--remaining accessible-show"><span class="wi-fullname brand-fg">Matthew&nbsp;Thompson,&nbsp;PhD<sup>4</sup></span><span class="al-author-delim">;&nbsp;</span><span class="wi-fullname brand-fg">Kay&nbsp;Wang,&nbsp;DPhil<sup>3</sup></span><span class="al-author-delim">;&nbsp;</span><span class="wi-fullname brand-fg">Denise&nbsp;Kendrick,&nbsp;FRCGP<sup>5</sup></span><span class="al-author-delim">;&nbsp;</span><span class="wi-fullname brand-fg">Elizabeth&nbsp;Orton,&nbsp;FFPH<sup>5</sup></span><span class="al-author-delim">;&nbsp;</span><span class="wi-fullname brand-fg">Sara T.&nbsp;Brookes,&nbsp;PhD<sup>6</sup></span><span class="al-author-delim">;&nbsp;</span><span class="wi-fullname brand-fg">Grace J.&nbsp;Young,&nbsp;MSc<sup>7</sup></span><span class="al-author-delim">;&nbsp;</span><span class="wi-fullname brand-fg">Margaret&nbsp;May,&nbsp;PhD<sup>6</sup></span><span class="al-author-delim">;&nbsp;</span><span class="wi-fullname brand-fg">Sandra&nbsp;Hollinghurst,&nbsp;PhD<sup>1</sup></span><span class="al-author-delim">;&nbsp;</span><span class="wi-fullname brand-fg">Fran E.&nbsp;Carroll,&nbsp;PhD<sup>8</sup></span><span class="al-author-delim">;&nbsp;</span><span class="wi-fullname brand-fg">Harriet&nbsp;Downing,&nbsp;MPhil<sup>1</sup></span><span class="al-author-delim">;&nbsp;</span><span class="wi-fullname brand-fg">David&nbsp;Timmins,&nbsp;BA<sup>3</sup></span><span class="al-author-delim">;&nbsp;</span><span class="wi-fullname brand-fg">Natasher&nbsp;Lafond,&nbsp;MSc<sup>5</sup></span><span class="al-author-delim">;&nbsp;</span><span class="wi-fullname brand-fg">Magdy&nbsp;El-Gohary,&nbsp;MRCGP<sup>2</sup></span><span class="al-author-delim">;&nbsp;</span><span class="wi-fullname brand-fg">Michael&nbsp;Moore,&nbsp;FRCGP<sup>2</sup></span></span></p>
<p>&nbsp;</p>
<h3>Key Points</h3>
<hr>
<p>&nbsp;</p>
<p><strong>Question</strong>&nbsp;&nbsp;Does a moderate dose of oral corticosteroid reduce the duration or severity of acute lower respiratory tract infection in adults without asthma presenting to primary care?</p>
<p><strong>Findings</strong>&nbsp;&nbsp;In this randomized trial of 401 adults with symptoms of acute lower respiratory tract infection, treatment with oral prednisolone, 40 mg/d for 5 days, compared with placebo did not significantly reduce the median duration of moderately bad or worse cough (5 days in each group) or the mean severity of symptoms between days 2 and 4 (1.99 vs 2.16 points out of 6).</p>
<p><strong>Meaning</strong>&nbsp;&nbsp;These findings do not support the use of oral steroids for the treatment of acute lower respiratory tract infection in the absence of asthma.</p>
<p>&nbsp;</p>
<h2>Abstract</h2>
<hr>
<p>&nbsp;</p>
<p><strong>Importance</strong>&nbsp;&nbsp;Acute lower respiratory tract infection is common and often treated inappropriately in primary care with antibiotics. Corticosteroids are increasingly used but without sufficient evidence.</p>
<p><strong>Objective</strong>&nbsp;&nbsp;To assess the effects of oral corticosteroids for acute lower respiratory tract infection in adults without asthma.</p>
<p><strong>Design, Setting, and Participants</strong>&nbsp;&nbsp;Multicenter, placebo-controlled, randomized trial (July 2013 to final follow-up October 2014) conducted in 54 family practices in England among 401 adults with acute cough and at least 1 lower respiratory tract symptom not requiring immediate antibiotic treatment and with no history of chronic pulmonary disease or use of asthma medication in the past 5 years.</p>
<p><strong>Interventions</strong>&nbsp;&nbsp;Two 20-mg prednisolone tablets (n = 199) or matched placebo (n = 202) once daily for 5 days.</p>
<p><strong>Main Outcomes and Measures</strong>&nbsp;&nbsp;The primary outcomes were duration of moderately bad or worse cough (0 to 28 days; minimal clinically important difference, 3.79 days) and mean severity of symptoms on days 2 to 4 (scored from 0 [not affected] to 6 [as bad as it could be]; minimal clinically important difference, 1.66 units). Secondary outcomes were duration and severity of acute lower respiratory tract infection symptoms, duration of abnormal peak flow, antibiotic use, and adverse events.</p>
<p><strong>Results</strong>&nbsp;&nbsp;Among 401 randomized patients, 2 withdrew immediately after randomization, and 1 duplicate patient was identified. Among the 398 patients with baseline data (mean age, 47 [SD, 16.0] years; 63% women; 17% smokers; 77% phlegm; 70% shortness of breath; 47% wheezing; 46% chest pain; 42% abnormal peak flow), 334 (84%) provided cough duration and 369 (93%) symptom severity data. Median cough duration was 5 days (interquartile range [IQR], 3-8 days) in the prednisolone group and 5 days (IQR, 3-10 days) in the placebo group (adjusted hazard ratio, 1.11; 95% CI, 0.89-1.39;&nbsp;<i>P</i> = .36 at an α = .05). Mean symptom severity was 1.99 points in the prednisolone group and 2.16 points in the placebo group (adjusted difference, −0.20; 95% CI, −0.40 to 0.00;&nbsp;<i>P</i> = .05 at an α = .001). No significant treatment effects were observed for duration or severity of other acute lower respiratory tract infection symptoms, duration of abnormal peak flow, antibiotic use, or nonserious adverse events. There were no serious adverse events.</p>
<p><strong>Conclusions and Relevance</strong>&nbsp;&nbsp;Oral corticosteroids should not be used for acute lower respiratory tract infection symptoms in adults without asthma because they do not reduce symptom duration or severity.</p>
<p><strong>Trial Registration</strong>&nbsp;&nbsp;ISRCTN.com Identifier:&nbsp;<a href="http://www.controlled-trials.com/ISRCTN57309858">ISRCTN57309858</a></p>
<p>&nbsp;</p>
<h2>Introduction</h2>
<hr>
<p>&nbsp;</p>
<p class="para"><span class="quizSection">Acute lower respiratory tract infection, defined as an acute cough with at least 1 of the symptoms of sputum, chest pain, shortness of breath, and wheeze,<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r1" data-tab-toggle=".tab-nav-references">1</a></sup>&nbsp;is one of the most common conditions managed in primary care internationally. In 2009-2011, an estimated 65% to 75%<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r2" data-tab-toggle=".tab-nav-references">2</a></sup><sup>,<a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r3" data-tab-toggle=".tab-nav-references">3</a></sup>&nbsp;of patients were prescribed antibiotics despite good evidence that they do not reduce symptom duration or severity<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r4" data-tab-toggle=".tab-nav-references">4</a></sup>&nbsp;and guidelines to the contrary.<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r1" data-tab-toggle=".tab-nav-references">1</a></sup>&nbsp;Annual antibiotic prescribing costs are estimated at US $726 million in the United States<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r5" data-tab-toggle=".tab-nav-references">5</a></sup>&nbsp;and US $300 million for consultations and antibiotics in the United Kingdom.<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r6" data-tab-toggle=".tab-nav-references">6</a></sup></span></p>
<p class="para">Antimicrobial resistance is one of the greatest challenges to modern public health.<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r7" data-tab-toggle=".tab-nav-references">7</a></sup>&nbsp;Primary care is responsible for 80% of health service antibiotic prescribing,<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r2" data-tab-toggle=".tab-nav-references">2</a></sup><sup>,<a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r8" data-tab-toggle=".tab-nav-references">8</a></sup>&nbsp;with a high proportion regarded as unnecessary<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r2" data-tab-toggle=".tab-nav-references">2</a></sup>&nbsp;and contributing to antimicrobial resistance.<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r9" data-tab-toggle=".tab-nav-references">9</a></sup>&nbsp;Both US<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r10" data-tab-toggle=".tab-nav-references">10</a></sup>&nbsp;and UK<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r11" data-tab-toggle=".tab-nav-references">11</a></sup>&nbsp;national antimicrobial resistance action plans recommend finding alternatives to antibiotics, but none is currently proven for acute lower respiratory tract infection in adults.</p>
<p class="para"><a name="q2"></a><span class="quizSection">Symptoms of acute lower respiratory tract infection are similar to those of exacerbated asthma.<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r12" data-tab-toggle=".tab-nav-references">12</a></sup>&nbsp;Bronchial epithelial changes are similar in people with and without asthma during a respiratory tract infection, with both groups showing reductions in forced expiratory volume and airways inflammation,<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r12" data-tab-toggle=".tab-nav-references">12</a></sup>&nbsp;and prolonged acute lower respiratory tract infection symptoms are thought to be due to bronchial hyperresponsiveness.<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r13" data-tab-toggle=".tab-nav-references">13</a></sup>&nbsp;Oral and inhaled corticosteroids are highly effective for acute asthma, but US, British, and European guidelines do not provide guidance on whether corticosteroids should be used for acute lower respiratory tract infection. Despite this, US and European clinicians are increasingly using oral and inhaled steroids, with 1 US study<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r14" data-tab-toggle=".tab-nav-references">14</a></sup>&nbsp;reporting oral prednisolone use in 15% of adults without asthma with acute lower respiratory tract infection.</span></p>
<p class="para">A previous systematic review<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r15" data-tab-toggle=".tab-nav-references">15</a></sup>&nbsp;found insufficient evidence regarding the role of inhaled corticosteroids and found no oral corticosteroid studies for acute lower respiratory tract infection. The aim of the current study was to investigate the effects of a moderate dose of oral corticosteroids in adults without asthma presenting to primary care with acute lower respiratory tract infection.</p>
<p>&nbsp;</p>
<h2>Methods</h2>
<hr>
<p>&nbsp;</p>
<div class="h4 cb section-type-section " bis_skin_checked="1">
<div class="heading-text " bis_skin_checked="1">Study Design, Recruitment, and Baseline Assessment</div>
</div>
<p class="para">Ethical approval for this study was granted by the Central Bristol Research Ethics Committee (12/SW/0180) and all patients gave written informed consent. The Oral Steroids for Acute Cough (OSAC) trial was a multicenter, placebo-controlled, individually randomized study conducted between July 2013 and October 2014.&nbsp;<a name="q3"></a><span class="quizSection">Family physicians and nurses (recruiting clinicians) were trained in study procedures by 4 centers at the Universities of Bristol, Southampton, Nottingham, and Oxford. They were asked to assess eligibility in consecutive patients: age 18 years or older and presenting for an acute (≤28 days) cough as the main symptom with at least 1 lower respiratory tract symptom (phlegm, chest pain, wheezing, or shortness of breath) in the previous 24 hours. Patients were excluded if they were clinically suspected to have or their medical records showed evidence of chronic pulmonary disease; had received any asthma medication in the past 5 years; met National Institute for Health and Clinical Excellence criteria for severe infection/complications<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r1" data-tab-toggle=".tab-nav-references">1</a></sup>; required same-day hospital admission; or required same day antibiotics</span>&nbsp;(see&nbsp;<a class="supplement-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#note-JOI170090-1" data-tab-toggle=".tab-nav-supplemental">Supplement 1</a>&nbsp;for full list). Participants were recruited on the day of or the day following presentation. Following consent, demographic and clinical data were collected, including self-reported ethnicity using UK-approved<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r16" data-tab-toggle=".tab-nav-references">16</a></sup>&nbsp;categories, to assess sample representativeness.</p>
<div class="h4 cb section-type-section " bis_skin_checked="1">
<div class="heading-text " bis_skin_checked="1">Randomization and Concealment</div>
</div>
<p class="para">The treatment allocation schedule was computer generated by a statistician independent of the trial team. Randomization to prednisolone or placebo in a 1:1 ratio used a variable block size (4, 6, 8, and 10) and was stratified by center. Allocated medication was added to numbered participant packs by pharmacists independent of the team. All packs were identical and centers distributed 4 packs at a time to family practices. Following eligibility confirmation, participants were given the next pack.</p>
<div class="h4 cb section-type-section " bis_skin_checked="1">
<div class="heading-text " bis_skin_checked="1">Intervention and Masking</div>
</div>
<p class="para">Participant packs contained either ten 20-mg oral prednisolone tablets (Galen Pharma GmbH) or placebo tablets matched on dimension, appearance, and taste (Piramal Healthcare Ltd). Participants were asked to take 2 tablets once daily for 5 days, starting on the day of consultation, if possible before starting any antibiotics (if receiving a “delayed” prescription). The dose and duration of prednisolone was selected to reflect the dose and duration known to be effective for acute asthma.<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r17" data-tab-toggle=".tab-nav-references">17</a></sup>&nbsp;Participants, recruiting clinicians, and the trial team were masked to treatment allocation until data analyses were complete.</p>
<div class="h4 cb section-type-section " bis_skin_checked="1">
<div class="heading-text " bis_skin_checked="1">Follow-up</div>
</div>
<p class="para">Participants were invited to report (using web or paper versions) the presence and severity of symptoms using a validated<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r18" data-tab-toggle=".tab-nav-references">18</a></sup>&nbsp;diary shown to be sensitive to change.<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r4" data-tab-toggle=".tab-nav-references">4</a></sup><sup>,<a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r19" data-tab-toggle=".tab-nav-references">19</a></sup>&nbsp;Symptoms were measured using a scale from 0 (no problem) to 3 (moderately bad) and up to 6 (as bad as it could be). All symptoms were measured daily, with twice-daily peak expiratory flow, for 28 days or until symptom resolution. Cough was measured for a further 28 days in case of late treatment effects. A research nurse telephoned participants weekly to support symptom diary completion. Participants were given £5 (US $6.60) shopping vouchers at 14 and 28 days. Medical notes were reviewed at 3 months for new diagnoses of asthma, chronic obstructive pulmonary disease, whooping cough, and lung cancer.</p>
<div class="h4 cb section-type-section " bis_skin_checked="1">
<div class="heading-text " bis_skin_checked="1">Primary Outcomes</div>
</div>
<p class="para">Two primary outcomes were assessed. The first was duration of moderately bad or worse cough, defined as the number of days from randomization to the last day with a score of at least 3 points prior to at least 2 consecutive days with a score of less than 3, up to a maximum of 28 days. This was regarded as the more important of the 2 primary outcomes because cough was the main presenting symptom of the illness, and it included measures of both duration and severity. The second primary outcome was the mean severity score (range, 0-6) of the 6 main symptoms (cough, phlegm, shortness of breath, sleep disturbance, feeling generally unwell, and activity disturbance) on days 2 to 4; the mean score was calculated across the symptoms for each day and then an overall mean was calculated, with a maximum value of 6.</p>
<div class="h4 cb section-type-section " bis_skin_checked="1">
<div class="heading-text " bis_skin_checked="1">Secondary Outcomes</div>
</div>
<p class="para">Secondary outcomes specified a priori were total duration and severity of each symptom up to 28 days (cough, phlegm, shortness of breath, wheeze, blocked/runny nose, chest pain, fever, muscle aching, headache, sleep disturbance, feeling generally unwell, activity disturbance), duration of moderately bad or worse and any cough up to 56 days, duration of abnormal peak flow, antibiotic use, adverse events, reconsultation with evidence of illness deterioration, patient satisfaction with treatment, and intention to use the same treatment if it were to be available in the future (more detail about the derivation of these outcomes is provided in&nbsp;<a class="supplement-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#note-JOI170090-1" data-tab-toggle=".tab-nav-supplemental">Supplement 1</a>). Quality of life, National Health Service treatment, and investigation costs are not reported in this article.</p>
<div class="h4 cb section-type-section " bis_skin_checked="1">
<div class="heading-text " bis_skin_checked="1">Subgroup Analyses</div>
</div>
<p class="para">Prespecified potential treatment effect modifiers were age; prior cough duration; presence of wheeze; antibiotic use; β-agonist use; smoking status; history of hay fever, asthma, or eczema; and new diagnoses (at 3 months) of asthma, chronic obstructive pulmonary disease, whooping cough, or lung cancer. Baseline impression of severity of illness was added as a post hoc subgroup analysis because the investigators determined it was important to differentiate between participants with severe vs mild symptoms.</p>
<div class="h4 cb section-type-section " bis_skin_checked="1">
<div class="heading-text " bis_skin_checked="1">Sample Size Calculation</div>
</div>
<p class="para">The distributions of both primary outcomes were expected to be positively skewed; hence, sample size calculations were based on the log-normal distribution. The mean durations of moderately bad or worse cough and symptoms severity score (days 2-4) were estimated to be 5.8 (SD, 4.1) days and 2.3 (SD, 1.1) points, respectively.<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r19" data-tab-toggle=".tab-nav-references">19</a></sup>&nbsp;This corresponds to 1.56 (SD, 0.64) log days (or a geometric mean of 4.74 days) for cough duration and 0.73 (SD, 0.45) points on the log scale (or a geometric mean of 2.08) for severity of symptoms. Because there were no previous studies of oral steroids to inform the minimum clinically important difference in both outcomes, the investigative team considered the balance of potential benefits and adverse effects and reached a minimum clinically important difference consensus of 20%, corresponding to a geometric mean in the active treatment group of 3.79 days (mean, 1.33 log days) for duration of cough and 1.66 points (mean, 0.51 log points) for severity of symptoms. Allowing for 20% attrition, 218 participants needed to be randomized per group to retain 174 at follow-up and achieve 90% power with a 2-sided α = .05 for primary outcome one. A final achieved sample size of 174 participants per group would provide 89% power to detect a 20% reduction in severity of symptoms, with an adjusted 2-sided α = .001 to reflect the second primary outcome status (<a class="supplement-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#note-JOI170090-1" data-tab-toggle=".tab-nav-supplemental">Supplement 1</a>).</p>
<div class="h4 cb section-type-section " bis_skin_checked="1">
<div class="heading-text " bis_skin_checked="1">Statistical Analyses</div>
</div>
<p class="para">A prespecified analysis plan was approved by the trial steering and data monitoring committees and the study protocol was published before data collection had finished (<a class="supplement-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#note-JOI170090-1" data-tab-toggle=".tab-nav-supplemental">Supplement 2</a>). Changes that were made to the statistical analysis plan after the analysis was begun are also described in&nbsp;<a class="supplement-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#note-JOI170090-1" data-tab-toggle=".tab-nav-supplemental">Supplement 2</a>. All analyses were performed in Stata software, version 13.1.<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r20" data-tab-toggle=".tab-nav-references">20</a></sup></p>
<p class="para">The primary comparative analyses considered patients in the groups to which they were randomized, without imputation for missing outcome data. These analyses were adjusted for center (Bristol, Nottingham, Oxford, and Southampton) and the relevant baseline measure (prior cough duration [1-28 days] for duration of moderately bad or worse cough and patient-reported illness severity in last 24 hours for severity of symptoms [0 = completely well; 10 = extremely unwell]). Time-to-event methods were used to analyze the duration of moderately bad or worse cough. Semiparametric Cox proportional hazard models were used (to enable comparison with previous studies) and the assumption of proportional hazards checked by visual inspection of log-log survival curves and calculation of Schoenfeld residuals.<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r21" data-tab-toggle=".tab-nav-references">21</a></sup>&nbsp;Hazard ratios were reported comparing the instantaneous rate of resolution of cough between the prednisolone and placebo groups, with 95% confidence intervals and&nbsp;<i>P</i>&nbsp;values. To assist interpretation against the minimum clinically important difference of a 20% reduction in time to resolution, for which hazard ratios are unhelpful, parametric Weibull accelerated failure time models were used to present cough duration treatment effects as time ratios. Such models can be formulated as proportional hazards or accelerated failure time models; hence, hazard ratios were also produced from the Weibull models to ensure comparability with the Cox models.</p>
<p class="para">To further aid interpretation, we calculated absolute measures of effect for the primary outcome of duration of moderately bad or worse cough. There is no single absolute measure of treatment effect for time-to-event data because it varies over the duration of follow-up; it can, however, be calculated at a specific time point. Of particular clinical interest is day 7, because this is a time in the illness trajectory when clinicians and patients want to know about expected benefits, and when steroids should have affected symptoms if effective. Survival curves were produced from the Cox regressions at given values of center (Bristol) and duration of prior cough (median value). Predicted survival probabilities at day 7 in the prednisolone and placebo groups were obtained and an absolute risk difference estimated as the survival probability in the prednisolone group minus that in the placebo group. Ninety-five percent confidence intervals were obtained using the method proposed by Altman and Andersen.<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r22" data-tab-toggle=".tab-nav-references">22</a></sup></p>
<p class="para">Mean severity score from days 2 to 4 was considered in linear regression models. Models considered mean severity score and log mean severity score, and distributional checks of residuals were undertaken to determine the most appropriate model. Differences between the prednisolone and placebo groups are reported with 95% confidence intervals and&nbsp;<i>P</i>&nbsp;values.</p>
<p class="para">For both primary outcomes, secondary analyses additionally adjusted for factors demonstrating imbalance at baseline (difference &gt;5% for binary and &gt;0.5 SD for continuous outcomes) and for smoking because it is known to be prognostically important.<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r15" data-tab-toggle=".tab-nav-references">15</a></sup></p>
<p class="para">Analyses of secondary outcomes used regression models as appropriate. Consideration of potential effect modifiers used formal tests of interaction. We calculated absolute measures of effect for time-to-event secondary outcomes as described above for the primary outcome. Absolute risk differences were also obtained (with 95% confidence intervals) for the binary secondary outcomes of antibiotic use (up to 7 and 28 days), patient satisfaction, and intention to use the same treatment if it were to be available. Sensitivity analyses considered multiple imputation of missing data (using a 2-fold fully conditional specification algorithm),<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r23" data-tab-toggle=".tab-nav-references">23</a></sup><sup>,<a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r24" data-tab-toggle=".tab-nav-references">24</a></sup>&nbsp;treatment adherence, day of recruitment, and inclusion of those with no moderately bad or worse cough at baseline (post hoc) (see&nbsp;<a class="supplement-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#note-JOI170090-1" data-tab-toggle=".tab-nav-supplemental">Supplement 1</a>&nbsp;for details).</p>
<p>&nbsp;</p>
<h2>Results</h2>
<hr>
<p>&nbsp;</p>
<div class="h4 cb section-type-section " bis_skin_checked="1">
<div class="heading-text " bis_skin_checked="1">Enrollment and Study Population</div>
</div>
<p class="para">Fifty-eight family physicians and 50 practice nurses based in 54 family practices assessed 525 patients for suitability, of whom 401 were eligible, consented, and were randomized, 199 to prednisolone and 202 to placebo (<a class="figure-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090f1" data-tab-toggle=".tab-nav-figure-table">Figure 1</a>), equating a mean patient recruitment rate of 0.5 patients per month per practice. Two placebo group patients requested complete withdrawal immediately after randomization, and a duplicate patient was subsequently identified in the prednisolone group (the participant remained in the group to which he/she was first allocated), leaving a sample of 398. Enrollment was stopped when the required number of participants was achieved. At baseline, participants had a mean age of 47.4 (SD, 16.0) years; 37% were men; 3.5% had diabetes; 17% were currently smoking; 5% had received asthma medication more than 5 years previously; 77% reported phlegm, 46% chest pain, 47% wheezing, and 70% shortness of breath; and 42% had abnormal (defined as &lt;80% expected) peak flow. Baseline characteristics were similar between the groups with respect to deprivation, smoking status, weight, height, and clinical characteristics of the acute lower respiratory tract infection, although compared with placebo, the prednisolone group was slightly more likely to be male, be older (and hence retired), and have received an influenza vaccine in the last 12 months (<a class="table-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090t1" data-tab-toggle=".tab-nav-figure-table">Table 1</a>).</p>
<div class="h4 cb section-type-section " bis_skin_checked="1">
<div class="heading-text " bis_skin_checked="1">Primary Outcome Data Completeness</div>
</div>
<p class="para">Symptom diaries were returned by 374 participants (94%; 192 in the prednisolone group and 182 in the placebo group). For duration of moderately bad or worse cough, data were available for 334 participants (84%), with 40 reporting an initial cough severity of less than 3 points (that is, not moderately bad or worse) and 24 lost to follow-up. For severity of symptoms, follow-up data were available in 370 (93%). However, 1 participant in the prednisolone group had no baseline measure of illness severity and this participant’s data could not be used in the adjusted analysis. Patients who withdrew or were lost to follow-up were younger (median, 30 years vs 49 years), were less likely to be white (85% vs 97%), were more likely to be employed (86% vs 69%), and had a higher English Index of Multiple Deprivation score (median score, 18 vs 11).</p>
<div class="h4 cb section-type-section " bis_skin_checked="1">
<div class="heading-text " bis_skin_checked="1">Primary Analyses</div>
</div>
<div class="h5 cb section-type-section " bis_skin_checked="1">
<div class="heading-text " bis_skin_checked="1">Moderately Bad or Worse Cough Duration</div>
</div>
<p class="para">The median duration of moderately bad or worse cough was 5 days (interquartile range, 3-8 days) in the prednisolone group and 5 days (interquartile range, 3-10 days) in the placebo group (<a class="table-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090t2" data-tab-toggle=".tab-nav-figure-table">Table 2</a>). Kaplan-Meier survival curves were similar for both groups (<a class="figure-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090f2" data-tab-toggle=".tab-nav-figure-table">Figure 2</a>). Visual inspection of the log-log survival curves and calculation of the Schoenfeld residuals (<i>P</i> = .52) provided no evidence against proportional hazards. Comparing prednisolone with placebo, the Cox model adjusting for center and baseline cough duration resulted in a hazard ratio of 1.11 (95% CI, 0.89-1.39;&nbsp;<i>P</i> = .36 with α = .05). The hazard ratio represents the instantaneous risk of resolution from moderately bad or worse cough in the prednisolone group compared with placebo; a hazard ratio greater than 1 demonstrates a beneficial effect of prednisolone. The Weibull accelerated failure time model ratio was 0.91 (95% CI, 0.76-1.10), indicating that the time to resolution was reduced by 9% (0.45 days) with prednisolone compared with placebo (<i>P</i> = .34); the lower limit of the 95% CI did not exclude the 20% a priori minimum clinically important difference. Further (secondary analysis) adjustment for factors demonstrating possible imbalance at baseline (age, sex, and influenza vaccine in last 12 months) and smoking had no effect on the models (<a class="table-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090t2" data-tab-toggle=".tab-nav-figure-table">Table 2</a>). The difference between the prednisolone group and the placebo group, expressed as the absolute difference in percentage with unresolved moderately bad or worse cough at day 7, was −3.61 (95% CI, −10.64 to 4.23) (<a class="table-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090t3" data-tab-toggle=".tab-nav-figure-table">Table 3</a>); this can be interpreted as 3.61% fewer participants in the prednisolone group who still had an unresolved moderately bad or worse cough at the end of day 7.</p>
<div class="h5 cb section-type-section " bis_skin_checked="1">
<div class="heading-text " bis_skin_checked="1">Severity of Symptoms on Days 2 to 4</div>
</div>
<p class="para">Mean symptoms severity scores (and residuals) were normally distributed. The mean symptoms severity scores were 1.99 (SD, 0.99) and 2.16 (SD, 1.09) points for the prednisolone and placebo groups, respectively. Adjusting for center and baseline illness severity, the mean symptoms severity difference was 0.20 point (95% CI, −0.40 to 0.00 point;&nbsp;<i>P</i> = .05 with a priori α = .001) between prednisolone and placebo (<a class="table-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090t2" data-tab-toggle=".tab-nav-figure-table">Table 2</a>). With a mean symptoms severity score of 2.16 in the placebo group, a difference of 0.20 equates to a relative reduction of 9.3%. The lower limit of the 95% CI of this reduction was 18.5% and excluded the 20% a priori minimum clinically important difference. Additional adjustment for factors demonstrating imbalance at baseline and smoking marginally attenuated the difference in means and reduced the strength of evidence against the null hypothesis (<a class="table-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090t2" data-tab-toggle=".tab-nav-figure-table">Table 2</a>).</p>
<div class="h5 cb section-type-section " bis_skin_checked="1">
<div class="heading-text " bis_skin_checked="1">Sensitivity Analyses</div>
</div>
<p class="para">None of the sensitivity analyses had any effect on the primary comparisons, including those with no moderately bad or worse cough at baseline, multiple imputation of missing data, per-protocol analysis, and adjusting for day of recruitment (eTable 1 in&nbsp;<a class="supplement-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#note-JOI170090-1" data-tab-toggle=".tab-nav-supplemental">Supplement 1</a>).</p>
<div class="h4 cb section-type-section " bis_skin_checked="1">
<div class="heading-text " bis_skin_checked="1">Secondary Outcomes</div>
</div>
<p class="para">There were no significant effects on any symptom duration or peak flow up to 28 days or cough duration up to 56 days (<a class="table-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090t4" data-tab-toggle=".tab-nav-figure-table">Table 4</a>). No significant effects were observed for antibiotic use; patient satisfaction or intention to use the same treatment if it were to be available in the future; nonserious adverse events (<a class="table-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090t4" data-tab-toggle=".tab-nav-figure-table">Table 4</a>); expected, unexpected, or cough-related adverse events; or reconsultations (eTable 2 in&nbsp;<a class="supplement-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#note-JOI170090-1" data-tab-toggle=".tab-nav-supplemental">Supplement 1</a>). The nature of the adverse events was similar between the groups (eTable 3 in&nbsp;<a class="supplement-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#note-JOI170090-1" data-tab-toggle=".tab-nav-supplemental">Supplement 1</a>), no new urinary or visual symptoms were reported, and none of the patients reporting fatigue, thirst, or dry throat (eTable 3 in&nbsp;<a class="supplement-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#note-JOI170090-1" data-tab-toggle=".tab-nav-supplemental">Supplement 1</a>) had diabetes. There were no serious adverse events. Four participants (3 in the prednisolone group and 1 in the placebo group presented to the emergency department but were not hospitalized.</p>
<div class="h4 cb section-type-section " bis_skin_checked="1">
<div class="heading-text " bis_skin_checked="1">Subgroup Analyses</div>
</div>
<p class="para">All 95% confidence intervals for the interaction effects included values consistent with no significant subgroup effect (eTable 4 in&nbsp;<a class="supplement-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#note-JOI170090-1" data-tab-toggle=".tab-nav-supplemental">Supplement 1</a>).</p>
<p>&nbsp;</p>
<h2>Discussion</h2>
<hr>
<p>&nbsp;</p>
<p class="para"><span class="quizSection">In this randomized trial of 401 adults, 5 days of moderate-dose oral prednisolone did not reduce the duration of moderately bad or worse cough, or the severity of symptoms between days 2 and 4 adults without asthma who presented to primary care with acute lower respiratory tract infection. No effects were observed for duration and severity of any acute lower respiratory tract infection symptom, duration of abnormal peak flow, antibiotic use, or adverse events, including worsening of glycemic control in patients with diabetes.</span></p>
<p class="para">This study has several strengths. It was an adequately powered, multicenter, fully masked, randomized trial with low rates of missing baseline and follow-up data. The design was pragmatic, using eligibility criteria easily reproduced in routine clinical practice and clinically relevant, validated<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r18" data-tab-toggle=".tab-nav-references">18</a></sup>&nbsp;outcomes. The final sample included participants with high rates of self-reported sputum production and wheeze and was generalizable to adults without asthma presenting to primary care with acute lower respiratory tract infection in whom an immediate antibiotic is not necessary. With 398 participants, this trial more than doubles the number of patients recruited to primary care trials of corticosteroids for acute lower respiratory tract infection<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r15" data-tab-toggle=".tab-nav-references">15</a></sup>&nbsp;and, to our knowledge, is the first to investigate the effects of oral rather than inhaled steroids. The trial also contributes to a growing body of evidence suggesting that systemic and topical corticosteroids have a limited role in the treatment of common infections and their postinfectious complications in primary care.<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r26" data-tab-toggle=".tab-nav-references">26</a></sup><sup>,<a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r27" data-tab-toggle=".tab-nav-references">27</a></sup>&nbsp;This contrasts with an increasing number of studies suggesting that corticosteroids are effective for secondary-care patients with community-acquired pneumonia,<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r28" data-tab-toggle=".tab-nav-references">28</a></sup>&nbsp;croup,<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r29" data-tab-toggle=".tab-nav-references">29</a></sup>&nbsp;acute sinusitis,<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r30" data-tab-toggle=".tab-nav-references">30</a></sup>&nbsp;and severe sore throat.<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r31" data-tab-toggle=".tab-nav-references">31</a></sup></p>
<p class="para">This study also has several limitations. First, the low patient recruitment rate suggests that patients may have been selectively invited to participate, affecting the generalizability of the final sample. However, the rate was higher than a similar previous trial,<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r19" data-tab-toggle=".tab-nav-references">19</a></sup>&nbsp;not all practices were active throughout the recruitment period, and the characteristics of the final sample appears representative of primary care adult patients with acute lower respiratory tract infection. Second, there was a higher than expected number of participants with zero duration of moderately bad or worse cough, although a sensitivity analysis including these participants did not influence the results. Third, other baseline biomarkers (eg, inflammatory, microbiological, spirometric, or radiographic) were not measured, and it is possible that patients with more severe, inflammatory, eosinophilic,<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r32" data-tab-toggle=".tab-nav-references">32</a></sup><sup>,<a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r33" data-tab-toggle=".tab-nav-references">33</a></sup>&nbsp;or microbiological (eg, rhinovirus)<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r34" data-tab-toggle=".tab-nav-references">34</a></sup>&nbsp;etiology entered the trial or could have differentially benefited. However, the study used readily recognized, pragmatic entry criteria facilitating replication in routine clinical practice. Fourth, study eligibility criteria might have included some patients with chronic or postinfectious cough rather than acute lower respiratory tract infection. However, 100% of participants had evidence of active lower respiratory tract involvement (sputum, shortness of breath, wheeze, or chest pain) and more than 75% had a preconsultation cough duration of less than 21 days. Fifth, the study used a patient-reported outcome rather than an objective primary outcome measure (such as digitally measured cough severity). This was chosen because it was considered the strongest option in the presence of a fully masked intervention, it closely reflected patient priorities, and it allowed comparison with other trials.<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r4" data-tab-toggle=".tab-nav-references">4</a></sup><sup>,<a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r19" data-tab-toggle=".tab-nav-references">19</a></sup>&nbsp;Sixth, the lack of effects and a similar between-group pattern of adverse events could reflect poor adherence. However, this is unlikely because standard methods<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r35" data-tab-toggle=".tab-nav-references">35</a></sup>&nbsp;were used to establish similar and high levels of adherence to both prednisolone and placebo, and adverse events were similar to another trial in which a similar dosage of prednisolone was proven effective.<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r35" data-tab-toggle=".tab-nav-references">35</a></sup></p>
<p class="para"><a name="q5"></a><span class="quizSection">This trial suggests that oral corticosteroids should not be used in adult primary care patients without asthma or chronic obstructive pulmonary disease who do not require treatment with an immediate antibiotic. Further research is needed to establish effectiveness in primary care patients with more severe infections, such as those with elevated C-reactive protein levels or requiring immediate antibiotic treatment, and larger studies or meta-analysis are needed to address effects in subgroups, such as those with longer preconsultation illness and nonsmokers.<sup><a class="ref-link section-jump-link" href="https://jamanetwork.com/journals/jama/fullarticle/2649201#joi170090r15" data-tab-toggle=".tab-nav-references">15</a></sup></span></p>
<p>&nbsp;</p>
<h2>Conclusions</h2>
<hr>
<p>&nbsp;</p>
<p>Among adults without asthma who developed acute lower respiratory tract infection, the use of oral prednisolone for 5 days did not reduce symptom duration or severity. These findings do not support oral steroids for treatment of acute lower respiratory tract infection in the absence of asthma.</p>
<p>&nbsp;</p>
<h2>Article Information</h2>
<hr>
<p>&nbsp;</p>
<p class="authorInfoSection"><strong>Corresponding Author:</strong>&nbsp;Alastair D. Hay, FRCGP, Centre for Academic Primary Care, NIHR School for Primary Care Research, Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Rd, Clifton, Bristol BS8 2PS, England (<a href="mailto:alastair.hay@bristol.ac.uk" target="_blank" rel="noopener">alastair.hay@bristol.ac.uk</a>).</p>
<p class="para"><strong>Accepted for Publication:</strong>&nbsp;July 21, 2017.</p>
<p class="paraauthor-contributions"><strong>Author Contributions:</strong>&nbsp;Dr Brookes had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p>
<p class="para"><i>Concept and design:</i>&nbsp;Hay, Little, Harnden, Thompson, Wang, Kendrick, Brookes, May, Carroll, El-Gohary, Moore.</p>
<p class="para"><i>Acquisition, analysis, or interpretation of data:</i>&nbsp;Harnden, Wang, Kendrick, Orton, Brookes, Young, May, Hollinghurst, Carroll, Downing, Timmins, Lafond, Moore.</p>
<p class="para"><i>Drafting of the manuscript:</i>&nbsp;Hay, Kendrick, Orton, Brookes, Young, Downing, Timmins, Lafond, El-Gohary, Moore.</p>
<p class="para"><i>Critical revision of the manuscript for important intellectual content:</i>&nbsp;Hay, Little, Harnden, Thompson, Wang, Kendrick, Orton, Brookes, Young, May, Hollinghurst, Carroll, Lafond, Moore.</p>
<p class="para"><i>Statistical analysis:</i>&nbsp;Brookes, Young, May.</p>
<p class="para"><i>Obtained funding:</i>&nbsp;Hay, Little, Harnden, Wang, Kendrick, Orton, Moore.</p>
<p class="para"><i>Administrative, technical, or material support:</i>&nbsp;Thompson, Orton, Downing, Timmins, Lafond, Moore.</p>
<p class="para"><i>Supervision:</i>&nbsp;Hay, Little, Harnden, Wang, Kendrick, Brookes, May, Hollinghurst, Lafond.</p>
<p class="parafinancial-disclosure"><strong>Conflict of Interest Disclosures:</strong>&nbsp;All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Thompson reports that he has received funding from Alere Inc to conduct research on C-reactive protein point-of-care tests, has received funding from Roche Molecular Diagnostics for consultancy work, and is a cofounder of Phoresa Inc, which is developing point-of-care tests for primary care. No other disclosures were reported.</p>
<p class="parafunding-statement"><strong>Funding/Support:</strong>&nbsp;This article presents independent research funded by the National Institute for Health Research (NIHR) School for Primary Care Research (grant reference 117a). Dr Hay is funded by an NIHR Research Professorship (NIHR-RP-02-12-012). The study sponsor was the University of Bristol.</p>
<p class="para"><strong>Role of the Funder/Sponsor:</strong>&nbsp;Neither the funder nor the sponsor had no involvement in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.</p>
<p class="para"><strong>Disclaimer:</strong>&nbsp;The views expressed herein are those of the authors and not necessarily those of the NIHR, the National Health Service, or the UK Department of Health.</p>
<p class="para"><strong>Additional Contributions:</strong>&nbsp;We thank the participants, the recruiting primary care sites, the NIHR Clinical Research Network, and all members of the OSAC team. We also thank the members of the trial steering committee (who provided independent supervision on behalf of the funder and sponsor) and the data monitoring committee (who oversaw safety), the Nottingham University Hospitals NHS Trust pharmacy, and the University Hospitals Bristol NHS Foundation Trust. We thank Mark Ebell, MD, University of Georgia, who (without compensation) conducted a secondary data analysis to estimate the use of oral prednisolone for acute lower respiratory tract infection using administrative data from the southeastern United States.</p>
<p>&nbsp;</p>
<h2>References</h2>
<hr>
<p>&nbsp;</p>
<p>1.<br>
National Institute for Health and Clinical Excellence. Respiratory tract infections: prescribing of antibiotics for self-limiting respiratory tract infections in adults and children in primary care. July 2008. https://www.nice.org.uk/guidance/cg69. Accessed August 1, 2017.<br>
2.<br>
Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011. JAMA. 2016;315(17):1864-1873.<br>
Article<br>
3.<br>
Butler CC, Hood K, Verheij T, et al. Variation in antibiotic prescribing and its impact on recovery in patients with acute cough in primary care: prospective study in 13 countries. BMJ. 2009;338:b2242.<br>
4.<br>
Little P, Stuart B, Moore M, et al; GRACE Consortium. Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial. Lancet Infect Dis. 2013;13(2):123-129.<br>
5.<br>
Gonzales R, Malone DC, Maselli JH, Sande MA. Excessive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis. 2001;33(6):757-762.<br>
6.<br>
Morice AH, McGarvey L, Pavord I; British Thoracic Society Cough Guideline Group. Recommendations for the management of cough in adults. Thorax. 2006;61(suppl 1):i1-i24.<br>
7.<br>
World Health Organization. Antimicrobial Resistance: Global Report on Surveillance. Geneva, Switzerland: World Health Organization; 2014.<br>
8.<br>
Public Health England. English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) 2010 to 2014. November 2015. https://www.gov.uk/mwg-internal/de5fs23hu73ds/progress?id=Lpkkp2P0R21gtGdImtDUQvQucNAADvg1F4z_9merBkU,&amp;dl. Accessed July 27, 2017.<br>
9.<br>
Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ. 2010;340:c2096.<br>
10.<br>
White House. National Strategy for Combating Antibiotic-Resistant Bacteria. September 2014. https://www.cdc.gov/drugresistance/pdf/executive-order_ar.pdf. Accessed July 27, 2017.<br>
11.<br>
Department of Health. UK Five Year Antimicrobial Resistance Strategy 2013 to 2018. September 2013. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/244058/20130902_UK_5_year_AMR_strategy.pdf. Accessed July 27, 2017.<br>
12.<br>
Bardin PG, Fraenkel DJ, Sanderson G, Lampe F, Holgate ST. Lower airways inflammatory response during rhinovirus colds. Int Arch Allergy Immunol. 1995;107(1-3):127-129.<br>
13.<br>
Gonzales R, Sande MA. Uncomplicated acute bronchitis. Ann Intern Med. 2000;133(12):981-991.<br>
14.<br>
Ebell MHR, Radke T. Antibiotic use for viral acute respiratory tract infections remains common. Am J Manag Care. 2015;21(10):e567-e575.PubMedGoogle Scholar<br>
15.<br>
El-Gohary M, Hay AD, Coventry P, Moore M, Stuart B, Little P. Corticosteroids for acute and subacute cough following respiratory tract infection: a systematic review. Fam Pract. 2013;30(5):492-500.<br>
16.<br>
Office for National Statistics. National population projections, 2012-based reference volume: series PP2. March 28, 2014. http://webarchive.nationalarchives.gov.uk/20160106063015/http://www.ons.gov.uk/ons/rel/npp/national-population-projections/2012-based-reference-volume–series-pp2/index.html. Accessed July 27, 2017.<br>
17.<br>
British Thoracic Network/Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma: A National Clinical Guideline. Edinburgh, Scotland: Scottish Intercollegiate Guidelines Network; 2016.<br>
18.<br>
Watson L, Little P, Moore M, Warner G, Williamson I. Validation study of a diary for use in acute lower respiratory tract infection. Fam Pract. 2001;18(5):553-554.<br>
19.<br>
Little P, Rumsby K, Kelly J, et al. Information leaflet and antibiotic prescribing strategies for acute lower respiratory tract infection: a randomized controlled trial. JAMA. 2005;293(24):3029-3035.<br>
Article<br>
20.<br>
Stata [computer program]. Version 13. College Station, TX: Stata Corp; 2013.<br>
21.<br>
Schoenfeld D. Chi-squared goodness-of-fit tests for the proportional hazards regression model. Biometrika. 1980;67(1):145-153.Google ScholarCrossref<br>
22.<br>
Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319(7223):1492-1495.<br>
23.<br>
Welch C, Bartlett J, Petersen I. Application of multiple imputation using the two-fold fully conditional specification algorithm in longitudinal clinical data. Stata J. 2014;14(2):418-431.PubMedGoogle Scholar<br>
24.<br>
Rubin D. Inference and missing data. Biometrika. 1976;63(3):581-592.Google ScholarCrossref<br>
25.<br>
Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ. 1990;300(6719):230-235.<br>
26.<br>
Hayward G, Heneghan C, Perera R, Thompson M. Intranasal corticosteroids in management of acute sinusitis: a systematic review and meta-analysis. Ann Fam Med. 2012;10(3):241-249.<br>
27.<br>
Venekamp RP, Bonten MJ, Rovers MM, Verheij TJ, Sachs AP. Systemic corticosteroid monotherapy for clinically diagnosed acute rhinosinusitis: a randomized controlled trial. CMAJ. 2012;184(14):E751-E757.<br>
28.<br>
Siemieniuk RA, Meade MO, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med. 2015;163(7):519-528.<br>
29.<br>
Russell K, Wiebe N, Saenz A, et al. Glucocorticoids for croup. Cochrane Database Syst Rev. 2004;(1):CD001955.PubMedGoogle Scholar<br>
30.<br>
Zalmanovici A, Yaphe J. Steroids for acute sinusitis. Cochrane Database Syst Rev. 2007;(2):CD005149.PubMedGoogle Scholar<br>
31.<br>
Hayward G, Thompson M, Heneghan C, Perera R, Del Mar C, Glasziou P. Corticosteroids for pain relief in sore throat: systematic review and meta-analysis. BMJ. 2009;339:b2976.<br>
32.<br>
Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186(1):48-55.<br>
33.<br>
Bjermer L, Alving K, Diamant Z, et al. Current evidence and future research needs for FeNO measurement in respiratory diseases. Respir Med. 2014;108(6):830-841.<br>
34.<br>
Beale J, Jayaraman A, Jackson DJ, et al. Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. Sci Transl Med. 2014;6(256):256ra134.<br>
35.<br>
Sullivan FM, Swan IRC, Donnan PT, et al. Early treatment with prednisolone or acyclovir in Bell’s palsy. N Engl J Med. 2007;357(16):1598-1607.</p>
<p>&nbsp;</p>
<h2>Source:</h2>
<p>https://jamanetwork.com/journals/jama/fullarticle/2649201</p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/04/28/effect-of-oral-prednisolone-on-symptom-duration-and-severity-in-nonasthmatic-adults-with-acute-lower-respiratory-tract-infection-a-randomized-clinical-trial/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/04/28/effect-of-oral-prednisolone-on-symptom-duration-and-severity-in-nonasthmatic-adults-with-acute-lower-respiratory-tract-infection-a-randomized-clinical-trial/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5198 post type-post status-publish format-standard hentry category-articles animated"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g" class="avatar avatar-144 photo lazyloaded" height="144" width="144" srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" data-ll-status="loaded"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>19.04.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/04/19/steroid-side-effects-how-to-reduce-drug-side-effects-of-corticosteroids/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/04/19/steroid-side-effects-how-to-reduce-drug-side-effects-of-corticosteroids/">Steroid Side Effects: How to Reduce Drug Side Effects of Corticosteroids</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><h2>How to reduce drug side effects</h2>
<hr>
<p>&nbsp;</p>
<p>How to think about the suggestions below: Any suggestion here which is not clear or which you think may not apply to you should be discussed with the your physician. Note also that the&nbsp;<strong>side effects of steroids very much depend on the dose and how long they are taken</strong>. If your dose is low, your risk of serious side effect is quite small, especially if precautions, as discussed below, are taken. Reading about these side effects may make you uncomfortable about taking steroids. You should be well aware of the risks before starting these medications. However, please be reassured that many people take steroids with minor or no side effects. Please also remember that steroids are often extremely effective and can be life-saving. If any of the suggestions here is unclear, or seems irrelevant to you, please discuss it with your physician.</p>
<p>Note: Which “steroids” are we talking about: The term “steroids” here refers to anti-inflammatory steroids (corticosteroids) such as prednisone and methylprednisolone (Medrol®) and dexamethasone (Decadron®). The information below&nbsp;<strong><em>does not</em></strong>&nbsp;refer to muscle-building or “androgenic” steroids (such as testosterone), which share some chemical similarities but function quite differently than anti-inflammatory steroids.</p>
<p>&nbsp;</p>
<h2>Understanding corticosteroid side effects</h2>
<hr>
<p>&nbsp;</p>
<p>With long-term use, corticosteroids can result in any of the following side effects. However, taking care of yourself as discussed below may reduce the risks.</p>
<h3>Increased doses needed for physical stress</h3>
<p>Steroid use for over two weeks can decrease the ability of your body to respond to physical stress. A higher dose of steroid may be needed at times of major stress, such as surgery or very extensive dental work or serious infection. This could be needed for as long as a year after you have stopped steroids.</p>
<p><em>Self-care tips:</em></p>
<ul>
<li>Discuss this possibility with the surgeon or dentist, etc. who is taking care of you at the time. Your physician or surgeon may not feel you need to take the extra steroid at the time of surgery, but if they know you have been on corticosteroids they can watch you more carefully after surgery.</li>
</ul>
<h3>Steroid withdrawal syndrome</h3>
<p>Rapid withdrawal of steroids may cause a syndrome that could include fatigue, joint pain, muscle stiffness, muscle tenderness, or fever. These symptoms could be hard to separate from those of your underlying disease.</p>
<p><em>Self-care tips:</em></p>
<ul>
<li>If you get symptoms like these when you taper your steroids, discuss them with the doctor. Your physician will work with you to continually try to taper your steroid dose, at a safe rate of decrease, depending on how you are doing. On each visit, discuss with the physician whether it is possible to decrease your steroid dose.</li>
<li>Note that even if you are having a steroid side effect, however, steroids still&nbsp;<strong>must be tapered slowly</strong>.</li>
<li>When used for less than two weeks, more rapid tapering of steroids is generally possible.</li>
</ul>
<h3>Infection</h3>
<p>Long-term steroids can suppress the protective role of your immune system and increase your risk of infection.</p>
<p><em>Self-care-tips:</em></p>
<ul>
<li>Since steroids can decrease your immunity to infection, you should have a yearly flu shot as long as you are on steroids. If you are on steroids for a prolonged period of time, you should also discuss with your doctor the possibility of getting “Pneumovax,” a vaccination against a certain type of pneumonia as well as “Prevnar 13,” another pneumonia vaccine. Shingles vaccination (Shingrix®) may also be considered. Your physician will take your age and risk factors into account when deciding which vaccinations you need.</li>
<li>Signs of possible infection, such as high fever, productive cough, pain while passing urine, or large “boils” on the skin should have prompt medical attention. If you have a history of tuberculosis, exposure to tuberculosis, or a positive skin test for tuberculosis, report this to your doctor.</li>
</ul>
<h3>Gastrointestinal symptoms</h3>
<p>Steroids may increase your risk of developing ulcers or gastrointestinal bleeding, especially if you take these medications along with non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen or aspirin. If at all possible, don’t combine steroids with NSAIDs. If you are on low-dose aspirin for heart protection, your physician may want you to continue this when you take the prednisone, but might consdier adding a medication for stomach protection during the course of steroids.</p>
<p><em>Self-care tips:</em></p>
<ul>
<li>Report to your physician any severe, persisting abdominal pain or black, tarry stools.</li>
<li>Take the steroid mediation&nbsp;<strong>after a full meal or with antacids</strong>, as this may help reduce irritation of the stomach. Steroids can increase your appetite.</li>
</ul>
<h3>Osteoporosis</h3>
<p>Steroid therapy can cause thinning of the bones (osteopenia&nbsp;and&nbsp;osteoporosis),&nbsp;and increase&nbsp;the risk of bone&nbsp;fractures. At the beginning or before your steroid therapy, many patients will be asked to have a bone density test, especially if the steroid dose is high. If density is low, the bone density study It will be repeated in the future to assess the effectiveness of measures you will be using to prevent bone loss. Preventative strategies are important: a person can lose 10% to 20% bone mass within the first six months of corticosteroid therapy.</p>
<p><em>Self-care tips:</em></p>
<ul>
<li>Most people taking corticosteroids will need to take a calcium supplement unless they can get enough calcium from their diet (if you can get it from your diet, that’s the best option). See this reference from the&nbsp;National Institutes of Health&nbsp;about how much calcium you need for your sex and age, and how to get as much as possible from diet.</li>
<li>The minimal daily requirement of vitamin D is 800 international units (UI) daily, and most people on corticosteroids should take this amount. Your physician may check your vitamin D level and see if you actually need a higher dose.</li>
<li>Smoking and alcohol increase the risk of osteoporosis, so limiting these is helpful.</li>
<li>Weight-bearing exercise (walking, running, dancing, etc) is helpful in stabilizing bone mass.</li>
<li>People on corticosteroids who have low bone density may be put on medications such as alendronate (Fosamax®) or Prolia®, and there are a number of others.</li>
<li>Assess risk of falls. Make a thorough examination of your home and correct situations that might result in a fall, such as eliminating scatter rugs and any obstacles between bedroom and bathroom, and installing night lights.</li>
</ul>
<h3>Weight gain</h3>
<p>Steroids affect your metabolism and how your body deposits fat. This can increase your appetite, leading to weight gain, and in particular lead to extra deposits of fat in your abdomen.</p>
<p><em>Self-care tips:</em></p>
<ul>
<li>Watch your calories and exercise regularly to try to prevent excessive weight gain. But don’t let weight gain damage your self-esteem. Know that the weight will be easier to take off in the six months to a year after you discontinue steroids.</li>
</ul>
<h3>Insomnia</h3>
<p>Steroids may impair your ability to fall asleep, especially when they are taken in the evening.</p>
<p><em>Self-care tips:</em></p>
<ul>
<li>If possible, the physician will try to have you take your entire daily dose in the morning. This may help you sleep better at night (evening doses sometimes make it difficult to fall asleep).</li>
</ul>
<h3>Mood changes</h3>
<p>Steroids, especially in doses over 30 milligrams per day, can affect your mood. Some people can feel depressed, some extremely “up” without any apparent reason. Just being aware that steroids can do this sometimes makes it less of a problem. Sometimes, this side effect requires that the steroid dosage be decreased. When the steroids are absolutely necessary, sometimes another medication can be added to help with the mood problem. Make sure your family knows about this possible side effect.</p>
<p><em>Self-care tips:</em></p>
<ul>
<li>Simply being aware that steroids can have an effect on your mood can sometimes make it less of a problem. But, at times, this side will require that the steroid dosage be decreased. If maintaining the same steroid dosage is absolutely necessary, sometimes another medication can be added to help with the mood problem.</li>
<li>Make sure your family and friends know about this possible side effect so they will know what’s going on if you respond to them in unexpected ways. Ideally, tell your family and friends about this possible side effect as you start the medication, so that they can help you detect any changes in your behavior.</li>
</ul>
<h3>Fluid retention and elevated blood pressure</h3>
<p>Because cortisone is involved in regulating the body’s balance of water, sodium, and other electrolytes, using these drugs can promote fluid retention and sometimes cause or worsen high blood pressure.</p>
<p><em>Self-care tips:</em></p>
<ul>
<li>Watch for&nbsp;<strong>swelling of your ankles</strong>, and report this to your doctor. Occasional patients benefit from diuretics (water pills). Low sodium diet helps reduce fluid accumulation and may help control blood pressure.</li>
<li>Have your blood pressure&nbsp;monitored regularly while you are on steroids, especially if you have a history of high blood pressure. Steroids can raise blood pressure in some patients.</li>
</ul>
<h3>Elevated blood sugar</h3>
<p>Since cortisone is involved in maintaining normal levels of glucose (sugar) in the blood, long-term use may lead to elevated blood sugar or even diabetes.</p>
<p><em>Self-care tips:</em></p>
<ul>
<li>Your blood sugar should be followed while you are on steroids, especially if you are a diabetic, since corticosteroids can raise blood sugar.</li>
</ul>
<h3>Eye problems</h3>
<p>Steroids can sometimes cause cataracts or glaucoma (increased pressure in the eye).</p>
<p><em>Self-care tips:</em></p>
<ul>
<li>If you have a history of glaucoma or cataract follow up closely with the ophthalmologist while on steroids. If you develop any visual problems while on steroids, you will need to see the ophthalmologist. Temporarily blurred vision when you start corticosteroids is often not a serious problem, but ophthalmology evaluation should always be arranged if you experience other, new visual symptoms while taking steroids.</li>
</ul>
<h3>Atherosclerosis (hardening of the arteries)</h3>
<p>It is possible that steroids may increase the rate of “hardening of the arteries,” which could increase the risk of heart disease. This risk is probably much more significant if steroids are taken for more than a year, and if taken in high dose.</p>
<p><em>Self-care tips:</em></p>
<ul>
<li>Low cholesterol diet may help. If you develop signs suggesting heart problem, such as chest pain, get medical attention quickly. Work with your physician to address any heart risks that can be modified, such as exercise, weight and cholesterol level.</li>
</ul>
<h3>Aseptic necrosis</h3>
<ul>
<li>Steroids, particularly at higher doses for long periods of time, can sometimes lead to damage to bones, called aseptic necrosis (also known as osteonecrosis or&nbsp;avascular necrosis). This can happen in a number of joints, but the hip is the most common.</li>
</ul>
<p><em>Self-care tips:</em></p>
<ul>
<li>Hip pain, especially if you have no known hip arthritis, could be an early sign of this damage. Report this to your doctor.</li>
</ul>
<p class="articledate">Updated: 10/31/2019</p>
<h3>Authors</h3>
<div class="authorslist" bis_skin_checked="1">
<div class="author floatleft" bis_skin_checked="1"><strong>Theodore R. Fields, MD, FACP</strong><br>
Attending Physician, Hospital for Special Surgery<br>
Professor of Clinical Medicine, Weill Cornell Medical College</div>
<div class="clear" bis_skin_checked="1"></div>
</div>
<div bis_skin_checked="1"></div>
<h2>Source:</h2>
<p>https://www.hindawi.com/journals/ijd/2015/472470/</p>
<p>&nbsp;</p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/04/19/steroid-side-effects-how-to-reduce-drug-side-effects-of-corticosteroids/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/04/19/steroid-side-effects-how-to-reduce-drug-side-effects-of-corticosteroids/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5196 post type-post status-publish format-standard hentry category-articles animated"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20144%20144'%3E%3C/svg%3E" data-lazy-srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" class="avatar avatar-144 photo" height="144" width="144" data-lazy-src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>12.04.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/04/12/anecortave-acetate-as-single-and-adjuvant-therapy-in-the-treatment-of-retinal-tumors-of-lhbetatag-mice/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/04/12/anecortave-acetate-as-single-and-adjuvant-therapy-in-the-treatment-of-retinal-tumors-of-lhbetatag-mice/">Anecortave Acetate as Single and Adjuvant Therapy in the Treatment of Retinal Tumors of LHBETATAG Mice</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><p><span class="wi-fullname brand-fg">Maria-Elena Jockovich</span><span class="al-author-delim">;&nbsp;</span><span class="wi-fullname brand-fg">Timothy G. Murray</span><span class="al-author-delim">;&nbsp;</span><span class="wi-fullname brand-fg">Erika Escalona-Benz</span><span class="al-author-delim">;&nbsp;</span><span class="wi-fullname brand-fg">Eleut Hernandez</span><span class="al-author-delim">;&nbsp;</span><span class="wi-fullname brand-fg">William Feuer</span></p>
<h2>Abstract</h2>
<hr>
<p>&nbsp;</p>
<div class="content-section clearfix " bis_skin_checked="1">
<section class="abstract">
<p class="para">purpose.&nbsp;To evaluate the tumor control efficacy of the antiangiogenic agent anecortave acetate as single and combined therapy, in retinal tumor reduction using the LH<sub>BETA</sub>T<sub>AG</sub>&nbsp;mouse model of retinoblastoma.</p>
<p class="para">methods.&nbsp;Group A: Ten-week-old, LH<sub>BETA</sub>T<sub>AG</sub>&nbsp;mice received a single subconjunctival injection of anecortave acetate (1200, 600, 300, and 150 μg) delivered to right eyes only. Group B: Ten-week-old, LH<sub>BETA</sub>T<sub>AG</sub>&nbsp;mice received a single subconjunctival injection of anecortave acetate (600, 300, and 150 μg) delivered to right eyes only, either during a cycle of carboplatin (six subconjunctival deliveries) or after the completed cycle. Carboplatin was delivered at the subtherapeutic concentration of 62.5 μg. All animals were euthanatized at 16 weeks of age, and the eyes were examined histopathologically.</p>
<p class="para">results.&nbsp;A statistically significant reduction in tumor burden was detected after a single periocular injection of anecortave acetate. The reduction of tumor burden followed a U-shaped dose–response curve. Tumor burden was significantly decreased when anecortave acetate and carboplatin were combined. However, varying doses and delivery schedule of these agents had significant impact on the effectiveness of the combined treatment. The most effective scheme was delivering a low dose (150–300 μg) of anecortave acetate after a complete cycle of carboplatin. Histopathological evaluation showed no signs of retinal toxicity to anecortave acetate delivery alone or in combination with carboplatin.</p>
<p class="para">conclusions.&nbsp;Anecortave acetate, as monotherapy or as adjuvant therapy, significantly controlled tumor burden in a murine model of retinoblastoma. Moreover, adjuvant therapy enabled the use of typically subtherapeutic carboplatin doses without decreasing efficacy of the therapy.</p>
</section>
</div>
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">Retinoblastoma represents one of the most common malignant tumors of childhood, with an incidence of 1 in 15,000 live births.<sup>&nbsp;<a class="revealLink refLink">1</a>&nbsp;</sup>Over the past century, significant advances in screening and treatment have led to virtually all children being cured of the primary eye cancer. Recently, clinical advances have focused on increasing tumor control and globe conservation with attendant preservation of sight.<sup>&nbsp;<a class="revealLink refLink">2</a>&nbsp;</sup><sup><a class="revealLink refLink">3</a>&nbsp;</sup><sup><a class="revealLink refLink">4</a>&nbsp;</sup><sup><a class="revealLink refLink">5</a>&nbsp;</sup><sup><a class="revealLink refLink">6</a>&nbsp;</sup>Current available treatments include laser therapy, cryotherapy, external beam radiotherapy, charged-particle radiation, and systemic chemotherapy.<sup>&nbsp;<a class="revealLink refLink">7</a>&nbsp;</sup><sup><a class="revealLink refLink">8</a>&nbsp;</sup>Serious concerns exist regarding the significant morbidity and potential mortality associated with current therapies in the treatment of retinoblastoma; therefore, newer therapeutic modalities are being investigated.<sup>&nbsp;<a class="revealLink refLink">9</a>&nbsp;</sup><sup><a class="revealLink refLink">10</a>&nbsp;</sup></div>
</div>
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">Vasculature is critical to the survival of solid tumors, and angiogenesis has been found to be a prerequisite for continued tumor growth.<sup>&nbsp;<a class="revealLink refLink">11</a>&nbsp;</sup><sup><a class="revealLink refLink">12</a>&nbsp;</sup>Angiogenesis involves the formation of new capillary blood vessels from preexisting vessels through a complex cascade of events.<sup>&nbsp;<a class="revealLink refLink">12</a>&nbsp;</sup>The inhibition of one or more of these events is of potential therapeutic value for those pathologic conditions in which abnormal angiogenesis is a factor. This finding has led to the development of many antiangiogenic agents for cancer therapy.<sup>&nbsp;<a class="revealLink refLink">13</a>&nbsp;</sup><sup><a class="revealLink refLink">14</a>&nbsp;</sup><sup><a class="revealLink refLink">15</a>&nbsp;</sup></div>
</div>
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">Retinoblastoma tumors are highly vascularized and depend on vascular supply for viability.<sup>&nbsp;<a class="revealLink refLink">16</a>&nbsp;</sup>The capacity of these tumors to promote angiogenesis has been demonstrated.<sup>&nbsp;<a class="revealLink refLink">17</a>&nbsp;</sup><sup><a class="revealLink refLink">18</a>&nbsp;</sup><sup><a class="revealLink refLink">19</a>&nbsp;</sup>Angiogenic factors, such as vascular endothelial growth factor (VEGF) and its receptors, Flt-1 and KDR, have been localized to areas of novel vasculature in human retinoblastoma tumors.<sup>&nbsp;<a class="revealLink refLink">20</a>&nbsp;</sup><sup><a class="revealLink refLink">21</a>&nbsp;</sup>The angiogenic potential of retinoblastoma correlates with invasive growth and metastasis and is associated with poor prognosis.<sup>&nbsp;<a class="revealLink refLink">22</a>&nbsp;</sup><sup><a class="revealLink refLink">23</a>&nbsp;</sup><sup><a class="revealLink refLink">24</a>&nbsp;</sup>The increased vascularity and propensity for stimulation of angiogenesis in retinoblastoma may make these tumors sensitive to vasculature targeting agents.</div>
</div>
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">Anecortave acetate is an antiangiogenic agent that inhibits blood vessel growth in several preclinical models of angiogenesis, including rat mammary carcinoma, rabbit cornea, rat cornea, rat model of retinopathy of prematurity, and murine intraocular tumors.<sup>&nbsp;<a class="revealLink refLink">25</a>&nbsp;</sup><sup><a class="revealLink refLink">26</a>&nbsp;</sup><sup><a class="revealLink refLink">27</a>&nbsp;</sup><sup><a class="revealLink refLink">28</a>&nbsp;</sup><sup><a class="revealLink refLink">29</a>&nbsp;</sup><sup><a class="revealLink refLink">30</a>&nbsp;</sup>Anecortave acetate is a cortisol derivative devoid of conventional glucocorticoid receptor–mediated activity (Clark AF et al.,&nbsp;<em>IOVS</em>&nbsp;1994;35:ARVO E-Abstract 1483).<sup>&nbsp;<a class="revealLink refLink">31</a>&nbsp;</sup>As a result, it also does not demonstrate the significant deleterious ocular side effects associated with ocular glucocorticoid therapy (cataracts and elevation of intraocular pressure). Anecortave acetate has been shown to inhibit pathologic retinal angiogenesis, while not significantly affecting physiologic retinal microvasculature.<sup>&nbsp;<a class="revealLink refLink">25</a>&nbsp;</sup>Furthermore, it has been shown to be safe in human clinical studies.<sup>&nbsp;<a class="revealLink refLink">32</a>&nbsp;</sup><sup><a class="revealLink refLink">33</a>&nbsp;</sup><sup><a class="revealLink refLink">34</a>&nbsp;</sup><sup><a class="revealLink refLink">35</a>&nbsp;</sup>This drug may therefore hold therapeutic potential for several ocular conditions in which angiogenesis appears to play a critical pathophysiological role, including intraocular tumors.</div>
</div>
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">The purpose of the present study was to evaluate the efficacy of anecortave acetate as a monotherapy and as an adjuvant therapy in controlling retinal tumor growth, using the LH<sub>BETA</sub>T<sub>AG</sub>&nbsp;mouse model of retinoblastoma.</div>
</div>
<div bis_skin_checked="1"></div>
<h2>Methods</h2>
<hr>
<p>&nbsp;</p>
<div bis_skin_checked="1">
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">The study protocol was approved by the School of Medicine Animal Care and Use Review Board, University of Miami. All experiments in the study were conducted in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.</div>
</div>
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">The LH<sub>BETA</sub>T<sub>AG</sub>&nbsp;transgenic mouse model used in the study has been characterized previously.<sup>&nbsp;<a class="revealLink refLink">36</a>&nbsp;</sup><sup><a class="revealLink refLink">37</a>&nbsp;</sup><sup><a class="revealLink refLink">38</a>&nbsp;</sup>Briefly, a highly expressed transgene drives retinal tumor development by overexpression of the SV40 large T antigen. In transgenic animals bilateral, retinal tumors develop that resemble human retinoblastoma. At 10 weeks of age, tumors in this animal model are typically moderate in size (occupying approximately 20%–25% of the retinal area and 10%–25% of the ocular volume). At 16 weeks of age retinal tumors in these mice usually fill the orbit.</div>
</div>
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">LH<sub>BETA</sub>T<sub>AG</sub>&nbsp;mice, six animals per treatment group, were treated at 10 weeks of age. This number was determined with a power study performed on computer (Solo Power Analysis program; BMDP Statistical Software, Los Angeles, CA) based on pilot studies from our laboratory.</div>
</div>
</div>
<div class="h7" data-magellan-destination="89743119" bis_skin_checked="1">Subconjunctival Injections in Transgenic Mice</div>
<div bis_skin_checked="1">
<div class="content-section clearfix " bis_skin_checked="1"></div>
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">Only right eyes received subconjunctival injections, left eyes remained untreated and are used as the internal control.</div>
</div>
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">LH<sub>BETA</sub>T<sub>AG</sub>&nbsp;mice received a single subconjunctival injection of anecortave acetate (Alcon Pharmaceuticals, Fort Worth, TX) to the right eyes at doses of 1200, 600, 300, or 150 μg in a 20-μL volume. Anecortave acetate dilutions were performed in vehicle (provided by the manufacturer). Injections were delivered with a 33-gauge needle inserted into the superotemporal subconjunctival space.</div>
</div>
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">For the combined treatment study anecortave acetate (600, 300, or 150 μg) was delivered after two (during the cycle) or six (completed cycle) carboplatin injections. Carboplatin was delivered at the subtherapeutic dose of 62.5 μg per injection,<sup>&nbsp;<a class="revealLink refLink">39</a>&nbsp;</sup>delivered every 72 hours. Anecortave acetate was delivered 24 hours after the second or sixth carboplatin treatment.</div>
</div>
</div>
<div class="h7" data-magellan-destination="89743123" bis_skin_checked="1">Histopathological Study of Transgenic Mice</div>
<div bis_skin_checked="1">
<div class="content-section clearfix " bis_skin_checked="1"></div>
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">At 16 weeks of age, all animals were euthanatized with CO<sub>2</sub>&nbsp;fumes. Both eyes were enucleated and immediately immersion fixed in 10% formalin. The eyes were embedded in paraffin, sectioned serially in 5-μm sections, and processed for standard hematoxylin-eosin (H&amp;E) analysis. Light microscopic examination was performed on all histopathologic sections in a masked fashion. Microscopic images of all hematoxylin and eosin (H&amp;E)–stained sections (sixty 5.0-μm sections per eye) were obtained with a digital camera at a magnification of 40×. Tumor boundaries were traced and areas analyzed (Image Pro Express Software; Media Cybernetics, Silver Spring, MD) to determine the section with the largest tumor. The maximum tumor area was used in subsequent analyses.</div>
</div>
</div>
<div class="h7" data-magellan-destination="89743125" bis_skin_checked="1">Statistical Analyses</div>
<div bis_skin_checked="1">
<div class="content-section clearfix " bis_skin_checked="1"></div>
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">Tumor size response to anecortave acetate dose was investigated with analysis of variance. Orthogonal polynomial decomposition was used to test for linear and quadratic trend effects of dose. The influence of delivery of anecortave acetate relative to carboplatin delivery was assessed by fitting tumor size as the dependent variable in a regression model with three independent variables: anecortave acetate dose, anecortave acetate delivery time relative to carboplatin delivery, and dose delivery time interaction. Similar results were obtained when models were constructed in which globe size was included as an independent variable and in which the ratio of tumor size to globe size was the dependent variable. The influence of combining both therapeutic agents, relative to untreated control subjects or to the single anecortave acetate treatment, was performed by using a least-significant-difference post hoc comparison after one-way ANOVA on tumor size square root transformed to effect homogeneity of variance.</div>
</div>
</div>
<div bis_skin_checked="1"></div>
<h2>Results</h2>
<hr>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">
<div bis_skin_checked="1">
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">A significant (<em>P</em>&nbsp;= 0.012, quadratic dose–response) reduction in tumor size was seen at the lower doses (150–600 μg) of anecortave acetate tested&nbsp;<a class="revealLink tablelink">(Fig. 1)</a>&nbsp;. Whereas the highest dose (1200 μg) did not significantly reduce tumor size. Variability in tumor size was not significantly related to anecortave acetate dose (<em>P</em>&nbsp;= 0.12, Levine test). The dose–response curve followed a U-shaped, biphasic trend. Although, tumor size in treated eyes was markedly reduced compared with that in fellow eyes and untreated control eyes, complete control of tumor burden did not occur at the tested doses. All eyes harbored tumors in fellow, untreated eyes.</div>
</div>
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">We evaluated the hypothesis that adjuvant therapy with anecortave acetate could reduce the necessary dose of the toxic chemotherapeutic drug carboplatin needed to treat retinoblastoma successfully. In this study, various doses of anecortave acetate were combined with a constant subtherapeutic dose of carboplatin. Previous studies have established the tumor control dose (TCD)<sub>50</sub>&nbsp;of carboplatin at six of 138.5 μg injections.<sup><a class="revealLink refLink">39</a></sup>Thus, a dose known to provide minimal tumor control (62.5 μg) was tested. To asses the effect of delivery schedule in the combined treatment, two delivery schemes were tested. Anecortave acetate was delivered during the six injection carboplatin treatment (after two carboplatin deliveries) or after the carboplatin series was completed.</div>
</div>
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">Complete tumor control was observed in two of the six eyes that received 150 μg anecortave acetate after six carboplatin deliveries. Statistical analysis found tumor size to be significantly related to anecortave acetate dose (<em>P</em>&nbsp;= 0.043;&nbsp;<a class="revealLink tablelink">Figs. 1</a>&nbsp;<a class="revealLink tablelink">2</a>&nbsp;) and time of anecortave acetate delivery relative to carboplatin (<em>P</em>&nbsp;= 0.027;&nbsp;<a class="revealLink tablelink">Fig. 2</a>&nbsp;). A statistical interaction between these two variables was found (<em>P</em>&nbsp;= 0.063). Further analyses of tumor size were performed, including control animals receiving no treatment and animals treated with anecortave acetate at doses of 150 and 300 μg alone or after the complete carboplatin cycle. This analysis demonstrated that anecortave acetate reduced tumor sizes compared with control tumors (<em>P</em>&nbsp;= 0.039) and that anecortave acetate delivery after a complete carboplatin cycle further reduced tumor sizes compared with anecortave acetate treatment alone (<em>P</em>&nbsp;= 0.008).</div>
</div>
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">Histopathology showed no evidence of corneal, lenticular, choroidal, or retinal toxicity after anecortave acetate delivery as monotherapy, or combined with subtherapeutic carboplatin&nbsp;<a class="revealLink tablelink">(Fig. 3)</a>&nbsp;. The uninvolved retina in the treated eyes showed normal morphology in all experimental eyes. No evidence of systemic toxicity was observed.</div>
</div>
</div>
<div class="h6" data-magellan-destination="89743132" bis_skin_checked="1">Discussion</div>
<div bis_skin_checked="1">
<div class="content-section clearfix " bis_skin_checked="1"></div>
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">Inhibition of angiogenesis has been proposed as a therapeutic strategy for solid tumors<sup><a class="revealLink refLink">13</a></sup><sup><a class="revealLink refLink">14</a></sup><sup><a class="revealLink refLink">15</a></sup>including pediatric malignancies.<sup><a class="revealLink refLink">40</a></sup>Antiangiogenic therapy is emerging as a possible treatment option for retinoblastoma, given the tumor’s dependence on vascular supply and its potential to promote angiogenesis, particularly in cases of advanced disease.</div>
</div>
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">In the LH<sub>BETA</sub>T<sub>AG</sub>&nbsp;model of retinoblastoma, two different vessel-targeting agents were effective treatments for this malignancy. Previously, we have reported that the first vessel-targeting agent, combretastatin A4, a tubulin-binding agent that disrupts blood flow through immature vasculature, effectively reduced retinal tumor burden in LH<sub>BETA</sub>T<sub>AG</sub>&nbsp;mice.<sup><a class="revealLink refLink">41</a></sup>In this study, we present data on the second vasculature targeting agent, the antiangiogenic anecortave acetate, that suggest that inhibition of novel blood vessel formation is also effective in retinal tumor reduction in this model. Although a statistically significant reduction in tumor size was measured after a single treatment with either vessel-targeting agent, complete control of tumor burden is not achieved. These data suggest that the most effective clinical application of vessel-targeting agents in the treatment of solid tumors is obtained in combination with existing anticancer treatment modalities, including chemotherapy.</div>
</div>
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">A challenge of using antiangiogenic agents as therapeutics is dose optimization. Many antiangiogenic agents display a nonconventional (U-shaped, biphasic) dose response.<sup><a class="revealLink refLink">42</a></sup><sup><a class="revealLink refLink">43</a></sup><sup><a class="revealLink refLink">44</a></sup>This dose–response curve was also seen when anecortave acetate is used in the treatment of retinal tumor burden within LH<sub>BETA</sub>T<sub>AG</sub>&nbsp;mice (this study) and in the treatment of subfoveal lesions in age-related macular degeneration.<sup><a class="revealLink refLink">34</a></sup><sup><a class="revealLink refLink">35</a></sup>This atypical dose–response was also evident in the combined treatment, where optimal delivery schedule was dose specific. Explanations of this atypical dose–response have included receptor desensitization,<sup><a class="revealLink refLink">45</a></sup>problems with drug penetration at higher doses or dose-dependent differences in biological response.<sup><a class="revealLink refLink">46</a></sup>However, the mechanism leading to this dose–response curve is still to be elucidated. This fact must be considered in the design of human anticancer trials.</div>
</div>
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">Antiangiogenic and cytotoxic chemotherapy potentially yield maximum effects when combined, because different compartments of the tumor are targeted: cancer cells and endothelial cells.<sup><a class="revealLink refLink">47</a></sup>Targeting vasculature, however, may compromise delivery of chemotherapy to the tumor and antagonize the effect of the combined therapy.<sup><a class="revealLink refLink">48</a></sup>The efficacy of the combined treatment modality thus depends on appropriate vasculature targeting relative to chemotherapy. As seen in the present study, delivery of the lowest dose of anecortave acetate during carboplatin treatment led to antagonism between the two therapies. Conversely, an additive effect was detected when vessels were targeted after the complete cycle of chemotherapy. These results can be interpreted to mean that vessel targeting during chemotherapy compromises further delivery of carboplatin. Vessel targeting after chemotherapy may trap carboplatin within tumors yielding better tumor control.</div>
</div>
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">Focally delivered carboplatin has been advocated due to existing concerns regarding significant morbidity and potential mortality caused by drug-related toxicity. Focal delivery has the benefits associated with chemoreductive treatment and conceivably spares children the associated toxicities and mutagenic potential of systemic delivery of chemotherapy.<sup><a class="revealLink refLink">10</a></sup>We have recently shown that focal delivery of carboplatin effectively distributes more drug to the ocular tissues than does systemic delivery.<sup><a class="revealLink refLink">49</a></sup>However, clinical trials to assess the efficacy of subconjunctival carboplatin suggest that although efficacious, toxicities such as optic atrophy<sup><a class="revealLink refLink">50</a></sup>and ocular motility changes due to soft tissue alterations<sup><a class="revealLink refLink">51</a></sup>are observed. Results from the present study suggest that carboplatin doses can be markedly reduced when combined with vessel-targeting adjuvant therapy, without compromising the efficacy of the drug. This combined treatment modality may provide an excellent therapeutic option for children with advanced disease.</div>
</div>
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">In summary, therapy using vasculature targeting agents in combination with subconjunctival chemotherapy may represent a novel option in the treatment of pediatric retinoblastoma. The potential of combination treatment incorporating anecortave acetate or other vessel-targeting agents may allow enhanced tumor reduction enabling a decrease in standard treatment doses for chemotherapy. However, dosage regimens must be optimized to prevent antagonizing effects.</div>
</div>
<div class="content-section clearfix " bis_skin_checked="1"></div>
<div class="content-section clearfix " bis_skin_checked="1">
<div class="para" bis_skin_checked="1">
<div class="para clearfix" bis_skin_checked="1">
<div id="" class="tablelink" bis_skin_checked="1">&nbsp;Supported by Alcon Laboratories, Inc., National Eye Institute Grant R01 EY013629 and Center Grant P30 EY014801; and an unrestricted grant to the University of Miami from Research to Prevent Blindness, Inc.</div>
</div>
<div class="para clearfix" bis_skin_checked="1">
<div id="" class="tablelink" bis_skin_checked="1">&nbsp;Submitted for publication September 7, 2005; revised October 19 and November 29, 2005; accepted January 19, 2006.</div>
</div>
<div class="para clearfix" bis_skin_checked="1">
<div id="" class="tablelink" bis_skin_checked="1">&nbsp;Disclosure:&nbsp;<strong>M.-E. Jockovich</strong>, Alcon Laboratories, Inc. (F);&nbsp;<strong>T.G. Murray</strong>, Alcon Laboratories, Inc. (F);&nbsp;<strong>E. Escalona-Benz</strong>, Alcon Laboratories, Inc. (F);&nbsp;<strong>E. Hernandez</strong>, Alcon Laboratories, Inc. (F);&nbsp;<strong>W. Feuer</strong>, Alcon Laboratories, Inc. (F)</div>
</div>
<div class="para clearfix" bis_skin_checked="1">
<div id="" class="tablelink" bis_skin_checked="1">&nbsp;The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked “<em>advertisement</em>” in accordance with 18 U.S.C. §1734 solely to indicate this fact.</div>
</div>
<div class="para clearfix" bis_skin_checked="1">
<div id="" class="tablelink" bis_skin_checked="1">&nbsp;Corresponding author: Timothy G. Murray, Bascom Palmer Eye Institute, P.O. Box 016880, Miami, FL 33101;&nbsp;<a href="https://iovs.arvojournals.org/content.aspx?legacySectionId=tmurray@med.miami.edu">tmurray@med.miami.edu</a>.</div>
</div>
</div>
</div>
</div>
</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"><strong>Figure&nbsp;1.</strong></div>
<div bis_skin_checked="1"><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Anecortave acetate, single therapy. A statistically significant reduction in tumor burden (P = 0.012) was measured after a single treatment of anecortave acetate. Tumor areas were normalized to the mean of the untreated controls. Error bars, SD." data-lazy-src="https://arvo.silverchair-cdn.com/arvo/content_public/journal/iovs/933597/m_z7g0030653310001.jpeg?Expires=1613510672&amp;Signature=dycR4gkUzmKtRxfXTcO4iHs9DdrfDAH0jezCA1TzDG74TOmwBK1GsuvWni4tn1Kh1nuB33YDoaqYRLgf2pVExrMrN4Ok~x~KN7vxEQ7DCEY1mb9x7StcUh~MsZrkupLGgmZJjsRujZrEwSDimdA8ZaUtuotHbGpZJKMu7z0YAth4RJ5vy85AxldGO2pD5P1cc8dgBu-b2J6sZaWN6CfVtJdNHutfqdQjrGlYtuAP3sPHeyrCoAr4Vvq3-ufFt50JEedkHala6cTRUx4p3OXSKaTf8-kBdItoZb2Nrekyqa9Cvsny8H~DihwZjXex2Puuiv6Z0h9DQvCG7SyiYim5Xg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"><noscript><img src="https://arvo.silverchair-cdn.com/arvo/content_public/journal/iovs/933597/m_z7g0030653310001.jpeg?Expires=1613510672&amp;Signature=dycR4gkUzmKtRxfXTcO4iHs9DdrfDAH0jezCA1TzDG74TOmwBK1GsuvWni4tn1Kh1nuB33YDoaqYRLgf2pVExrMrN4Ok~x~KN7vxEQ7DCEY1mb9x7StcUh~MsZrkupLGgmZJjsRujZrEwSDimdA8ZaUtuotHbGpZJKMu7z0YAth4RJ5vy85AxldGO2pD5P1cc8dgBu-b2J6sZaWN6CfVtJdNHutfqdQjrGlYtuAP3sPHeyrCoAr4Vvq3-ufFt50JEedkHala6cTRUx4p3OXSKaTf8-kBdItoZb2Nrekyqa9Cvsny8H~DihwZjXex2Puuiv6Z0h9DQvCG7SyiYim5Xg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Anecortave acetate, single therapy. A statistically significant reduction in tumor burden (P = 0.012) was measured after a single treatment of anecortave acetate. Tumor areas were normalized to the mean of the untreated controls. Error bars, SD." /></noscript></div>
<div bis_skin_checked="1">Anecortave acetate, single therapy. A statistically significant reduction in tumor burden (<em>P</em>&nbsp;= 0.012) was measured after a single treatment of anecortave acetate. Tumor areas were normalized to the mean of the untreated controls. Error bars, SD.</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Anecortave acetate and carboplatin combined therapy. Tumor response after combined therapy with anecortave acetate delivered after two (▒) or six (□) carboplatin injections. Untreated, carboplatin only (62.5 μg), and the anecortave acetate control (▪) are shown for comparison. Tumor size was significantly related to anecortave acetate dose (P = 0.043) and time of anecortave acetate delivery relative to carboplatin (P = 0.027). A statistical interaction between these two variables was found (P = 0.063). Tumor areas were normalized to the mean of the untreated control. Error bars, SD." data-lazy-src="https://arvo.silverchair-cdn.com/arvo/content_public/journal/iovs/933597/m_z7g0030653310002.jpeg?Expires=1613510672&amp;Signature=iGpGcrydoWO0hnfzUZ0wC-VTRVUne9YJXtaz4uBxAHC5JjkfOb83gGFnJn-CtVuJAYPnxm~587NhA0dfvjC0xFXNGD2slRWDNAS3leznTREXhwDTdUoMmYEnQEDfyEnRmclRNTuBJ1npM682mvDOjk7uk3PsiqSE36wSsvVnN2WxNUt3Q7w6~~2KTlnh3keeDILGZkPZjLwMftpcXLQ5QNorjMa3SnJhB28lnIuBycJNMAAequZKRF10FmIqzJJ-PRAWsE7miisU5ym4Spia7UmU-ldu6hT0gJ~mN1bH7ux8jSeWhgWIe~IX3V-sHNvQ~U1XtFOpFFCFoipzebLZ0A__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"><noscript><img src="https://arvo.silverchair-cdn.com/arvo/content_public/journal/iovs/933597/m_z7g0030653310002.jpeg?Expires=1613510672&amp;Signature=iGpGcrydoWO0hnfzUZ0wC-VTRVUne9YJXtaz4uBxAHC5JjkfOb83gGFnJn-CtVuJAYPnxm~587NhA0dfvjC0xFXNGD2slRWDNAS3leznTREXhwDTdUoMmYEnQEDfyEnRmclRNTuBJ1npM682mvDOjk7uk3PsiqSE36wSsvVnN2WxNUt3Q7w6~~2KTlnh3keeDILGZkPZjLwMftpcXLQ5QNorjMa3SnJhB28lnIuBycJNMAAequZKRF10FmIqzJJ-PRAWsE7miisU5ym4Spia7UmU-ldu6hT0gJ~mN1bH7ux8jSeWhgWIe~IX3V-sHNvQ~U1XtFOpFFCFoipzebLZ0A__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Anecortave acetate and carboplatin combined therapy. Tumor response after combined therapy with anecortave acetate delivered after two (▒) or six (□) carboplatin injections. Untreated, carboplatin only (62.5 μg), and the anecortave acetate control (▪) are shown for comparison. Tumor size was significantly related to anecortave acetate dose (P = 0.043) and time of anecortave acetate delivery relative to carboplatin (P = 0.027). A statistical interaction between these two variables was found (P = 0.063). Tumor areas were normalized to the mean of the untreated control. Error bars, SD." /></noscript></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">Anecortave acetate and carboplatin combined therapy. Tumor response after combined therapy with anecortave acetate delivered after two (▒) or six (□) carboplatin injections. Untreated, carboplatin only (62.5 μg), and the anecortave acetate control (▪) are shown for comparison. Tumor size was significantly related to anecortave acetate dose (<em>P</em>&nbsp;= 0.043) and time of anecortave acetate delivery relative to carboplatin (<em>P</em>&nbsp;= 0.027). A statistical interaction between these two variables was found (<em>P</em>&nbsp;= 0.063). Tumor areas were normalized to the mean of the untreated control. Error bars, SD.</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"><strong>Figure&nbsp;3.</strong></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"><img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="Histopathology sections of enucleated globes. Representative globe sections of 16-week-old LHBETATAG mice: (A) untreated; (B) 150 μg anecortave acetate; (C) 150 μg anecortave acetate after two carboplatin injections; (D) 150 μg anecortave acetate after six carboplatin injections. H&amp;E; magnification, ×40." data-lazy-src="https://arvo.silverchair-cdn.com/arvo/content_public/journal/iovs/933597/m_z7g0030653310003.jpeg?Expires=1613510672&amp;Signature=0RU2giZSNCHJjxwtYJ7SIZI~XloXLwS03w-v6Lye7t02WiAmcIS9w4XqbqiOuukZW63PXQ3NnSNAzt00gT-o~f45ARYnv8YFk3rLuPLXpWfyW1Gdavt9oAuc-PlZibOrwHiZtCB6cCsC8NZ24ZiByQkcSMpV0Uw-y2p6ZhmjbAjXxrgP7fMK0Cr3ks9staydyL9MfUA0L5-Kdis0Xs-Sce6o2aT9s-vLTfm5bNyVnjTZfkhv8JN03tGKX8nAYpr3ZKuT-AVQD14MsW--EBRvWpF7-eC~MTuK3ORzc9O3grk1WDSqN2zjqc0PljR~-O0bfTWKE-Rfq7CPq5cQffFihw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"><noscript><img src="https://arvo.silverchair-cdn.com/arvo/content_public/journal/iovs/933597/m_z7g0030653310003.jpeg?Expires=1613510672&amp;Signature=0RU2giZSNCHJjxwtYJ7SIZI~XloXLwS03w-v6Lye7t02WiAmcIS9w4XqbqiOuukZW63PXQ3NnSNAzt00gT-o~f45ARYnv8YFk3rLuPLXpWfyW1Gdavt9oAuc-PlZibOrwHiZtCB6cCsC8NZ24ZiByQkcSMpV0Uw-y2p6ZhmjbAjXxrgP7fMK0Cr3ks9staydyL9MfUA0L5-Kdis0Xs-Sce6o2aT9s-vLTfm5bNyVnjTZfkhv8JN03tGKX8nAYpr3ZKuT-AVQD14MsW--EBRvWpF7-eC~MTuK3ORzc9O3grk1WDSqN2zjqc0PljR~-O0bfTWKE-Rfq7CPq5cQffFihw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Histopathology sections of enucleated globes. Representative globe sections of 16-week-old LHBETATAG mice: (A) untreated; (B) 150 μg anecortave acetate; (C) 150 μg anecortave acetate after two carboplatin injections; (D) 150 μg anecortave acetate after six carboplatin injections. H&amp;E; magnification, ×40." /></noscript></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">Histopathology sections of enucleated globes. Representative globe sections of 16-week-old LH<sub>BETA</sub>T<sub>AG</sub>&nbsp;mice: (<strong>A</strong>) untreated; (<strong>B</strong>) 150 μg anecortave acetate; (<strong>C</strong>) 150 μg anecortave acetate after two carboplatin injections; (<strong>D</strong>) 150 μg anecortave acetate after six carboplatin injections. H&amp;E; magnification, ×40.</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1">1<br>
TamboliA, PodgorMJ, HormJW. The incidence of retinoblastoma in the United States: 1974 through 1985. Arch Ophthalmol. 1990;108:128–132.<br>
2<br>
AbramsonDH. Retinoblastoma: diagnosis and management. Cancer J Clin. 1982;32:130–140.<br>
3<br>
CharD. Clinical Ocular Oncology. 1989;207–224.Churchill Livingstone Inc New York.<br>
4<br>
SheildsJS, ShieldsCL. Intraocular Tumors: A Text and Atlas. 1992;377–392.WB Saunders Co Philadelphia.<br>
5<br>
ShieldsJA, ShieldsCL. Current management of retinoblastoma. Mayo Clin Proc. 1994;69:50–56.<br>
6<br>
ScottIU, MurrayTG, FeuerWJ, et al. External beam radiotherapy in retinoblastoma: a comparison of two techniques. Arch Ophthalmol. 1999;117:766–770.<br>
7<br>
ScottIU, O’BrienJM, MurrayTG. Retinoblastoma: a review emphasizing genetics and management strategies. Semin Ophthalmol. 1997;12:59–71.<br>
8<br>
O’BrienJM, SmithBJ. Chemotherapy in the treatment of retinoblastoma. Int Ophthalmol Clin. 1996;36:11–24.<br>
9<br>
MohneyBG, RobertsonDM, SchombergPJ, et al. Second nonocular tumors in survivors of heritable retinoblastoma and prior radiation therapy. Am J Ophthalmol. 1998;126:269–277.<br>
10<br>
BenzMS, ScottIU, MurrayTG, et al. Complications of systemic chemotherapy as treatment of retinoblastoma. Arch Ophthalmol. 2000;118:577–578.<br>
11<br>
FolkmanJ, CotranR. Relation of vascular proliferation to tumor growth. Int Rev Exp Pathol. 1976;16:207–248.<br>
12<br>
HanahanD, FolkmanJ. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–634.<br>
13<br>
LiekensS, De ClercqE, NeytsJ. Angiogenesis: regulators and clinical applications. Biochem Pharmacol. 2001;61:253–270.<br>
14<br>
RosenL. Antiangiogenic strategies and agents in clinical trials. The Oncologist. 2000;5:20–27.<br>
15<br>
NiheiY, SuzukiM, OkanoA, et al. Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Can Res. 1999;90:1387–1395.<br>
16<br>
BurnierMN, McLeanIW, ZimmermanLE, RosenbergSH. retinoblastoma: the relationship of proliferating cells to blood vessels. Invest Ophthalmol Vis Sci. 1990;31:2037–2040.<br>
17<br>
AlbertDM, TapperD, RobinsonNL, FelmanR. Retinoblastoma and angiogenesis activity. Retina. 1984;4:189–194.<br>
18<br>
TapperD, LangerR, BellowsAR, FolkmanJ. Angiogenesis capacity as a diagnostic marker for human eye tumors. Surgery. 1979;86:36–40.<br>
19<br>
WaltonDS, GrantWM. Retinoblastoma and iris neovascularization. Am J Ophthalmol. 1968;65:598–599.<br>
20<br>
StittAW, SimpsonDA, BoocockC, et al. Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. J Pathol. 1998;186:306–312.<br>
21<br>
KvantaA, SteenB, SeregardS. Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma. Exp Eye Res. 1996;63:511–518.<br>
22<br>
MarbackEF, AriasVE, ParanhosA, Jr, et al. Tumour angiogenesis as a prognostic factor for disease dissemination in retinoblastoma. Br J Ophthalmol. 2003;87:1224–1228.<br>
23<br>
KerimoggluH, KiratliH, DincturkAA, SoylemezogluF, BilgicS. Quantitative analysis of proliferation, apoptosis, and angiogenesis in retinoblastoma and their association with the clinicopathologic parameters. Jpn J Ophthalmol. 2003;47:565–571.<br>
24<br>
RosslerJ, DietrichT, PavlakovicH, et al. Higher vessel densities in retinoblastoma with local invasive growth and metastasis. Am J Pathol. 2004;164:391–394.<br>
25<br>
PennJS, RajaratnamVS, CollierRJ, ClarkAF. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2001;42:283–290.<br>
26<br>
OikawaT, HiragunA, YoshidaY, et al. Angiogenic activity of rat mammary carcinomas induced by 7,12-dimethylbenz[a]anthracene and its inhibitions by medroxyprogesterone acetate: possible involvement of antiangiogenic action of medroxyprogesterone acetate in its tumor growth inhibition. Cancer Lett. 1988;43:85–92.<br>
27<br>
McNattLG, LiWW, CaseyR, GonzalezEM, FolkmanJ. Angiostatic steroids potentiated by sulfated cyclodextrins inhibit corneal neovascularization. Invest Ophthalmol Vis Sci. 1991;32:2898–2905.<br>
28<br>
BenEzraD, GriffinBW, MaftzirG, et al. Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Invest Ophthalmol Vis Sci. 1997;38:1954–1962.<br>
29<br>
ProiaAD, HirakataA, McInnesJS, et al. The effect of angiostatic steroids and b-cyclodextrin tetradecasulfate on corneal neovascularization in the rat. Exp Eye Res. 1993;57:693–698.<br>
30<br>
ClarkAF, MellonJ, LiXY, et al. Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Invest Ophthalmol Vis Sci. 1999;40:2158–2162.<br>
31<br>
ClarkAF. AL-3789: a novel ophthalmic angiostatic steroid. Exp Opin Invest Drugs. 1997;6:1867–1877.<br>
32<br>
Schmidt-ErfurthU, MichelsS, MichelsR, AueA. Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Eur J Ophthalmol. 2005;15:482–485.<br>
33<br>
AugustinAJ, D’AmicoDJ, MielerWF, SchneebaumC, BeasleyC. Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2005;243:9–12.<br>
34<br>
D’AmicoDJ, GoldbergMF, HudsonH, Anecortave Acetate Clinical Study Groupet al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology. 2003;110:2372–2333.<br>
35<br>
D’AmicoDJ, GoldbergMF, HudsonH, et al. Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina. 2003;23:14–23.<br>
36<br>
WindleJJ, AlbertDM, O’BrienJM, et al. Retinoblastoma in transgenic mice. Nature. 1990;343:665–669.<br>
37<br>
MillsMD, WindleJJ, AlbertDM. Retinoblastoma in transgenic mice: models of hereditary retinoblastoma. Surv Ophthalmol. 1999;43:508–518.<br>
38<br>
AlbertDM, GriepAE, LambertPF, et al. Transgenic models of retinoblastoma: what they tell us about its cause and treatment. Trans Am Ophthalmol Soc. 1994;92:385–401.<br>
39<br>
HaydenBC, MurrayTG, ScottIU, et al. Subconjunctival carboplatin in retinoblastoma: impact of tumor burden and dose schedule. Arch Ophthalmol. 2000;118:1549–1554.<br>
40<br>
SchweigererL. Antiangiogenesis as a novel therapeutic concept in pediatric oncology. J Mol Med. 1995;73:497–508.<br>
41<br>
Escalona-BenzE, JockovichME, MurrayTG, et al. Combretastatin A-4 prodrug in the treatment of a murine model of retinoblastoma. Invest Ophthalmol Vis Sci. 2005;46:8–11.<br>
42<br>
PepperMS, VassalliJD, OrciL, MontesanoR. Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis. Exp Cell Res. 1993;204:356–363.<br>
43<br>
WeisM, HeeschenC, GlassfordAJ, CookeJP. Statins have biphasic effects on angiogenesis. Circulation. 2002;105:739–745.<br>
44<br>
NybergP, HeikkilaP, SorsaT, et al. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J Biol Chem. 2003;278:22404–22411.<br>
45<br>
ClarkeMS. Anecortave acetate (Letter). Ophthalmology. 2004;111:2316.author reply 2316–2317.<br>
46<br>
MillerJW, LaneAM, Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes (Discussion). Ophthalmology. 2003;110:2384–2385.<br>
47<br>
TeicherBA. A systems approach to cancer therapy: antioncogenics + standard cytotoxics→mechanism(s) of interaction. Cancer Metastasis Rev. 1996;15:247–272.<br>
48<br>
MaJ, PulferS, LiS, ChuJ, ReedK, GalloJM. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res. 2001;61:5491–5498.<br>
49<br>
HaydenBC, JockovichME, MurrayTG, et al. Pharmacokinetics of systemic versus focal carboplatin chemotherapy in the rabbit eye: possible implication in the treatment of retinoblastoma. Invest Ophthalmol Vis Sci. 2004;45:3644–3649.<br>
50<br>
AbramsonDH, FrankCM, DunkelIJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology. 1999;106:1947–1950.<br>
51<br>
MulvihillA, BudningA, JayV, et al. Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol. 2003;121:1120–1124.</div>
<div bis_skin_checked="1"></div>
<div bis_skin_checked="1"></div>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/04/12/anecortave-acetate-as-single-and-adjuvant-therapy-in-the-treatment-of-retinal-tumors-of-lhbetatag-mice/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/04/12/anecortave-acetate-as-single-and-adjuvant-therapy-in-the-treatment-of-retinal-tumors-of-lhbetatag-mice/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><article class="btArticleListItem animate animate-fadein animate-moveup gutter btHasAuthorInfo post-5187 post type-post status-publish format-standard hentry category-articles animated"><div class="port" bis_skin_checked="1"><div class="boldCell" bis_skin_checked="1"><div class="boldRow" bis_skin_checked="1"><div class="rowItem col-sm-12" bis_skin_checked="1"><div class="rowItemContent btTextLeft" bis_skin_checked="1"><div class="articleSideGutter btTextCenter" bis_skin_checked="1"><div class="asgItem avatar" bis_skin_checked="1"><a href="/../../../../author/ikigai/"><img alt="" src="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&amp;d=mm&amp;r=g" class="avatar avatar-144 photo lazyloaded" height="144" width="144" srcset="https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&amp;d=mm&amp;r=g 2x" data-ll-status="loaded"><noscript><img alt='' src='//secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=144&#038;d=mm&#038;r=g' srcset='https://secure.gravatar.com/avatar/1c81a5e3046061e14068f52bc3d75961?s=288&#038;d=mm&#038;r=g 2x' class='avatar avatar-144 photo' height='144' width='144' /></noscript></a></div><div class="asgItem date" bis_skin_checked="1"><small>05.04.2021</small></div></div><div class="btArticleListBody" bis_skin_checked="1"><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><header class="header btClear large btDash bottomDash"><div class="btSuperTitle" bis_skin_checked="1"><span><span class="btArticleCategories"><a href="/../../../../category/articles/" class="btArticleCategory cat-item-52">Articles</a></span><a href="/../../../../2021/04/05/the-effect-of-spironolactone-on-morbidity-and-mortality-in-patients-with-severe-heart-failure/#comments" class="btArticleComments">0</a></span></div><div class="dash" bis_skin_checked="1"><h2><span class="headline"><a href="/../../../../2021/04/05/the-effect-of-spironolactone-on-morbidity-and-mortality-in-patients-with-severe-heart-failure/">The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure</a></span></h2></div></header><div class="btArticleListBodyContent" bis_skin_checked="1"><div class="bt_bb_wrapper" bis_skin_checked="1"><ul class="m-article-header__authors f-ui">
<li>Bertram Pitt, M.D.,&nbsp;Faiez Zannad, M.D.,&nbsp;Willem J. Remme, M.D.,&nbsp;Robert Cody, M.D.,&nbsp;Alain Castaigne, M.D.,&nbsp;Alfonso Perez, M.D.,&nbsp;Jolie Palensky, M.S.,&nbsp;and Janet Wittes, Ph.D.&nbsp;for the Randomized Aldactone Evaluation Study Investigators<sup>*</sup></li>
</ul>
<h2 class="o-article-body__section-title a-article-h1 a-article-h1--underline f-h3">Abstract</h2>
<hr>
<p>&nbsp;</p>
<h4 class="a-article-h2 f-h12">BACKGROUND AND METHODS</h4>
<p class="f-body">Aldosterone is important in the pathophysiology of heart failure. In a double-blind study, we enrolled 1663 patients who had severe heart failure and a left ventricular ejection fraction of no more than 35 percent and who were being treated with an angiotensin-converting–enzyme inhibitor, a loop diuretic, and in most cases digoxin. A total of 822 patients were randomly assigned to receive 25 mg of spironolactone daily, and 841 to receive placebo. The primary end point was death from all causes.</p>
<h4 class="a-article-h2 f-h12">RESULTS</h4>
<p class="f-body">The trial was discontinued early, after a mean follow-up period of 24 months, because an interim analysis determined that spironolactone was efficacious. There were 386 deaths in the placebo group (46 percent) and 284 in the spironolactone group (35 percent; relative risk of death, 0.70; 95 percent confidence interval, 0.60 to 0.82; P&lt;0.001). This 30 percent reduction in the risk of death among patients in the spironolactone group was attributed to a lower risk of both death from progressive heart failure and sudden death from cardiac causes. The frequency of hospitalization for worsening heart failure was 35 percent lower in the spironolactone group than in the placebo group (relative risk of hospitalization, 0.65; 95 percent confidence interval, 0.54 to 0.77; P&lt;0.001). In addition, patients who received spironolactone had a significant improvement in the symptoms of heart failure, as assessed on the basis of the New York Heart Association functional class (P&lt;0.001). Gynecomastia or breast pain was reported in 10 percent of men who were treated with spironolactone, as compared with 1 percent of men in the placebo group (P&lt;0.001). The incidence of serious hyperkalemia was minimal in both groups of patients.</p>
<p>&nbsp;</p>
<h4 class="a-article-h2 f-h12">CONCLUSIONS</h4>
<p class="f-body">Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure. (N Engl J Med 1999:341:709-17.)</p>
<p>&nbsp;</p>
<p class="f-body f-body--w-dropcap">Aldosterone has an important role in the pathophysiology of heart failure.<sup>1-4</sup>&nbsp;Aldosterone promotes the retention of sodium, the loss of magnesium and potassium, sympathetic activation, parasympathetic inhibition, myocardial and vascular fibrosis, baroreceptor dysfunction, and vascular damage and impairs arterial compliance.<sup>4-8</sup>&nbsp;Many physicians have assumed that inhibition of the renin–angiotensin–aldosterone system by an angiotensin-converting–enzyme (ACE) inhibitor will suppress the formation of aldosterone. In addition, treatment with an aldosterone-receptor blocker in conjunction with an ACE inhibitor has been considered relatively contraindicated because of the potential for serious hyperkalemia.<sup>9,10</sup></p>
<p class="f-body">Consequently, aldosterone-receptor blockers are used infrequently in patients with heart failure.<sup>11,12</sup>&nbsp;There is increasing evidence to suggest, however, that ACE inhibitors only transiently suppress the production of aldosterone.<sup>7,13-16</sup>&nbsp;Furthermore, treatment with the aldosterone-receptor blocker spironolactone at a daily dose of 12.5 to 25 mg in conjunction with standard doses of an ACE inhibitor, a loop diuretic, and in most cases digoxin is pharmacologically effective and well tolerated, decreases atrial natriuretic peptide concentrations, and does not lead to serious hyperkalemia (defined as a serum potassium concentration of at least 6.0 mmol per liter).<sup>17</sup>&nbsp;On the basis of this information, we designed the Randomized Aldactone Evaluation Study (RALES) to test the hypothesis that daily treatment with 25 mg of spironolactone would significantly reduce the risk of death from all causes among patients who had severe heart failure as a result of systolic left ventricular dysfunction and who were receiving standard therapy, including an ACE inhibitor, if tolerated.</p>
<p>&nbsp;</p>
<h2 class="o-article-body__section-title a-article-h1 a-article-h1--underline f-h3" tabindex="0" data-collapsible-trigger="" aria-title="Methods toggle">Methods</h2>
<hr>
<p>&nbsp;</p>
<h2 class="a-article-h2 f-h12" tabindex="0" data-collapsible-trigger="" aria-title="Patients toggle">PATIENTS</h2>
<p class="f-body">Patients were eligible for enrollment if they had had New York Heart Association (NYHA) class IV heart failure within the six months before enrollment and were in NYHA class III or IV at the time of enrollment, had been given a diagnosis of heart failure at least six weeks before enrollment, were being treated with an ACE inhibitor (if tolerated) and a loop diuretic, and had a left ventricular ejection fraction of no more than 35 percent within the six months before enrollment (with no clinically significant intercurrent event). Treatment with digitalis and vasodilators was allowed, but potassium-sparing diuretics were not permitted. Oral potassium supplements were not recommended unless hypokalemia (defined as a serum potassium concentration of less than 3.5 mmol per liter) developed.</p>
<p class="f-body">Patients were excluded from the study if they had primary operable valvular heart disease (other than mitral or tricuspid regurgitation with clinical symptoms due to left ventricular systolic heart failure), congenital heart disease, unstable angina, primary hepatic failure, active cancer, or any life-threatening disease (other than heart failure). Patients who had undergone heart transplantation or were awaiting the procedure were also ineligible. Other criteria for exclusion were a serum creatinine concentration of more than 2.5 mg per deciliter (221 μmol per liter) and a serum potassium concentration of more than 5.0 mmol per liter. The institutional review boards or ethics committees of all participating institutions approved the protocol, and all patients gave written informed consent.</p>
<h2 class="a-article-h2 f-h12" tabindex="0" data-collapsible-trigger="" aria-title="Procedures toggle">PROCEDURES</h2>
<p class="f-body">After the initial evaluation, patients were randomly assigned in a double-blind fashion to receive either 25 mg of spironolactone (Aldactone, Searle, Skokie, Ill.) once daily or a matching placebo. After eight weeks of treatment, the dose could be increased to 50 mg once daily if the patient showed signs or symptoms of progression of heart failure without evidence of hyperkalemia. If hyperkalemia developed at any time, the dose could be decreased to 25 mg every other day; however, the investigator was encouraged first to adjust the doses of concomitant medications. Follow-up evaluations and laboratory measurements, including measurements of serum potassium, were conducted every 4 weeks for the first 12 weeks, then every 3 months for up to 1 year and every 6 months thereafter until the end of the study. Additional clinical laboratory tests were also performed at weeks 1 and 5. Serum potassium was also measured at week 9 in patients for whom the dose was increased to 50 mg. Study medication could be withheld in the event of serious hyperkalemia, a serum creatinine concentration of more than 4.0 mg per deciliter (354 μmol per liter), intercurrent illness, or any condition in which such a course was deemed medically necessary to protect the patient’s best interests. However, all patients remained in the study so that we could track hospitalizations and deaths.</p>
<p class="f-body">An independent data and safety monitoring board periodically reviewed the results in a blinded fashion. Event committees whose members were unaware of the patients’ treatment assignments assessed the causes of death and reasons for hospitalization.</p>
<h2 class="a-article-h2 f-h12" tabindex="0" data-collapsible-trigger="" aria-title="End Points toggle">END POINTS</h2>
<p class="f-body">The primary end point of the study was death from any cause. Secondary end points included death from cardiac causes, hospitalization for cardiac causes, the combined incidence of death from cardiac causes or hospitalization for cardiac causes, and a change in the NYHA class. The effect of spironolactone was also assessed with the use of six prerandomization variables: left ventricular ejection fraction, the cause of heart failure, the serum creatinine concentration, age, the use of ACE inhibitors, and the use of digitalis.</p>
<h2 class="a-article-h2 f-h12" tabindex="0" data-collapsible-trigger="" aria-title="Statistical Analysis toggle">STATISTICAL ANALYSIS</h2>
<p class="f-body">The analysis of death from all causes (the primary end point) included all patients, according to the intention-to-treat principle. Kaplan–Meier<sup>18</sup>&nbsp;methods were used to construct cumulative survival curves for the two groups. The primary comparison between the two groups was based on a log-rank test.<sup>19</sup>&nbsp;Cox proportional-hazards regression models<sup>20</sup>&nbsp;were developed to explore the effects of base-line variables on the estimated effect of spironolactone. Formal assessment of efficacy used a group sequential monitoring plan with a Lan–DeMets<sup>21</sup>&nbsp;stopping boundary and an O’Brien–Fleming<sup>22</sup>&nbsp;spending function.</p>
<p class="f-body">The sample size was calculated on the basis of the following assumptions: the mortality rate in the placebo group would be 38 percent, the risk of death would be 17 percent lower in the spironolactone group than in the placebo group, and approximately 5 percent of the patients in the spironolactone group would discontinue treatment during each year of the study.<sup>23</sup>&nbsp;The power of the study to detect a difference between treatment groups was set at 90 percent (with a two-tailed α level of 0.05).</p>
<p class="f-body">At each of its meetings, the data and safety monitoring board evaluated the available data for evidence of efficacy and safety and calculated the cumulative type I error with respect to efficacy. In two large studies of patients with heart failure,<sup>24,25</sup>&nbsp;the distributions of the time to death were nonexponential; therefore, the computations for group sequential monitoring of mortality from all causes were based on life-table calculations of event rates. The critical z value required to establish that treatment with spironolactone was efficacious was 2.02, corresponding to a P value of 0.043.</p>
<p>&nbsp;</p>
<h2 class="o-article-body__section-title a-article-h1 a-article-h1--underline f-h3" tabindex="0" data-collapsible-trigger="" aria-title="Results toggle">Results</h2>
<hr>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p class="f-body">Randomization was begun on March 24, 1995; recruitment was completed on December 31, 1996, with follow-up scheduled to continue through December 31, 1999. However, at the fifth planned interim analysis, the observed effect of spironolactone on the risk of death from all causes exceeded the prespecified critical z value. Hence, the trial was stopped on August 24, 1998, after a mean follow-up of 24 months, on the recommendation of the data and safety monitoring board. The analysis includes all events through midnight on August 24, 1998.</p>
<p><img src="https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/1999/nejm_1999.341.issue-10/nejm199909023411001/production/images/img_medium/nejm199909023411001_t1.jpeg" class="lazyloaded" data-ll-status="loaded"><noscript><img src="https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/1999/nejm_1999.341.issue-10/nejm199909023411001/production/images/img_medium/nejm199909023411001_t1.jpeg" /></noscript></p>
<p><span class="m-cta m-cta--narrow figure article__tabFigure" data-rel="article-figure"><span class="m-cta__figure-link open-figure-link" title="View full size" data-rid="t01"><span class="a-subtitle a-subtitle--alt" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJM199909023411001-t01">Table 1.</span><span class="m-cta__figure"><span class="m-cta__figure-img"><span class="m-cta__figcaption f-caption figcaption m-figure-item__figcaption"><span class="f-caption f-caption--title" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJM199909023411001-t01">Base-Line Characteristics of the Patients.</span></span></span></span></span></span></p>
<p class="f-body">A total of 1663 patients from 195 centers in 15 countries underwent randomization: 841 were assigned to receive placebo and 822 were assigned to receive spironolactone. As shown in&nbsp;<span id="t01" class="holder"><a class="js__showFigure" title="View full size" href="https://www.nejm.org/doi/full/10.1056/NEJM199909023411001#" data-figure-id="t01" data-multimedia-type-ff="Table" data-multimedia-content="Table" data-multimedia-contentid-ff="10.1056/NEJM199909023411001-t01" data-rid="t01" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJM199909023411001-t01" data-fv-download-contentid="10.1056/NEJM199909023411001-t01" data-fv-interactiontype="multimedia_download" data-fv-download-type="Table">Table 1</a></span>, the two groups had similar characteristics at base line. Seven patients (three in the placebo group and four in the spironolactone group) who had a history of NYHA class IV heart failure were in NYHA class II at the time of randomization. During the study, 414 patients (200 in the placebo group and 214 in the spironolactone group) discontinued treatment because of a lack of response, because of adverse events, or for administrative reasons. Treatment was stopped in an additional 19 patients (11 in the placebo group and 8 in the spironolactone group) because of the need for heart transplantation; 2 patients, both of whom were in the placebo group, died after heart transplantation. Patients who discontinued treatment were followed by means of regularly scheduled telephone calls to determine their vital status. After 24 months of follow-up, the mean daily dose of study medication for the patients who continued to receive treatment was 31 mg in the placebo group and 26 mg in the spironolactone group.</p>
<h2 class="a-article-h2 f-h12" tabindex="0" data-collapsible-trigger="" aria-title="Survival toggle">SURVIVAL</h2>
<p><span class="m-cta m-cta--narrow figure article__tabFigure" data-rel="article-figure"><span class="m-cta__figure-link open-figure-link" title="View full size" data-rid="f01"><span class="a-subtitle a-subtitle--alt" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-format="Image" data-multimedia-contentid="10.1056/NEJM199909023411001-f01">Figure 1.</span><span class="m-cta__figure"><span class="m-cta__figure-img"><span class="m-cta__figcaption f-caption figcaption m-figure-item__figcaption"><span class="f-caption f-caption--title" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-format="Image" data-multimedia-contentid="10.1056/NEJM199909023411001-f01">Kaplan–Meier Analysis of the Probability of Survival among Patients in the Placebo Group and Patients in the Spironolactone Group.</span></span></span></span></span></span><span class="m-cta m-cta--narrow figure article__tabFigure" data-rel="article-figure"><span class="m-cta__figure-link open-figure-link" title="View full size" data-rid="t02"><span class="a-subtitle a-subtitle--alt" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJM199909023411001-t02">Table 2.</span><span class="m-cta__figure"><span class="m-cta__figure-img"><span class="m-cta__figcaption f-caption figcaption m-figure-item__figcaption"><span class="f-caption f-caption--title" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJM199909023411001-t02">Relative Risks of Death and Hospitalization.</span></span></span></span></span></span></p>
<p><img src="https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/1999/nejm_1999.341.issue-10/nejm199909023411001/production/images/img_medium/nejm199909023411001_f1.jpeg" class="lazyloaded" data-ll-status="loaded"><noscript><img src="https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/1999/nejm_1999.341.issue-10/nejm199909023411001/production/images/img_medium/nejm199909023411001_f1.jpeg" /></noscript></p>
<p class="f-body fig-paragraph">There were 386 deaths in the placebo group (46 percent) and 284 deaths in the spironolactone group (35 percent), representing a 30 percent reduction in the risk of death (relative risk of death among the patients in the spironolactone group, 0.70 by a Cox proportional-hazards model; 95 percent confidence interval, 0.60 to 0.82; P&lt;0.001) (<span id="f01" class="holder"><a class="js__showFigure" title="View full size" href="https://www.nejm.org/doi/full/10.1056/NEJM199909023411001#" data-figure-id="f01" data-multimedia-type-ff="Image" data-multimedia-content="Figure" data-multimedia-contentid-ff="10.1056/NEJM199909023411001-f01" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-format="Image" data-multimedia-contentid="10.1056/NEJM199909023411001-f01" data-fv-download-contentid="10.1056/NEJM199909023411001-f01" data-fv-interactiontype="multimedia_download" data-fv-download-type="Figure">Figure 1</a></span>&nbsp;and&nbsp;<span id="t02" class="holder"><a class="js__showFigure" title="View full size" href="https://www.nejm.org/doi/full/10.1056/NEJM199909023411001#" data-figure-id="t02" data-multimedia-type-ff="Table" data-multimedia-content="Table" data-multimedia-contentid-ff="10.1056/NEJM199909023411001-t02" data-rid="t02" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJM199909023411001-t02" data-fv-download-contentid="10.1056/NEJM199909023411001-t02" data-fv-interactiontype="multimedia_download" data-fv-download-type="Table">Table 2</a></span>). A total of 314 deaths in the placebo group (37 percent) and 226 deaths in the spironolactone group (27 percent) were attributed to cardiac causes, representing a 31 percent reduction in the risk of death from cardiac causes (relative risk, 0.69; 95 percent confidence interval, 0.58 to 0.82; P&lt;0.001). The reduction in the risk of death among the patients in the spironolactone group was attributed to significantly lower risks of both death from progressive heart failure and sudden death from cardiac causes (<span id="t02" class="holder"><a class="js__showFigure" title="View full size" href="https://www.nejm.org/doi/full/10.1056/NEJM199909023411001#" data-figure-id="t02" data-multimedia-type-ff="Table" data-multimedia-content="Table" data-multimedia-contentid-ff="10.1056/NEJM199909023411001-t02" data-rid="t02" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJM199909023411001-t02" data-fv-download-contentid="10.1056/NEJM199909023411001-t02" data-fv-interactiontype="multimedia_download" data-fv-download-type="Table">Table 2</a></span>).</p>
<p><img src="https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/1999/nejm_1999.341.issue-10/nejm199909023411001/production/images/img_medium/nejm199909023411001_f2.jpeg" class="lazyloaded" data-ll-status="loaded"><noscript><img src="https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/1999/nejm_1999.341.issue-10/nejm199909023411001/production/images/img_medium/nejm199909023411001_f2.jpeg" /></noscript></p>
<p><span class="m-cta m-cta--narrow figure article__tabFigure" data-rel="article-figure"><span class="m-cta__figure-link open-figure-link" title="View full size" data-rid="f02"><span class="a-subtitle a-subtitle--alt" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-format="Image" data-multimedia-contentid="10.1056/NEJM199909023411001-f02">Figure 2.</span><span class="m-cta__figure"><span class="m-cta__figure-img"><span class="m-cta__figcaption f-caption figcaption m-figure-item__figcaption"><span class="f-caption f-caption--title" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-format="Image" data-multimedia-contentid="10.1056/NEJM199909023411001-f02">Relative Risks of Death from All Causes and According to Demographic and Clinical Characteristics.</span></span></span></span></span></span></p>
<p class="f-body">The reduction in the risk of death among patients in the spironolactone group was similar in analyses of all six prespecified subgroups as well as in retrospective analyses performed according to sex, NYHA class, base-line serum potassium concentration, use of potassium supplements, and use of beta-blockers (<span id="f02" class="holder">Figure 2</span>). The estimated beneficial effect was similar across geographic regions.</p>
<h4 class="a-article-h2 f-h12" tabindex="0" aria-title="Death from Cardiac Causes and Hospitalization for Cardiac Causes toggle">DEATH FROM CARDIAC CAUSES AND HOSPITALIZATION FOR CARDIAC CAUSES</h4>
<p><span class="m-cta m-cta--narrow figure article__tabFigure" data-rel="article-figure"><span class="m-cta__figure-link open-figure-link" title="View full size" data-rid="t03"><span class="a-subtitle a-subtitle--alt" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJM199909023411001-t03">Table 3.</span><span class="m-cta__figure"><span class="m-cta__figure-img"><span class="m-cta__figcaption f-caption figcaption m-figure-item__figcaption"><span class="f-caption f-caption--title" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJM199909023411001-t03">Relative Risks of the Combined End Points of Death or Hospitalization in the Spironolactone Group.</span></span></span></span></span></span></p>
<p><img src="https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/1999/nejm_1999.341.issue-10/nejm199909023411001/production/images/img_medium/nejm199909023411001_t3.jpeg" class="lazyloaded" data-ll-status="loaded"><noscript><img src="https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/1999/nejm_1999.341.issue-10/nejm199909023411001/production/images/img_medium/nejm199909023411001_t3.jpeg" /></noscript></p>
<p class="f-body fig-paragraph">During the trial, 336 patients in the placebo group and 260 patients in the spironolactone group were hospitalized at least once for cardiac reasons (<span id="t02" class="holder"><a class="js__showFigure" title="View full size" href="https://www.nejm.org/doi/full/10.1056/NEJM199909023411001#" data-figure-id="t02" data-multimedia-type-ff="Table" data-multimedia-content="Table" data-multimedia-contentid-ff="10.1056/NEJM199909023411001-t02" data-rid="t02" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJM199909023411001-t02" data-fv-download-contentid="10.1056/NEJM199909023411001-t02" data-fv-interactiontype="multimedia_download" data-fv-download-type="Table">Table 2</a></span>). In total, there were 753 hospitalizations for cardiac causes in the placebo group and 515 in the spironolactone group, representing a 30 percent reduction in the risk of hospitalization for cardiac causes among patients in the spironolactone group (relative risk, 0.70; 95 percent confidence interval, 0.59 to 0.82; P&lt;0.001) (<span id="t02" class="holder">Table 2</span>). Analysis of the combined end point of death from cardiac causes or hospitalization for cardiac causes revealed a 32 percent reduction in the risk of this end point among patients in the spironolactone group as compared with those in the placebo group (relative risk, 0.68; 95 percent confidence interval, 0.59 to 0.78; P&lt;0.001) (<span id="t03" class="holder">Table 3</span>).</p>
<h2 class="a-article-h2 f-h12" tabindex="0" data-collapsible-trigger="" aria-title="Changes in NYHA Class toggle">CHANGES IN NYHA CLASS</h2>
<p class="f-body">Three categories were used to assess changes in the symptoms of heart failure: improvement, no change, and worsening or death. The condition of patients who were in NYHA class III at base line was considered to have improved if they were in NYHA class I or II at the end of the study and considered to have worsened if they were in NYHA class IV (or had died). The condition of patients who were in NYHA class IV at base line was considered to have improved if they were in NYHA class I, II, or III at the end of the study; other patients in NYHA class IV at base line either had no change at the end of the study or died. In the placebo group, the condition of 33 percent of the patients improved; it did not change in 18 percent, and it worsened in 48 percent. In the spironolactone group, the condition of 41 percent of the patients improved; it did not change in 21 percent, and it worsened in 38 percent. The difference between groups was significant (P&lt;0.001 by the Wilcoxon test).</p>
<h2 class="a-article-h2 f-h12" tabindex="0" data-collapsible-trigger="" aria-title="Safety toggle">SAFETY</h2>
<p class="f-body">There were no significant differences between the two groups in serum sodium concentration, blood pressure, or heart rate during the study. The median creatinine and potassium concentrations did not change in the placebo group during the first year of follow-up, the period for which the data were most complete. During the same period, however, the median creatinine concentration in the spironolactone group increased by approximately 0.05 to 0.10 mg per deciliter (4 to 9 μmol per liter) and the median potassium concentration increased by 0.30 mmol per liter. The differences between the two groups were significant (P&lt;0.001) but were not clinically important.</p>
<p><span class="m-cta m-cta--narrow figure article__tabFigure" data-rel="article-figure"><span class="m-cta__figure-link open-figure-link" title="View full size" data-rid="t04"><span class="a-subtitle a-subtitle--alt" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJM199909023411001-t04">Table 4.</span><span class="m-cta__figure"><span class="m-cta__figure-img"><span class="m-cta__figcaption f-caption figcaption m-figure-item__figcaption"><span class="f-caption f-caption--title" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJM199909023411001-t04">Adverse Events.</span></span></span></span></span></span></p>
<p><img src="https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/1999/nejm_1999.341.issue-10/nejm199909023411001/production/images/img_medium/nejm199909023411001_t4.jpeg" class="lazyloaded" data-ll-status="loaded"><noscript><img src="https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/1999/nejm_1999.341.issue-10/nejm199909023411001/production/images/img_medium/nejm199909023411001_t4.jpeg" /></noscript></p>
<p class="f-body"><span id="t04" class="holder"><a class="js__showFigure" title="View full size" href="https://www.nejm.org/doi/full/10.1056/NEJM199909023411001#" data-figure-id="t04" data-multimedia-type-ff="Table" data-multimedia-content="Table" data-multimedia-contentid-ff="10.1056/NEJM199909023411001-t04" data-rid="t04" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-format="Table" data-multimedia-contentid="10.1056/NEJM199909023411001-t04" data-fv-download-contentid="10.1056/NEJM199909023411001-t04" data-fv-interactiontype="multimedia_download" data-fv-download-type="Table">Table 4</a></span>&nbsp;lists the adverse reactions in the two groups. Serious hyperkalemia occurred in 10 patients in the placebo group (1 percent) and 14 patients in the spironolactone group (2 percent, P=0.42). Gynecomastia or breast pain was reported by 10 percent of the men in the spironolactone group and 1 percent of the men in the placebo group (P&lt;0.001), causing more patients in the spironolactone group than in the placebo group to discontinue treatment (10 vs. 1, P=0.006).</p>
<p>&nbsp;</p>
<h2 class="o-article-body__section-title a-article-h1 a-article-h1--underline f-h3" tabindex="0" data-collapsible-trigger="" aria-title="Discussion toggle">Discussion</h2>
<hr>
<p>&nbsp;</p>
<section id="article_discussion_s014" class="o-article-body__section o-article-body__section--collapsible o-article-body__section--collapsible-open@medium+ section-in-viewport" data-behavior="CollapsibleArea" data-article-section-title="Discussion">
<div class="o-article-body__collapsible" data-collapsible-block="" bis_skin_checked="1">
<div class="o-article-body__collapsible-content" bis_skin_checked="1">
<p class="f-body">We found that treatment with spironolactone reduced the risk of death from all causes, death from cardiac causes, hospitalization for cardiac causes, and the combined end point of death from cardiac causes or hospitalization for cardiac causes among patients who had severe heart failure as a result of left ventricular systolic dysfunction and who were receiving standard therapy including an ACE inhibitor. Spironolactone also improved the symptoms of heart failure, as measured by changes in the NYHA functional class. The reductions in the risk of death and hospitalization were observed after 2 to 3 months of treatment and persisted throughout the study (mean follow-up, 24 months). The results were consistent among subgroups. Serious hyperkalemia requiring the discontinuation of treatment was uncommon, occurring in one patient in the placebo group and three in the spironolactone group.</p>
<p class="f-body">The patients in our study were at higher risk than those in studies of the effects of bisoprolol,<sup>26</sup>&nbsp;digoxin,<sup>27</sup>&nbsp;amlodipine,<sup>28</sup>&nbsp;or carvedilol<sup>29</sup>&nbsp;on heart failure resulting from systolic left ventricular dysfunction and treated with standard therapy, including an ACE inhibitor, but they were at lower risk than patients in a study of the effects of enalapril.<sup>25</sup>&nbsp;The reduction in the risk of death with spironolactone treatment was due to significant decreases in the risk of both death from progressive heart failure and sudden death from cardiac causes. These results are consistent with the current understanding of the effect of aldosterone in patients with heart failure.<sup>30-32</sup></p>
<p class="f-body">Aldosterone was originally thought to be important in the pathophysiology of heart failure only because of its ability to increase sodium retention and potassium loss. However, in the past several years, research has shown that aldosterone also causes myocardial and vascular fibrosis,<sup>33,34</sup>&nbsp;direct vascular damage,<sup>8</sup>&nbsp;and baroreceptor dysfunction<sup>6</sup>&nbsp;and prevents the uptake of norepinephrine by myocardium.<sup>4,32</sup>&nbsp;The reduction in the risk of death in our study does not appear to be due entirely to an effect of spironolactone on sodium retention or potassium loss; instead, it is likely that spironolactone is also cardioprotective. In our previous dose-finding study,<sup>17</sup>&nbsp;a dose of 25 mg of spironolactone daily had no apparent diuretic effect — that is, there was no change in total body weight, the sodium-retention score, or urinary sodium excretion. In the present study, spironolactone (mean dose, 26 mg daily) did not have a clinically significant hemodynamic effect. Although we cannot rule out the possibility that spironolactone had some effect on sodium excretion in the present study, this effect would most likely be minor, as compared with the effect of the high doses of loop diuretics used. Also, although there was a significant increase from base line in serum potassium concentrations in the patients in the spironolactone group, this change was not clinically important.</p>
<p class="f-body">The 35 percent reduction in the risk of hospitalization for worsening heart failure may be attributable to the ability of spironolactone to reduce myocardial and vascular fibrosis. Although the exact cause of the reduction in the risk of death in our study remains speculative, we postulate that an aldosterone-receptor blocker can prevent progressive heart failure by averting sodium retention and myocardial fibrosis and prevent sudden death from cardiac causes by averting potassium loss and by increasing the myocardial uptake of norepinephrine. Spironolactone may prevent myocardial fibrosis by blocking the effects of aldosterone on the formation of collagen,<sup>5,35,36</sup>&nbsp;which in turn could play a part in reducing the risk of sudden death from cardiac causes, since myocardial fibrosis could predispose patients to variations in ventricular-conduction times and, hence, to reentry ventricular arrhythmias.<sup>32,35-37</sup></p>
<p class="f-body">Few patients (11 percent) in the spironolactone group were receiving a beta-blocker at base line, and the reduction in the risk of death did not differ significantly between those who were treated with a beta-blocker and those who were not so treated. Since our patients were at higher risk than patients who were evaluated in recent studies of beta-blockers in heart failure,<sup>26,29</sup>&nbsp;studies are needed to examine both the tolerability and the effectiveness of beta-blockers in such a high-risk population as well as the effects of the concomitant use of an aldosterone-receptor blocker and a beta-blocker.</p>
<p class="f-body">Our finding that an aldosterone-receptor blocker reduced the risk of both morbidity and death among patients who were receiving an ACE inhibitor emphasizes the point that standard doses of an ACE inhibitor do not effectively suppress the production of aldosterone.<sup>7,14</sup>&nbsp;Although higher doses of ACE inhibitors may be more effective than lower doses in reducing the risk of morbidity and death among patients with heart failure,<sup>38</sup>&nbsp;there is no evidence that higher doses suppress aldosterone production more effectively in the long term. ACE inhibitors cannot totally suppress the production of aldosterone, because other factors in addition to angiotensin II (e.g., serum potassium) are important in the production of aldosterone and may override the effects of angiotensin II.<sup>39-41</sup>&nbsp;Since aldosterone remains in the circulation, only the presence of an aldosterone-receptor blocker will completely suppress the effects of this hormone.</p>
<p class="f-body">The fact that spironolactone significantly reduced the risk of both morbidity and death among the high-risk patients in our study with only a very low incidence of serious hyperkalemia can be attributed to our previous efforts in determining an effective and safe dose of spironolactone when used in conjunction with an ACE inhibitor.<sup>17</sup>&nbsp;We found that spironolactone at a dose of 12.5 to 25 mg daily was pharmacologically effective in blocking the aldosterone receptors and decreasing atrial natriuretic peptide concentrations and that serious hyperkalemia occurred most frequently with daily doses of 50 mg or greater.<sup>17</sup>&nbsp;In the present study, therefore, spironolactone therapy was initiated at a daily dose of 25 mg, and physicians were given the option of reducing the dose to 25 mg every other day if serum potassium concentrations started to rise to a hyperkalemic level or of increasing the dose to 50 mg daily after eight weeks in patients who had symptoms or signs of worsening heart failure but no evidence of hyperkalemia. It should be emphasized, however, that a serum creatinine concentration of more than 2.5 mg per deciliter and a serum potassium concentration of more than 5.0 mmol per liter were exclusion criteria. In addition, the long-term use of agents known to interact with spironolactone, increase the risk of hyperkalemia, or do both was not allowed. Although potassium supplements were used by 29 percent of the patients in the spironolactone group, the benefit of spironolactone in these patients was similar to that in patients who did not use potassium supplements.</p>
<p class="f-body">Overall, spironolactone therapy was tolerated well: 8 percent of the patients in the spironolactone group discontinued treatment because of adverse events, as compared with 5 percent of the patients in the placebo group. This difference was due in part to a significant incidence of gynecomastia or breast pain among men in the spironolactone group (P&lt;0.001). The rate of discontinuation of treatment because of this event was higher in the spironolactone group than in the placebo group (2 percent vs. 0.2 percent, P=0.006). Gynecomastia has previously been observed in patients who were treated with spironolactone.<sup>42,43</sup>&nbsp;Specifically, gynecomastia has been reported to occur in 6.9 percent of men who received daily doses of spironolactone of 50 mg or less for hypertension.<sup>43</sup>&nbsp;The use of a selective aldosterone-receptor antagonist such as eplerenone, which has a lower affinity for androgen and progesterone receptors than does spironolactone,<sup>44</sup>&nbsp;may minimize the risk of gynecomastia. The risk of gynecomastia should not, however, be an argument against the use of spironolactone in men with severe heart failure, since spironolactone reduces the risk of both morbidity and death. The effectiveness and risks of treatment with spironolactone in patients at lower risk than those in our study, such as those with less severe heart failure, will require further prospective study.</p>
<p class="f-body">Our finding that an aldosterone-receptor antagonist, when used in conjunction with an ACE inhibitor, reduces the risk of both death from progressive heart failure and sudden death from cardiac causes contributes to our understanding of the pathophysiology of heart failure and has implications for the treatment of patients with other conditions in which ACE inhibitors are beneficial, such as patients with hypertension and those who have had a myocardial infarction.</p>
</div>
</div>
</section>
<section id="disclosures" class="o-article-body__section o-article-body__section--collapsible o-article-body__section--collapsible-open@medium+ o-article-body__section--hide-title@medium+" data-behavior="CollapsibleArea" data-article-section-title="Funding and Disclosures">
<div class="o-article-body__collapsible" data-collapsible-block="" bis_skin_checked="1">
<div class="o-article-body__collapsible-content" bis_skin_checked="1">
<div id="" bis_skin_checked="1">
<p class="f-body--sm">Preliminary data were presented at the American Heart Association meeting, Dallas, November 8–11, 1998.</p>
</div>
<div id="" bis_skin_checked="1">
<p class="f-body--sm">Supported by a grant from Searle, Skokie, Ill.</p>
</div>
<p class="f-body--sm">We are indebted to Lorraine R. Baer, Pharm.D., for editorial contributions and assistance in the preparation of the manuscript.</p>
</div>
</div>
</section>
<h2 class="o-article-body__section-title a-article-h1 a-article-h1--underline f-h3" data-collapsible-trigger="" aria-title="Affiliations toggle">Author Affiliations</h2>
<hr>
<p>&nbsp;</p>
<div id="" bis_skin_checked="1">
<p class="f-body--sm">From the Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor (B.P., R.C.); the Centre d’Investigation, Clinique de Nancy, Nancy, France (F.Z.); STICARES, Cardiovascular Research Foundation, Rotterdam, the Netherlands (W.J.R.); the Service de Cardiologie, Hôpital Henri Mondor, Creteil, France (A.C.); Global Medical Operations, Searle, Skokie, Ill. (A.P.); and the Statistics Collaborative, Washington, D.C. (J.P., J.W.).</p>
</div>
<p class="f-body--sm">Address reprint requests to Dr. Pitt at the Division of Cardiology, University of Michigan Medical Center, 3910 Taubman, 1500 E. Medical Center Dr., Ann Arbor, MI 48109-0366.</p>
<div id="FN1" bis_skin_checked="1">
<p class="f-body--sm">Other investigators are listed in the Appendix.</p>
</div>
<p>&nbsp;</p>
<h2 class="o-article-body__section-title a-article-h1 a-article-h1--underline f-h3" tabindex="0" data-collapsible-trigger="" aria-title="Appendix toggle">Appendix</h2>
<hr>
<p>&nbsp;</p>
<p>In addition to the authors, the following persons participated in the study:&nbsp;<i>Data and Safety Monitoring Board</i>&nbsp;— D. Julian (chair), J.-P. Boissel, C. Furberg, H. Kulbertus, S. Pocock;&nbsp;<i>Primary End-Point Committee</i>&nbsp;— J. Blumenfeld, J.A. Ramires;&nbsp;<i>Nonfatal Hospitalization End-Point Committee</i>&nbsp;— S. Sasayama (chair), C. Brilla, D. Duprez, R. Muñoz;&nbsp;<i>Medical Monitors</i>&nbsp;— D. Asner, B. Roniker;&nbsp;<i>Investigators:</i>&nbsp;<i>Belgium</i>&nbsp;— P. Block, G. Boxho, J.-M. Chaudron, V. Conraads, J. Creplet, P. De Salle, F. Deman, D. Duprez, O. Gurnee, G. Heyndrickx, S. Janssens, G. Jouret, C. Mortier, L. Pierard, P. Timmermans, J.L. Vandenbossche, W. Van Mieghem, J. Vanwelden, J. Vincke;&nbsp;<i>Brazil —&nbsp;</i>F.M. Albanesi Filho, F.A. de Almeida, J.C.A. Ayoub, E.T. Barbosa, M. Batlouni, L.C. Bodanese, R.M. Carrasco, A.C. de C. Carvalho, I. Castro, O.R. Coelho, D. Dauar, C. Drumond Neto, G.S. Feitosa, R.A. Franken, P.C.B.V. Jardim, C. Mady, M.F. de C. Maranhão, J.A. Marin Neto, L.F. de Miranda, J.C. Nicolau, W. Oigman, W.A. de Oliveira Júnior, W.C. Pereira Filho, J.A.F. Ramires, J.J.F. Rapozo Filho, S. Rassi, J.M. Ribeiro, J.P. Ribeiro, P.R.F. Rossi, J.F.K. Saraiva, A.S. Sbissa, M.A.D. da Silva, J.E. de Sigueira, J. Souza Filho;&nbsp;<i>Canada</i>&nbsp;— I.M. Arnold, D. Beanlands, C. Koilppillai, S. Lepage, A. Morris, M. White;&nbsp;<i>France</i>&nbsp;— F. Albert, G. Amat, F. Apffel, M.C. Aumont, S. Baleynaud, P. Battistella, J. Beaune, L. Bonnefoy, A. Bonneau, J. Bonnet, M. Bory, J.P. Bousser, J.A. Boutarin, B. Charbonnier, A. Cohen, A. Cohen-Solal, M.T. Courbet-Andrejak, A. Cribier, F. Delahaye, C. D’Ivernois, J.P. Doazan, V. Dormagen, H. Douard, F. Dravet, A. Dutoit, J.M. Fayard, M. Ferriere, C. Fournier, Y. Frances, F. Funck, M. Galinier, L.F. Garnier, P. Gibelin, P. Gosse, B. Grivet, L. Guize, B. d’Hautefeuille, A. Heraudeau, J.F. Huret, L. Janin-Manificat, G. Jarry, Y. Jobic, E. Jullien, J.C. Kahn, K. Khalife, A. Koenig, F. Latour, C. Leclercq, F. Leclercq, L. Ledain, H. Le Marec, S. Levy, J.M. Mallion, P. Maribas, G. Mialet, P.L. Michel, J.P. Millet, B. Moquet, J.P. Normand, T. Olive, P. Poncelet, J. Ponsonnaille, J. Puel, A. Rifai, P. Sans, J.P. Simon, M. Toussaint, A. Verdun, B. Veyre, S. Werquin;&nbsp;<i>Germany</i>&nbsp;— C. Brilla, G. Riegger, M. Zehender;&nbsp;<i>Japan</i>&nbsp;— Y. Aizawa, M. Hori, H. Inoue, H. Kasanuki, A. Kitabatake, M. Matsuzaki, S. Ogawa, M. Omata, S. Sasayama, A. Takeshita, Y. Yazaki, M. Yokoyama;&nbsp;<i>Mexico</i>&nbsp;— L. Avila, F.J. Guerrero, H. Gutiérrez-Leonard, J.L. Leyva-Garza;&nbsp;<i>the Netherlands</i>&nbsp;— P.J.L.M. Bernink, H. Fintelman, J.A. Kragten, J.B.L. ten Kate, D.J.A. Lok, A.R. Ramdat Misier, G.P. Molhoek, G.M.G. Paulussen, L.H.J. van Kempen, D.J. van Veldhuisen, L.G.P.M. van Zeijl, A.J.A.M. Withagen;&nbsp;<i>New Zealand&nbsp;</i>— H. Ikram;&nbsp;<i>South Africa</i>&nbsp;— J.D. Marx, D.P. Naidoo;&nbsp;<i>Spain</i>&nbsp;— J.M. Aguirre, S. Alcasena, M. Artaza, J. Azpitarte, J.R. Berrazueta, A. Castro-Beiras, P. Conthe, A. Cortina, J.M. Cruz-Fernández, J. Farré, I. Ferreira, M. García-Moll, V. López-García-de-Aranda, J.L. López-Sendón, R. Muñoz, F. Navarro, J. Palomo, J.M. Ribera-Casado, J.L. Rodríguez-Lambert, J. Soler-Soler, E. de-Teresa, J.A. de-Velasco;&nbsp;<i>Switzerland&nbsp;</i>— P. Delafontaine, O.M. Hess, L. Kappenberger, G. Noll, W. Rutishauser, J. Sztajzel;&nbsp;<i>United Kingdom</i>&nbsp;— A.J.S. Coats, T.S. Callaghan, A.D. Struthers;&nbsp;<i>United States</i>&nbsp;— G.W. Dec, P. Deedwania, J. Nicklas, K.T. Weber;&nbsp;<i>Venezuela</i>&nbsp;— N. Lopez, S. Waich.</p>
<p>&nbsp;</p>
<h2 class="o-article-body__section-title a-article-h1 a-article-h1--underline f-h3" tabindex="0" data-collapsible-trigger="" aria-title="References toggle" data-interactiontype="article_tab" data-tabname="referencesJump" aria-expanded="false">References&nbsp;<em class="a-article-h1__count">(44)</em></h2>
<hr>
<p>&nbsp;</p>
<p>Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981;63:645-651</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
2.Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990;82:1730-1736</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
3.Weber KT, Villarreal D. Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993;71:Suppl:3A-11A</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
4.Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-1265</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
5.MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30-34</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
6.Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994;24:571-575</p>
<p>Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
7.Duprez DA, De Buyzere ML, Rietzschel ER, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998;19:1371-1376</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
8.Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31:451-458</p>
<p>Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
9.Capoten tablets: captopril tablets. In: Physicians’ desk reference. 52nd ed. Montvale, N.J.: Medical Economics, 1998:784-7.</p>
<p>Google Scholar. opens in new tab<br>
10.Vasotec tablets: enalapril maleate. In: Physicians’ desk reference. 52nd ed. Montvale, N.J.: Medical Economics, 1998:1771-4.</p>
<p>Google Scholar. opens in new tab<br>
11.Cleland JG, Swedberg K, Poole-Wilson PA. Successes and failures of current treatment of heart failure. Lancet 1998;352:Suppl 1:SI19-SI28</p>
<p>Crossref. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
12.Cohn JN. The management of chronic heart failure. N Engl J Med 1996;335:490-498</p>
<p>Full Text<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
13.Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993;33:40-45</p>
<p>Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
14.Cleland JGF, Dargie HJ, Hodsman GP, et al. Captopril in heart failure: a double blind controlled trial. Br Heart J 1984;52:530-535</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
15.Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982;4:966-972</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
16.Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981;91:457-465</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
17.The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996;78:902-907</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
18.Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Google Scholar. opens in new tab<br>
19.Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170</p>
<p>Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
20.Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-202</p>
<p>Google Scholar. opens in new tab<br>
21.Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-663</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Google Scholar. opens in new tab<br>
22.O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
23.Lakatos E. Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics 1988;44:229-241[Erratum, Biometrics 1988;44:923.]</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
24.The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302</p>
<p>Free Full Text<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
25.The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435</p>
<p>Full Text<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
26.The CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
27.The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533</p>
<p>Free Full Text<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
28.Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-1114</p>
<p>Free Full Text<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
29.Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355</p>
<p>Free Full Text<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
30.Zannad F. Angiotensin-converting enzyme inhibitor and spironolactone combination therapy: new objectives in congestive heart failure treatment. Am J Cardiol 1993;71:Suppl:34A-39A</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
31.Pitt B. “Escape“ of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995;9:145-149</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
32.Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996;2:47-54</p>
<p>Crossref. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
33.Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-1865</p>
<p>Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
34.Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990;67:1355-1364</p>
<p>Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
35.Klug D, Robert V, Swynghedauw B. Role of mechanical and hormonal factors in cardiac remodeling and the biologic limits of myocardial adaptation. Am J Cardiol 1993;71:Suppl:46A-54A</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
36.Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993;25:563-575</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
37.Barr CS, Naas A, Freeman M, Lang CC, Struthers AD. QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994;343:327-329</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
38.Hobbs RE. Results of the ATLAS study — high or low doses of ACE inhibitors for heart failure? Cleve Clin J Med 1998;65:539-542</p>
<p>Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
39.Hajnoczky G, Varnai P, Hollo Z, et al. Thapsigargin-induced increase in cytoplasmic Ca2+ concentration and aldosterone production in rat adrenal glomerulosa cells: interaction with potassium and angiotensin-II. Endocrinology 1991;128:2639-2644</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
40.Szalay KS, Beck M, Toth M, de Chatel R. Interactions between ouabain, atrial natriuretic peptide, angiotensin-II and potassium: effects on rat zona glomerulosa aldosterone production. Life Sci 1998;62:1845-1852</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
41.Okubo S, Niimura F, Nishimura H, et al. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest 1997;99:855-860</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
42.Aldactone: spironolactone. In: Physicians’ desk reference. 53rd ed. Montvale, N.J.: Medical Economics, 1999:2928-9.</p>
<p>Google Scholar. opens in new tab<br>
43.Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987;60:820-825</p>
<p>Crossref. opens in new tab<br>
Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar. opens in new tab<br>
44.de Gasparo M, Joss U, Ramjoue HP, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987;240:650-656</p>
<p>Web of Science. opens in new tab<br>
Medline. opens in new tab<br>
Google Scholar</p>
<p>&nbsp;</p>
<h2>Source:</h2>
<hr>
<p>&nbsp;</p>
<p>https://www.nejm.org/doi/full/10.1056/NEJM199909023411001</p>
</div></div><div class="btClear btSeparator bottomSmallSpaced noBorder" bis_skin_checked="1"><hr></div><div class="boldRow btArticleFooter btTableRow" bis_skin_checked="1"><div class="boldRowInner" bis_skin_checked="1"><div class="rowItem col-md-6 col-ms-12 btShareArticle btMiddleVertical btTextLeft" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><div class="btIconRow" bis_skin_checked="1"><span class="btIco btIcoDefaultType btIcoDefaultColor btIcoExtraSmallSize btIcoFacebook"><a href="https://www.facebook.com/sharer/sharer.php?u=/../../../../2021/04/05/the-effect-of-spironolactone-on-morbidity-and-mortality-in-patients-with-severe-heart-failure/" target="_self" data-ico-fa="" class="btIcoHolder"></a></span></div></div></div><div class="rowItem col-md-6 col-ms-12 btReadArticle btMiddleVertical btTextRight" bis_skin_checked="1"><div class="rowItemContent" bis_skin_checked="1"><a href="/../../../../2021/04/05/the-effect-of-spironolactone-on-morbidity-and-mortality-in-patients-with-severe-heart-failure/" class="btBtn btnRightPosition btContinueReading btnOutlineStyle btnNormalColor btnExtraSmall btnNormalWidth btnIco"><span class="btnInnerText">CONTINUE READING</span><span class="btIco "><span data-ico-fa="" class="btIcoHolder"></span></span></a></div></div></div></div></div></div></div></div></div></div></article><div class="btPagination boldSection gutter" bis_skin_checked="1"><div class="port" bis_skin_checked="1"><div class="paging onLeft" bis_skin_checked="1"><p class="pagePrev"><a href="/../../../../category/articles/">Newer Posts</a></p></div><div class="paging onRight" bis_skin_checked="1"><p class="pageNext"><a href="/../../../../category/articles/page/3/">Older Posts</a></p></div></div></div>
</div>
</div>
</div>
<!--PAGE-CONTENT-END-HERE-->

<div class="bt_bb_wrapper"><section id="bt_section610e3a31c4f1c" data-parallax="0.7" data-parallax-offset="0" class="boldSection btDivider topSpaced bottomSemiSpaced btDarkSkin gutter boxed inherit btParallax" style="background-color:#1a86d3  !important;"><div class="port"><div class="boldCell"><div class="boldCellInner"><div class="boldRow "><div class="boldRowInner">
<div class="rowItem col-md-3 col-sm-6 col-ms-12 btTextLeft" data-width="3"><div class="rowItemContent">
<header class="header btClear small btDash bottomDash  regular"><div class="btSuperTitle"><span>HONG KONG</span></div>
<div class="dash"><h4><span class="headline">Headquarter</span></h4></div></header><span class="btIco btIcoDefaultType btIcoSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../index.html" target="no_target" data-ico-es="&#xe964;" class="btIcoHolder"><span>+852 3575 9046 </span></a></span><div class="btClear btSeparator noBorder"><hr></div>
<span class="btIco btIcoDefaultType btIcoSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../index.html" target="_self" data-ico-fa="&#xf0c1;" class="btIcoHolder"><span>www.ikigaicorporation.com</span></a></span><div class="btClear btSeparator noBorder"><hr></div>
<div class="bpgPhoto btDefaultHoverType">
<a href="./../../../../index.html" target="_self" title=""></a>
<div class="boldPhotoBox"><div class="bpbItem"><div class="btImage">
<img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="" title="" data-lazy-src="./../../../../wp-content/uploads/2020/05/HK-e1588760431256.png"><noscript><img src="./../../../../wp-content/uploads/2020/05/HK-e1588760431256.png" alt="" title=""></noscript>
</div></div></div>
<div class="captionPane btDarkSkin btTextCenter">
<div class="captionTable">
<div class="captionCell">
<div class="captionTxt"></div>
</div>
</div>
</div>
</div>
</div></div>
<div class="rowItem col-md-6 col-sm-12 btTextLeft" data-width="6"><div class="rowItemContent">
<header class="header btClear small btDash bottomDash  regular"><div class="btSuperTitle"><span>LOCATIONS</span></div>
<div class="dash"><h4><span class="headline">Our network</span></h4></div></header><div class="btClear btSeparator bottomSmallSpaced noBorder"><hr></div>
<div class="boldRow "><div class="boldRowInner">
<div class="rowItem rowInnerItem col-sm-6  btTextLeft"><div class="rowItemContent">
<div class="bpgPhoto btDefaultHoverType"><div class="btImage">
<img src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E" alt="" title="						" data-lazy-src="./../../../../wp-content/uploads/2016/10/world-dot-map-gray-320x156.png"><noscript><img src="./../../../../wp-content/uploads/2016/10/world-dot-map-gray-320x156.png" alt="" title="						"></noscript>
</div></div>
<div class="btClear btSeparator topSmallSpaced noBorder"><hr></div>
</div></div>
<div class="rowItem rowInnerItem col-sm-6  btTextLeft"><div class="rowItemContent">
<header class="header btClear small  "><div class="btSuperTitle"><span>OUR NETWORK</span></div></header><div class="btClear btSeparator bottomExtraSmallSpaced noBorder"><hr></div>
<span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Asia</span></a></span><span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Americas</span></a></span><span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Middle East</span></a></span><span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Europe</span></a></span><span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Africa</span></a></span><span class="btIco btIcoDefaultType btIcoExtraSmallSize btIcoDefaultColor btIconCircleShape"><a href="./../../../../contact/index.html" target="no_target" data-ico-fa="&#xf041;" class="btIcoHolder"><span>Oceania</span></a></span>
</div></div>
</div></div>
<div class="btClear btSeparator bottomExtraSmallSpaced noBorder"><hr></div>
<div class="btClear btSeparator bottomSemiSpaced noBorder"><hr></div>
</div></div>
<div class="rowItem col-md-3 col-sm-6 col-ms-12 btTextLeft" data-width="3"><div class="rowItemContent">
<header class="header btClear small btDash bottomDash  regular"><div class="btSuperTitle"><span>GET IN TOUCH</span></div>
<div class="dash"><h4><span class="headline">Follow us</span></h4></div></header><div class="btClear btSeparator bottomSmallSpaced noBorder"><hr></div>
<span class="btIco btIcoFilledType btIcoBigSize btIcoAccentColor btIconCircleShape"><a href="https://www.facebook.com/ikigaicorporationcom" target="no_target" data-ico-fa="&#xf09a;" class="btIcoHolder"></a></span><span class="btIco btIcoFilledType btIcoBigSize btIcoAccentColor btIconCircleShape"><a href="https://www.instagram.com/ikigaicorporation" target="no_target" data-ico-fa="&#xf16d;" class="btIcoHolder"></a></span><span class="btIco btIcoFilledType btIcoBigSize btIcoAccentColor btIconCircleShape"><a href="https://www.google.com/maps/place/IKIGAI+CORPORATION+LTD/@22.3937048,113.9694348,17z/data=!3m1!4b1!4m5!3m4!1s0x3403fb18add189e3:0xccf4eec041856f0d!8m2!3d22.3936999!4d113.9716288" target="no_target" data-ico-fa="&#xf1a0;" class="btIcoHolder"></a></span><span class="btIco btIcoFilledType btIcoBigSize btIcoAccentColor btIconCircleShape"><a href="https://wa.me/message/UZHAWI3JZQDVB1" target="no_target" data-ico-fa="&#xf232;" class="btIcoHolder"></a></span><div class="btClear btSeparator bottomSemiSpaced noBorder"><hr></div>
</div></div>
</div></div></div></div></div></section></div>
<footer>
  <section class="boldSection gutter btSiteFooter btGutter">
<div class="port">
<div class="boldRow">
<div class="rowItem btFooterCopy col-md-6 col-sm-12 btTextLeft">
<p class="copyLine">Ikigai Corporation Company is a leading pharmaceutical contract development and manufacturing organisation (CDMO) for both APIs and finished dose forms.</p> </div>
<div class="rowItem btFooterMenu col-md-6 col-sm-12 btTextRight">
<ul id="menu-primary-menu-1" class="menu">
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-home menu-item-3253"><a title="						" href="./../index.html">Home</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3403"><a href="./../about-us/index.html">About us</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page current-menu-item page_item page-item-3451 current_page_item menu-item-3459"><a href="./index.html" aria-current="page">Our Technology</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3256"><a title="						" href="./../services/index.html">Product Portfolio</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-3872"><a href="./../policies/index.html">Policies</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3594"><a href="./../services/partner_with_us/index.html">Partner with us</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3494"><a href="./../careers/index.html">Careers</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4734"><a href="./../library/index.html">Library</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-3438"><a href="./../contact/index.html">Contact</a></li>
</ul> </div>
</div>
</div>
</section>
</footer>
</div>
<script >window.addEventListener('DOMContentLoaded', function() {
				(function( $ ) {
					$( document ).ready(function() {
						
						var time_notation = '24';
						
						var time = function() {
							
							if ( time_notation == '12' ) {
								var time = moment().tz( 'Asia/Hong_Kong' ).format( 'h:mm A' );
							} else {
								var time = moment().tz( 'Asia/Hong_Kong' ).format( 'H:mm' );
							}

							$( '#time610e3a31c10e7 .btIconWidgetText' ).html( time );
						}
						setInterval( function() {
							time();
						}, 1000 );
						time();
					});
				})( jQuery );
			});</script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-includes/js/comment-reply.min.js?ver=5.8" id="comment-reply-js" defer></script>
<script type="06cd7e663a0e46d4271fe72d-text/javascript" id="buttonizer_frontend_javascript-js-extra">
/* <![CDATA[ */
var buttonizer_ajax = {"ajaxurl":".\/wp-admin\/admin-ajax.php","version":"2.4.3","buttonizer_path":".\/wp-content\/plugins\/buttonizer-multifunctional-button","buttonizer_assets":".\/wp-content\/plugins\/buttonizer-multifunctional-button\/assets\/","base_url":".","current":[],"in_preview":"","is_admin":"","cache":"ec7e88ea4f3f1891d22d4075828b5b63","enable_ga_clicks":"1"};
/* ]]> */
</script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/plugins/buttonizer-multifunctional-button/assets/frontend.min.js?v=7ab4fd8a7cd8bd136942183145de39a0&#038;ver=5.8" id="buttonizer_frontend_javascript-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/modal-for-elementor/js/bootstrap.js?ver=1620657753" id="bootstrap-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/modal-for-elementor/js/popup.js?ver=1620657753" id="modal-popup-js-js" defer></script>
<script  data-rocket-type="text/javascript" id="rocket-browser-checker-js-after">
"use strict";var _createClass=function(){function defineProperties(target,props){for(var i=0;i<props.length;i++){var descriptor=props[i];descriptor.enumerable=descriptor.enumerable||!1,descriptor.configurable=!0,"value"in descriptor&&(descriptor.writable=!0),Object.defineProperty(target,descriptor.key,descriptor)}}return function(Constructor,protoProps,staticProps){return protoProps&&defineProperties(Constructor.prototype,protoProps),staticProps&&defineProperties(Constructor,staticProps),Constructor}}();function _classCallCheck(instance,Constructor){if(!(instance instanceof Constructor))throw new TypeError("Cannot call a class as a function")}var RocketBrowserCompatibilityChecker=function(){function RocketBrowserCompatibilityChecker(options){_classCallCheck(this,RocketBrowserCompatibilityChecker),this.passiveSupported=!1,this._checkPassiveOption(this),this.options=!!this.passiveSupported&&options}return _createClass(RocketBrowserCompatibilityChecker,[{key:"_checkPassiveOption",value:function(self){try{var options={get passive(){return!(self.passiveSupported=!0)}};window.addEventListener("test",null,options),window.removeEventListener("test",null,options)}catch(err){self.passiveSupported=!1}}},{key:"initRequestIdleCallback",value:function(){!1 in window&&(window.requestIdleCallback=function(cb){var start=Date.now();return setTimeout(function(){cb({didTimeout:!1,timeRemaining:function(){return Math.max(0,50-(Date.now()-start))}})},1)}),!1 in window&&(window.cancelIdleCallback=function(id){return clearTimeout(id)})}},{key:"isDataSaverModeOn",value:function(){return"connection"in navigator&&!0===navigator.connection.saveData}},{key:"supportsLinkPrefetch",value:function(){var elem=document.createElement("link");return elem.relList&&elem.relList.supports&&elem.relList.supports("prefetch")&&window.IntersectionObserver&&"isIntersecting"in IntersectionObserverEntry.prototype}},{key:"isSlowConnection",value:function(){return"connection"in navigator&&"effectiveType"in navigator.connection&&("2g"===navigator.connection.effectiveType||"slow-2g"===navigator.connection.effectiveType)}}]),RocketBrowserCompatibilityChecker}();
</script>
<script type="06cd7e663a0e46d4271fe72d-text/javascript" id="rocket-preload-links-js-extra">
/* <![CDATA[ */
var RocketPreloadLinksConfig = {"excludeUris":"\/(.+\/)?feed\/?.+\/?|\/(?:.+\/)?embed\/|\/(index\\.php\/)?wp\\-json(\/.*|$)|\/wp-admin\/|\/logout\/|\/pudra\/","usesTrailingSlash":"1","imageExt":"jpg|jpeg|gif|png|tiff|bmp|webp|avif","fileExt":"jpg|jpeg|gif|png|tiff|bmp|webp|avif|php|pdf|html|htm","siteUrl":".","onHoverDelay":"100","rateThrottle":"3"};
/* ]]> */
</script>
<script  data-rocket-type="text/javascript" id="rocket-preload-links-js-after">
(function() {
"use strict";var r="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"==typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},e=function(){function i(e,t){for(var n=0;n<t.length;n++){var i=t[n];i.enumerable=i.enumerable||!1,i.configurable=!0,"value"in i&&(i.writable=!0),Object.defineProperty(e,i.key,i)}}return function(e,t,n){return t&&i(e.prototype,t),n&&i(e,n),e}}();function i(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}var t=function(){function n(e,t){i(this,n),this.browser=e,this.config=t,this.options=this.browser.options,this.prefetched=new Set,this.eventTime=null,this.threshold=1111,this.numOnHover=0}return e(n,[{key:"init",value:function(){!this.browser.supportsLinkPrefetch()||this.browser.isDataSaverModeOn()||this.browser.isSlowConnection()||(this.regex={excludeUris:RegExp(this.config.excludeUris,"i"),images:RegExp(".("+this.config.imageExt+")$","i"),fileExt:RegExp(".("+this.config.fileExt+")$","i")},this._initListeners(this))}},{key:"_initListeners",value:function(e){-1<this.config.onHoverDelay&&document.addEventListener("mouseover",e.listener.bind(e),e.listenerOptions),document.addEventListener("mousedown",e.listener.bind(e),e.listenerOptions),document.addEventListener("touchstart",e.listener.bind(e),e.listenerOptions)}},{key:"listener",value:function(e){var t=e.target.closest("a"),n=this._prepareUrl(t);if(null!==n)switch(e.type){case"mousedown":case"touchstart":this._addPrefetchLink(n);break;case"mouseover":this._earlyPrefetch(t,n,"mouseout")}}},{key:"_earlyPrefetch",value:function(t,e,n){var i=this,r=setTimeout(function(){if(r=null,0===i.numOnHover)setTimeout(function(){return i.numOnHover=0},1e3);else if(i.numOnHover>i.config.rateThrottle)return;i.numOnHover++,i._addPrefetchLink(e)},this.config.onHoverDelay);t.addEventListener(n,function e(){t.removeEventListener(n,e,{passive:!0}),null!==r&&(clearTimeout(r),r=null)},{passive:!0})}},{key:"_addPrefetchLink",value:function(i){return this.prefetched.add(i.href),new Promise(function(e,t){var n=document.createElement("link");n.rel="prefetch",n.href=i.href,n.onload=e,n.onerror=t,document.head.appendChild(n)}).catch(function(){})}},{key:"_prepareUrl",value:function(e){if(null===e||"object"!==(void 0===e?"undefined":r(e))||!1 in e||-1===["http:","https:"].indexOf(e.protocol))return null;var t=e.href.substring(0,this.config.siteUrl.length),n=this._getPathname(e.href,t),i={original:e.href,protocol:e.protocol,origin:t,pathname:n,href:t+n};return this._isLinkOk(i)?i:null}},{key:"_getPathname",value:function(e,t){var n=t?e.substring(this.config.siteUrl.length):e;return n.startsWith("/")||(n="/"+n),this._shouldAddTrailingSlash(n)?n+"/":n}},{key:"_shouldAddTrailingSlash",value:function(e){return this.config.usesTrailingSlash&&!e.endsWith("/")&&!this.regex.fileExt.test(e)}},{key:"_isLinkOk",value:function(e){return null!==e&&"object"===(void 0===e?"undefined":r(e))&&(!this.prefetched.has(e.href)&&e.origin===this.config.siteUrl&&-1===e.href.indexOf("?")&&-1===e.href.indexOf("#")&&!this.regex.excludeUris.test(e.href)&&!this.regex.images.test(e.href))}}],[{key:"run",value:function(){"undefined"!=typeof RocketPreloadLinksConfig&&new n(new RocketBrowserCompatibilityChecker({capture:!0,passive:!0}),RocketPreloadLinksConfig).init()}}]),n}();t.run();
}());
</script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/themes/industrial/framework/js/slick.min.js?ver=5.8" id="slick-min-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/themes/industrial/framework/js/jquery.magnific-popup.min.js?ver=5.8" id="jquery-magnific-popup-min-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/iscroll.js?ver=1620657753" id="iscroll-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/fancySelect.js?ver=1620657753" id="fancySelect-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/misc.js?ver=1620657753" id="industrial-misc-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/dir.hover.js?ver=1620657753" id="industrial-dir-hover-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/sliders.js?ver=1620657753" id="industrial-sliders-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/themes/industrial/framework/js/bt_parallax.js?ver=1620657753" id="industrial-bt-parallax-js" defer></script>
<script type="06cd7e663a0e46d4271fe72d-text/javascript" id="cookie-notice-front-js-extra">
/* <![CDATA[ */
var cnArgs = {"ajaxUrl":".\/wp-admin\/admin-ajax.php","nonce":"870ef1de7b","hideEffect":"fade","position":"bottom","onScroll":"1","onScrollOffset":"100","onClick":"0","cookieName":"cookie_notice_accepted","cookieTime":"604800","cookieTimeRejected":"604800","cookiePath":"\/","cookieDomain":"","redirection":"0","cache":"1","refuse":"0","revokeCookies":"0","revokeCookiesOpt":"automatic","secure":"1"};
/* ]]> */
</script>
<script  async data-rocket-type="text/javascript" src="./../../../../wp-content/plugins/cookie-notice/includes/../js/front.min.js?ver=2.1.0" id="cookie-notice-front-js"></script>
<script type="06cd7e663a0e46d4271fe72d-text/javascript" src="./../../../../wp-includes/js/wp-embed.min.js?ver=5.8" id="wp-embed-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/industrial/moment.js?ver=1620657753" id="bt_moment-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/industrial/moment-timezone-with-data.js?ver=1620657753" id="bt_moment_timezone-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/plugins/industrial/imagesloaded.pkgd.min.js?ver=5.8" id="boldthemes_imagesloaded-js" defer></script>
<script  data-rocket-type="text/javascript" src="./../../../../wp-content/plugins/industrial/packery.pkgd.min.js?ver=5.8" id="boldthemes_packery-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/industrial/bt_grid_tweak.js?ver=1620658021" id="boldthemes_grid_tweak-js" defer></script>
<script  data-minify="1" data-rocket-type="text/javascript" src="./../../../../wp-content/cache/min/1/wp-content/plugins/industrial/bt_grid.js?ver=1620658021" id="boldthemes_grid-js" defer></script>

<div id="cookie-notice" role="banner" class="cookie-notice-hidden cookie-revoke-hidden cn-position-bottom" aria-label="Cookie Notice" style="background-color: rgba(0,0,0,1);">
<div class="cookie-notice-container" style="color: #fff;">
<span id="cn-notice-text" class="cn-text-container">We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.</span><span id="cn-notice-buttons" class="cn-buttons-container"><a href="#" id="cn-accept-cookie" data-cookie-set="accept" class="cn-set-cookie cn-button bootstrap" aria-label="I AGREE, thank you.">I AGREE, thank you.</a><a href="./../../../../services/privacy-policy/index.html" target="_blank" id="cn-more-info" class="cn-more-info cn-button bootstrap" aria-label="Privacy policy">Privacy policy</a></span><a href="javascript:void(0);" id="cn-close-notice" data-cookie-set="accept" class="cn-close-icon" aria-label="I AGREE, thank you."></a>
</div>
</div>
 <script  data-rocket-type="text/javascript">window.addEventListener('DOMContentLoaded', function() {
        jQuery(document).ready(function ($) {
            //$( document ).ajaxStart(function() {
            //});

			
            for (var i = 0; i < document.forms.length; ++i) {
                var form = document.forms[i];
				if ($(form).attr("method") != "get") { $(form).append('<input type="hidden" name="kNEuIGs" value="ToGFEeP2A" />'); }
if ($(form).attr("method") != "get") { $(form).append('<input type="hidden" name="-rgtSF" value="PeoHbQdFwGR2kU" />'); }
            }

			
            $(document).on('submit', 'form', function () {
				if ($(this).attr("method") != "get") { $(this).append('<input type="hidden" name="kNEuIGs" value="ToGFEeP2A" />'); }
if ($(this).attr("method") != "get") { $(this).append('<input type="hidden" name="-rgtSF" value="PeoHbQdFwGR2kU" />'); }
                return true;
            });

			
            jQuery.ajaxSetup({
                beforeSend: function (e, data) {

                    //console.log(Object.getOwnPropertyNames(data).sort());
                    //console.log(data.type);

                    if (data.type !== 'POST') return;

                    if (typeof data.data === 'object' && data.data !== null) {
						data.data.append("kNEuIGs", "ToGFEeP2A");
data.data.append("-rgtSF", "PeoHbQdFwGR2kU");
                    }
                    else {
                        data.data =  data.data + '&kNEuIGs=ToGFEeP2A&-rgtSF=PeoHbQdFwGR2kU';
                    }
                }
            });

        });
	});</script>
<script src="./../../../../live_search.js"></script>
<script type="06cd7e663a0e46d4271fe72d-text/javascript">window.lazyLoadOptions={elements_selector:"img[data-lazy-src],.rocket-lazyload",data_src:"lazy-src",data_srcset:"lazy-srcset",data_sizes:"lazy-sizes",class_loading:"lazyloading",class_loaded:"lazyloaded",threshold:300,callback_loaded:function(element){if(element.tagName==="IFRAME"&&element.dataset.rocketLazyload=="fitvidscompatible"){if(element.classList.contains("lazyloaded")){if(typeof window.jQuery!="undefined"){if(jQuery.fn.fitVids){jQuery(element).parent().fitVids()}}}}}};window.addEventListener('LazyLoad::Initialized',function(e){var lazyLoadInstance=e.detail.instance;if(window.MutationObserver){var observer=new MutationObserver(function(mutations){var image_count=0;var iframe_count=0;var rocketlazy_count=0;mutations.forEach(function(mutation){for(i=0;i<mutation.addedNodes.length;i++){if(typeof mutation.addedNodes[i].getElementsByTagName!=='function'){continue}
if(typeof mutation.addedNodes[i].getElementsByClassName!=='function'){continue}
images=mutation.addedNodes[i].getElementsByTagName('img');is_image=mutation.addedNodes[i].tagName=="IMG";iframes=mutation.addedNodes[i].getElementsByTagName('iframe');is_iframe=mutation.addedNodes[i].tagName=="IFRAME";rocket_lazy=mutation.addedNodes[i].getElementsByClassName('rocket-lazyload');image_count+=images.length;iframe_count+=iframes.length;rocketlazy_count+=rocket_lazy.length;if(is_image){image_count+=1}
if(is_iframe){iframe_count+=1}}});if(image_count>0||iframe_count>0||rocketlazy_count>0){lazyLoadInstance.update()}});var b=document.getElementsByTagName("body")[0];var config={childList:!0,subtree:!0};observer.observe(b,config)}},!1)</script><script data-no-minify="1" async src="./../../../../wp-content/plugins/wp-rocket/assets/js/lazyload/16.1/lazyload.min.js" type="06cd7e663a0e46d4271fe72d-text/javascript"></script><script src="./../../../../cdn-cgi/scripts/7d0fa10a/cloudflare-static/rocket-loader.min.js" data-cf-settings="06cd7e663a0e46d4271fe72d-|49" defer></script><script type="text/javascript">(function(){window['__CF$cv$params']={r:'67b14aa0bd2192f8',m:'43df34172ca0f4f68ebbecbcf9a5a00029aba502-1628347556-1800-AVTlhDW4t9yA80xF5UdjoXKJiq7B7xNjRkAuPvixBxFixLosCDHCFG2h63XgOhBwRiCIDj2P9TKIHYBnV4kRgrcIoT5BrroyHzIFxwvjgkVmd115AGEcIIJPkP66qAQCQm/6tYO8Bkqd31TIv3OlW/z8inBUFtnaZsPjnH1RBzcf',s:[0xc47a4f690a,0xb1c6885590],}})();</script><script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67b14aa0bd2192f8","version":"2021.7.0","r":1,"token":"e3b748a178054eff95051ca851daefa1","si":10}'></script>
</body>
</html>